Quarterlytics / Financial Services / Asset Management / Hercules Capital

Hercules Capital

htgc · NASDAQ Financial Services
Claim this profile
Ticker htgc
Exchange NASDAQ
Sector Financial Services
Industry Asset Management
Employees 51-200
← All annual reports
FY2021 Annual Report · Hercules Capital
Sign in to download
Loading PDF…
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 

FORM 10-K 

(Mark One) 
(cid:0)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the fiscal year ended December 31, 2021

OR 

(cid:0)  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 

For the transition period from        to        

Commission File No. 814-00702 

HERCULES CAPITAL, INC.

(Exact name of Registrant as specified in its charter) 

Maryland
(State or other jurisdiction of
incorporation or organization)

74-3113410
(I.R.S. Employer
Identification Number)

400 Hamilton Avenue, Suite 310
Palo Alto, California 94301
(Address of principal executive offices)
(650) 289-3060 
(Registrant’s telephone number, including area code) 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Common Shares, par value $0.001 per share 
6.25% Notes due 2033

Trading Symbol(s)
HTGC
HCXY

Name of each exchange on which registered
New York Stock Exchange
New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes  (cid:0)    No  (cid:0) 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.     Yes  (cid:0)    No  (cid:0)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months 

(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:    Yes  (cid:0)    No  (cid:0) 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this 

chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  (cid:0)    No  (cid:0) 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See 

the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒   Accelerated filer   ☐ Non-accelerated filer   ☐ Smaller reporting company   ☐ Emerging growth company ☐

  If  an  emerging  growth  company,  indicate  by  check  mark  if  the  registrant  has  elected  not  to  use  the  extended  transition  period  for  complying  with  a  new  or  revised  financial 

accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under 

Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. (cid:0)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  (cid:0)    No   (cid:0) 
The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed 
second fiscal quarter was approximately $1.95 billion based upon a closing price of $17.06 reported for such date on the New York Stock Exchange. Common shares held by each executive 
officer and director and by each person who owns 5% or more of the outstanding common shares have been excluded in that such persons may be deemed to be affiliates. This determination of 
affiliate status is not intended and shall not be deemed to be an admission that, such persons are affiliates of the Registrant.

On  February 16, 2022, there were 119,769,139 shares outstanding of the registrant’s common stock, $0.001 par value.
DOCUMENTS INCORPORATED BY REFERENCE
Documents incorporated by reference: Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders to be filed within 120 days after the close of the 

registrant’s year end are incorporated by reference into Part III of this Annual Report on Form 10-K.

1

 
  
  
  
  
  
  
  
   
  
  
 
Business
Risk Factors
Unresolved SEC Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures

HERCULES CAPITAL, INC.
FORM 10-K 
ANNUAL REPORT

Part I.

Part II.

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Reserved
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosure About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information

Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.

Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.

Item 10.
Item 11.
Item 12.
Item 13.
Item 14.

Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions and Director Independence
Principal Accountant Fees and Services

Part III.

Part IV.

Item 15.
Item 16.
Signatures

Exhibits and Financial Statement Schedules
Form 10-K Summary

Page

3
27
67
67
67
67

68
71
71
88
89
157
157
158

162
162
162
162
162

163
164
174

Hercules Capital, Inc., our logo and other trademarks of Hercules Capital, Inc. are the property of Hercules Capital, Inc. All other trademarks or trade names referred to 

in this Annual Report on Form 10-K are the property of their respective owners. 

2

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
In this Annual Report on Form 10-K, or Annual Report, the “Company,” “Hercules,” “we,” “us,” and “our” refer to Hercules Capital, Inc. and its wholly owned 

subsidiaries and its affiliated securitization trusts unless the context otherwise requires.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that involve substantial risks and uncertainties that are within the meaning of Section 27A of the Securities Act of 
1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can identify these statements using 
forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “target,” “estimate,” “intend,” “continue” or “believe” or the negatives of, or 
other variations on, these terms or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects, 
and expectations concerning our business, operating results, financial condition, and other similar matters. We believe that it is important to communicate our future 
expectations to our investors. Our forward-looking statements include information in this report regarding general domestic and global economic conditions, our future 
financing plans, our ability to operate as a business development company (“BDC”) and the expected performance of, and the yield on, our portfolio companies. There may be 
events in the future, however, that we are not able to predict accurately or control. The factors listed under “Risk Factors” in this annual report on Form 10-K, as well as any 
cautionary language in this report, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in 
our forward-looking statements. The occurrence of the events described in these risk factors and elsewhere in this report could have a material adverse effect on our business, 
results of operations and financial position. Any forward-looking statement made by us in this report speaks only as of the date of this report. Factors or events that could cause 
our actual results to differ from our forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to 
publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Item 1.   Business 

PART I 

GENERAL 

Hercules Capital, Inc. is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-

backed companies in a variety of technology, life sciences and sustainable and renewable technology industries. Our goal is to be the leading structured debt financing provider 
for venture capital-backed and institutional-backed companies in technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to 
evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and 
sustainable and renewable technology and to offer a full suite of growth capital products. 

Our primary business objectives are to increase our net income, net investment income, and net asset value (“NAV”) by investing in debt, typically with warrants or 

equity, of venture capital-backed and institutional-backed companies in a variety of technology-related industries at attractive current yields and the potential for equity 
appreciation and realized gains. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt 
investments and capital appreciation from our warrant and equity investments.  Our equity ownership in our portfolio companies may exceed 25% of the voting securities of 
such companies, which represents a controlling interest under the Investment Company Act of 1940 (“1940 Act”). In some cases, we receive the right to make additional equity 
investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide is generally used for growth and general working capital 
purposes as well as in select cases for acquisitions or recapitalizations. We invest primarily in private companies but also have investments in public companies. 

Our investments are focused in companies that are active in a variety of technology industry sub-sectors or are characterized by products or services that require 

advanced technologies, including, but not limited to, computer software and hardware, networking systems, semiconductors, semiconductor capital equipment, information 
technology infrastructure or services, internet consumer and business services, telecommunications, telecommunications equipment, media, life sciences, and renewable or 
alternative energy. Within the life sciences sub-sector, we generally focus on medical devices, bio-pharmaceutical, drug discovery and development, drug delivery, health care 
services and information systems companies. Within the sustainable and renewable technology sub-sector, we focus on sustainable and renewable energy technologies and 
energy efficiency and monitoring technologies. We refer to all of these companies as “technology-related” companies and intend, under normal circumstances, to invest at least 
80% of the value of our total assets in such businesses.

3

 
  
 
We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We use the term “structured debt with warrants” to 

refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase or 
convert into common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We also 
invest in  “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position. In addition to our debt investments, we regularly 
engage in discussions with third parties with respect to various potential transactions to explore all alternatives. Through such alternatives, we may acquire an investment, a 
portfolio of investments, an entire company, or sell portions of our portfolio on an opportunistic basis. 

We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a 

variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from 
which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction 
will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a 
number of other factors and conditions, which may include, depending on the transaction and without limitation, the approval of our Board of Directors (the "Board"), required 
regulatory or third-party consents, and/or the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of 
these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

CORPORATE STRUCTURE

We are an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the 

1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying 
assets,” including securities of private U.S. companies, cash, cash equivalents, U.S. government securities and high-quality debt investments that mature in one year or less. As 
a BDC, we must also meet a coverage ratio of total net assets to total senior securities, which include all of our borrowings (including accrued interest payable) except for 
debentures issued by the Small Business Administration (the “SBA”) and any preferred stock we may issue in the future, of at least 150% subsequent to each borrowing or 
issuance of senior securities. Certain of our wholly owned subsidiaries are licensed to operate as a small business investment company (a “SBIC” or “SBICs”) under the 
authority of the SBA. Through SBIC licensed vehicles we may access capital from the SBA debenture program. See “Regulation” for additional information related to our 
capital requirements. 

We are internally managed under the supervision of our Board. We do not pay management or advisory fees, but instead incur costs customary for an operating 
company. Some of those costs include recruiting and marketing expenses as well as the costs associated with employing management, investment and portfolio management 
professionals, and technology, secretarial and other support personnel. In connection with our recruiting, branding and marketing efforts, we may, among other things, make 
charitable contributions in amounts we believe to be immaterial and that do not exceed $500 thousand in the aggregate in any year. We believe that many of these contributions 
help us raise our profile in the communities and benefit us in attracting and retaining talent and investment opportunities.

Effective January 1, 2006, we elected to be treated for tax purposes as a regulated investment company (“RIC”) under the Internal Revenue Code of 1986, as amended 

(“the Code”). As a RIC, we generally will not be subject to U.S. federal income tax on the portion of our investment company taxable income and net capital gain (i.e., net 
realized long-term capital gains in excess of net realized short-term capital losses) we distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes 
to stockholders with respect to that taxable year. We will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income and gains unless we make 
distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year subject to certain requirements as 
defined for RICs. See “Certain United States Federal Income Tax Considerations” for additional information. Additionally, we have established wholly owned subsidiaries that 
are not consolidated for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio 
investments.

In May 2020, Hercules Adviser LLC (the “Adviser Subsidiary”) was formed as a wholly owned Delaware limited liability subsidiary to provide investment advisory 
and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary receives fee 
income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow 
the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”). See “— Regulation—No-action 
and Exemptive Relief Obtained” for additional information regarding our Adviser Subsidiary. 

4

  
 
We are a Maryland corporation formed in December 2003 that began investment operations in September 2004. On February 25, 2016, we changed our name from 

“Hercules Technology Growth Capital, Inc.” to “Hercules Capital, Inc.” Our principal executive offices are located at 400 Hamilton Avenue, Suite 310, Palo Alto, California 
94301, and our telephone number is (650) 289-3060. We also have offices in Boston, MA, New York, NY, Bethesda, MD, Westport, CT, Chicago, IL, San Diego, CA, and 
London, United Kingdom. 

CORPORATE HISTORY AND OFFICES 

AVAILABLE INFORMATION

We file with or submit to the SEC our annual, quarterly, current reports, proxy statements and other information meeting the informational requirements of the 

Securities Exchange Act of 1934, as amended (“the Exchange Act”). We make available, free of charge, on our website our proxy statement, annual report on Form 10-K, 
quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports and other publicly filed information available as soon as reasonably practicable 
after we electronically file such material with, or furnish it to the SEC. Our Internet address where these documents and other information can be found is www.htgc.com. 
Information contained on our website is not incorporated by reference into this Annual Report, and you should not consider that information to be part of this Annual Report. 
Our annual, quarterly, periodic and current reports, proxy statements and other public filings are also available free of charge on the EDGAR Database on the SEC's Internet 
website at www.sec.gov. 

OUR MARKET OPPORTUNITY

We believe that technology-related companies compete in one of the largest and most rapidly growing sectors of the U.S. economy and that continued growth is 

supported by ongoing innovation and performance improvements in technology products as well as the adoption of technology across virtually all industries in response to 
competitive pressures. We believe that an attractive market opportunity exists for a specialty finance company focused primarily on investments in structured debt with 
warrants in technology-related companies for the following reasons:

•

•

•

technology-related companies have generally been underserved by traditional lending sources; 

unfulfilled demand exists for structured debt financing to technology-related companies due to the complexity of evaluating risk in these investments; and

structured debt with warrants products are less dilutive and complement equity financing from venture capital and private equity funds.

Technology-Related Companies are Underserved by Traditional Lenders. 

We believe many viable technology-related companies backed by financial sponsors have been unable to obtain sufficient growth financing from traditional lenders, 
including financial services companies such as commercial banks and finance companies because traditional lenders have continued to consolidate and have adopted a more 
risk-averse approach to lending. More importantly, we believe traditional lenders are typically unable to underwrite the risk associated with these companies effectively. 

The unique cash flow characteristics of many technology-related companies typically include significant research and development expenditures and high projected 

revenue growth thus often making such companies difficult to evaluate from a credit perspective. In addition, the balance sheets of these companies often include a 
disproportionately large amount of intellectual property assets, which can be difficult to value. Finally, the speed of innovation in technology and rapid shifts in consumer 
demand and market share add to the difficulty in evaluating technology-related companies. 

Due to the difficulties described above, we believe traditional lenders generally refrain from entering the structured debt financing marketplace, instead preferring the 

risk-reward profile of asset-based lending. Traditional lenders generally do not have flexible product offerings that meet the needs of technology-related companies. The 
financing products offered by traditional lenders typically impose on borrowers many restrictive covenants and conditions, including limiting cash outflows and requiring a 
significant depository relationship to facilitate rapid liquidation. 

Unfulfilled Demand for Structured Debt Financing to Technology-Related Companies. 

Private debt capital in the form of structured debt financing from specialty finance companies continues to be an important source of funding for technology-related 

companies. We believe that the level of demand for structured debt financing is a function of the level of annual venture equity investment activity. 

5

 
  
 
We believe that demand for structured debt financing is currently underserved. The venture capital market for the technology-related companies in which we invest has 

been active. Therefore, to the extent we have capital available, we believe this is an opportune time to be active in the structured lending market for technology-related 
companies. 

Structured Debt with Warrants Products Complement Equity Financing from Venture Capital and Private Equity Funds. 

We believe that technology-related companies and their financial sponsors will continue to view structured debt securities as an attractive source of capital because it 

augments the capital provided by venture capital and private equity funds. We believe that our structured debt with warrants products provide access to growth capital that 
otherwise may only be available through incremental investments by existing equity investors. As such, we provide portfolio companies and their financial sponsors with an 
opportunity to diversify their capital sources. Generally, we believe many technology-related companies at all stages of development target a portion of their capital to be debt 
in an attempt to achieve a higher valuation through internal growth. In addition, because financial sponsor-backed companies have reached a more mature stage prior to 
reaching a liquidity event, we believe our investments could provide the debt capital needed to grow or recapitalize during the extended period sometimes required prior to 
liquidity events. 

Our strategy to achieve our investment objective includes the following key elements: 

Leverage the Experience and Industry Relationships of Our Management Team and Investment Professionals. 

OUR BUSINESS STRATEGY

We have assembled a team of experienced investment professionals with extensive experience as venture capitalists, commercial lenders, and originators of structured 
debt and equity investments in technology-related companies. Our investment professionals have, on average, more than 10 years of experience as equity investors in, and/or 
lenders to, technology-related companies. In addition, our team members have originated structured debt, debt with warrants and equity investments in over 500 technology-
related companies, representing more than $13.0 billion in commitments from inception to December 31, 2021, and have developed a network of industry contacts with 
investors and other participants within the venture capital and private equity communities. Members of our management team also have operational, research and development 
and finance experience with technology-related companies. Furthermore, we have established contacts with leading venture capital and private equity fund sponsors, public and 
private companies, research institutions and other industry participants, which we believe will enable us to identify and attract well-positioned prospective portfolio companies.

We focus our investing activities generally in industries in which our investment professionals have investment experience. We believe that our focus on financing 

technology-related companies will enable us to leverage our expertise in structuring prospective investments, to assess the value of both tangible and intangible assets, to 
evaluate the business prospects and operating characteristics of technology-related companies and to identify and originate potentially attractive investments with these types of 
companies. 

Mitigate Risk of Principal Loss and Build a Portfolio of Warrant and Equity Securities. 

We expect that our investments have the potential to produce attractive risk-adjusted returns through current income, in the form of interest and fee income, as well as 

capital appreciation from warrant and equity securities. We believe that we can mitigate the risk of loss on our debt investments through the combination of loan principal 
amortization after an initial interest only period, cash interest payments, relatively short maturities (typically between 36-48 months), security interests in the assets of our 
portfolio companies, and on select investment covenants requiring prospective portfolio companies to have certain amounts of available cash at the time of our investment and 
the continued support from a venture capital or private equity firm at the time we make our investment. Although we do not currently engage in hedging transactions, we may 
engage in hedging transactions in the future utilizing instruments such as forward contracts, currency options and interest rate swaps, caps, collars, and floors. 

Historically our structured debt investments to technology-related companies typically include warrants or other equity interests, giving us the potential to realize 

equity-like returns on a portion of our investment. In addition, in some cases, we receive the right to make additional equity investments in our portfolio companies, including 
the right to convert some portion of our debt into equity, in connection with future equity financing rounds. We believe these equity interests will create the potential for 
meaningful long-term capital gains in connection with the future liquidity events of these technology-related companies. 

6

 
  
 
Provide Customized Financing Complementary to Financial Sponsors’ Capital. 

We offer a broad range of investment structures and possess expertise and experience to effectively structure and price investments in technology-related companies. 

Unlike many of our competitors that only invest in companies that fit a specific set of investment parameters, we have the flexibility to structure our investments to suit the 
particular needs of our portfolio companies. We offer customized financing solutions ranging from senior debt, including below-investment grade debt instruments, also known 
as “junk bonds”, to equity capital, with a focus on structured debt with warrants. 

We use our relationships in the financial sponsor community to originate investment opportunities. Because venture capital and private equity funds typically invest 

solely in the equity securities of their portfolio companies, we believe that our debt investments will be viewed as an attractive and complimentary source of capital, both by the 
portfolio company and by the portfolio company’s financial sponsor. In addition, we believe that many venture capital and private equity fund sponsors encourage their 
portfolio companies to use debt financing for a portion of their capital needs as a means of potentially enhancing equity returns, minimizing equity dilution and increasing 
valuations prior to a subsequent equity financing round or a liquidity event. 

Invest at Various Stages of Development. 

We provide growth capital to technology-related companies at all stages of development, including select publicly listed companies and select special opportunity lower 

middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancings and established-stage companies. We believe that this provides 
us with a broader range of potential investment opportunities than those available to many of our competitors, who generally focus their investments on a particular stage in a 
company’s development. Because of the flexible structure of our investments and the extensive experience of our investment professionals, we believe we are well positioned to 
take advantage of these investment opportunities at all stages of prospective portfolio companies’ development. 

Benefit from Our Efficient Organizational Structure. 

We believe that the perpetual nature of our corporate structure enables us to be a long-term partner for our portfolio companies in contrast to traditional investment 

funds, which typically have a limited life. In addition, because of our access to the equity markets, we believe that we may benefit from a lower cost of capital than that 
available to private investment funds. We are not subject to requirements to return invested capital to investors nor do we have a finite investment horizon. Capital providers 
that are subject to such limitations are often required to seek a liquidity event more quickly than they otherwise might, which can result in a lower overall return on an 
investment. 

Deal Sourcing Through Our Proprietary Database. 

We have developed a proprietary and comprehensive database to track various aspects of our investment process including sourcing, originations, transaction 

monitoring and post-investment performance. As of December 31, 2021, our proprietary database included more than 55,000 technology-related companies and more than 
13,000 venture capital firms, private equity sponsors or investors, as well as various other industry contacts. This proprietary database allows us to maintain, cultivate and grow 
our industry relationships while providing us with comprehensive details on companies in the technology-related industries and their financial sponsors. 

OUR INVESTMENTS AND OPERATIONS 

We principally invest in debt securities and, to a lesser extent, equity securities, with a particular emphasis on structured debt with warrants. We generally seek to invest 

in companies that have been operating for at least six to twelve months prior to the date of our investment. We anticipate that such entities may, at the time of investment, be 
generating revenues or will have a business plan that anticipates generation of revenues within 24 to 48 months. Further, we anticipate that on the date of our investment we 
will generally obtain a lien on available assets, which may or may not include intellectual property, and these companies will have sufficient cash on their balance sheet to 
operate as well as potentially amortize their debt for at least three to nine months following our investment. We generally require that a prospective portfolio company, in 
addition to having sufficient capital to support leverage, demonstrate an operating plan capable of generating cash flows or raising the additional capital necessary to cover its 
operating expenses and service its debt, for an additional six to twelve months subject to market conditions. 

7

  
 
We expect that our investments will generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below this range. We 

typically structure our debt securities to provide for amortization of principal over the life of the loan, but may include a period of interest-only payments. Our loans will 
typically be collateralized by a security interest in the borrower’s assets, although we may not have the first claim on these assets and the assets may not include intellectual 
property. Our debt investments carry fixed or variable contractual interest rates which generally ranged from approximately 7.0% to 14.5% as of December 31, 2021. 
Approximately 94.0% of our loans were at floating rates or floating rates with a floor and 6.0% of the loans were at fixed rates as of December 31, 2021. 

In addition to the cash yields received on our loans, our loans generally include one or more of the following: exit fees, balloon payment fees, commitment fees, success 

fees, or prepayment fees. In some cases, our loans also include contractual payment-in-kind ("PIK") interest arrangements. The increases in loan balances as a result of 
contractual PIK arrangements are included in income for the period in which such PIK interest was accrued, which is often in advance of receiving cash payment, and are 
separately identified on our statements of cash flows. We also may be required to include in income for tax purposes certain other amounts prior to receiving the related cash. 

In addition, our investments in the structured debt of venture capital-backed and institutional-backed companies generally have equity enhancement features, typically 

in the form of warrants or other equity securities that are considered original issue discounts ("OID") to our loans and are designed to provide us with an opportunity for 
potential capital appreciation. The warrants typically will be immediately exercisable upon issuance and generally will remain exercisable for the lesser of five to ten years or 
three to five years after completion of an initial public offering (“IPO”). The exercise prices for the warrants varies from nominal exercise prices to exercise prices that are at or 
above the current fair market value of the equity for which we receive warrants. We may structure warrants to provide minority rights provisions or, on a very select basis, put 
rights upon the occurrence of certain events. We generally target a total annualized return (including interest, fees and value of warrants) of 12% to 25% for our debt 
investments. 

Typically, our structured debt and equity investments take one of the following forms: 

•

•

•

Structured Debt with Warrants. We seek to invest a majority of our assets in structured debt with warrants of prospective portfolio companies. Our investments 
in structured debt with warrants may be the only debt capital on the balance sheet of our portfolio companies, and in many cases we have a first priority security 
interest in all of our portfolio company’s assets, or in certain investments we may have a negative pledge on intellectual property. Our structured debt with 
warrants typically has a maturity of between two and five years, and it may provide for full amortization after an interest only period. Our structured debt with 
warrants generally carries a contractual interest rate up to 11.0% and may include an additional exit fee payment or contractual PIK interest arrangements. We 
may structure our structured debt with warrants with restrictive affirmative and negative covenants, default penalties, prepayment penalties, lien protection, 
equity calls, change-in-control provisions or board observation rights. 

Senior Debt. We seek to invest a limited portion of our assets in senior debt. Senior debt may be collateralized by accounts receivable and/or inventory 
financing of prospective portfolio companies. Senior debt has a senior position with respect to a borrower’s scheduled interest and principal payments and holds 
a first priority security interest in the assets pledged as collateral. Senior debt also may impose covenants on a borrower with regard to cash flows and changes 
in capital structure, among other items. We generally collateralize our investments by obtaining security interests in our portfolio companies’ assets, which may 
include their intellectual property. In other cases, we may obtain a negative pledge covering a company’s intellectual property. Our senior loans, in certain 
instances, may be tied to the financing of specific assets. In connection with a senior debt investment, we may also provide the borrower with a working capital 
line-of-credit that will carry an interest rate ranging from Prime or LIBOR plus a spread with a floor, generally maturing in three to five years, and typically 
secured by accounts receivable and/or inventory. We also provide “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally 
in a first lien position with security interest in all the assets of the portfolio company. The loans can either be “first out” or “last out”, whereby the “last-out” 
loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition.

Equity Securities. The equity securities we hold consist primarily of warrants or other equity interests generally obtained in connection with our structured debt 
investments. In addition to the warrants received as a part of a structured debt financing, we typically receive the right to make equity investments in a portfolio 
company in connection with that company’s next round of equity financing. We may also hold certain debt investments that have the right to convert a portion 
of the debt investment into equity. These rights will provide us with the opportunity to further enhance our returns over time through opportunistic equity 
investments in our portfolio companies. These equity investments are typically in the form of preferred or common equity and may be structured with a 
dividend yield, providing us with a current return, and with customary anti-dilution protection and preemptive rights. We may achieve liquidity through a 
merger or acquisition of a portfolio company, a public offering of a portfolio company’s stock or by exercising our right, if any, to require a portfolio company 
to buy back the equity securities we hold. We may also make stand-alone direct equity 

8

  
 
investments into portfolio companies in which we may not have any debt investment in the company. As of December 31, 2021, we held warrant and equity 
securities in 155 portfolio companies. 

In addition to the characteristics described above, the table below compares the typical features of our investments. 

Typical Structure
Investment Horizon
Covenants

Structured Debt with Warrants
Term debt with warrants
Long-term: 2 to 5 years; Average of 3.5 years
Less restrictive; mostly financial

Senior Debt
Term or revolving debt
Generally under 4 years
Generally borrowing base and financial

Equity Securities
Preferred stock or common stock
3 to 7 years
None

Investment Criteria  

We have identified several criteria, among others, that we believe are important in achieving our investment objective with respect to prospective portfolio companies. 

These criteria, while not inclusive, provide general guidelines for our investment decisions. 

Portfolio Composition - While we generally focus our investments in venture capital-backed and institutional-backed companies in a variety of technology-related 
industries, we seek to invest across various financial sponsors as well as across various stages of companies’ development and various technology industry sub-sectors and 
geographies. As of December 31, 2021, approximately 80.1% of the fair value of our portfolio was composed of investments in three industries: 39.7% was composed of 
investments in the "Drug Discovery & Development" industry, 24.1% was composed of investments in the "Software" industry, and 16.3% was composed of investments in the 
"Internet Consumer & Business Services" industry.

Continuing Support from One or More Financial Sponsors - We generally invest in companies in which one or more established financial sponsors have previously 

invested and continue to make a contribution to the management of the business. We believe that having established financial sponsors with meaningful commitments to the 
business is a key characteristic of a prospective portfolio company. In addition, we look for representatives of one or more financial sponsors to maintain seats on the board of 
directors of a prospective portfolio company as an indication of such commitment. 

Company Stage of Development - While we invest in companies at various stages of development, we generally require that prospective portfolio companies be 
beyond the seed stage of development and generally have received or anticipate having commitments for their first institutional round of equity financing for early stage 
companies. We expect a prospective portfolio company to demonstrate progress in its product development or demonstrate a path towards revenue generation or increase its 
revenues and operating cash flow over time. The anticipated growth rate of a prospective portfolio company is a key factor in determining the value that we ascribe to any 
warrants or other equity securities that we may acquire in connection with an investment in debt securities. 

Operating Plan -  We generally require that a prospective portfolio company, in addition to having potential access to capital to support leverage, demonstrate an 
operating plan capable of generating cash flows or the ability to potentially raise the additional capital necessary to cover its operating expenses and service its debt for a 
specific period. Specifically, we require that a prospective portfolio company demonstrate at the time of our proposed investment that in addition to having sufficient capital to 
support leverage, it has an operating plan capable of generating cash flows or raising the additional capital necessary to cover its operating expenses and service its debt for an 
additional six to twelve months subject to market conditions. 

Security Interest - In many instances we seek a first priority security interest in all of the portfolio company’s tangible and intangible assets as collateral for our debt 
investment, subject in some cases to permitted exceptions. In other cases, we may obtain a negative pledge prohibiting a company from pledging or otherwise encumbering 
their intellectual property. Although we do not intend to operate as an asset-based lender, the estimated liquidation value of the assets, if any, collateralizing the debt securities 
that we hold is an important factor in our credit analysis and subject to assumptions that may change over the life of the investment especially when attempting to estimate the 
value of intellectual property. We generally evaluate both tangible assets, such as accounts receivable, inventory and equipment, and intangible assets, such as intellectual 
property, customer lists, networks and databases. 

9

 
 
 
  
 
Covenants - Our investments may include one or more of the following covenants: cross-default; material adverse change provisions; requirements that the portfolio 
company provide periodic financial reports and operating metrics; and limitations on the portfolio company’s ability to incur additional debt, sell assets, dividend recapture, 
engage in transactions with affiliates and consummate an extraordinary transaction, such as a merger or recapitalization without our consent. In addition, we may require other 
performance or financial based covenants, as we deem appropriate. 

Exit Strategy - Prior to making a debt investment that is accompanied by a warrant or other equity security in a prospective portfolio company, we analyze the potential 

for that company to increase the liquidity of its equity through a future event that would enable us to realize appreciation in the value of our equity interest. Liquidity events 
may include an IPO, a private sale of our equity interest to a third party, a merger or an acquisition of the company or a purchase of our equity position by the company or one 
of its stockholders. 

Investment Process 

We have organized our management team around the four key elements of our investment process: 

•

•

•

•

Origination; 

Underwriting; 

Documentation; and 

Loan and Compliance Administration. 

Our investment process is summarized in the following chart: 

10

 
  
 
Origination 

The origination process for our investments includes sourcing, screening, preliminary due diligence and deal structuring and negotiation, all leading to an executed non-

binding term sheet. As of December 31, 2021, our investment origination team, which consists of approximately 53 investment professionals, is headed by our Chief 
Investment Officer and Chief Executive Officer. The origination team is responsible for sourcing potential investment opportunities and members of the investment origination 
team use their extensive relationships with various leading financial sponsors, management contacts within technology-related companies, trade sources, technology 
conferences and various publications to source prospective portfolio companies. Our investment origination team is divided into life sciences, technology, SaaS finance, 
sustainable and renewable technology, and special situation sub-teams to better source potential portfolio companies. 

In addition, we have developed a comprehensive proprietary database to track various aspects of our investment process including sourcing, originations, transaction 
monitoring and post-investment performance. Our proprietary database allows our origination team to maintain, cultivate and grow our industry relationships while providing 
our origination team with comprehensive details on companies in the technology-related industries and their financial sponsors. 

If a prospective portfolio company generally meets certain underwriting criteria, we perform preliminary due diligence, which may include high level company and 
technology assessments, evaluation of its financial sponsors’ support, market analysis, competitive analysis, identifying key management, risk analysis and transaction size, 
pricing, return analysis and structure analysis. If the preliminary due diligence is satisfactory, and the origination team recommends moving forward, we then structure, 
negotiate and execute a non-binding term sheet with the potential portfolio company. Upon execution of a term sheet, the investment opportunity moves to the underwriting 
process to complete formal due diligence review and approval. 

Underwriting 

The underwriting review includes formal due diligence and approval of the proposed investment in the portfolio company. 

Due Diligence - Our due diligence on a prospective investment is typically completed by two or more investment professionals whom we define as the underwriting 

team. The underwriting team for a proposed investment consists of the deal sponsor who typically possesses general industry knowledge and is responsible for originating and 
managing the transaction, other investment professionals who perform due diligence, credit and corporate financial analyses and our legal professionals, as needed. To ensure 
consistent underwriting, we generally use our standardized due diligence methodologies, which include due diligence on financial performance and credit risk as well as an 
analysis of the operations and the legal and applicable regulatory framework of a prospective portfolio company. The members of the underwriting team work together to 
conduct due diligence and understand the relationships among the prospective portfolio company’s business plan, operations and financial performance. 

As part of our evaluation of a proposed investment, the underwriting team prepares an investment memorandum for presentation to the investment committee. In 

preparing the investment memorandum, the underwriting team typically interviews select key management of the company and select financial sponsors and assembles 
information necessary to the investment decision. If and when appropriate, the investment professionals may also contact industry experts and customers, vendors or, in some 
cases, competitors of the company. The underwriting team collaborates with the credit and legal teams to ensure the final credit underwriting deal structure meets our standards. 
In addition to the aforementioned members of the investment team, each deal is also assigned to a member of the credit team. The credit team is responsible for making sure 
that all material risks in the transaction are identified and mitigated to the extent possible in the investment memorandum and that the legal documentation properly reflects the 
transaction as approved by the investment committee.

Approval Process - The sponsoring managing director or principal presents the investment memorandum to our investment committee for consideration. The approval 

of a majority of our investment committee is required before we proceed with any investment. The investment committee members include our Chief Executive Officer and 
Chief Investment Officer, Chief Financial Officer, Chief Credit Officer, and Senior Managing Director of Risk Management. The investment committee meets on an as-needed 
basis. 

Documentation 

Our legal department administers the documentation process for our investments. This department is responsible for documenting the transactions approved by our 

investment committee with a prospective portfolio company. This department negotiates loan documentation and, subject to appropriate approvals, final documents are 
prepared for execution by all parties. The legal department generally uses the services of external law firms to complete the necessary documentation. 

11

  
 
Loan and Compliance Administration 

Our investment committee, supported by our investment team, credit team, and finance department, administers loans and tracks covenant compliance, if applicable, of 
our investments and oversees periodic reviews of our critical functions to ensure adherence with our internal policies and procedures. After the funding of a loan in accordance 
with the investment committee’s approval, the loan is recorded in our loan administration software and our proprietary database. The investment team, credit team, and finance 
department are responsible for ensuring timely interest and principal payments and collateral management as well as advising the investment committee on the financial 
performance and trends of each portfolio company, including any covenant violations that occur, to aid us in assessing the appropriate course of action for each portfolio 
company and evaluating overall portfolio quality. In addition, the investment team and credit team advise the investment committee and the Audit Committee of our Board, 
accordingly, regarding the credit and investment grading for each portfolio company as well as changes in the value of collateral that may occur. 

The investment team and credit team monitor our portfolio companies in order to determine whether the companies are meeting our financing criteria and their 
respective business plans and also monitors the financial trends of each portfolio company from its monthly or quarterly financial statements to assess the appropriate course of 
action for each company and to evaluate overall portfolio quality. In addition, our management team closely monitors the status and performance of each individual company 
through our proprietary database and periodic contact with our portfolio companies’ management teams and their respective financial sponsors. 

Credit and Investment Grading System. Our investment and credit teams use an investment grading system to characterize and monitor our outstanding loans. They 

monitor and when appropriate, recommend changes to investment grading. Our investment committee reviews and approves the recommendations and/or changes to the 
investment grading. These approved investment gradings are provided on a quarterly basis to the Audit Committee and our Board, along with valuations for our investments 
which are submitted for approval. 

From time to time, we will identify investments that require closer monitoring or become workout assets. We develop a workout strategy for workout assets and our 

investment committee monitors the progress against the strategy. We may incur losses from our investing activities; however, we work with our troubled portfolio companies to 
recover as much of our investments as is practicable, including possibly taking control of the portfolio company. There can be no assurance that principal will be recovered.

We use the following investment grading system approved by our Board:

Grade 1

Loans involve the least amount of risk in our portfolio. The borrower is performing above expectations, and the trends and risk profile is generally favorable. 

Grade 2

The borrower is performing as expected and the risk profile is neutral to favorable. All new loans are initially graded 2. 

Grade 3

Grade 4

The borrower may be performing below expectations, and the loan’s risk has increased materially since origination. We typically increase procedures to 
monitor a borrower when it is determined that credit risk has increased meaningfully since origination, such as, when the borrower is approaching a low 
liquidity point and an expected capital raise event is not imminent, when an expected milestone has slipped or failed, when performance or new business is 
materially below our plan, or if the estimated fair value of the enterprise is materially lower than it was when the loan was originated.

The borrower is performing materially below expectations, and the loan risk has substantially increased since origination with the prospect of raising 
additional capital significantly in question. Loans graded 4 may experience some partial loss or full return of principal but are expected to realize some loss of 
interest which is not anticipated to be repaid in full, which, to the extent not already reflected, may require the fair value of the loan to be reduced to the 
amount we anticipate will be recovered. Grade 4 investments are closely monitored. 

Grade 5

The borrower is in workout, materially performing below expectations and a significant risk of principal loss is probable. Loans graded 5 will experience 
some partial principal loss or full loss of remaining principal outstanding is expected. Grade 5 loans will require the fair value of the loans be reduced to the 
amount, if any, we anticipate will be recovered. 

As of December 31, 2021, our investment portfolio had a weighted average investment grading of 2.10. 

12

  
 
Managerial Assistance 

As a BDC we are generally required to offer and provide, upon request, significant managerial assistance to our portfolio companies. This assistance could involve 

monitoring the operations of our portfolio companies, participating in board and management meetings, consulting with and advising officers of portfolio companies and 
providing other organizational and financial guidance, among other things. We may, from time to time, receive fees for these services. In the event that such fees are received, 
they are incorporated into our operating income and are passed through to our stockholders, given the nature of our structure as an internally managed BDC. See “—Regulation
—Significant Managerial Assistance” for additional information.

COMPETITION 

Our primary competitors provide financing to prospective portfolio companies and include non-bank financial institutions, federally or state-chartered banks, venture 

debt funds, financial institutions, venture capital funds, private equity funds, investment funds and investment banks. Many of these entities have greater financial and 
managerial resources than we have, and the 1940 Act imposes certain regulatory restrictions on us as a BDC to which many of our competitors are not subject. However, we 
believe that few of our competitors possess the expertise to properly structure and price debt investments to venture capital-backed and institutional capital-backed companies 
in technology-related industries. We believe that our specialization in financing technology-related companies will enable us to determine a range of potential values of 
intellectual property assets, evaluate the business prospects and operating characteristics of prospective portfolio companies and, as a result, identify investment opportunities 
that produce attractive risk-adjusted returns. For additional information concerning the competitive risks we face, see “Item 1A. Risk Factors—Risks Related to our Business 
Structure—We operate in a highly competitive market for investment opportunities, and we may not be able to compete effectively.” 

HUMAN CAPITAL DISCLOSURES 

As an internally managed BDC, we believe that one of the strengths and principal reasons for the long-term success of our company is the quality and dedication of our 

people. As of December 31, 2021, our team comprises over 90 professionals across our 8 offices globally.  Within our team, 53 team members are experienced investment 
professionals who have on an average more than 10 years of experience in venture capital, structured finance, origination of debt and equity investments, commercial lending 
and acquisition finance with technology and biomedical companies, as well as our executive officers and treasury, finance, risk management, administrative support, IT and 
human resources professionals. We leverage the experience and relationships of our management team to successfully identify attractive investment opportunities, underwrite 
prospective portfolio companies and structure customized financing solutions. From inception to December 31, 2021, our team has originated structured debt, debt with 
warrants and equity investments in over 500 companies, representing more than $13.0 billion in commitments. Our investment team leverages established contacts with leading 
venture capital and private equity fund sponsors, public and private companies, research institutions and other industry participants, to identify and source our investments. We 
believe that leveraging the relationships that our investment teams have established will enable us to continue to identify and attract well-positioned prospective portfolio 
companies. 

Talent Acquisition and Retention 

Our goal is to ensure that we have the right blend of talent supporting our business. We seek to accomplish this goal through our commitment to attracting, developing, 

and retaining our high quality team. The process by which we attract, recruit and select new members to join our team is strategic and purposeful to ensure our business and 
culture continue to thrive. As part of our commitment to recruit, develop talent, and provide mentorship, we offer an internship program that invites high quality college 
students from a diverse pool of institutions to learn our business and contribute to our work as temporary employees for a period of approximately six months. These 
internships are expected to lead to permanent roles for high performing and high potential interns. Additionally, we aim to recruit a diverse group of interns and analysts, 
representing different ethnic and cultural backgrounds, by partnering with organizations that help us achieve that goal and that encourage diverse candidates to explore financial 
services as a career.

 As strategic needs are identified, we contract with employment agencies to hire new members. Through our internship program, individuals who want to join the 

investment team have the opportunity to see the full investment process from due diligence to closing, as well as ongoing portfolio management activities.  Additionally, from 
time to time, we may contract with independent contractors on a temporary basis. 

 The retention of our personnel is important to the management of our business. The departure of key management personnel could adversely affect our business and 

cause us to lose current and potential investment opportunities. We believe that compensation 

13

  
  
  
 
and benefits are a key part of retaining personnel. As such, we offer a competitive, equitable, compensation and benefits structure that we believe is attractive to our current and 
prospective professionals relative to their local markets and industry. Our compensation strategy includes, for certain professionals, equity incentive plans, which we have 
structured to further align the interests of our professionals with our stockholders, and to cultivate a strong sense of ownership and commitment to our Company. As part of our 
commitment to developing our team and to foster a culture of learning, we provide many training opportunities for our employees to continue to build their skills and increase 
their effectiveness as members of a team, including offering a variety of external and internal classes and training sessions as well as hands-on learning and one-on-one 
mentorship. Through our annual goal setting and performance review processes, our employees are annually evaluated by managers and our senior management team to ensure 
employees continue to develop and advance as expected. As we hire and develop individuals, we also take succession planning into account and have succession plans in place 
for each of our named executive officers.

The pandemic has presented new challenges with respect to employee engagement and well-being, both of which are fundamental to the success of our business. The 

safety of our employees, clients, customers, and vendors remains at the forefront of our decisions regarding when it is safe for employees to return to work in the office. 
Accordingly, we have allowed employees to work from home in regions where doing so is recommended by local guidance. Following local and CDC guidance, we have made 
our offices accessible to those who prefer to work in the office, with restrictions and safety protocols in place. Throughout this time, we have made continuous efforts to support 
our employees with increased dialogue with managers, colleagues and leaders, flexibility to address different working environments and schedules, information regarding stress 
management and physical and mental health, and virtual engagements. Our Employee Assistance Program provides additional, ongoing support and information for our 
employees and their families.

Our Culture 

We are committed to fostering a workplace conducive to the open communication of any concerns regarding unethical, fraudulent or illegal activities. We seek to 

promote a safe environment that is free of harassment or bullying. We do not tolerate discrimination or harassment of any kind, including, but not limited to, sexual, gender 
identity, race, religion, ethnicity, age, or disability, among others. We seek feedback from employees on matters related to their employment or our operations including its 
financial statement disclosures, accounting, internal accounting controls or auditing matters. Under our Whistleblower Policy, each director, officer, regular full-time, part-time 
and temporary employee of the Company has the ability to confidentially report: any questionable or improper accounting, internal controls, auditing matters, disclosure, or 
fraudulent business practices or other illegal or unethical behavior. We seek to protect the confidentiality of those making reports of possible misconduct and our Whistleblower 
Policy prohibits retaliation against those who report activities believed in good faith to be a violation of any law, rule, regulation or internal policy. 

 Our Code of Business Conduct and Ethics establishes applicable policies, guidelines, and procedures that promote ethical practices and conduct by the Company and 

all its employees, officers, and directors. Upon joining and annually, all employs receive compliance training. Our Whistleblower Policy and Code of Business Conduct and 
Ethics Policy can be found on our website at investor.htgc.com/corporate-governance/governance-documents.

Diversity, Equity, and Inclusion 

At Hercules, we feel strongly that building a diverse and inclusive team is an important priority. We aim to attract, motivate, and retain a diverse group of individuals 

and to create an inclusive community where all individuals are welcomed, valued, respected, and heard. We are proud that our workforce consists of diverse professionals 
including over 60% that are women or people of diverse ethnic backgrounds. Over 50% of our senior leaders, which includes our managing directors on the investment team 
and senior executives are women or people of diverse ethnic backgrounds. We strive to continue to create a welcoming and inclusive work environment for our employees. 

Philanthropy 

Hercules encourages and supports our employees to be active participants in our local communities.  As a Company, we support local non-profit organizations by 

hosting annual fundraising, food, and toy drives.  In addition to our Company sponsored philanthropic initiatives, we also provide employees with paid days off to volunteer at 
organizations of their choice. Hercules supports a variety of non-profit organizations through corporate sponsorship and donations.  In addition, we support our employees and 
the causes that are most important to them through our Charitable Donation Matching program, in which we match donations our employees make to qualified 501(c)(3) non-
profits (subject to maximum limits per employee).   

For more information on our approach to social, governance, and environmental topics, please refer to our Environmental, Social and Governance Policy (“ESG 

Policy”), which can be found on our website at investor.htgc.com/esg.

14

  
  
  
  
  
 
REGULATION 

We have elected to be regulated as a BDC under the 1940 Act. The following discussion is a general summary of the material prohibitions and descriptions governing 

BDCs. It does not purport to be a complete description of all of the laws and regulations affecting BDCs. 

Regulation as a Business Development Company

A BDC primarily focuses on investing in or lending to private companies and making significant managerial assistance available to them, while providing its 
stockholders with the ability to retain the liquidity of a publicly traded stock. The 1940 Act contains prohibitions and restrictions relating to transactions between BDCs and 
their directors and officers and principal underwriters and certain other related persons and requires that a majority of the directors be persons other than “interested persons,” as 
that term is defined in the 1940 Act. In addition, the 1940 Act provides that we may not change the nature of our business so as to cease to be, or to withdraw our election as, a 
BDC unless approved by a majority of our outstanding voting securities as defined in the 1940 Act. A majority of the outstanding voting securities of a company is defined 
under the 1940 Act as the lesser of: (i) 67% or more of such company’s shares present at a meeting if more than 50% of the outstanding shares of such company are present or 
represented by proxy, or (ii) more than 50% of the outstanding shares of such company. 

Qualifying Assets 

Under the 1940 Act, a BDC may not acquire any asset other than assets of the type listed in Section 55(a) of the 1940 Act, which are referred to as qualifying assets, 
unless, at the time the acquisition is made, qualifying assets represent at least 70% of the company’s total assets. The principal categories of qualifying assets relevant to our 
business are the following: 

(1)  Securities purchased in transactions not involving any public offering from the issuer of such securities, which issuer (subject to certain limited exceptions) is an 

eligible portfolio company, or from any person who is, or has been during the preceding 13 months, an affiliated person of an eligible portfolio company, or 
from any other person, subject to such rules as may be prescribed by the SEC. An eligible portfolio company is defined in the 1940 Act as any issuer which: 

(a) 

is organized under the laws of, and has its principal place of business in, the United States; 

(b) 

is not an investment company (other than a SBIC wholly owned by the BDC) or a company that would be an investment company but for certain 

exclusions under the 1940 Act; and 

(c)  does not have any class of securities listed on a national securities exchange; or if it has securities listed on a national securities exchange such company 
has a market capitalization of less than $250 million; is controlled by the BDC and has an affiliate of a BDC on its Board; or meets such other criteria 
as may be established by the SEC. 

(2)  Securities of any portfolio company which we control.

(3)  Securities purchased in a private transaction from a U.S. issuer that is not an investment company or from an affiliated person of the issuer, or in transactions 

incident thereto, if the issuer is in bankruptcy and subject to reorganization or if the issuer, immediately prior to the purchase of its securities was unable to meet 
its obligations as they came due without material assistance other than conventional lending or financing arrangements. 

(4)  Securities of an eligible portfolio company purchased from any person in a private transaction if there is no ready market for such securities and we already own 

60% of the outstanding equity of the eligible portfolio company. 

(5)  Securities received in exchange for or distributed on or with respect to securities described in (1) through (4) above, or pursuant to the exercise of warrants or 

rights relating to such securities. 

(6)  Cash, cash equivalents, U.S. Government securities or high-quality debt securities maturing in one year or less from the time of investment. 

Control, as defined by the 1940 Act, is presumed to exist where a BDC beneficially owns more than 25% of the outstanding voting securities of the portfolio company 

or has greater than 50% representation on its board. 

We do not intend to acquire securities issued by any investment company, including other BDCs, that exceed the limits imposed by the 1940 Act. Under these limits, we 

generally cannot acquire more than 3% of the voting stock of any investment company (as defined in the 1940 Act), invest more than 5% of the value of our total assets in the 
securities of one such investment company or invest more than 10% of the value of our total assets in the securities of such other investment companies in the aggregate. SEC 
rules permit us to exceed these limits, subject to certain conditions. With regard to that portion of our portfolio invested in securities issued by investment companies, it should 
be noted that such investments might subject our stockholders to additional expenses. 

15

  
 
Significant Managerial Assistance 

BDCs generally must offer to make available to the issuer of the securities significant managerial assistance, except in circumstances where either (i) the BDC controls 
such issuer of securities or (ii) the BDC purchases such securities in conjunction with one or more other persons acting together and one of the other persons in the group makes 
available such managerial assistance. Making available significant managerial assistance means, among other things, any arrangement whereby the BDC, through its directors, 
officers or employees, offers to provide and, if accepted, does so provide, significant guidance and counsel concerning the management, operations or business objectives and 
policies of a portfolio company through monitoring of portfolio company operations, selective participation in board and management meetings, consulting with and advising a 
portfolio company’s officers or other organizational or financial guidance. 

Temporary Investments 

Pending investment in other types of qualifying assets, as described above, our investments may consist of cash, cash equivalents, U.S. government securities or high-

quality debt securities maturing in one year or less from the time of investment, which we refer to, collectively, as temporary investments, so that 70% of our assets are 
qualifying assets. We may invest in U.S. Treasury bills or in repurchase agreements, provided that such agreements are fully collateralized by cash or securities issued by the 
U.S. government or its agencies. A repurchase agreement involves the purchase by an investor, such as us, of a specified security and the simultaneous agreement by the seller 
to repurchase it at an agreed upon future date and at a price which is greater than the purchase price by an amount that reflects an agreed-upon interest rate. There is no 
percentage restriction on the proportion of our assets that may be invested in such repurchase agreements. However, if more than 25% of our total assets constitute repurchase 
agreements from a single counterparty, we generally would not meet the diversification tests imposed on us by the Code in order to qualify as a RIC for federal income tax 
purposes. Thus, we do not intend to enter into repurchase agreements with a single counterparty in excess of this limit. We will monitor the creditworthiness of the 
counterparties with which we enter into repurchase agreement transactions. 

Warrants, Options, and Restricted Stock

Under the 1940 Act, a BDC is subject to restrictions on the amount of warrants, options, restricted stock or rights to purchase shares of capital stock that it may have 

outstanding at any time. In particular, the amount of capital stock that would result from the conversion or exercise of all outstanding warrants, options or other rights to 
purchase or convert into capital stock cannot exceed 25% of the BDC’s total outstanding shares of capital stock. This amount is reduced to 20% of the BDC’s total outstanding 
shares of capital stock if the amount of warrants, options or rights issued pursuant to an executive compensation plan would exceed 15% of the BDC’s total outstanding shares 
of capital stock. We have received exemptive relief from the SEC permitting us to issue stock options and restricted stock to our employees and directors subject to the above 
conditions, among others. For a discussion regarding the conditions of this exemptive relief, see “—No-action and Exemptive Relief” below and "Note 8 - Equity Incentive 
Plans" to our consolidated financial statements. 

Reduced Asset Coverage Requirements

In accordance with the Small Business Credit Availability Act ("SBCAA"), our Board and stockholders approved the reduction of our minimum asset coverage ratio 

applicable under Section 61(a)(2) of the 1940 Act on September 4, 2018 and December 6, 2018, respectively. As a result, effective December 7, 2018, the minimum asset 
coverage ratio under the 1940 Act applicable to us decreased from 200% to 150%, permitting us to incur additional leverage.

Senior Securities; Coverage Ratio 

We will be permitted, under specified conditions, to issue multiple classes of indebtedness and one class of stock senior to our common stock if our asset coverage, as 
defined in the 1940 Act, is at least equal to 150% immediately after each such issuance. In addition, we may not be permitted to declare any cash dividend distribution on our 
outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 150% after deducting the 
amount of such distribution or purchase price. On April 5, 2007, we received approval from the SEC on our request for exemptive relief that permits us to exclude the 
indebtedness of our wholly owned subsidiaries that are SBICs from the 150% asset coverage requirement applicable to us. We may also borrow amounts up to 5% of the value 
of our total assets for temporary or emergency purposes. For a discussion of the risks associated with the resulting leverage, see “Item 1A. Risk Factors—Risks Related to Our 
Business Structure—Because we have substantial indebtedness, there could be increased risk in investing in our company.”

16

  
 
Capital Structure 

Subject to limited exceptions, we are not generally able to issue and sell our common stock at a price per share below NAV. We may, however, sell our common stock, 

or warrants, options or other rights to acquire such common stock, at a price below the current NAV if our Board determines that such sale is in the best interests of our 
stockholders and if stockholders, including a majority of those stockholders that are not affiliated with us, approve of such sale.

In any such case, the price at which our securities are to be issued and sold may not be less than a price that, in the determination of the Board, closely approximates the 

market value of such securities (less any distribution commission or discount). We do not currently have authorization from our stockholders to issue common stock at a price 
below its then current NAV per share. 

Other 1940 Act Regulations

As a closed-end investment company that has elected to be regulated as a BDC under the 1940 Act, we are periodically examined by, and required to submit 
information to, the SEC for compliance with the Exchange Act and the 1940 Act. We are also prohibited under the 1940 Act from knowingly participating in certain 
transactions with our affiliates without the prior approval of our Board who are not interested persons and, in some cases, prior approval by the SEC. We are required by the 
1940 Act to provide and maintain a bond issued by a reputable fidelity insurance company to protect us against larceny and embezzlement. Furthermore, as a BDC, we are 
prohibited from protecting any director or officer against any liability to our stockholders arising from willful misfeasance, bad faith, gross negligence or reckless disregard of 
the duties involved in the conduct of such person’s office. We are also required to adopt and implement written policies and procedures reasonably designed to prevent violation 
of the federal securities laws, review these policies and procedures annually for their adequacy and the effectiveness of their implementation. Our Chief Compliance Officer is 
responsible for administering these policies and procedures.

Code of Ethics 

We have adopted and will maintain a code of ethics that establishes procedures for personal investments and restricts certain personal securities transactions. Personnel 

subject to the code may invest in securities for their personal investment accounts, including securities that may be purchased or held by us, so long as such investments are 
made in accordance with the code’s requirements. We may be prohibited under the 1940 Act from conducting certain transactions with our affiliates without the prior approval 
of our directors who are not interested persons and, in some cases, the prior approval of the SEC. 

Our current code of ethics is posted on our website at investor.htgc.com/corporate-governance/governance.documents. In addition, the code of ethics is available on the 
EDGAR Database on the SEC’s Internet site at http://www.sec.gov. You may also obtain copies of the code of ethics, after paying a duplicating fee, by electronic request at the 
following e-mail address: publicinfo@sec.gov. 

Privacy Principles 

We are committed to maintaining the privacy of our stockholders and safeguarding their non-public personal information. The following information is provided to help 

you understand what personal information we collect, how we protect that information and why, in certain cases, we may share information with select other parties. 

Generally, we do not receive any non-public personal information relating to our stockholders, although certain non-public personal information of our stockholders 

may become available to us. We do not disclose any non-public personal information about our stockholders or former stockholders, except as permitted by law or as is 
necessary in order to service stockholder accounts (for example, to a transfer agent). 

We restrict access to non-public personal information about our stockholders to our employees with a legitimate business need for the information. We maintain 

physical, electronic and procedural safeguards designed to protect the non-public personal information of our stockholders. 

Proxy Voting Policies and Procedures 

We vote proxies relating to our portfolio securities in the best interest of our stockholders. Our proxy voting decisions are made by members of the Company's 
investment team, who review on a case-by-case basis each proposal submitted to a stockholder vote to determine its impact on the portfolio securities held by us. Although we 
generally vote against proposals that may have a negative impact on our portfolio securities, we may vote for such a proposal if there exists compelling long-term reasons to do 
so. We generally 

17

  
 
do not believe it is necessary to engage the services of an independent third party to assist in issue analysis and vote recommendation for proxy proposals. 

To ensure that our vote is not the product of a conflict of interest, we require that: (i) anyone involved in the decision making process disclose to our Chief Compliance 

Officer any potential conflict that he or she is aware of and any contact that he or she has had with any interested party regarding a proxy vote; and (ii) employees involved in 
the decision making process or vote administration are prohibited from revealing how we intend to vote on a proposal in order to reduce any attempted influence from 
interested parties.

Small Business Administration Regulations 

We make investments in qualifying small businesses through wholly owned SBIC subsidiaries. SBICs are designed to stimulate the flow of private equity capital to 
eligible small businesses. Under present SBA regulations, eligible small businesses include businesses that have a tangible net worth not exceeding $19.5 million and have 
average annual fully taxed net income not exceeding $6.5 million for the two most recent fiscal years. In addition, SBICs must devote 25.0% of its investment activity to 
“smaller” enterprises as defined by the SBA. A smaller enterprise is one that has a tangible net worth not exceeding $6.0 million and has average annual fully taxed net income 
not exceeding $2.0 million for the two most recent fiscal years. SBA regulations also provide alternative size standard criteria to determine eligibility, which depend on the 
industry in which the business is engaged and are based on such factors as the number of employees and gross sales. According to SBA regulations, SBICs may make long-
term loans to small businesses, invest in the equity securities of such businesses and provide them with consulting and advisory services. 

Each SBIC subsidiary is subject to regulation and oversight by the SBA, including requirements with respect to maintaining certain minimum financial ratios and other 

covenants. As part of the SBA's oversight, each SBIC is periodically examined and audited by the SBA’s staff to determine their compliance with SBA regulations. If any of 
our SBICs fails to comply with applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit our SBICs' use of debentures, declare 
outstanding debentures immediately due and payable, and/or limit our SBICs from making new investments. In addition, our SBICs may also be limited in their ability to make 
distributions to us if they do not have sufficient capital in accordance with SBA regulations. Such actions by the SBA would, in turn, negatively impact us because our SBICs 
are wholly owned subsidiaries. Further, the SBA restricts the ability of SBICs to repurchase their capital stock. SBA regulations also include restrictions on a “change of 
control” or transfer of an SBIC and require that SBICs invest idle funds in accordance with SBA regulations.  As of December 31, 2021, as a result of having sufficient capital 
as defined under the SBA regulations, our SBICs were in compliance with the terms of the SBA’s leverage requirements.  

 The receipt of an SBIC license does not assure that a SBIC will receive SBA guaranteed debenture funding, which is dependent upon our SBICs continuing to be in 

compliance with SBA regulations and policies. The SBA, as a creditor, will have a superior claim to our SBICs’ assets over our stockholders in the event we liquidate our 
SBICs or the SBA exercises its remedies under the SBA-guaranteed debentures issued by our SBICs upon an event of default.

Compliance with the Securities Exchange Act of 1934 and Sarbanes-Oxley Act

We are subject to the reporting and disclosure requirements of the Exchange Act, including the filing of quarterly, annual and current reports, proxy statements and 

other required items. In addition, we are subject to the Sarbanes-Oxley Act of 2002, which imposes a wide variety of regulatory requirements on publicly-held companies and 
their insiders. For example:
•

pursuant to Rule 13a-14 of the Exchange Act, our Chief Executive Officer and Chief Financial Officer are required to certify the accuracy of the 
consolidated financial statements contained in our periodic reports;
pursuant to Item 307 of Regulation S-K, our periodic reports are required to disclose our conclusions about the effectiveness of our disclosure controls and 
procedures;
pursuant to Rule 13a-15 of the Exchange Act, our management is required to prepare a report regarding its assessment of our internal control over financial 
reporting, which must be audited by our independent registered public accounting firm;
pursuant to Item 308 of Regulation S-K and Rule 13a-15 of the Exchange Act, our periodic reports must disclose whether there were significant changes in 
our internal control over financial reporting or in other factors that could significantly affect these controls subsequent to the date of their evaluation, 
including any corrective actions with regard to significant deficiencies and material weaknesses.

•

•

•

18

 
 
  
 
The Sarbanes-Oxley Act requires us to review our policies and procedures to determine whether we comply with the Sarbanes-Oxley Act and the regulations 

promulgated thereunder. We will continue to monitor our compliance with all future regulations that are adopted under the Sarbanes-Oxley Act and will take actions necessary 
to ensure that we are in compliance therewith.

Compliance with The New York Stock Exchange (NYSE) Corporate Governance Regulations

Our common stock is listed on the NYSE under the symbol “HTGC”. As a listed company on the NYSE, we are subject to various listing standards including corporate 

governance listing standards. We believe we are in compliance with such corporate governance listing standards. We intend to monitor our compliance with all future listing 
standards and to take all necessary actions to ensure that we stay in compliance.

Brokerage Allocations and Other Practices

Because we generally acquire and dispose of our investments in privately negotiated transactions, we typically do not use brokers in the normal course of business. 
However, from time to time, we may work with brokers to sell positions we have acquired in the securities of publicly listed companies or to acquire positions (principally 
equity) in companies where we see a market opportunity to acquire such securities at attractive valuations. In cases where we do use a broker, we do not execute transactions 
through any particular broker or dealer, but will seek to obtain the best net results for the Company, taking into account such factors as price (including the applicable brokerage 
commission or dealer spread), size of order, difficulty of execution, and operational facilities of the firm and the firm’s risk and skill in positioning blocks of securities. While 
we generally seek reasonably competitive execution costs, we may not necessarily pay the lowest spread or commission available. Subject to applicable legal requirements, we 
may select a broker based partly upon brokerage or research services provided to us. In return for such services, we may pay a higher commission than other brokers would 
charge if we determine in good faith that such commission is reasonable in relation to the services provided. 

No-action and Exemptive Relief Obtained

On May 11, 2020, we received no-action relief from the SEC staff that allowed us to form the Adviser Subsidiary as a registered investment adviser under the Advisers 

Act. Separately, for information regarding our SEC exemptive relief obtained, please see the section entitled “Regulation – Exemptive Relief Obtained” in our Annual Report 
on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 20, 2020 (the “2019 10-K”), which is incorporated by reference. 

Investment Adviser Regulation

The Adviser Subsidiary, which is wholly owned by us, is subject to regulation under the Advisers Act. The Advisers Act establishes, among other things, recordkeeping 

and reporting requirements, disclosure requirements, limitations on transactions between the adviser's account and an advisory client's account, limitations on transactions 
between the accounts of advisory clients, and general anti-fraud prohibitions. The Adviser Subsidiary may be examined by the SEC from time to time for compliance with the 
Advisers Act.

19

 
 
 
 
 
 
 
 
  
 
CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

The following discussion is a general summary of certain material U.S. federal income tax considerations relating to our qualification and taxation as a RIC and the 
acquisition, ownership and disposition of our preferred stock or common stock, but does not purport to be a complete description of the income tax considerations relating 
thereto. Except as otherwise noted, this discussion assumes you are a taxable U.S. person (as defined for U.S. federal income tax purposes) and that you hold your shares of our 
stock as capital assets for U.S. federal income tax purposes (generally, assets held for investment). This discussion is based upon current provisions of the Code, the regulations 
promulgated thereunder and judicial and administrative authorities, all of which are subject to change or differing interpretations by the courts or the Internal Revenue Service 
(the “IRS”), possibly with retroactive effect. No attempt is made to present a detailed explanation of all U.S. federal income tax concerns affecting us and our stockholders 
(including stockholders subject to special rules under U.S. federal income tax law).

The discussions set forth herein do not constitute tax advice. We have not sought and will not seek any ruling from the IRS regarding any matters discussed herein. No 
assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to those set forth below. This summary does not discuss any aspects 
of foreign, state or local tax. Prospective investors must consult their own tax advisers as to the U.S. federal income tax consequences (including the alternative minimum tax 
consequences) of acquiring, holding and disposing of shares of our stock, as well as the effects of state, local, and non-U.S. tax laws.

Election to be Subject to Tax as a RIC

Through December 31, 2005, we were subject to U.S. federal income tax as an ordinary corporation under Subchapter C of the Code. Effective beginning on January 1, 

2006, we met the criteria specified below to qualify as a RIC and elected to be treated as a RIC under Subchapter M of the Code with the filing of our U.S. federal income tax 
return for 2006. To qualify for treatment as a RIC we must, among other things, meet certain source of income and asset diversification requirements (as described below). In 
addition, we must distribute to our stockholders, in respect of each taxable year, dividends for federal income tax purposes of an amount generally at least equal to 90% of our 
“investment company taxable income,” which is generally equal to the sum of our net ordinary income plus the excess of our realized net short-term capital gains over our 
realized net long-term capital losses, determined without regard to any deduction for distributions paid (the “Annual Distribution Requirement”). Upon satisfying these 
requirements in respect of a taxable year, we generally will not be subject to corporate taxes on any income we distribute to our stockholders as dividends for federal income tax
purposes, which will allow us to reduce our liability for corporate-level income tax.

20

  
 
Taxation as a Regulated Investment Company

For any taxable year in which we:

•

•

qualify as a RIC; and 

distribute dividends for federal income tax purposes to our stockholders of an amount at least equal to the Annual Distribution Requirement;

We generally will not be subject to U.S. federal income tax on the portion of our investment company taxable income and net capital gain (i.e., net realized long-term 

capital gains in excess of net realized short-term capital losses) we distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes to stockholders 
with respect to that taxable year.

We made the election to recognize built-in gains as of the effective date of our election to be treated as a RIC and therefore were not subject to built-in gains tax when 
we sold those assets. However, if we subsequently acquire built-in gain assets from a C corporation in a carryover basis transaction, then we may be subject to tax on the gains 
recognized by us on dispositions of such assets unless we make a special election to pay corporate-level tax on such built-in gain at the time the assets are acquired. We will be 
subject to U.S. federal income tax at the regular corporate rates on any income or capital gains not distributed (or deemed distributed) as dividends for U.S. federal income tax 
purposes to our stockholders.

In order to qualify as a RIC for federal income tax purposes and obtain the tax benefits of RIC status, in addition to satisfying the Annual Distribution Requirement, 

we must, among other things:

•

•

•

have in effect at all times during each taxable year an election to be regulated as a BDC under the 1940 Act;

derive in each taxable year at least 90% of our gross income from (a) dividends, interest, payments with respect to certain securities loans, gains from the sale of 
stock or other securities, or other income derived with respect to our business of investing in such stock or securities and (b) net income derived from an interest 
in a “qualified publicly traded partnership”, or the 90% Income Test;

diversify our holdings so that at the end of each quarter of the taxable year:

o

o

at least 50% of the value of our assets consists of cash, cash equivalents, U.S. government securities, securities of other RICs, and other securities if 
such other securities of any one issuer do not represent more than 5% of the value of our assets or more than 10% of the outstanding voting securities of 
such issuer; and

no more than 25% of the value of our assets is invested in (i) securities (other than U.S. government securities or securities of other RICs) of one issuer, 
(ii) securities of two or more issuers that are controlled, as determined under applicable tax rules, by us and that are engaged in the same or similar or 
related trades or businesses or (iii) securities of one or more “qualified publicly traded partnerships”, or the Diversification Tests.

We may invest in partnerships which may result in our being subject to state, local, or foreign income, franchise or other tax liabilities.  In addition, some of the 
income and fees that we may recognize will not be qualifying income under the 90% Income Test.  In order to mitigate the risk that such income and fees would disqualify us as 
a RIC as a result of a failure to satisfy the 90% Income Test, we may be required to recognize such income and fees indirectly through one or more entities classified as 
corporations for U.S. federal income tax purposes. Such corporations generally will be subject to corporate income taxes on their earnings, which ultimately will reduce our 
return on such income and fees.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as 
dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of our 
ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of our capital gain net income (adjusted for certain ordinary losses) for 
the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar 
years (“Excise Tax Avoidance Requirement”). We are not subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax 
imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated 

as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The 
maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as 
dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over 
taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from 

21

  
 
our taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable 
income carried over into and distributed in the current taxable year, or returns of capital.

Under applicable Treasury regulations and other administrative guidance issued by the IRS, we are permitted to treat certain distributions payable in our stock as 

taxable distributions that will satisfy the Annual Distribution Requirement as well as the Excise Tax Avoidance Requirement provided that stockholders have the opportunity to 
elect to receive the distribution in cash. Taxable stockholders receiving such distributions will be required to include the full amount of such distributions as ordinary income 
(or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and profits for 
United States federal income tax purposes. As a result, a U.S. stockholder may be subject to tax with respect to such distributions in excess of any cash received. If a U.S. 
stockholder sells the stock it receives as a distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the 
distribution, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. tax 
with respect to such distributions, including in respect of all or a portion of such distribution that is payable in stock. In addition, if a significant number of our stockholders 
determine to sell shares of our stock in order to pay taxes owed on distributions, then such sales may put downward pressure on the trading price of our stock. We may in the 
future determine to make taxable distributions that are payable in part in our common stock.

We may be required to recognize taxable income in circumstances in which we do not receive a corresponding payment in cash. For example, if we hold debt 
obligations that are treated under applicable tax rules as having OID (such as debt instruments with PIK interest provisions or, in certain cases, increasing interest rates or debt 
instruments that were issued with warrants), we must include in income each taxable year a portion of the OID that accrues over the life of the obligation, regardless of whether 
cash representing such income is received by us in the same taxable year. Because any OID accrued is generally required to be included in our investment company taxable 
income for the taxable year of accrual, we may be required to make a distribution to our stockholders in order to satisfy the Annual Distribution Requirement and the Excise 
Tax Avoidance Requirement, even though we will not have received any corresponding cash amount.

Gain or loss realized by us from the sale or exchange of warrants acquired by us as well as any loss attributable to the lapse of such warrants generally will be treated 

as capital gain or loss. Such gain or loss generally will be long-term or short-term, depending on how long we held a particular warrant.  

We are authorized to borrow funds and to sell assets in order to satisfy the Annual Distribution Requirement and the Excise Tax Avoidance Requirement (collectively 

the “Distribution Requirements”). However, under the 1940 Act, we are not permitted to make distributions to our stockholders while our debt obligations and other senior 
securities are outstanding unless certain “asset coverage” tests are met. See “Regulation—Senior Securities; Coverage Ratio”. We may be restricted from making distributions 
under the terms of our debt obligations themselves unless certain conditions are satisfied. Moreover, our ability to dispose of assets to meet the Distribution Requirements may 
be limited by (1) the illiquid nature of our portfolio, or (2) other requirements relating to our status as a RIC, including the Diversification Tests. If we dispose of assets in order 
to meet the Distribution Requirements, we may make such dispositions at times that, from an investment standpoint, are not advantageous. If we are prohibited from making 
distributions or are unable to obtain cash from other sources to make the distributions, we may fail to be subject to tax as a RIC, which would result in us becoming subject to 
corporate-level income taxes.

In addition, we will be partially dependent on our SBICs for cash distributions to enable us to meet the RIC Distribution Requirements. Our SBIC subsidiaries may be 

limited by the Small Business Investment Act of 1958, as amended, and SBA regulations governing SBICs, from making certain distributions to us that may be necessary to 
maintain our status as a RIC. We may have to request a waiver of the SBA’s restrictions for our SBICs to make certain distributions to maintain our RIC status. We cannot 
assure you that the SBA will grant such waiver. If our SBICs are unable to obtain a waiver, compliance with the SBA regulations may cause us to fail to be subject to tax as a 
RIC, which would result in us becoming subject to corporate-level income taxes.

Certain of our investment practices are subject to special and complex U.S. federal income tax provisions that may, among other things, (i) convert distributions that 

would otherwise constitute qualified dividend income into ordinary income, (ii) treat distributions that would otherwise be eligible for deductions available to certain U.S. 
corporations under the Code as ineligible for such treatment, (iii) disallow, suspend or otherwise limit the allowance of certain losses or deductions, (iv) convert long-term 
capital gains into short-term capital gains or ordinary income, (v) convert short-term capital losses into long-term capital losses, (vi) convert an ordinary loss or deduction into a 
capital loss (the deductibility of which is more limited), (vii) cause us to recognize income or gain without a corresponding receipt of cash, (viii) adversely alter the 
characterization of certain complex financial transactions, and (ix) produce gross income that will not constitute qualifying gross income for purposes of the 90% Income Test. 
These rules also could affect the amount, timing and character of distributions to stockholders.

22

  
 
A RIC is limited in its ability to deduct expenses in excess of its “investment company taxable income.” If our otherwise deductible expenses in a given taxable year 

exceed our ordinary taxable gross income (e.g., as the result of large amounts of equity-based compensation), we would incur a net operating loss for that taxable year. 
However, a RIC is not permitted to carry back or carry forward net operating losses, respectively, to prior and subsequent taxable years, and such net operating losses do not 
pass through to the RIC’s stockholders. In addition, deductible expenses can be used only to offset investment company taxable income, not net capital gain. A RIC may not use 
any net capital losses (that is, realized capital losses in excess of realized capital gains) to offset the RIC’s investment company taxable income, but may carry forward such net 
capital losses, and generally use them to offset capital gains indefinitely. Due to these limits on the deductibility of expenses and net capital losses, we may for tax purposes 
have aggregate taxable income for several taxable years that we are required to distribute and that is taxable to our stockholders even if such taxable income is greater than the 
aggregate net income we actually earned during those taxable years. Such required distributions may be made from our cash assets or by liquidation of investments, if 
necessary. We may realize gains or losses from such liquidations. In the event we realize net capital gains from such transactions, you may receive a larger capital gain 
distribution than you would have received in the absence of such transactions.

Investment income received from sources within foreign countries, or capital gains earned by investing in securities of foreign issuers, may be subject to foreign 

income taxes withheld at the source. In this regard, withholding tax rates in countries with which the United States does not have a tax treaty are often as high as 35% or more. 
The United States has entered into tax treaties with many foreign countries that may entitle us to a reduced rate of tax or exemption from tax on this related income and gains. 
The effective rate of foreign tax cannot be determined at this time since the amount of our assets to be invested within various countries is not now known. We do not anticipate 
being eligible for the special election that allows a RIC to treat foreign income taxes paid by such RIC as having been paid by its stockholders.

If we acquire the equity securities of certain foreign corporations that earn at least 75% of their annual gross income from passive sources (such as interest, dividends, 
rents, royalties or capital gain) or hold at least 50% of their total assets in investments producing such passive income ("PFICs"), we could be subject to federal income tax and 
additional interest charges on “excess distributions” received from such companies or gain from the sale of stock in such companies, even if all income or gain actually received 
by us is timely distributed to our stockholders to the extent that such income or gain is attributable to our ownership of PFIC stock in a prior taxable year. We would not be able 
to pass through to our stockholders any credit or deduction for such a tax. Certain elections may, if available, ameliorate these adverse tax consequences, but any such election 
could require us to recognize taxable income or gain without the concurrent receipt of cash. We intend to limit and/or manage our holdings in PFICs to minimize our liability 
for any such taxes and related interest charges.

If we hold greater than 10% of the interests treated as equity for U.S. federal income tax purposes in a foreign corporation that is treated as a controlled foreign 
corporation ("CFC"), we may be treated as receiving a deemed distribution (taxable as ordinary income) each taxable year from such foreign corporation in an amount equal to 
our pro rata share of the corporation’s income for such taxable year (including both ordinary earnings and capital gains), whether or not the corporation makes an actual 
distribution during such taxable year. We would be required to include the amount of a deemed distribution from a CFC when computing our investment company taxable 
income as well as in determining whether we satisfy the distribution requirements applicable to RICs, even to the extent the amount of our income deemed recognized from the 
CFC exceeds the amount of any actual distributions from the CFC and our proceeds from any sales or other dispositions of CFC stock during a taxable year.  In general, a 
foreign corporation will be considered a CFC if greater than 50% of the shares of the corporation, measured by reference to combined voting power or value, is owned (directly, 
indirectly or by attribution) by U.S. Stockholders. A “U.S. Stockholder,” for this purpose, is any U.S. person that possesses (actually or constructively) 10% or more of the 
combined voting power or value of all classes of shares of a foreign corporation. Income derived by us from a CFC would generally constitute qualifying income for purposes 
of determining our ability to be subject to tax as a RIC if the CFC makes distributions of that income to us in the same year of the CFC in which we are treated as having 
received a deemed distribution of such income or if the income is derived with respect to our business of investing in stocks and securities. As such, we may limit and/or 
manage our holdings in issuers that could be treated as CFCs in order to limit our tax liability or maximize our after-tax return from these investments.

Our functional currency, for U.S. federal income tax purposes, is the U.S. dollar. Under the Code, foreign exchange gains and losses realized by us in connection with 
certain transactions involving foreign currencies, or payables or receivables denominated in a foreign currency, as well as certain non-U.S. dollar denominated debt securities, 
certain foreign currency futures contracts, foreign currency option contracts, foreign currency forward contracts, and similar financial instruments are subject to Code 
provisions that generally treat such gains and losses as ordinary income and losses and may affect the amount, timing and character of distributions to our stockholders. Any 
such transactions that are not directly related to our investment in securities (possibly including speculative currency positions or currency derivatives not used for hedging 
purposes) also could, under future Treasury regulations, produce income not among the types of “qualifying income” from which a RIC must derive at least 90% of its annual 
gross income.

23

 
  
 
Failure to Qualify as a Regulated Investment Company

If we fail to satisfy the 90% Income Test or the Diversification Tests for any taxable year, we may nevertheless continue to qualify as a RIC for such taxable year if 

certain relief provisions are applicable (which may, among other things, require us to pay certain corporate-level federal taxes or to dispose of certain assets).

If we were unable to qualify for treatment as a RIC and the foregoing relief provisions are not applicable, we would be subject to tax on all of our taxable income at 

regular corporate rates. We would not be able to deduct distributions to stockholders, nor would they be required to be made. Such distributions would be taxable to our 
stockholders and provided certain holding period and other requirements were met, could qualify for treatment as “qualified dividend income” eligible for the 20% maximum 
U.S. federal income tax rate if earned by certain U.S. resident non-corporate stockholders to the extent of our current and accumulated earnings and profits. Subject to certain 
limitations under the Code, corporate distributions generally would be eligible for the dividends-received deduction with respect to distributions current and accumulated 
earnings and profits if earned by certain U.S. resident corporate stockholders. Distributions in excess of our current and accumulated earnings and profits would be treated first 
as a return of capital to the extent of the stockholder’s tax basis, and any remaining distributions would be treated as a capital gain. To requalify as a RIC in a subsequent 
taxable year, we would be required to satisfy the RIC qualification requirements for that taxable year and dispose of any earnings and profits from any taxable year in which we 
failed to qualify as a RIC. Subject to a limited exception applicable to a corporation that qualified as a RIC under Subchapter M of the Code for at least one taxable year prior to 
disqualification and that requalify as a RIC no later than the second taxable year following the nonqualifying taxable year, we also could be subject to tax on any unrealized net 
built-in gains in the assets held by us during the period in which we failed to qualify as a RIC that are recognized within the subsequent five taxable years, unless we made a 
special election to incur a corporate-level income tax on such built-in gain at the time of our requalification as a RIC.

DETERMINATION OF NET ASSET VALUE

We determine the NAV per share of our common stock quarterly. The NAV per share is equal to the value of our total assets minus liabilities and any preferred stock 

outstanding divided by the total number of shares of common stock outstanding. As of the date of this report, we do not have any preferred stock outstanding. 

As of December 31, 2021, approximately 93.6% of our total assets represented investments in portfolio companies whose fair value is determined in good faith by the 

Board. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other 
securities and assets, fair value is as determined in good faith by the Board. Our investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and 
measured in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. Our debt securities are primarily invested in venture capital-backed and institutional-
backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and 
renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of our investments in these portfolio companies are 
considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As 
such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy by our Board in accordance with the 
provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, 
the fair value of our investments determined in good faith by our Board may differ significantly from the value that would have been used had a readily available market existed 
for such investments, and the differences could be material. 

We intend to continue to engage one or more independent valuation firm(s) to provide us with assistance regarding our determination of the fair value of selected 

portfolio investments each quarter unless directed by the Board to cancel such valuation services. Specifically, on a quarterly basis, we will identify portfolio investments with 
respect to which an independent valuation firm will assist in valuing. We select these portfolio investments based on a number of factors, including, but not limited to, the 
potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The 
scope of the services rendered by an independent valuation firm is at the discretion of the Board. Our Board is ultimately, and solely, responsible for determining the fair value 
of our investments in good faith.

See “Note 2 – Summary of Significant Accounting Policies” in the notes to the consolidated financial statements for a detailed discussion of our investment portfolio 

valuation process and procedures.

24

  
 
Determinations in Connection with Offerings 

In connection with each offering of shares of our common stock, the Board or a committee thereof is required to make the determination that we are not selling shares 
of our common stock at a price below our then current NAV at the time at which the sale is made, unless it is determined by the Board that such sale is in the best interests of 
our stockholders. The Board considers the following factors, among others, in making such determination: 

•

•

•

the NAV of our common stock disclosed in the most recent periodic report we filed with the SEC; 

our management’s assessment of whether any material change in the NAV has occurred (including through the realization of net gains on the sale of our 
portfolio investments) from the period beginning on the date of the most recently disclosed NAV to the period ending two days prior to the date of the sale of 
our common stock; and 

the magnitude of the difference between (i) a value that our Board or an authorized committee thereof has determined reflects the current NAV of our common 
stock, which is generally based upon the NAV of our common stock disclosed in the most recent periodic report that we filed with the SEC, as adjusted to 
reflect our management’s assessment of any material change in the NAV of our common stock since the date of the most recently disclosed NAV of our 
common stock, and (ii) the offering price of the shares of our common stock in the proposed offering. 

Importantly, this determination does not require that we calculate NAV in connection with each offering of shares of our common stock, but instead it involves the 
determination by the Board or a committee thereof that we are not selling shares of our common stock at a price below the then current NAV at the time at which the sale is 
made. 

Moreover, to the extent that there is a possibility that we may (i) issue shares of our common stock at a price below the then current NAV of our common stock at the 
time at which the sale is made or (ii) trigger the undertaking (which we will provide to the SEC in a registration statement to which a prospectus will be a part) to suspend the 
offering of shares of our common stock pursuant to a prospectus if the NAV fluctuates by certain amounts in certain circumstances until such prospectus is amended, the Board 
or a committee thereof will elect, in the case of clause (i) above, either to postpone the offering until such time that there is no longer the possibility of the occurrence of such, 
events or to undertake to determine NAV within two days prior to any such sale to ensure that such sale will not be below our then current NAV, and, in the case of clause (ii) 
above, to comply with such undertaking or to undertake to determine NAV to ensure that such undertaking has not been triggered. 

These processes and procedures are part of our compliance policies and procedures. Records will be made contemporaneously with all determinations described in this 

section and these records will be maintained with other records we are required to maintain under the 1940 Act.

Summary Risk Factors

The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should 

carefully consider these risk factors, together with the risk factors set forth in Item 1A. of this Annual Report on Form 10-K and other reports and documents filed by us with 
the SEC.

Risks Related to our Business Structure 

•
•
•
•
•

•
•

•

As an internally managed BDC, we are subject to certain restrictions that may adversely affect our business. 
We operate in a highly competitive market for investment opportunities, and we may not be able to compete effectively. 
Because we have substantial indebtedness, there could be increased risk in investing in our company. 
Regulations governing our operations as a BDC may affect our ability to, and the manner in which, we raise additional capital. 
Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds or separately managed accounts, which 
includes funds from External Parties, that operate in the same or a related line of business as we do, which may result in significant conflicts of interest.
There is a risk that you may not receive distributions or that our distributions may not grow over time. 
We are exposed to risks associated with changes in interest rates, including fluctuations in interest rates which could adversely affect our profitability or the 
value of our portfolio. 
Our operating flexibility and financial condition could be negatively affected if we fail to qualify as a BDC or RIC.

25

 
 
 
  
 
Risks Related to Our Investments 

•

•
•
•

•
•

•

•

•

•

•

•
•

Our investments are concentrated in certain industries and in a number of technology-related companies, which subjects us to the risk of significant loss if any 
of these companies default on their obligations under any of their debt securities that we hold, or if any of the technology-related industry sectors experience a 
downturn. 
Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. 
Our investments may be in portfolio companies that have limited operating histories and resources. 
Our investment strategy focuses on technology-related companies, which are subject to many risks, including volatility, intense competition, shortened product 
life cycles, changes in regulatory and governmental programs and periodic downturns, and you could lose all or part of your investment. 
Our investments in the life sciences industry are subject to extensive government regulation, litigation risk, and certain other risks particular to that industry. 
Price declines and illiquidity in the corporate debt markets could adversely affect the fair value of our portfolio investments, reducing our NAV through 
increased net unrealized depreciation. 
A lack of IPO or merger and acquisition opportunities may cause companies to stay in our portfolio longer, leading to lower returns, unrealized depreciation, or 
realized losses. 
An investment strategy focused on privately-held companies presents certain challenges, including the lack of available information about these companies, a 
dependence on the talents and efforts of only a few key portfolio company personnel, and a greater vulnerability to economic downturns. 
Our financial condition, results of operations and cash flows could be negatively affected if we are unable to recover our principal investment as a result of a 
negative pledge or lack of a security interest on the intellectual property of our venture growth stage companies. 
The lack of liquidity in our investments may adversely affect our business and, if we need to sell any of our investments, we may not be able to do so at a 
favorable price. 
Our warrant and equity investments can be volatile, and we may not realize gains from these investments. If our warrant and equity investments do not generate 
gains, then the return on our invested capital will be lower than it would otherwise be which could result in a decline in the value of shares of our common 
stock.
Prepayments of our debt investments by our portfolio companies could adversely impact our results of operations and reduce our return on equity. 
Our loans could be subject to equitable subordination by a court which would increase our risk of loss with respect to such loans or we could be subject to 
lender liability claims.

Risks Related to Our Securities 

•
•
•

•
•

Our common stock may trade below its NAV per share, which could limit our ability to raise additional equity capital. 
If we issue preferred stock, debt securities or convertible debt securities, the NAV and market value of our common stock may become more volatile. 
A downgrade, suspension, or withdrawal of the credit rating assigned by a rating agency to us or our debt securities, if any, or change in the debt markets could 
cause the liquidity or market value of our debt securities to decline significantly.  
Our common stock price has been and continues to be volatile and may decrease substantially.
We may be unable to invest a significant portion of the net proceeds from an offering or from exiting an investment or other capital on acceptable terms, which 
could harm our financial condition and operating results. 

General Risk Factors

•

•
•

Global macro-economic and political events, terrorist attacks, acts of war, natural disasters or other public health emergencies may affect the market for our 
securities, impact the businesses in which we invest and harm our business, operating results and financial condition. 
We may be the target of litigation. 
Changes in laws or regulations governing our business could negatively affect the profitability of our operations. 

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also have a material adverse effect on our business, financial 
condition and/or operating results.

26

 
 
  
  
 
Item 1A. Risk Factors 

Investing in our securities may be speculative and involves a high degree of risk. You should consider carefully the risks described below and all other information 

contained in this Annual Report, including our financial statements and the related notes and the schedules and exhibits to this Annual Report. The risks set forth below are not 
the only risks we face. Additional risks and uncertainties not presently known to us or not presently deemed material by us may also impair our operations and performance. If 
any of the following risks occur, our business, financial condition, and results of operations could be materially adversely affected. In such case, our NAV and the trading price 
of our securities could decline, and you may lose all or part of your investment. 

Risks Related to our Business Structure 

As an internally managed BDC, we are subject to certain restrictions that may adversely affect our business. 

As an internally managed BDC, the size and categories of our assets under management is limited, and we are unable to offer as wide a variety of financial products to 
prospective portfolio companies and sponsors (potentially limiting the size and diversification of our asset base). We therefore may not achieve efficiencies of scale and greater 
management resources available to externally managed business development companies. In addition, if we fail to comply with restrictions applicable to an internally managed 
BDC, for example with respect to the portion of our assets representing qualifying assets, we may be subject to further restrictions that could have a negative impact on our 
business. See “Item 1. Business — Regulation.”

Additionally, as an internally managed BDC, our ability to offer more competitive and flexible compensation structures, such as offering both a profit-sharing plan and 
an equity incentive plan, is subject to the limitations imposed by the 1940 Act, which limits our ability to attract and retain talented investment management professionals. As 
such, these limitations could inhibit our ability to grow, pursue our business plan and attract and retain professional talent, any or all of which may have a negative impact on 
our business, financial condition and results of operations.

As an internally managed BDC, we are dependent upon the availability of key management personnel for our future success, particularly Scott Bluestein, and if we are 
not able to hire and retain qualified personnel, or if we lose any member of our senior management team, our ability to implement our business strategy could be 
significantly harmed. 

As an internally managed BDC, our ability to achieve our investment objectives and to make distributions to our stockholders depends upon the performance of our 

senior management. We depend upon the members of our senior management, particularly Mr. Bluestein, as well as other key personnel for the identification, final selection, 
structuring, closing and monitoring of our investments. These employees have critical industry experience and relationships on which we rely to implement our business plan. 
If we lose the services of Mr. Bluestein or any senior management members, we may not be able to operate the business as we expect, and our ability to compete could be 
harmed, which could cause our operating results to suffer. Furthermore, we do not have an employment agreement with Mr. Bluestein or our senior management that restricts 
them from creating new investment vehicles subject to compliance with applicable law. We believe our future success will depend, in part, on our ability to identify, attract and 
retain sufficient numbers of highly skilled employees. If we do not succeed in identifying, attracting and retaining such personnel, we may not be able to operate our business as 
we expect. In connection with our recruiting, branding and marketing efforts, we may, among other things, make charitable contributions in amounts we believe to be 
immaterial and that do not exceed $500,000 in the aggregate in any year. We believe that many of these contributions help us raise our profile in the communities and benefit us 
in attracting and retaining talent and investment opportunities.

As an internally managed BDC, our compensation structure is determined and set by our Board. This structure currently includes salary and bonus and incentive 
compensation, which is issued through grants and subsequent vesting of restricted stock. We are not generally permitted by the 1940 Act to employ an incentive compensation 
structure that directly ties performance of our investment portfolio and results of operations to compensation owing to our granting of restricted stock as incentive 
compensation. 

Members of our senior management may receive offers of more flexible and attractive compensation arrangements from other companies, particularly from investment 

advisers to externally managed BDCs that are not subject to the same limitations on incentive-based compensation that we, as an internally managed BDC, are subject to. We 
do not currently have agreements with certain members of our senior management that prohibit them from leaving and competing with our business and certain States limit our 
ability to have such agreements. A departure by one or more members of our senior management could have a negative impact on our business, financial condition and results 
of operations. 

27

  
 
Our business model depends to a significant extent upon strong referral relationships with venture capital and private equity fund sponsors, and our inability to 
develop or maintain these relationships, or the failure of these relationships to generate investment opportunities, could adversely affect our business. 

We expect that members of our management team will maintain their relationships with venture capital and private equity firms, and we will rely to a significant extent 

upon these relationships to provide us with our deal flow. If we fail to maintain our existing relationships, our relationships become strained as a result of enforcing our rights 
with respect to non-performing portfolio companies in protecting our investments or we fail to develop new relationships with other firms or sources of investment 
opportunities, then we will not be able to grow our investment portfolio. In addition, persons with whom members of our management team have relationships are not obligated 
to provide us with investment opportunities and, therefore, there is no assurance that such relationships will lead to the origination of debt or other investments. 

We operate in a highly competitive market for investment opportunities, and we may not be able to compete effectively. 

A number of entities compete with us to make the types of investments that we plan to make in prospective portfolio companies. We compete with a large number of 
venture capital and private equity firms, as well as with other investment funds, business development companies, investment banks and other sources of financing, including 
traditional financial services companies such as commercial banks and finance companies. Many of our competitors are substantially larger and have considerably greater 
financial, technical, marketing and other resources than we do. For example, some competitors may have a lower cost of funds and/or access to funding sources that are not 
available to us. This may enable some competitors to make loans with interest rates that are comparable to or lower than the rates that we typically offer. 

A significant increase in the number and/or the size of our competitors, including traditional commercial lenders and other financing sources, in technology-related 

industries could force us to accept less attractive investment terms. We may be unable to capitalize on certain opportunities if we do not match competitors’ pricing, terms and 
structure. If we do match competitors’ pricing, terms or structure, we may experience decreased net interest income and increased risk of credit losses. In addition, some of our 
competitors may have higher risk tolerances or different risk assessments, which could allow them to consider a wider variety of investments, establish more relationships and 
build their market shares. An increasing number of competitors may also have the effect of compressing our margins, which could harm our ability to retain employees, 
increase our operating costs, and decrease the amount and frequency of future distributions. Furthermore, many potential competitors are not subject to the regulatory 
restrictions that the 1940 Act imposes on us as a BDC or that the Code imposes on us as a RIC. Varying responses to the coronavirus ("COVID-19") by states, local 
governments and other authorities may cause us to be subject to more operational restrictions than are our competitors in other geographies. If we are not able to compete 
effectively, our business, financial condition, and results of operations will be adversely affected. As a result of this competition, there can be no assurance that we will be able 
to identify and take advantage of attractive investment opportunities, or that we will be able to fully invest our available capital. 

If we are unable to manage our future growth effectively, we may be unable to achieve our investment objective, which could adversely affect our financial condition 
and results of operations and cause the value of your investment to decline. 

Our ability to achieve our investment objective will depend on our ability to sustain growth. Sustaining growth will depend, in turn, on our senior management team’s 

ability to identify, evaluate, finance and invest in suitable companies that meet our investment criteria. Accomplishing this result on a cost-effective basis is largely a function of 
our marketing capabilities, our management of the investment process, our ability to provide and receive efficient services and our access to financing sources on acceptable 
terms. Organizational growth and scale-up of our investments could strain our existing managerial, investment, financial and other resources. Management of our growth could 
divert financial resources from other projects. Failure to manage our future growth effectively could lead to a decrease in our future distributions and have a material adverse 
effect on our business, financial condition and results of operations. 

28

  
 
Because we intend to distribute substantially all of our income to our stockholders in order to qualify as a RIC, we will continue to need additional capital to finance 
our growth. If additional funds are unavailable or not available on favorable terms, our ability to grow will be impaired. 

In order to satisfy the tax requirements applicable to a RIC and to minimize or avoid being subject to income and excise taxes, we intend to make distributions to our 

stockholders treated as dividends for U.S. federal income tax purposes generally of an amount at least equal to substantially all of our net ordinary income and realized net 
capital gains except for certain realized net capital gains, which we may retain, pay applicable income taxes with respect thereto and elect to treat as deemed distributions to our 
stockholders. As a BDC, we generally are required to meet a coverage ratio of total assets to total borrowings and other senior securities, which includes all of our borrowings 
and any preferred stock that we may issue in the future, of at least 150%, subject to certain disclosure requirements. This requirement limits the amount that we may borrow. 
This limitation may prevent us from incurring debt (including under any of our existing revolving credit facilities) and require us to raise additional equity at a time when it 
may be disadvantageous to do so. We cannot assure you that debt and equity financing will be available to us on favorable terms, or at all, and debt financings may be restricted 
by the terms of any of our outstanding borrowings. If we are unable to incur additional debt, we may be required to raise additional equity at a time when it may be 
disadvantageous to do so. In addition, shares of closed-end investment companies, including BDCs, have recently traded at discounts to their NAV. 

This characteristic of closed-end investment companies, including BDCs, is separate and distinct from the risk that our NAV per share may decline. We cannot predict 
whether shares of our common stock will trade above, at or below our NAV. If our common stock trades below its NAV, we generally will not be able to issue additional shares 
of our common stock at its market price without first obtaining the approval for such issuance from our stockholders and our independent directors. If additional funds are not 
available to us, we could be forced to curtail or cease new lending and investment activities, and our NAV could decline. In addition, our results of operations and financial 
condition could be adversely affected. 

Because most of our investments typically are not in publicly-traded securities, there is uncertainty regarding the value of our investments, which could adversely affect 
the determination of our NAV. 

As of December 31, 2021, portfolio investments, whose fair value is determined in good faith by the Board were approximately 93.6% of our total assets. We expect 
our investments to continue to consist primarily of securities issued by privately-held companies, the fair value of which is not readily determinable. In addition, we are not 
permitted to maintain a general reserve for anticipated loan losses. Instead, we are required by the 1940 Act to specifically value each investment and record an unrealized gain 
or loss for any asset that we believe has increased or decreased in value. 

There is no single standard for determining fair value in good faith. We value these securities at fair value as determined in good faith by our Board, based on the 

recommendations of our Audit Committee. In making a good faith determination of the value of these securities, we generally start with the cost basis of each security, which 
includes the amortized OID and PIK interest, if any. The Audit Committee uses its best judgment in arriving at the fair value of these securities. As a result, determining fair 
value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while applying a valuation process for the types of investments we 
make, which includes but is not limited to deriving a hypothetical exit price. 

However, the Board retains ultimate authority as to the appropriate valuation of each investment. Because such valuations are inherently uncertain and may be based on 

estimates, our determinations of fair value may differ materially from the values that would be assessed if a ready market for these securities existed. We adjust quarterly the 
valuation of our portfolio to reflect the Board’s determination of the fair value of each investment in our portfolio. Any changes in fair value are recorded in our consolidated 
statements of operations as net change in unrealized appreciation or depreciation. Our NAV could be adversely affected if our determinations regarding the fair value of our 
investments were materially higher than the values that we ultimately realize upon the disposal of such securities.

Legislation allows us to incur additional leverage, which may increase the risk of investing with us. 

Historically, the 1940 Act generally prevented us, as BDC, from incurring indebtedness unless immediately after such borrowing we had an asset coverage for total 
borrowings of at least 200% (i.e., the amount of debt may not exceed 50% of the value of our assets). The SBCAA, which was signed into law in March 2018, modifies this 
section of the 1940 Act and decreases this percentage from 200% to 150% (subject to either stockholder approval or approval of both a majority of the Board and a majority of 
directors who are not interested persons). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of 
the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act.  As a 
result, as of December 7, 2018, we are able to incur additional indebtedness, subject to certain disclosure requirements and, therefore, your risk of an investment in us may 
increase. Rating agencies may also decide to review our credit ratings and those of other BDCs in light of this new law as well as any 

29

 
  
 
corresponding changes to asset coverage ratios and consider downgrading such ratings, including a downgrade from an investment grade rating to a non-investment grade 
rating. Such a downgrade in our credit ratings may adversely affect our securities. See “—A downgrade, suspension or withdrawal of the credit rating assigned by a rating 
agency to us or our debt securities, if any, or change in the debt markets could cause the liquidity or market value of our debt securities to decline significantly.” 

Because we have substantial indebtedness, there could be increased risk in investing in our company. 

Lenders have fixed dollar claims on our assets that are superior to the claims of stockholders, and we have granted, and may in the future grant, lenders a security 

interest in our assets in connection with borrowings. In the case of a liquidation event, those lenders would receive proceeds before our stockholders. In addition, borrowings, 
also known as leverage, magnify the potential for gain or loss on amounts invested and, therefore, increase the risks associated with investing in our securities. Leverage is 
generally considered a speculative investment technique. If the value of our assets increases, then leverage would cause the NAV attributable to our common stock to increase 
more than it otherwise would have had we not leveraged. Conversely, if the value of our assets decreases, leverage would cause the NAV attributable to our common stock to 
decline more than it otherwise would have had we not used leverage. Similarly, any increase in our revenue in excess of interest expense on our borrowed funds would cause 
our net income to increase more than it would without the leverage. Any decrease in our revenue would cause our net income to decline more than it would have had we not 
borrowed funds and could negatively affect our ability to make distributions on common stock. Our ability to service any debt that we incur will depend largely on our financial 
performance and will be subject to prevailing economic conditions and competitive pressures. We and, indirectly, our stockholders will bear the cost associated with our 
leverage activity. If we are not able to service our substantial indebtedness, our business could be harmed materially. 

Our secured credit facilities with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”) and MUFG Union Bank, N.A., (the “Union Bank Facility” and 

together with the SMBC Facility our “Credit Facilities”), as well as the 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, March 2026 A Notes, March 
2026 B Notes, September 2026 Notes, 2033 Notes, 2022 Convertible Notes, and January 2027 Notes (as each term is individually defined below and collectively, the “Notes”) 
contain financial and operating covenants that could restrict our business activities, including our ability to declare dividend distributions if we default under certain provisions. 

As of December 31, 2021, we had $29.9 million in borrowings outstanding under the SMBC Facility and none outstanding under the Union Bank Facility. As of 

December 31, 2021, we had approximately $150.5 million of indebtedness outstanding incurred by our SBIC subsidiary, and approximately $1,070.0 million in aggregate 
principal outstanding Notes. 

There can be no assurance that we will be successful in obtaining any additional debt capital on terms acceptable to us or at all. If we are unable to obtain debt capital, 
then our equity investors will not benefit from the potential for increased returns on equity resulting from leverage to the extent that our investment strategy is successful and 
we may be limited in our ability to make new commitments or fundings to our portfolio companies.

 As discussed in the previous risk factor, we are only permitted to incur indebtedness if immediately after such borrowing we have an asset coverage for total 
borrowings of at least 150%. In addition, we may not be permitted to declare any cash distribution on our outstanding common shares, or purchase any such shares, unless, at 
the time of such declaration or purchase, we have asset coverage of at least 150% after deducting the amount of such distribution or purchase price. If this ratio declines below 
150%, we may not be able to incur additional debt and may need to sell a portion of our investments to repay debt when it is disadvantageous to do so, and we may not be able 
to make distributions. As of December 31, 2021, our asset coverage ratio under our regulatory requirements as a BDC was 218.9%, excluding our SBIC debentures as a result 
of our exemptive order from the SEC that allows us to exclude all SBA leverage from our asset coverage ratio and was 204.6% when including all SBA leverage.

Based on our current capital structure, assuming leverage remains equal to 95.6% of our net assets as of December 31, 2021, our investment portfolio would have been 

required to generate an annual return of at least 2.5% to cover our annual interest payments.

Illustration. The following table illustrates the effect of leverage on returns from an investment in our common stock assuming that we employ (1) our actual asset 

coverage ratio as of December 31, 2021, (2) a hypothetical asset coverage ratio of 200%, and (3) a hypothetical asset coverage ratio of 150% (each excluding our SBA 
debentures as permitted by our exemptive relief) each at various annual returns on our portfolio as of December 31, 2021, net of expenses. 

30

 
  
 
The calculations in the table below are hypothetical, and actual returns may be higher or lower than those appearing in the table below.

(1)

Corresponding return to common stockholder assuming our actual asset coverage of 218.9% as of December 
31, 2021 
Corresponding return to common stockholder assuming 200% asset coverage 
Corresponding return to common stockholder assuming 150% asset coverage 

(3)

(2)

Annual Return on Our Portfolio
(Net of Expenses)

-10%

-5%

0%

5%  

10%  

(24.56 %)
(26.93 %)
(41.82 %)

(14.63 %)
(16.20 %)
(26.10 %)

(4.69 %)
(5.47 %)
(10.38 %)

  5.24 %  
  5.26 %  
  5.35 %  

  15.18 %
  15.98 %
  21.07 %

(1)

(2)

(3)

Assumes $2.6 billion in total assets, $1.3 billion in debt outstanding, $1.3 billion in stockholders’ equity, and an average cost of funds of 4.9%, which is the approximate average cost of 
our Notes and Credit Facilities for the period ended December 31, 2021.  Actual interest payments may be different. 
Assumes $2.8 billion in total assets including debt issuance costs on a pro forma basis, $1.5 billion in debt outstanding, $1.3 billion in stockholders’ equity, and an average cost of funds 
of 4.9%, which is the approximate average cost of our Notes and Credit Facilities for the period ended December 31, 2021, along with the hypothetical estimated incremental cost of debt 
that would be incurred on offering the maximum permissible debt under the 200% asset coverage. Actual interest payments may be different.
Assumes $4.1 billion in total assets including debt issuance costs on a pro forma basis, $2.8 billion in debt outstanding, $1.3 billion in stockholders’ equity, and an average cost of funds 
of 4.9%, which is the approximate average cost of our Notes and Credit Facilities for the period ended December 31, 2021, along with the hypothetical estimated incremental cost of debt 
that would be incurred on offering the maximum permissible debt under the 150% asset coverage. Actual interest payments may be different.

It is likely that the terms of any current or future long-term or revolving credit or warehouse facility we may enter into in the future could constrain our ability to grow 
our business. 

Under our borrowings and our Credit Facilities, current lenders have, and any future lender or lenders may have, fixed dollar claims on our assets that are senior to the 

claims of our stockholders and, thus, will have a preference over our stockholders with respect to our assets pledged as collateral under the Credit Facilities. Our Credit 
Facilities and borrowings also subject us to various financial and operating covenants, including, but not limited to, maintaining certain financial ratios and minimum tangible 
net worth amounts. Future credit facilities and borrowings will likely subject us to similar or additional covenants. In addition, we may grant a security interest in our assets in 
connection with any such credit facilities and borrowings. 

Our Credit Facilities generally contain customary default provisions such as a minimum net worth amount, a profitability test, and a restriction on changing our 

business and loan quality standards. In addition, our Credit Facilities require or are expected to require the repayment of all outstanding debt on the maturity date which may 
disrupt our business and potentially the business of our portfolio companies that are financed through the facilities. An event of default under these facilities would likely result, 
among other things, in termination of the availability of further funds under the facilities and accelerated maturity dates for all amounts outstanding under the facilities, which 
would likely disrupt our business and, potentially, the business of the portfolio companies whose loans we finance through the facilities. This could reduce our revenues and, by 
delaying any cash payment allowed to us under our facilities until the lender has been paid in full, reduce our liquidity and cash flow and impair our ability to grow our business 
and our ability to make distributions sufficient to maintain our ability to be subject to tax as a RIC. 

The terms of future available financing may place limits on our financial and operation flexibility. If we are unable to obtain sufficient capital in the future, we may be 

forced to reduce or discontinue our operations, not be able to make new investments, or otherwise respond to changing business conditions or competitive pressures.

In addition to regulatory requirements that restrict our ability to raise capital, our Notes, and Credit Facilities contain various covenants which, if not complied with, 
could require accelerated repayment under the facility or require us to repurchase the Notes thereby materially and adversely affecting our liquidity, financial 
condition, results of operations and ability to pay distributions.

The credit indentures governing our Notes and Credit Facilities require us to comply with certain financial and operational covenants. These covenants require us to, 
among other things, maintain certain financial ratios, including asset coverage, debt to equity and interest coverage. Our ability to continue to comply with these covenants in 
the future depends on many factors, some of which are beyond our control. There are no assurances that we will be able to comply with these covenants. Failure to comply with 
these covenants would result in a default, which if we were unable to obtain a waiver from the lenders under our Credit Facilities or holders of our Notes, could accelerate 
repayment under the Credit Facilities or Notes and thereby have a material adverse impact on our liquidity, financial condition, results of operations and ability to pay a 
sufficient amount of distributions and maintain our ability to be subject to tax as a RIC. We may not have enough available cash or be able to obtain financing at the time we are 
required to make repurchases. See “Note 5 – Debt”.

31

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
The SMBC Facility and the Union Bank Facility mature in November 2026 and February 2024, respectively, and any inability to renew, extend or replace our Credit 
Facilities could adversely impact our liquidity and ability to find new investments or maintain distributions to our stockholders.

As of December 31, 2021, we had two available secured credit facilities, the SMBC Facility and the Union Bank Facility, which mature in November 2026 and February 
2024, respectively. There can be no assurance that we will be able to renew, extend or replace our Credit Facilities upon maturity on terms that are favorable to us, if at all. Our 
ability to renew, extend or replace the Credit Facility will be constrained by then-current economic conditions affecting the credit markets. In the event that we are not able to 
renew, extend or replace either Credit Facility at the time of its maturity, this could have a material adverse effect on our liquidity and ability to fund new investments, our 
ability to make distributions to our stockholders and our ability to qualify as a RIC.

We may be unable to obtain debt capital on favorable terms or at all, in which case we would not be able to use leverage to increase the return on our investments. 

If we are unable to obtain debt capital, then our equity investors will not benefit from the potential for increased returns on equity resulting from leverage to the extent 
that our investment strategy is successful and we may be limited in our ability to make new commitments or fundings to our portfolio companies. An inability to obtain debt 
capital may also limit our ability to refinance existing indebtedness, particularly during periods of adverse credit market conditions when refinancing indebtedness may not be 
available under interest rates and other terms acceptable to us or at all.

Our investments in a portfolio company, whether debt, equity, or a combination thereof, may lead to our receiving material non-public information ("MNPI") or 
obtaining "control" of the target company.  Our ability to exit an investment where we have MNPI or control could be limited and could result in a realized loss on the 
investment. 

If we receive MNPI, or a controlling interest in a portfolio company, our ability to divest ourselves from a debt or equity investment could be restricted. Causes of such 
restriction could include market factors, such as liquidity in a private stock, or limited trading volume in a public company’s securities, or regulatory factors, such as the receipt 
of MNPI or insider blackout periods, where we are legally prohibited from selling. Additionally, we may choose not to take certain actions to protect a debt investment in a 
controlled investment portfolio company. As a result, we could experience a decrease in the value of our portfolio company holdings and potentially incur a realized loss on the 
investment. 

Regulations governing our operations as a BDC may affect our ability to, and the manner in which, we raise additional capital, which may expose us to risks. 

Our business requires a substantial amount of capital. We may acquire additional capital from the issuance of senior securities, including borrowings, securitization 

transactions or other indebtedness, or the issuance of additional shares of our common stock. However, we may not be able to raise additional capital in the future on favorable 
terms or at all. We may issue debt securities, other evidence of indebtedness or preferred stock, and we may borrow money from banks or other financial institutions, which we 
refer to collectively as “senior securities,” up to the maximum amount permitted by the 1940 Act. As discussed above, under the 1940 Act, we are not permitted to incur 
indebtedness unless immediately after such borrowing we have an asset coverage for total borrowings of at least 150%. In addition, we may not be permitted to declare any 
cash distribution on our outstanding common shares, or purchase any such shares, unless, at the time of such declaration or purchase, we have asset coverage of at least 150% 
after deducting the amount of such distribution or purchase price. Our ability to pay distributions or issue additional senior securities would be restricted if our asset coverage 
ratio were not at least 150%.

If the value of our assets declines, we may be unable to satisfy this test. If that happens, we may be required to liquidate a portion of our investments and repay a portion 

of our indebtedness at a time when such transaction may be disadvantageous. As a result of issuing senior securities, we would also be exposed to risks associated with 
leverage, including an increased risk of loss. If we issue preferred stock, the preferred stock would rank “senior” to common stock in our capital structure, preferred 
stockholders would have separate voting rights and might have rights, preferences, or privileges more favorable than those of our common stockholders and the issuance of 
preferred stock could have the effect of delaying, deferring, or preventing a transaction or a change of control that might involve a premium price for holders of our common 
stock or otherwise be in your best interest. It is likely that any senior securities or other indebtedness we issue will be governed by an indenture or other instrument containing 
covenants restricting our operating flexibility. Additionally, some of these securities or other indebtedness may be rated by rating agencies, and in obtaining a rating for such 
securities and other indebtedness, we may be required to abide by operating and investment guidelines that further restrict operating and financial flexibility. 

To the extent that we are constrained in our ability to issue debt or other senior securities, we will depend on issuances of common stock to finance operations. We 

currently do not have requisite approval from our stockholders to issue shares of our 

32

  
 
common stock at a price below its then current NAV per share. We may, but are under no obligation to and cannot guarantee that we will, seek to obtain such approval in the 
future.  In connection with any such approval, we will limit the number of shares that we issue at a price below NAV per share pursuant to the stockholder authorization so that 
the aggregate dilutive effect on our then outstanding shares will not exceed 20%; however, our Board, subject to its fiduciary duties and regulatory requirements, will have the 
discretion to determine the amount of the discount. As a result, the discount could be up to 100% of NAV per share. If we raise additional funds by issuing more common stock 
or senior securities convertible into, or exchangeable for, our common stock, then the percentage ownership of our stockholders at that time will decrease, and you might 
experience dilution. Moreover, we can offer no assurance that we will be able to issue and sell additional equity securities in the future, on favorable terms or at all. 

Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds or separately managed accounts, which includes 
funds from External Parties, that operate in the same or a related line of business as we do, which may result in significant conflicts of interest.

Our executive officers and employees, through the Adviser Subsidiary, are expected to manage the Adviser Funds that operate in the same or a related line of business as 

we do, and which funds may be invested in by us and/or our executive officers and employees. Accordingly, they may have obligations to such other entities, the fulfillment of 
which obligations may not be in the interests of us or our stockholders. Our relationship with the Adviser Subsidiary may require us to commit resources to achieving the 
Adviser Funds or External Parties’ investment objectives, while such resources were previously solely devoted to achieving our investment objective. Our investment objective 
and investment strategies may be very similar to those of the Adviser Funds and External Parties and it is likely that an investment appropriate for us, the Adviser Funds, or 
External Parties would be appropriate for the other entity. Because the Adviser Subsidiary may receive performance-based fee compensation from the Adviser Funds or 
External Parties, this may provide an incentive to allocate opportunities to the Adviser Funds or External Parties instead of us. Accordingly, we and the Adviser Subsidiary have 
established policies and procedures governing the allocation investment opportunities between us, the Adviser Funds, and External Parties. We may be limited in or unable to 
participate in certain investments based upon such allocation policy. Although we will endeavor to allocate investment opportunities in a fair and equitable manner, we may 
face conflicts in allocating investment opportunities between us, the Adviser Funds and External Parties managed by the Adviser Subsidiary. 

Investments in Adviser Funds managed by our Adviser Subsidiary may create conflicts of interests.

Our Adviser Subsidiary is committed to make contributions as a limited partner to certain Adviser Funds, it is also entitled to receive distributions on such interest. Our 
officers and employees may dedicate more time or resources to the Adviser Funds or allocate more favorable investment opportunities to the Adviser Funds instead of us. The 
Adviser Funds will, at times, acquire, hold, or sell investments that are also suitable for us. Investments allocated to the Adviser Funds may reduce the amount of investments 
available to us. Our officers and employees may make investment decisions or recommendations for the Adviser Funds that differ from the investment decisions that are made 
for us. The Adviser Subsidiary could determine to sell a loan for one or more Adviser Funds while all or a portion of such loan is retained by us, or vice-versa. The Adviser 
Subsidiary makes its decisions as to whether the Adviser Funds should invest pursuant to, among other things, its duties under the applicable governing documents for the 
Adviser Funds. Conflicts of interest can arise if the Adviser Subsidiary seeks to acquire or sell portions of one or more loans for one or more of the Adviser Funds while we 
also seek to acquire or sell portions of such loans. We and the Adviser Subsidiary have implemented an investment allocation policy and procedures designed to ensure that 
investment opportunities are allocated among us and the Adviser Funds fairly and equitably over time; however, there can be no assurance that the application of our allocation 
policy will result in our desired participation in every investment opportunity that may be suitable for both us and the Adviser Funds.

In addition, we may make investments in the Adviser Funds in the form of loans. For example, prior to the receipt by the Adviser Funds of capital contributions from 

investors for which a capital call notice has or will be given, we expect to provide loan financing to such Adviser Funds to fund such amounts on a temporary basis in order to 
permit the Adviser Funds to invest in a target portfolio company within the applicable time constraints prior to the receipt by the Adviser Funds of a capital call in respect of 
such investment. In addition, we may provide loan financing to the Adviser Funds to cover start-up and initial operating costs prior to the receipt by the Adviser Funds of a 
capital call in respect of such expenses. The provision of debt financing to the Adviser Funds may cause conflicts of interest, including in situations where our interest as a 
lender to the Adviser Funds conflicts with the interest of holders of third-party equity interests.

Our revenues and results of operations relating to our Adviser Subsidiary’s business depend on the management fees and performance fees received from the Adviser 
Funds.

We will derive our revenues related to the Adviser Subsidiary primarily from dividend income, which the Adviser Subsidiary will pay from net profits generated from 

advisory fees charged to the Adviser Funds. The Adviser Funds may be established with different fee structures, including management fees payable at varying rates and 
carried interest or performance fees that are payable 

33

 
  
  
 
at varying hurdle rates. Investment advisory, carried interest, and performance fee revenues can be adversely affected by several factors, including market factors, third-party 
investor preferences, and our Adviser Subsidiary’s performance and track record. A reduction in revenues of our Adviser Subsidiary, without a commensurate reduction in 
expenses, would adversely affect our Adviser Subsidiary’s business and our revenues and results of operations derived from the Adviser Subsidiary.

When we are a debt or minority equity investor in a portfolio company, we may not be in a position to control the entity, and management of the company may make 
decisions that could decrease the value of our portfolio holdings. 

We make both debt and minority equity investments; therefore, we are subject to the risk that a portfolio company may make business decisions with which we 
disagree, and the stockholders and management of such company may take risks or otherwise act in ways that do not serve our interests. As a result, a portfolio company may 
make decisions that could decrease the value of our portfolio holdings.

If we do not invest a sufficient portion of our assets in qualifying assets, we could fail to qualify as a BDC or be precluded from investing according to our current 
business strategy. 

As a BDC, we may not acquire any assets other than “qualifying assets” as defined under the 1940 Act, unless, at the time of and after giving effect to such acquisition, 

at least 70% of our total assets are qualifying assets. See “Item 1. Business –Regulation.” 

We believe that most of the investments we make will constitute qualifying assets. However, we may be precluded from investing in what we believe are attractive 

investments if such investments are not qualifying assets for purposes of the 1940 Act. If we do not invest a sufficient portion of our assets in qualifying assets, we could lose 
our status as a BDC, which would have a material adverse effect on our business, financial condition and results of operations. In addition, a rise in the equity markets may 
result in increased market valuations of certain of our existing and prospective portfolio companies, which may lead to new investments with such companies being qualified as 
non-eligible portfolio company assets and would require that we invest in qualified assets going forward. Similarly, these rules could prevent us from making follow-on 
investments in existing portfolio companies (which could result in the dilution of our position) or could require us to dispose of investments at inopportune times in order to 
comply with the 1940 Act. If we need to dispose of such investments quickly, it may be difficult to dispose of such investments on favorable terms. For example, we may have 
difficulty in finding a buyer and, even if we do find a buyer, we may have to sell the investments at a substantial loss. Although we are exploring investment structures, such as 
entering into joint venture arrangements, to increase our flexibility to make investments in assets that are not qualifying assets, there can be no assurance that we will ultimately 
pursue such investment structures or that such investment structures will achieve this goal. 

A failure on our part to maintain our qualification as a BDC would significantly reduce our operating flexibility. 

If we fail to continuously qualify as a BDC, we might be subject to regulation as a registered closed-end investment company under the 1940 Act, which would 
significantly decrease our operating flexibility, and lead to situations where we might have to, among other things, restrict our borrowings, reduce our leverage, sell securities 
and pursue other activities that we are allowed to engage in as a BDC. In addition, failure to comply with the requirements imposed on BDCs by the 1940 Act could cause the 
SEC to bring an enforcement action against us. For additional information on the qualification requirements of a BDC, see “Item 1. Business – Regulation.”

To the extent OID and PIK interest constitute a portion of our income, we will be exposed to risks associated with such income being required to be included in taxable 
and accounting income prior to receipt of cash representing such income. 

Our investments may include OID instruments and contractual PIK interest arrangements, which represent contractual interest added to a loan balance and due at the 

end of such loan’s term. To the extent OID or PIK interest constitutes a portion of our income, we are exposed to risks associated with such income being required to be 
included in taxable and accounting income prior to receipt of cash, including the following: 

•

•

•

The higher interest rates of OID and PIK instruments reflect the payment deferral and increased credit risk associated with these instruments, and OID and PIK 
instruments generally represent a significantly higher credit risk than coupon loans.

Even if the accounting conditions for income accrual are met, the borrower could still default when our actual collection is due at the maturity of the obligation, 
which could lead to future losses.

OID and PIK instruments may have unreliable valuations because their continuing accruals require continuing judgments about the collectability of the deferred 
payments and the value of any associated collateral. OID and PIK income may also create uncertainty about the source of our cash distributions.

34

  
 
•

•

•

For accounting purposes, any cash distributions to stockholders representing OID and PIK income are not treated as coming from paid-in capital, even though 
the cash to pay them comes from the offering proceeds. As a result, despite the fact that a distribution representing OID and PIK income could be paid out of 
amounts invested by our stockholders, the 1940 Act does not require that stockholders be given notice of this fact by reporting it as a return of capital.

The deferral of PIK interest may have a negative impact on our liquidity as it represents non-cash income that may require cash distributions to our stockholders 
in order to maintain our ability to be subject to tax as a RIC.

Tax rules require that income be recognized for tax purposes no later than when recognized for financial reporting purposes.

If we are unable to satisfy Code requirements for qualification as a RIC, then we will be subject to corporate-level income tax, which would adversely affect our results 
of operations and financial condition. 

We elected to be treated as a RIC for U.S. federal income tax purposes with the filing of our federal corporate income tax return for 2006. We will not qualify for the tax 

treatment allowable to RICs if we are unable to comply with the source of income, asset diversification and distribution requirements contained in Subchapter M of the Code, 
or if we fail to maintain our election to be regulated as a BDC under the 1940 Act. If we fail to qualify as a RIC for any reason and become subject to a corporate-level income 
tax, the resulting taxes could substantially reduce our net assets, the amount of income available for distribution to our stockholders and the actual amount of our distributions. 
Such a failure would have a material adverse effect on us, the NAV of our common stock and the total return, if any, earned from your investment in our common stock.

We may have difficulty paying our required distributions under applicable tax rules if we recognize income before or without receiving cash representing such income.

In accordance with U.S. federal tax requirements, we are required to include in income for tax purposes certain amounts that we have not yet received in cash, such as 

OID and contractual PIK interest arrangements, which represent contractual interest added to a loan balance and due at the end of such loan’s term. In addition to the cash 
yields received on our loans, in some instances, our loans generally include one or more of the following: exit fees, balloon payment fees, commitment fees, success fees or 
prepayment fees. In some cases our loans also include contractual PIK interest arrangements. The increases in loan balances as a result of contractual PIK arrangements are 
included in income for the period in which such PIK interest was accrued, which is often in advance of receiving cash payment, and are separately identified on our statements 
of cash flows. We also may be required to include in income for tax purposes certain other amounts prior to receiving the related cash. Also, tax rules require that income be 
recognized for tax purposes no later than when recognized for financial reporting purposes.

Any warrants that we receive in connection with our debt investments will generally be valued as part of the negotiation process with the particular portfolio company. 

As a result, a portion of the aggregate purchase price for the debt investments and warrants will be allocated to the warrants that we receive. This will generally result in OID 
for tax purposes, which we must recognize as ordinary income, increasing the amount that we are required to distribute in order to be subject to tax as a RIC. Because these 
warrants generally will not produce distributable cash for us at the same time as we are required to make distributions in respect of the related OID, if ever, we would need to 
obtain cash from other sources or to pay a portion of our distributions using shares of newly issued common stock, consistent with IRS guidelines and the Code, to satisfy such 
distribution requirements. 

35

  
 
Other features of the debt instruments that we hold may also cause such instruments to generate OID in excess of current cash interest received. Since in certain cases 

we may recognize income before or without receiving cash representing such income, we may have difficulty meeting the RIC tax requirement to make distributions each 
taxable year to our stockholders treated as dividends for U.S. federal income tax purposes generally of an amount equal to at least 90% of our investment company taxable 
income, determined without regard to any deduction for dividends paid. Under such circumstances, we may have to sell some of our assets, raise additional debt or equity 
capital or reduce new investment originations to meet these distribution requirements. If we are unable to obtain cash from other sources and are otherwise unable to satisfy 
such distribution requirements, we may fail to qualify to be subject to tax as a RIC and, thus, become subject to a corporate-level income tax on all our taxable income 
(including any net realized securities gains). 

Furthermore, we may invest in the equity securities of non-U.S. corporations (or other non-U.S. entities classified as corporations for U.S. federal income tax purposes) 

that could be treated under the Code and U.S. Treasury regulations as PFICs and/or CFCs. The rules relating to investment in these types of non-U.S. entities are designed to 
ensure that U.S. taxpayers are either, in effect, taxed currently (or on an accelerated basis with respect to corporate level events) or taxed at increased tax rates at distribution or 
disposition. In certain circumstances, these rules also could require us to recognize taxable income or gains where we do not receive a corresponding payment in cash. Income 
derived by us either from a PFIC with respect to which we have made a certain U.S. tax election or from a CFC would generally constitute qualifying income for purposes of 
determining our ability to be subject to tax as a RIC if the PFIC or CFC respectively makes distributions of that income to us or if the income is derived with respect to our 
business of investing in stocks and securities. As such, we may be restricted in our ability to make qualified electing fund (“QEF”) elections with respect to our holdings in 
issuers that could either be treated as PFICs or CFCs in order to limit our tax liability or maximize our after-tax return from these investments.

Our portfolio investments may present special tax issues.

Investments in below-investment grade debt instruments and certain equity securities may present special tax issues for us. U.S. federal income tax rules are not entirely 

clear about issues such as when we may cease to accrue interest, OID or market discount, when and to what extent deductions may be taken for bad debts or worthless debt in 
equity securities, how payments received on obligations in default should be allocated between principal and interest income, as well as whether exchanges of debt instruments 
in a bankruptcy or workout context are taxable. Such matters could cause us to recognize taxable income for U.S. federal income tax purposes, even in the absence of cash or 
economic gain, and require us to make taxable distributions to our stockholders to maintain our RIC status or preclude the imposition of either U.S. federal corporate income or 
excise taxation. Additionally, because such taxable income may not be matched by corresponding cash received by us, we may be required to borrow money or dispose of other 
investments to be able to make distributions to our stockholders. These and other issues will be considered by us, to the extent determined necessary, in order that we minimize 
the level of any U.S. federal income or excise tax that we would otherwise incur. See “Item 1. Business—Certain United States Federal Income Tax Considerations—Taxation 
as a Regulated Investment Company.”

There is a risk that you may not receive distributions or that our distributions may not grow over time. 

We intend to make distributions on a quarterly basis to our stockholders. We cannot assure you that we will achieve investment results, or our business may not perform 
in a manner that will allow us to make a specified level of distributions or year-to-year increases in cash distributions. In addition, due to the asset coverage test applicable to us 
as a BDC, we may be limited in our ability to make distributions. Also, our Credit Facilities limit our ability to declare distributions to our stockholders if we default under 
certain provisions of our Credit Facilities. Furthermore, while we may have undistributed earnings, those earnings may not yield distributions because we may incur unrealized 
losses or otherwise be unable to distribute such earnings.

36

  
 
We have and may in the future choose to pay distributions in our own stock, in which case you may be required to pay tax in excess of the cash you receive. 

Under applicable Treasury regulations and other general guidelines issued by the IRS, RICs are permitted to treat certain distributions payable in their stock, as taxable 

dividends that will satisfy their annual distribution obligations for U.S. federal income tax and excise tax purposes provided that stockholders have the opportunity to elect to 
receive all or a portion of such distribution in cash. Taxable stockholders receiving distributions will be required to include the full amount of such distributions as ordinary 
income (or as long-term capital gain to the extent such distribution is properly reported as a capital gain dividend) to the extent of our current and accumulated earnings and 
profits for U.S. federal income tax purposes. As a result, a U.S. stockholder may be required to pay tax with respect to such distributions in excess of any cash received. If a 
U.S. stockholder sells the stock it receives as a distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the 
distribution, depending on the market price of our stock at the time of the sale. Furthermore, with respect to non-U.S. stockholders, we may be required to withhold U.S. federal 
income tax with respect to such distributions, including in respect of all or a portion of such distribution that is payable in stock. In addition, if a significant number of our 
stockholders determine to sell shares of our stock in order to pay taxes owed on such distributions, then such sales may put downward pressure on the trading price of our stock. 
We may in the future determine to distribute taxable distributions that are partially payable in our common stock. 

We are exposed to risks associated with changes in interest rates, including fluctuations in interest rates which could adversely affect our profitability or the value of 
our portfolio. 

General interest rate fluctuations may have a substantial negative impact on our investments and investment opportunities, and, accordingly, may have a material 
adverse effect on our investment objective and rate of return on investment capital. A portion of our income will depend upon the difference between the rate at which we 
borrow funds and the interest rate on the debt securities in which we invest. Because we will borrow money to make investments and may issue debt securities, preferred stock 
or other securities, our net investment income is dependent upon the difference between the rate at which we borrow funds or pay interest or dividends on such debt securities, 
preferred stock or other securities and the rate at which we invest these funds. Typically, we anticipate that our interest-earning investments will accrue and pay interest at both 
variable and fixed rates, and that our interest-bearing liabilities will generally accrue interest at fixed rates. 

A significant increase in market interest rates could harm our ability to attract new portfolio companies and originate new loans and investments. In addition to 
potentially increasing the cost of our debt, increasing interest rates may also have a negative impact on our portfolio companies’ ability to repay or service their loans, which 
could enhance the risk of loan defaults. We expect that most of our current initial investments in debt securities will be at floating rate with a floor. However, in the event that 
we make investments in debt securities at variable rates, a significant increase in market interest rates could also result in an increase in our non-performing assets and a 
decrease in the value of our portfolio because our floating-rate loan portfolio companies may be unable to meet higher payment obligations. As of December 31, 2021, 
approximately 94.0% of our debt investments were at floating rates or floating rates with a floor and 6.0% of the debt investments were at fixed rates. 

In periods of rising interest rates, our cost of funds would increase on our floating rate liabilities, potentially resulting in a decrease in our net investment income. In 

addition, a decrease in interest rates may reduce net income, because new investments may be made at lower rates despite the increased demand for our capital that the decrease 
in interest rates may produce. We may, but will not be required to, hedge against the risk of adverse movement in interest rates in our short-term and long-term borrowings 
relative to our portfolio of assets. If we engage in hedging activities, it may limit our ability to participate in the benefits of lower interest rates with respect to the hedged 
portfolio. Adverse developments resulting from changes in interest rates or hedging transactions could have a material adverse effect on our business, financial condition, and 
results of operations.

The discontinuation of LIBOR may affect the value of the financial obligations to be held or issued by us that are linked to LIBOR.

In July 2017, the head of the United Kingdom Financial Conduct Authority (the "FCA") announced that it will phase out the use of LIBOR by December 31, 2021. To 
identify a successor rate for U.S. dollar LIBOR, the Federal Reserve System, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised 
of large U.S. financial institutions, has identified the Secured Overnight Financing Rate ("SOFR") as its preferred alternative rate for LIBOR. SOFR is a measure of the cost of 
borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. Although there have 
been a few transactions utilizing SOFR or the Sterling Overnight Index Average ("SONIA"), an alternative reference rate that is based on transactions, at this time, it is not 
possible to predict whether either of these alternative reference rates will attain market traction as a LIBOR replacement tool or the effect of any such changes as the 
establishment of alternative reference rates or other reforms to LIBOR may be enacted in the United States, United Kingdom or elsewhere. 

37

 
  
 
On November 30, 2020, ICE Benchmark Administration, the administrator of LIBOR (the “IBA”), announced its intention to continue publication of overnight and one-, 

three-, six- and 12-month USD LIBOR rates through June 30, 2023. However, it is impossible to predict whether and to what extent banks will continue to provide LIBOR 
submissions to the administrator of LIBOR or whether any additional reforms to LIBOR may be enacted. Concurrent with the IBA’s announcement, the Federal Reserve Board, 
the Office of the Comptroller of the Currency, and the Federal Deposit Insurance Corporation released a statement that (i) encouraged banks to cease entering into new 
contracts that use US dollar LIBOR as a reference rate as soon as practicable and in any event by December 31, 2021, (ii) indicated that new contracts entered into before 
December 31, 2021 should either utilize a reference rate other than US dollar LIBOR or have robust fallback language that includes a clearly defined alternative reference rate 
after US dollar LIBOR’s discontinuation and (iii) explained that extending the publication of certain US dollar LIBOR tenors until June 30, 2023 would allow most legacy US 
dollar LIBOR contracts to mature before LIBOR experiences disruptions. It is possible that the IBA and the panel banks could continue to produce LIBOR after June 30, 2023, 
or the FCA could deem LIBOR to be no longer representative of its underlying market prior to that date, but no assurance can be given that LIBOR will survive in its current 
form, or at all.

On March 8, 2021, the Alternative Reference Rates Committee confirmed that in its opinion the March 5, 2021, announcements by the IBA and the FCA on the future 

cessation and loss of the representativeness of the LIBOR benchmark rates constitutes a “benchmark transition event” with respect to all U.S. dollar LIBOR settings. A 
“benchmark transition event” may cause, or allow for, certain contracts to replace LIBOR with an alternative reference rate and such replacement could have a material and 
adverse impact on the debt market and/or us. On July 29, 2021, the Alternative Reference Rates Committee formally announced that it recommends the Chicago Mercantile 
Exchange’s forward-looking SOFR term rates for use in business loans, including securities backed by such assets. However, forward-looking SOFR term rates will not be 
representative of three-month LIBOR, and there is no requirement that the Chicago Mercantile Exchange continue to publish forward-looking SOFR term rates, in which case 
we, our lenders, and our portfolio company borrowers may be required to use other measurements of SOFR, as applicable. As such, if LIBOR in its current form does not 
survive and a replacement rate is not widely agreed upon or if a replacement rate is significantly different from LIBOR, it could cause a disruption in the credit markets 
generally. Such a disruption could also negatively impact the market value and/or transferability of our portfolio company investments. Further, any additional changes or 
reforms to the determination or supervision of LIBOR may result in a sudden or prolonged increase or decrease in reported LIBOR, which could have an adverse impact on the 
market value for or value of any LIBOR-linked securities, loans, and other financial obligations or extensions of credit held by or due to us and could have a material adverse 
effect on our business, financial condition and results of operations. 

Alteration of the terms of a debt instrument or a modification of the terms of other types of contracts to replace an interbank offered rate with a new reference rate could 

result in a taxable exchange and the realization of income and gain/loss for U.S. federal income tax purposes. The IRS has issued final regulations regarding the tax 
consequences of the transition from interbank offered rates to new reference rates in debt instruments and non-debt contracts. Under the final regulations, alteration or 
modification of the terms of a debt instrument to replace an operative rate that uses a discontinued LIBOR with a qualified rate (as defined in the final regulations) including 
true up payments equalizing the fair market value of contracts before and after LIBOR transition, to add a qualified rate as a fallback rate to a contract whose operative rate uses 
a discontinued LIBOR or replace a fallback rate that uses a discontinued LIBOR with a qualified rate would not be taxable.  The IRS may provide additional guidance, with 
potential retroactive effect.

We may expose ourselves to risks if we engage in hedging transactions.

If we engage in hedging transactions, we may expose ourselves to risks associated with such transactions. We may utilize instruments such as forward contracts, 
currency options and interest rate swaps, caps, collars and floors to seek to hedge against fluctuations in the relative values of our portfolio positions from changes in currency 
exchange rates and market interest rates. Hedging against a decline in the values of our portfolio positions does not eliminate the possibility of fluctuations in the values of such 
positions or prevent losses if the values of such positions decline. However, such hedging can establish other positions designed to gain from those same developments, thereby 
offsetting the decline in the value of such portfolio positions. Such hedging transactions may also limit the opportunity for gain if the values of the underlying portfolio 
positions should increase. It may not be possible to hedge against an exchange rate or interest rate fluctuation that is so generally anticipated that we are not able to enter into a 
hedging transaction at an acceptable price. Moreover, for a variety of reasons, we may not seek to establish a perfect correlation between such hedging instruments and there 
can be no assurance that any such hedging arrangements will achieve the desired effect. During the year ended December 31, 2021, we did not engage in any hedging activities.

38

 
 
  
 
We are subject to SBA regulations, as one of our wholly owned subsidiaries is licensed by the U.S. SBA, and as a result this could limit our capital or investment 
decisions. 

Our wholly owned subsidiary Hercules Capital IV, LP ("HC IV") is licensed to act as an SBIC and is regulated by the SBA. HC IV holds approximately $245.7 million 

in assets and it accounted for approximately 9.5% of the Company’s total assets, prior to consolidation as of December 31, 2021. The SBIC license allows HC IV to obtain 
leverage by issuing SBA-guaranteed debentures, subject to the issuance of a capital commitment by the SBA and other customary procedures. We may, subject to SBA rules 
and regulations, seek to renew or obtain additional SBIC licenses in the future. The SBA regulations require that a licensed SBIC be periodically examined and audited by the 
SBA to determine its compliance with the relevant SBA regulations. The SBA prohibits, without prior SBA approval, a “change of control” of an SBIC or transfers that would 
result in any person (or a group of persons acting in concert) owning 10.0% or more of a class of capital stock of a licensed SBIC. If our SBIC subsidiary fails to comply with 
applicable SBA regulations, the SBA could, depending on the severity of the violation, limit or prohibit our SBIC subsidiary’s use of debentures, declare outstanding 
debentures immediately due and payable, and/or limit HC IV from making new investments. Such actions by the SBA would, in turn, negatively affect us because HC IV is a 
wholly owned subsidiaries. 

HC IV was in compliance with the terms of the SBIC’s leverage as of December 31, 2021 as a result of having sufficient capital as defined under the SBA regulations. 

Compliance with SBA requirements may cause our SBIC subsidiary to forego attractive investment opportunities that are not permitted under SBA regulations. See “Item 1. 
Business — Regulation—Small Business Administration Regulations.”

SBA regulations limit the outstanding dollar amount of SBA guaranteed debentures that may be issued by an SBIC or group of SBICs under common control. 

The SBA regulations currently limit the dollar amount of SBA-guaranteed debentures that can be issued by any one SBIC to $175.0 million or to a group of SBICs 

under common control to $350.0 million. An SBIC may not borrow an amount in excess of two times (and in certain cases, up to three times) its regulatory capital. As of 
December 31, 2021, we have $150.5 million in SBA-guaranteed debentures in HC IV. Under our existing license, $175.0 million is the maximum capacity for HC IV to issue 
SBA-guaranteed debentures. During times that we reach the maximum dollar amount of SBA-guaranteed debentures permitted, and if we require additional capital, our cost of 
capital is likely to increase, and there is no assurance that we will be able to obtain additional financing on acceptable terms. 

Moreover, the current status of HC IV as an SBIC does not automatically assure that our SBIC subsidiary will continue to receive SBA-guaranteed debenture funding. 

Receipt of SBA leverage funding is dependent upon our SBIC subsidiary's continued compliance with SBA regulations and policies and available SBA funding. The amount of 
SBA leverage funding available to a SBIC is dependent upon annual Congressional authorizations and in the future may be subject to annual Congressional appropriations. 
There can be no assurance that there will be sufficient debenture funding available at the times desired by our SBIC subsidiary. 

The debentures guaranteed by the SBA have a maturity of ten years and require semi-annual payments of interest. HC IV has debentures outstanding with maturity 

dates beginning September 2031. HC IV will need to generate sufficient cash flow to make required interest payments on the debentures. If HC IV is unable to meet its 
financial obligations under the debentures, the SBA, as a creditor, will have a superior claim to our SBIC subsidiary’s assets over our stockholders in the event we liquidate our 
SBIC subsidiary or the SBA exercises its remedies under such debentures as the result of a default by us. 

Our wholly owned SBIC subsidiary may be unable to make distributions to us that will enable us to maintain RIC status, which could result in the imposition of an 
entity-level tax. 

In order for us to continue to qualify for RIC tax treatment and to minimize corporate-level taxes, we will be required to distribute substantially all of our investment 

company taxable income, determined without regard to any deduction for dividends paid, and net capital gains, including income from certain of our subsidiaries, which 
includes the income from our SBIC subsidiary. We will be partially dependent on our SBIC subsidiary for cash distributions to enable us to meet the RIC distribution 
requirements. Our SBIC subsidiary may be limited by the Small Business Investment Act of 1958, as amended, and SBA regulations governing SBICs, from making certain 
distributions to us that may be necessary to maintain our ability to be subject to tax as a RIC. We may have to request a waiver of the SBA’s restrictions for our SBIC subsidiary 
to make certain distributions to maintain our ability to be subject to tax as a RIC. We cannot assure you that the SBA will grant such waiver. If our SBIC subsidiary is unable to 
obtain waivers, compliance with the SBA regulations may result in loss of RIC tax treatment and a consequent imposition of an entity-level tax on us. 

39

  
 
Our Board may change our investment objective, operating policies and strategies without prior notice or stockholder approval, the effects of which may be adverse. 

Our Board has the authority, except as otherwise provided in the 1940 Act, to modify or waive certain of our operating policies and strategies without prior notice and 
without stockholder approval. However, absent stockholder approval, we may not change the nature of our business so as to cease to be, or withdraw our election as, a BDC. 
We cannot predict the effect any changes to our current operating policies and strategies would have on our business, operating results and the market price of our common 
stock. Nevertheless, any such changes could materially and adversely affect our business and impair our ability to make distributions to our stockholders.

Risks Related to Our Investments 

Our investments are concentrated in certain industries and in a number of technology-related companies, which subjects us to the risk of significant loss if any of these 
companies default on their obligations under any of their debt securities that we hold, or if any of the technology-related industry sectors experience a downturn. 

We have invested and intend to continue investing in a limited number of technology-related companies. A consequence of this limited number of investments is that 

the aggregate returns we realize may be significantly adversely affected if a small number of investments perform poorly or if we need to write down the value of any one 
investment. Beyond the asset diversification requirements to which we are subject as a BDC and a RIC, we do not have fixed guidelines for diversification or limitations on the 
size of our investments in any one portfolio company and our investments could be concentrated in relatively few issuers. In addition, we have invested and intend to continue 
to invest, under normal circumstances, at least 80% of the value of our total assets (including the amount of any borrowings for investment purposes) in technology-related 
companies. 

As of December 31, 2021, approximately 80.1% of the fair value of our portfolio comprised investments in three industries: 39.7% comprised investments in the "Drug 

Discovery & Development" industry, 24.1% comprised investments in the "Software" industry, and 16.3% comprised investments in the "Internet Consumer & Business 
Services" industry.

As a result, a downturn in technology-related industry sectors and particularly those in which we are heavily concentrated could materially adversely affect our financial 

condition.

We are a non-diversified investment company within the meaning of the 1940 Act, and therefore we generally are not limited with respect to the proportion of our 
assets that may be invested in securities of a single issuer. 

We are classified as a non-diversified investment company within the meaning of the 1940 Act, which means that we are not limited by the 1940 Act with respect to the 

proportion of our assets that we may invest in securities of a single issuer, excluding limitations under the 1940 Act on investments in other investment companies and certain 
other issuers. To the extent that we assume large positions in the securities of a small number of issuers, our NAV may fluctuate to a greater extent than that of a diversified 
investment company as a result of changes in the financial condition or the market’s assessment of the issuer. We may also be more susceptible to any single economic or 
regulatory occurrence than a diversified investment company might be. Beyond the asset diversification requirements to which we are subject as a BDC and a RIC, we do not 
have fixed guidelines for portfolio diversification, and our investments could be concentrated in relatively few portfolio companies or industries. Although we are classified as a 
non-diversified investment company within the meaning of the 1940 Act, we maintain the flexibility to operate as a diversified investment company and have done so for an 
extended period of time. To the extent that we operate as a non-diversified investment company in the future, we may be subject to greater risk.

40

  
 
Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. 

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform 

as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more 
companies. 

The following table shows the fair value of the totals of investments held in portfolio companies as of December 31, 2021, that represent greater than 5% of our net 

assets: 

(in thousands)
Zepz (p.k.a. Worldremit Group Limited)
Corium, Inc.
Rocket Lab Global Services, LLC
Phathom Pharmaceuticals, Inc.
uniQure B.V.
Delphix Corp.

December 31, 2021

Fair Value

Percentage of Net Assets

$

102,460  
90,997  
90,505  
86,382  
79,111  
65,620    

7.8 %
7.0 %
6.9 %
6.6 %
6.0 %
5.0 %

•

•

•

•

•

•

Zepz (p.k.a. WorldRemit Group Limited) is a global online money transfer business.

Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport.

Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal 
diseases and disorders.

uniQure B.V. is a leader in the field of gene therapy, developing proprietary therapies to treat patients with severe genetic diseases of the central nervous system 
and liver.

Delphix Corp. is a provider of a Data as a Service platform intended to help enterprises to accelerate cloud migrations, custom development and ERP rollouts. 

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial 

difficulty and fail to repay their obligations or to perform as expected.

Our investments may be in portfolio companies that have limited operating histories and resources. 

We expect that our portfolio will continue to consist of investments that may have relatively limited operating histories. These companies may be particularly 

vulnerable to U.S. and foreign economic downturns may have more limited access to capital and higher funding costs, may have a weaker financial position and may need more 
capital to expand or compete. These businesses also may experience substantial variations in operating results. They may face intense competition, including from larger, more 
established companies with greater financial, technical and marketing resources. Furthermore, some of these companies do business in regulated industries and could be 
affected by changes in government regulation applicable to their given industry. Accordingly, these factors could impair their cash flow or result in other events, such as 
bankruptcy, which could limit their ability to repay their obligations to us, and may adversely affect the return on, or the recovery of, our investment in these companies. We 
cannot assure you that any of our investments in our portfolio companies will be successful. We may lose our entire investment in any or all of our portfolio companies. 

Investing in publicly traded companies can involve a high degree of risk and can be speculative. 

We have invested, and expect to continue to invest, a portion of our portfolio in publicly traded companies or companies that are in the process of completing their IPO. 
As publicly traded companies, the securities of these companies may not trade at high volumes, and prices can be volatile, particularly during times of general market volatility, 
which may restrict our ability to sell our positions and may have a material adverse impact on us. 

41

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Our ability to invest in public companies may be limited in certain circumstances.

To maintain our status as a BDC, we are not permitted to acquire any assets other than “qualifying assets” specified in the 1940 Act unless, at the time the acquisition is 

made and giving effect to it, at least 70% of our total assets are qualifying assets (with certain limited exceptions). Subject to certain exceptions for follow-on investments and 
distressed companies, an investment in an issuer that has outstanding securities listed on a national securities exchange may be treated as a qualifying asset only if such issuer 
has a market capitalization that is less than $250.0 million at any point in the 60 days prior to the time of such investment and meets the other specified requirements.

Our investment strategy focuses on technology-related companies, which are subject to many risks, including volatility, intense competition, shortened product life 
cycles, changes in regulatory and governmental programs and periodic downturns, and you could lose all or part of your investment. 

We have invested and will continue investing primarily in technology-related companies, many of which may have narrow product lines and small market shares, which 
tend to render them more vulnerable to competitors’ actions and market conditions, as well as to general economic downturns. The revenues, income (or losses), and valuations 
of technology-related companies can and often do fluctuate suddenly and dramatically. In addition, technology-related industries are generally characterized by abrupt business 
cycles and intense competition. Overcapacity in technology-related industries, together with cyclical economic downturns, may result in substantial decreases in the market 
capitalization of many technology-related companies. Such decreases in market capitalization may occur again, and any future decreases in technology-related company 
valuations may be substantial and may not be temporary in nature. Therefore, our portfolio companies may face considerably more risk of loss than do companies in other 
industry sectors. 

Because of rapid technological change, the average selling prices of products and some services provided by technology-related companies have historically decreased 

over their productive lives. As a result, the average selling prices of products and services offered by technology-related companies may decrease over time, which could 
adversely affect their operating results, their ability to meet obligations under their debt securities and the value of their equity securities. This could, in turn, materially 
adversely affect our business, financial condition and results of operations. 

Our investments in sustainable and renewable technology companies are subject to substantial operational risks, such as underestimated cost projections, unanticipated 
operation and maintenance expenses, loss of government subsidies, and inability to deliver cost-effective alternative energy solutions compared to traditional energy products. 
In addition, sustainable and renewable technology companies employ a variety of means of increasing cash flow, including increasing utilization of existing facilities, 
expanding operations through new construction or acquisitions, or securing additional long-term contracts. Thus, some energy companies may be subject to construction risk, 
acquisition risk or other risks arising from their specific business strategies. Furthermore, production levels for solar, wind and other renewable energies may be dependent 
upon adequate sunlight, wind, or biogas production, which can vary from market to market and period to period, resulting in volatility in production levels and profitability. 
Demand for sustainable and renewable technology is also influenced by the available supply and prices for other energy products, such as coal, oil and natural gases. A change 
in prices in these energy products could reduce demand for alternative energy. 

A natural disaster may also impact the operations of our portfolio companies, including our technology-related portfolio companies. The nature and level of natural 

disasters cannot be predicted and may be exacerbated by global climate change. A portion of our technology-related portfolio companies rely on items assembled or produced 
in areas susceptible to natural disasters, and may sell finished goods into markets susceptible to natural disasters. A major disaster, such as an earthquake, tsunami, flood or 
other catastrophic event could result in disruption to the business and operations of our technology-related portfolio companies. 

We will invest in technology-related companies that are reliant on U.S. and foreign regulatory and governmental programs. Any material changes or discontinuation, 
due to change in administration or U.S. Congress or otherwise could have a material adverse effect on the operations of a portfolio company in these industries and, in turn, 
impair our ability to timely collect principal and interest payments owed to us to the extent applicable. 

42

  
 
We have invested in and may continue investing in technology-related companies that do not have venture capital or private equity firms as equity investors, and these 
companies may entail a higher risk of loss than do companies with institutional equity investors, which could increase the risk of loss of your investment. 

Our portfolio companies will often require substantial additional equity financing to satisfy their continuing working capital and other cash requirements and, in most 
instances, to service the interest and principal payments on our investment. Portfolio companies that do not have venture capital or private equity investors may be unable to 
raise any additional capital to satisfy their obligations or to raise sufficient additional capital to reach the next stage of development. Portfolio companies that do not have 
venture capital or private equity investors may be less financially sophisticated and may not have access to independent members to serve on their boards of directors, which 
means that they may be less successful than portfolio companies sponsored by venture capital or private equity firms. Accordingly, financing these types of companies may 
entail a higher risk of loss than would financing companies that are sponsored by venture capital or private equity firms. 

Sustainable and renewable technology companies are subject to extensive government regulation and certain other risks particular to the sectors in which they operate 
and our business and growth strategy could be adversely affected if government regulations, priorities and resources impacting such sectors change or if our portfolio 
companies fail to comply with such regulations. 

As part of our investment strategy, we plan to invest in portfolio companies in sustainable and renewable technology sectors that may be subject to extensive regulation 

by foreign, U.S. federal, state and/or local agencies. Changes in existing laws, rules or regulations, or judicial or administrative interpretations thereof, or new laws, rules or 
regulations could have an adverse impact on the business and industries of our portfolio companies. In addition, changes in government priorities or limitations on government 
resources could also adversely impact our portfolio companies. We are unable to predict whether any such changes in laws, rules or regulations will occur and, if they do occur, 
the impact of these changes on our portfolio companies and our investment returns. Furthermore, if any of our portfolio companies fail to comply with applicable regulations, 
they could be subject to significant penalties and claims that could materially and adversely affect their operations, which would also impact our ability to realize value since 
our exit from the investment may be subject to the portfolio company obtaining the necessary regulatory approvals. Our portfolio companies may be subject to the expense, 
delay and uncertainty of the regulatory approval process for their products and, even if approved, these products may not be accepted in the marketplace. 

In addition, there is considerable uncertainty about whether foreign, U.S., state and/or local governmental entities will enact or maintain legislation or regulatory 

programs that mandate reductions in greenhouse gas emissions or provide incentives for sustainable and renewable technology companies. Without such regulatory policies, 
investments in sustainable and renewable technology companies may not be economical and financing for sustainable and renewable technology companies may become 
unavailable, which could materially adversely affect the ability of our portfolio companies to repay the debt they owe to us. Any of these factors could materially and adversely 
affect the operations and financial condition of a portfolio company and, in turn, the ability of the portfolio company to repay the debt they owe to us. 

Cyclicality within the energy sector may adversely affect some of our portfolio companies.

Industries within the energy sector are cyclical with fluctuations in commodity prices and demand for, and production of commodities driven by a variety of factors. 

The highly cyclical nature of the industries within the energy sector may lead to volatile changes in commodity prices. While we generally do not invest directly in oil and gas 
companies, commodity price fluctuation may adversely affect the earnings of technology-related companies in which we may invest and the performance and valuation of our 
portfolio.

43

  
 
Our investments in the life sciences industry are subject to extensive government regulation, litigation risk, and certain other risks particular to that industry. 

We have invested and plan to continue investing in companies in the life sciences industry that are subject to extensive regulation by the FDA and to a lesser extent, 

other federal, state, and other foreign agencies. If any of these portfolio companies fail to comply with applicable regulations, they could be subject to significant penalties and 
claims that could materially and adversely affect their operations. Portfolio companies that produce medical devices or drugs are subject to the expense, delay and uncertainty 
of the regulatory approval process for their products and, even if approved, these products may not be accepted in the marketplace. In addition, governmental budgetary 
constraints effecting the regulatory approval process, new laws, regulations or judicial interpretations of existing laws and regulations might adversely affect a portfolio 
company in this industry. Portfolio companies in the life sciences industry may also have a limited number of suppliers of necessary components or a limited number of 
manufacturers for their products, and therefore face a risk of disruption to their manufacturing process if they are unable to find alternative suppliers when needed. Any of these 
factors could materially and adversely affect the operations of a portfolio company in this industry and, in turn, impair our ability to timely collect principal and interest 
payments owed to us. 

Our investments in the drug discovery industry are subject to numerous risks, including competition, extensive government regulation, product liability, and 
commercial difficulties. 

Our investments in the drug discovery industry are subject to numerous risks. The successful and timely implementation of the business model of our drug discovery 

portfolio companies depends on their ability to adapt to changing technologies and introduce new products. As competitors continue to introduce competitive products, the 
development and acquisition of innovative products and technologies that improve efficacy, safety, patient’s and clinician’s ease of use and cost-effectiveness are important to 
the success of such portfolio companies. The success of new product offerings will depend on many factors, including the ability to properly anticipate and satisfy customer 
needs, obtain regulatory approvals on a timely basis, develop and manufacture products in an economic and timely manner, obtain or maintain advantageous positions with 
respect to intellectual property, and differentiate products from those of competitors. Failure by our portfolio companies to introduce planned products or other new products or 
to introduce products on schedule could have a material adverse effect on our business, financial condition and results of operations. 

Further, the development of products by drug discovery companies requires significant research and development, clinical trials and regulatory approvals. The results of 

product development efforts may be affected by a number of factors, including the ability to innovate, develop and manufacture new products, complete clinical trials, obtain 
regulatory approvals and reimbursement in the U.S. and abroad, or gain and maintain market approval of products. In addition, regulatory review processes by U.S. and foreign 
agencies may extend longer than anticipated as a result of decreased funding and tighter fiscal budgets. Further, patents attained by others can preclude or delay the 
commercialization of a product. There can be no assurance that any products now in development will achieve technological feasibility, obtain regulatory approval, or gain 
market acceptance. Failure can occur at any point in the development process, including after significant funds have been invested. Products may fail to reach the market or 
may have only limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory 
approvals, failure to achieve market adoption, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or 
the infringement of intellectual property rights of others. 

Future legislation, and/or regulations and policies adopted by the FDA or other U.S. or foreign regulatory authorities may increase the time and cost required by some 
of our portfolio companies to conduct and complete clinical trials for the product candidates that they develop, and there is no assurance that these companies will 
obtain regulatory approval to market and commercialize their products in the U.S. and in foreign countries. 

The FDA has established regulations, guidelines and policies to govern the drug development and approval process, as have foreign regulatory authorities, which affect 
some of our portfolio companies. Any change in regulatory requirements due to the adoption by the FDA and/or foreign regulatory authorities of new legislation, regulations, or 
policies may require some of our portfolio companies to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to 
existing protocols and/or clinical trial applications or the need for new ones, may significantly impact the cost, timing and completion of the clinical trials. 

In addition, increased scrutiny by the U.S. Congress of the FDA’s and other authorities’ approval processes may significantly delay or prevent regulatory approval, as 
well as impose more stringent product labeling and post-marketing testing and other requirements. Foreign regulatory authorities may also increase their scrutiny of approval 
processes resulting in similar delays. Increased scrutiny and approvals processes may limit the ability of our portfolio companies to market and commercialize their products in 
the U.S. and in foreign countries. 

44

  
 
Life sciences companies, including drug development companies, device manufacturers, service providers and others, are also subject to material pressures when there 
are changes in the outlook for healthcare insurance markets. The ability for individuals, along with private and public insurers, to account for the costs of paying for healthcare 
insurance can place strain on the ability of new technology, devices and services to enter those markets, particularly when they are new or untested.  As a result, it is not 
uncommon for changes in the insurance marketplace to lead to a slower rate of adoption, price pressure and other forces that may materially limit the success of companies 
bringing such technologies to market.  Changes in the health insurance sector might then have an impact on the value of companies in our portfolio or our ability to invest in the 
sector generally.

Changes in healthcare laws and other regulations, or the enforcement or interpretation of such laws or regulations, applicable to some of our portfolio companies’ 
businesses may constrain their ability to offer their products and services. 

Changes in healthcare or other laws and regulations, or the enforcement or interpretation of such laws or regulations, applicable to the businesses of some of our 

portfolio companies may occur that could increase their compliance and other costs of doing business, require significant systems enhancements, or render their products or 
services less profitable or obsolete, any of which could have a material adverse effect on their results of operations. There has also been an increased political and regulatory 
focus on healthcare laws in recent years, and new legislation could have a material effect on the business and operations of some of our portfolio companies. 

Additionally, because of the possibility of additional changes to healthcare laws and regulations under the current U.S. presidential administration, we cannot quantify 

or predict with any certainty the likely impact on our portfolio companies, our business model, prospects, financial condition or results of operations. We also anticipate that 
Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and 
adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare delivery system. We cannot assure you as to the ultimate 
content, timing, or effect of changes, nor is it possible at this time to estimate the impact of any such potential legislation on certain of our portfolio companies, our business 
model, prospects, financial condition or results of operations.

Price declines and illiquidity in the corporate debt markets could adversely affect the fair value of our portfolio investments, reducing our NAV through increased net 
unrealized depreciation. 

As a BDC, we are required to carry our investments at market value or, if no market value is ascertainable, at fair market value as determined in good faith by or under 

the direction of our Board. As part of the valuation process, we may take into account the following types of factors, if relevant, in determining the fair value of our 
investments: the enterprise value of a portfolio company (an estimate of the total fair value of the portfolio company’s debt and equity), the nature and realizable value of any 
collateral, the portfolio company’s ability to make payments and its earnings and discounted cash flow, the markets in which the portfolio company does business, a comparison 
of the portfolio company’s securities to similar publicly traded securities, changes in the interest rate environment and the credit markets generally that may affect the price at 
which similar investments may be made in the future and other relevant factors. When an external event such as a purchase transaction, public offering or subsequent equity 
sale occurs, we use the pricing indicated by the external event to corroborate our valuation. While most of our investments are not publicly traded, applicable accounting 
standards require us to assume as part of our valuation process that our investments are sold in a principal market to market participants (even if we plan on holding an 
investment through its maturity). As a result, volatility in the capital markets can also adversely affect our investment valuations. Decreases in the market values or fair values 
of our investments are recorded as unrealized depreciation. The effect of all of these factors on our portfolio can reduce our NAV by increasing net unrealized depreciation in 
our portfolio. 

Depending on market conditions, we could incur substantial realized losses and may suffer substantial unrealized depreciation in future periods, which could have a 

material adverse impact on our business, financial condition and results of operations. 

45

  
 
Economic recessions or slowdowns could impair the ability of our portfolio companies to repay loans, which, in turn, could increase our non-performing assets, 
decrease the value of our portfolio, reduce our volume of new loans and have a material adverse effect on our results of operations. 

Many of our portfolio companies may be susceptible to economic slowdowns or recessions in both the U.S. and foreign countries, and may be unable to repay our loans 

during such periods. Therefore, during such periods, our non-performing assets are likely to increase and the value of our portfolio is likely to decrease. Adverse economic 
conditions also may decrease the value of collateral securing some of our loans and the value of our equity investments. Economic slowdowns or recessions could lead to 
financial losses in our portfolio and a decrease in revenues, net income and assets. Unfavorable economic conditions also could increase our funding costs, limit our access to 
the capital markets or result in a decision by lenders not to extend credit to us. These events could prevent us from increasing investments and harm our operating results. A 
reduction in liquidity caused by or associated with economic slowdowns or recessions may also incentivize our portfolio companies to draw on most, if not all, of the unfunded 
portion of any revolving or delayed draw term loans made by us, subject to availability under the terms of such loans. 

In particular, intellectual property owned or controlled by our portfolio companies may constitute an important portion of the value of the collateral of our loans to our 

portfolio companies. Adverse economic conditions may decrease the demand for our portfolio companies’ intellectual property and consequently its value in the event of a 
bankruptcy or required sale through a foreclosure proceeding. As a result, our ability to fully recover the amounts owed to us under the terms of the loans may be impaired by 
such events. 

A portfolio company’s failure to satisfy financial or operating covenants imposed by us or other lenders could lead to defaults and, potentially, termination of the 

portfolio company’s loans and foreclosure on its secured assets, which could trigger cross-defaults under other agreements and jeopardize the portfolio company’s ability to 
meet its obligations under the debt securities that we hold. We may incur expenses to the extent necessary to seek recovery upon default or to negotiate new terms with a 
defaulting portfolio company.

Our portfolio companies may be unable to repay or refinance outstanding principal on their loans at or prior to maturity, and rising interest rates may make it more 
difficult for portfolio companies to make periodic payments on their loans.

Our portfolio companies may be unable to repay or refinance outstanding principal on their loans at or prior to maturity. This risk and the risk of default is increased to 

the extent that the loan documents do not require the portfolio companies to pay down the outstanding principal of such debt prior to maturity. In addition, if general interest 
rates rise, there is a risk that our portfolio companies will be unable to pay escalating interest amounts, which could result in a default under their loan documents with us. Any 
failure of one or more portfolio companies to repay or refinance its debt at or prior to maturity or the inability of one or more portfolio companies to make ongoing payments 
following an increase in contractual interest rates could have a material adverse effect on our business, financial condition, results of operations and cash flows.

The disposition of our investments may result in contingent liabilities.

We currently expect that a portion of our investments will involve private securities. In connection with the disposition of an investment in private securities, we may be 

required to make representations about the business and financial affairs of the portfolio company typical of those made in connection with the sale of a business. We may also 
be required to indemnify the purchasers of such investment to the extent that any such representations turn out to be inaccurate or with respect to certain potential liabilities. 
These arrangements may result in contingent liabilities that ultimately yield funding obligations that must be satisfied through our return of certain distributions previously 
made to us.

The health and performance of our portfolio companies could be adversely affected by political and economic conditions in the countries in which they conduct 
business. 

Some of the products of our portfolio companies are developed, manufactured, assembled, tested or marketed outside the U.S. Any conflict or uncertainty in these 

countries, including due to natural disasters, public health concerns, political unrest or safety concerns, among other things, could harm their business, financial condition and 
results of operations. In addition, if the government of any country in which their products are developed, manufactured or sold sets technical or regulatory standards for 
products developed or manufactured in or imported into their country that are not widely shared, it may lead some of their customers to suspend imports of their products into 
that country, require manufacturers or developers in that country to manufacture or develop products with different technical or regulatory standards and disrupt cross-border 
manufacturing, marketing or business relationships which, in each case, could harm their businesses. 

46

  
 
Any unrealized depreciation we experience on our investment portfolio may be an indication of future realized losses, which could reduce our income available for 
distribution and could impair our ability to service our borrowings. 

As a BDC, we are required to carry our investments at market value or, if no market value is ascertainable, at fair value as determined in good faith by our Board. 

Decreases in the market values or fair values of our investments will be recorded as unrealized depreciation. Any unrealized depreciation in our investment portfolio could be 
an indication of a portfolio company’s inability to meet its repayment obligations to us with respect to the affected investments. This could result in realized losses in the future 
and ultimately in reductions of our income available for distribution in future periods and could materially adversely affect our ability to service our outstanding borrowings. 

A lack of IPO or merger and acquisition opportunities may cause companies to stay in our portfolio longer, leading to lower returns, unrealized depreciation, or 
realized losses. 

A lack of IPO or merger and acquisition, or M&A, opportunities for private companies, including venture capital-backed and institutional-backed companies could lead 

to companies staying longer in our portfolio as private entities still requiring funding. This situation may adversely affect the amount of available funding for early-stage 
companies in particular as, in general, venture-capital and other sponsor firms are being forced to provide additional financing to late-stage companies that cannot complete an 
IPO or M&A transaction. In the best case, such stagnation would dampen returns, and in the worst case, could lead to unrealized depreciation and realized losses as some 
companies run short of cash and have to accept lower valuations in private fundings or are not able to access additional capital at all. A lack of IPO or M&A opportunities for 
private companies can also cause some venture capital and other sponsor firms to change their strategies, leading some of them to reduce funding of their portfolio companies 
and making it more difficult for such companies to access capital and to fulfill their potential, which can result in unrealized depreciation and realized losses in such companies 
by other companies, such as ourselves, who are co-investors in such companies. 

The majority of our portfolio companies will need multiple rounds of additional financing to repay their debts to us and continue operations. Our portfolio companies 
may not be able to raise additional financing, which could harm our investment returns. 

The majority of our portfolio companies will often require substantial additional equity financing to satisfy their continuing working capital and other cash requirements 

and, in most instances, to service the interest and principal payments on our investment. Each round of venture financing is typically intended to provide a company with only 
enough capital to reach the next stage of development. We cannot predict the circumstances or market conditions under which our portfolio companies will seek additional 
capital. It is possible that one or more of our portfolio companies will not be able to raise additional financing or may be able to do so only at a price or on terms unfavorable to 
us, either of which would negatively impact our investment returns. Some of these companies may be unable to obtain sufficient financing from private investors, public capital 
markets or traditional lenders. This may have a significant impact if the companies are unable to obtain certain federal, state or foreign agency approval for their products or the 
marketing thereof, or if regulatory review processes extend longer than anticipated, and the companies need continued funding for their operations during these times. 
Accordingly, financing these types of companies may entail a higher risk of loss than would financing companies that are able to utilize traditional credit sources. 

If the assets securing the loans that we make decrease in value, then we may lack sufficient collateral to cover losses. 

To attempt to mitigate credit risks, we will typically take a security interest in the available assets of our portfolio companies. There is no assurance that we will obtain 

or properly perfect our liens. 

There is a risk that the collateral securing our loans may decrease in value over time, may be difficult to sell in a timely manner, may be difficult to appraise and may 

fluctuate in value based upon the success of the business and market conditions, including as a result of the inability of a portfolio company to raise additional capital. In some 
circumstances, our lien could be subordinated to claims of other creditors. Consequently, the fact that a loan is secured does not guarantee that we will receive principal and 
interest payments according to the loan’s terms, or that we will be able to collect on the loan should we be forced to enforce our remedies. 

In addition, because we invest in technology-related companies, a substantial portion of the assets securing our investment may be in the form of intellectual property, if 
any, inventory and equipment and, to a lesser extent, cash and accounts receivable. Intellectual property, if any, that is securing our loan could lose value if, among other things, 
the company’s rights to the intellectual property are challenged or if the company’s license to the intellectual property is revoked or expires, the technology fails to achieve its 
intended results or a new technology makes the intellectual property functionally obsolete. Inventory may not be adequate to secure our loan if our valuation of the inventory at 
the time that we made the loan was not accurate or if there is a reduction in the demand for the inventory.  

47

  
 
We may from time-to-time provide loans that will be collateralized partially or only by equipment of the portfolio company. If the portfolio company defaults on the 
loan, we would take possession of the underlying equipment to satisfy the outstanding debt. If there are changes in technology or advances in new equipment that render the 
particular equipment obsolete or of limited value, or if the company fails to adequately maintain or repair the equipment, the residual value of the equipment at the time we take 
possession may not be sufficient to satisfy the outstanding debt. We could therefore experience a loss on the disposition of the equipment and a material impairment of our 
ability to recover earned interest and principal in a foreclosure.

In most cases, we collateralize our investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. 
In other cases, we may obtain a negative pledge covering a company’s intellectual property. As of December 31, 2021, approximately 77.0% of our debt investments were in a 
senior secured first lien position, with (a) 37.5% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, (b) 31.6% 
secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited from pledging or encumbering its intellectual property, 
and (c) 7.9% secured as a "last-out” secured position with security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the 
“first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 20.6% of our debt investments were secured by a second priority security interest in 
all of the portfolio company’s assets, and 2.4% were unsecured.  

We may suffer a loss if a portfolio company defaults on a loan and the underlying collateral is not sufficient. 

In the event of a default by a portfolio company on a secured loan, we will only have recourse to the assets collateralizing the loan. If the underlying collateral value is 

less than the loan amount, we will suffer a loss. In addition, we sometimes make loans that are unsecured, which are subject to the risk that other lenders may be directly 
secured by the assets of the portfolio company. In the event of a default, those collateralized lenders would have priority over us with respect to the proceeds of a sale of the 
underlying assets. In cases described above, we may lack control over the underlying asset collateralizing our loan or the underlying assets of the portfolio company prior to a 
default, and as a result the value of the collateral may be reduced by acts or omissions by owners or managers of the assets. 

In the event of bankruptcy of a portfolio company, we may not have full recourse to its assets in order to satisfy our loan, or our loan may be subject to “equitable 
subordination.” This means that depending on the facts and circumstances, including the extent to which we actually provided significant “managerial assistance,” if any, to that 
portfolio company, a bankruptcy court might re-characterize our debt holding and subordinate all or a portion of our claim to that of other creditors. In addition, certain of our 
loans are subordinate to other debt of the portfolio company. If a portfolio company defaults on our loan or on debt senior to our loan, or in the event of a portfolio company 
bankruptcy, our loan will be satisfied only after the senior debt receives payment. Where debt senior to our loan exists, the presence of inter-creditor arrangements may limit 
our ability to amend our loan documents, assign our loans, accept prepayments, exercise our remedies (through “standstill” periods) and control decisions made in bankruptcy 
proceedings relating to the portfolio company. Bankruptcy and portfolio company litigation can significantly increase collection losses and the time needed for us to acquire the 
underlying collateral in the event of a default, during which time the collateral may decline in value, causing us to suffer losses. 

If the value of collateral underlying our loan declines or interest rates increase during the term of our loan, a portfolio company may not be able to obtain the necessary 

funds to repay our loan at maturity through refinancing. Decreasing collateral value and/or increasing interest rates may hinder a portfolio company’s ability to refinance our 
loan because the underlying collateral cannot satisfy the debt service coverage requirements necessary to obtain new financing. If a borrower is unable to repay our loan at 
maturity, we could suffer a loss which may adversely impact our financial performance. 

The inability of our portfolio companies to commercialize their technologies or create or develop commercially viable products or businesses would have a negative 
impact on our investment returns. 

The possibility that our portfolio companies will not be able to commercialize their technology, products or business concepts presents significant risks to the value of 

our investment. Additionally, although some of our portfolio companies may already have a commercially successful product or product line when we invest, technology-
related products and services often have a more limited market or life-span than have products in other industries. Thus, the ultimate success of these companies often depends 
on their ability to continually innovate, or raise additional capital, in increasingly competitive markets. Their inability to do so could affect our investment return. In addition, 
the intellectual property held by our portfolio companies often represents a substantial portion of the collateral, if any, securing our investments. We cannot assure you that any 
of our portfolio companies will successfully acquire or develop any new technologies, or that the intellectual property the companies currently hold will remain viable. Even if 
our portfolio companies are able to develop commercially viable products, the market for new products and services is highly competitive and rapidly changing. Neither our 
portfolio companies nor we have any control over the pace of technology development. Commercial success is difficult to predict, and the marketing efforts of our portfolio 
companies may not be successful. 

48

  
 
An investment strategy focused on privately-held companies presents certain challenges, including the lack of available information about these companies, a 
dependence on the talents and efforts of only a few key portfolio company personnel, and a greater vulnerability to economic downturns. 

We invest primarily in privately-held companies. Generally, very little public information exists about these companies, and we are required to rely on the ability of our 
management and investment teams to obtain adequate information to evaluate the potential returns from investing in these companies. Such small, privately held companies as 
we routinely invest in may also lack quality infrastructures, thus leading to poor disclosure standards or control environments. If we are unable to uncover all material 
information about these companies, then we may not make a fully informed investment decision, and we may not receive the expected return on our investment or lose some or 
all of the money invested in these companies.

Also, privately-held companies frequently have less diverse product lines and a smaller market presence than do larger competitors. Privately-held companies are, thus, 
generally more vulnerable to economic downturns and may experience more substantial variations in operating results than do larger competitors. These factors could affect our 
investment returns and our results of operations and financial condition. 

In addition, our success depends, in large part, upon the abilities of the key management personnel of our portfolio companies, who are responsible for the day-to-day 
operations of our portfolio companies. Competition for qualified personnel is intense at any stage of a company’s development, and high turnover of personnel is common in 
technology-related companies. The loss of one or more key managers can hinder or delay a company’s implementation of its business plan and harm its financial condition. Our 
portfolio companies may not be able to attract and retain qualified managers and personnel. Any inability to do so may negatively impact our investment returns and our results 
of operations and financial condition. 

If our portfolio companies are unable to protect their intellectual property rights or are required to devote significant resources to protecting their intellectual property 
rights, then our investments could be harmed. 

Our future success and competitive position depend in part upon the ability of our portfolio companies to obtain and maintain proprietary technology used in their 

products and services, which will often represent a significant portion of the collateral, if any, securing our investment. The portfolio companies will rely, in part, on patent, 
trade secret and trademark law to protect that technology, but competitors may misappropriate their intellectual property, and disputes as to ownership of intellectual property 
may arise. Portfolio companies may, from time to time, be required to institute litigation in order to enforce their patents, copyrights or other intellectual property rights, to 
protect their trade secrets, to determine the validity and scope of the proprietary rights of others or to defend against claims of infringement. Such litigation could result in 
substantial costs and diversion of resources. At the same time, failure to pursue such litigation may result in increased competition from infringing parties and adverse impacts 
to the portfolio company's business.  Similarly, if a portfolio company is found to infringe upon or misappropriate a third party’s patent or other proprietary rights, that portfolio 
company could be required to pay damages to such third party, alter its own products or processes, obtain a license from the third party and/or cease activities utilizing such 
proprietary rights, including making or selling products utilizing such proprietary rights. Any of the foregoing events could negatively affect both the portfolio company’s 
ability to service our debt investment and the value of any related debt and equity securities that we own, as well as any collateral securing our investment. 

We generally will not control our portfolio companies. 

In some instances, we may control our portfolio companies or provide our portfolio companies with significant managerial assistance. However, we generally do not, 

and do not expect to, control the ultimate decision making in many of our portfolio companies, even though we may have board representation or board observation rights, and 
our debt agreements may contain certain restrictive covenants. As a result, we are subject to the risk that a portfolio company in which we invest will make business decisions 
with which we disagree and the management of such company, as representatives of the holders of their common equity, will take risks or otherwise act in ways that do not 
serve our interests as investors. Due to the lack of liquidity for our investments in non-traded companies, we may not be able to dispose of our interests in our portfolio 
companies as readily as we would like or at an appropriate valuation. As a result, a portfolio company may make decisions that would decrease the value of our portfolio 
holdings.

Our financial condition, results of operations and cash flows could be negatively affected if we are unable to recover our principal investment as a result of a negative 
pledge or lack of a security interest on the intellectual property of our venture growth stage companies. 

In some cases, we collateralize our loans with a secured collateral position in a portfolio company's assets, which may include a negative pledge or, to a lesser extent, no 
security on their intellectual property. In the event of a default on a loan, the intellectual property of the portfolio company will most likely be liquidated to provide proceeds to 
pay the creditors of the company. There can be 

49

  
 
no assurance that our security interest, if any, in the proceeds of the intellectual property will be enforceable in a court of law or bankruptcy court or that there will not be others 
with senior or pari passu credit interests. 

Our relationship with certain portfolio companies may expose us to our portfolio companies' trade secrets and confidential information which may require us to be 
parties to non-disclosure agreements and restrict us from engaging in certain transactions. 

Our relationship with some of our portfolio companies may expose us to our portfolio companies' trade secrets and confidential information (including transactional 

data and personal data about their employees and clients) which may require us to be parties to non-disclosure agreements and restrict us from engaging in certain transactions. 
Unauthorized access or disclosure of such information may occur, resulting in theft, loss or other misappropriation. Any theft, loss, improper use, such as insider trading, or 
other misappropriation of confidential information could have a material adverse impact on our competitive positions, our relationship with our portfolio companies and our 
reputation and could subject us to regulatory inquiries, enforcement and fines, civil litigation (which may cause us to incur significant expense or expose us to losses) and 
possible financial liability or costs. 

Portfolio company litigation could result in additional costs, the diversion of management time and resources and have an adverse impact on the fair value of our 
investment. 

To the extent that litigation arises with respect to any of our portfolio companies, we may be named as a defendant, which could result in additional costs and the 

diversion of management time and resources. Furthermore, if we are providing managerial assistance to the portfolio company or have representatives on the portfolio 
company’s Board, our costs and diversion of our management’s time and resources in assessing the portfolio company could be substantial in light of any such litigation 
regardless of whether we are named as a defendant. In addition, litigation involving a portfolio company may be costly and affect the operations of the portfolio company’s 
business, which could in turn have an adverse impact on the fair value of our investment in such company. 

Our investments in foreign securities or investments denominated in foreign currencies may involve significant risks in addition to the risks inherent in U.S. and U.S. 
denominated investments. 

Our investment strategy contemplates that a portion of our investments may be in securities of foreign companies. Our total investments at value in foreign companies 

were approximately $296.3 million or 12.2% of total investments as of December 31, 2021. Investing in foreign companies may expose us to additional risks not typically 
associated with investing in U.S. companies. 

These risks include changes in exchange control regulations, political and social instability, expropriation, imposition of foreign taxes, less liquid markets and less 

available information than is generally the case in the U.S., higher transaction costs, less government supervision of exchanges, brokers and issuers, less developed bankruptcy 
laws, difficulty in enforcing contractual obligations, lack of uniform accounting and auditing standards and greater price volatility, among other things.

Although most of our investments will be U.S. dollar denominated, any investments denominated in a foreign currency will be subject to the risk that the value of a 

particular currency will change in relation to one or more other currencies. Among the factors that may affect currency values are trade balances, the level of short-term interest 
rates, differences in relative values of similar assets in different currencies, long-term opportunities for investment and capital appreciation, and political developments.

We may not have sufficient funds to make follow-on investments. Our decision not to make a follow-on investment may have a negative impact on a portfolio company 
in need of such an investment or may result in a missed opportunity for us.

After our initial investment in a portfolio company, we may be called upon from time to time to provide additional funds to such company or have the opportunity or 

need to increase our investment in a successful situation or attempt to preserve or enhance the value of our initial investment, for example, the exercise of a warrant to purchase 
common stock, or a negative situation, to protect an existing investment. We have the discretion to make any follow-on investments, subject to the availability of capital 
resources and regulatory considerations. We may elect not to make follow-on investments or otherwise lack sufficient funds to make those investments. Any decision we make 
not to make a follow-on investment or any inability on our part to make such an investment may have a negative impact on a portfolio company in need of such an investment 
or may result in a missed opportunity for us to increase our participation in a successful operation and may dilute our equity interest or otherwise reduce the expected yield on 
our investment. Moreover, a follow-on investment may limit the number of companies in which we can make initial investments. In determining whether to make a follow-on 
investment, our management will exercise its business judgment and apply criteria similar to those used when making the initial investment. There is no assurance that we will 
make, or will have sufficient funds to make, follow-on investments and this could adversely affect our success and result in the loss of a substantial portion or all of our 
investment in a portfolio company.  

50

  
 
The lack of liquidity in our investments may adversely affect our business and, if we need to sell any of our investments, we may not be able to do so at a favorable 
price. As a result, we may suffer losses. 

We generally invest in debt securities with terms of up to seven years and hold such investments until maturity, and we do not expect that our related holdings of equity 

securities will provide us with liquidity opportunities in the near-term. We invest and expect to continue investing in companies whose securities have no established trading 
market and whose securities are and will be subject to legal and other restrictions on resale or whose securities are and will be less liquid than publicly traded securities. The 
illiquidity of these investments may make it difficult for us to sell these investments when desired. In addition, if we are required to liquidate all or a portion of our portfolio 
quickly, we may realize significantly less than the value at which we had previously recorded these investments. As a result, we do not expect to achieve liquidity in our 
investments in the near-term. However, to maintain our qualification as a BDC and as a RIC, we may have to dispose of investments if we do not satisfy one or more of the 
applicable criteria under the respective regulatory frameworks. 

Our portfolio companies may incur debt or issue equity securities that rank equally with, or senior to, our investments in such companies. 

We invest primarily in debt securities issued by our portfolio companies. In some cases, portfolio companies will be permitted to incur other debt, or issue other equity 
securities, that rank equally with, or senior to, our investment. Such instruments may provide that the holders thereof are entitled to receive payment of distributions, interest or 
principal on or before the dates on which we are entitled to receive payments in respect of our investments. These debt instruments would usually prohibit the portfolio 
companies from paying interest on or repaying our investments in the event and during the continuance of a default under such debt. Also, in the event of insolvency, 
liquidation, dissolution, reorganization or bankruptcy of a portfolio company, holders of securities ranking senior to our investment in that portfolio company would typically 
be entitled to receive payment in full before we receive any distribution in respect of our investment. After repaying such holders, the portfolio company might not have any 
remaining assets to use for repaying its obligation to us. In the case of securities ranking equally with our investments, we would have to share on a pari passu basis any 
distributions with other security holders in the event of an insolvency, liquidation, dissolution, reorganization or bankruptcy of the relevant portfolio company. 

The rights we may have with respect to the collateral securing any junior priority loans we make to our portfolio companies may also be limited pursuant to the terms of 

one or more inter-creditor agreements that we enter into with the holders of senior debt. Under such an inter-creditor agreement, at any time that senior obligations are 
outstanding, we may forfeit certain rights with respect to the collateral to the holders of the senior obligations. These rights may include the right to commence enforcement 
proceedings against the collateral, the right to control the conduct of such enforcement proceedings, the right to approve amendments to collateral documents, the right to 
release liens on the collateral and the right to waive past defaults under collateral documents. We may not have the ability to control or direct such actions, even if as a result 
our rights as junior lenders are adversely affected. 

Our warrant and equity investments can be volatile, and we may not realize gains from these investments. If our warrant and equity investments do not generate gains, 
then the return on our invested capital will be lower than it would otherwise be, which could result in a decline in the value of shares of our common stock. 

When we invest in debt securities, we generally expect to acquire warrants or other equity securities as well. Our goal is ultimately to dispose of these equity interests 

and realize gains upon disposition of such interests. Over time, the gains that we realize on these equity interests may offset, to some extent, losses that we experience on 
defaults under debt and other securities that we hold. However, the equity interests that we receive may not appreciate in value and, in fact, may decline in value. Accordingly, 
we may not be able to realize gains from our equity interests, and any gains that we do realize on the disposition of any equity interests may not be sufficient to offset any other 
losses that we experience. In addition, we anticipate that approximately 50% of our warrants may not realize and exit or generate any returns. Furthermore, because of the 
financial reporting requirements under U.S. generally accepted accounting principles ("U.S. GAAP"), of those approximately 50% of warrants that we do not realize and exit, 
the assigned costs to the initial warrants may lead to realized write-offs when the warrants either expire or are not exercised.

51

  
 
Prepayments of our debt investments by our portfolio companies could adversely impact our results of operations and reduce our return on equity. 

During the year ended December 31, 2021, we received debt investment early principal repayments and pay down of working capital debt investments of approximately 

$1,185.0 million. We are subject to the risk that the investments we make in our portfolio companies may be repaid prior to maturity. When this occurs, we will generally 
reinvest these proceeds in temporary investments, pending their future investment in new portfolio companies. These temporary investments will typically have substantially 
lower yields than the debt being prepaid and we could experience significant delays in reinvesting these amounts. Any future investment in a new portfolio company may also 
be at lower yields than the debt that was repaid. As a result, our results of operations could be materially adversely affected if one or more of our portfolio companies elect to 
prepay amounts owed to us. Additionally, prepayments could negatively impact our return on equity, which could result in a decline in the market price of our common stock. 

We may choose to waive or defer enforcement of covenants in the debt securities held in our portfolio, which may cause us to lose all or part of our investment in these 
companies. 

We structure the debt investments in our portfolio companies to include business and financial covenants placing affirmative and negative obligations on the operation 
of the company’s business and its financial condition. However, from time to time we may elect to waive breaches of these covenants, including our right to payment, or waive 
or defer enforcement of remedies, such as acceleration of obligations or foreclosure on collateral, depending upon the financial condition and prospects of the particular 
portfolio company. These actions may reduce the likelihood of receiving the full amount of future payments of interest or principal and be accompanied by a deterioration in the 
value of the underlying collateral as many of these companies may have limited financial resources, may be unable to meet future obligations and may go bankrupt. This could 
negatively impact our ability to pay distributions, could adversely affect our results of operation and financial condition and cause the loss of all or part of your investment. 

We may also be subject to lender liability claims for actions taken by us with respect to a borrower’s business or instances where we exercise control over the borrower. 
It is possible that we could become subject to a lender’s liability claim, including as a result of actions taken in rendering significant managerial assistance or actions to compel 
and collect payments from the borrower outside the ordinary course of business. 

Our loans could be subject to equitable subordination by a court which would increase our risk of loss with respect to such loans or we could be subject to lender 
liability claims. 

Courts may apply the doctrine of equitable subordination to subordinate the claim or lien of a lender against a borrower to claims or liens of other creditors of the 

borrower, when the lender or its affiliates is found to have engaged in unfair, inequitable or fraudulent conduct. The courts have also applied the doctrine of equitable 
subordination when a lender or its affiliates is found to have exerted inappropriate control over a client, including control resulting from the ownership of equity interests in a 
client or providing of significant managerial assistance. We have made direct equity investments or received warrants in connection with loans. These investments represent 
approximately 9.2% of the outstanding value of our investment portfolio as of December 31, 2021. Payments on one or more of our loans, particularly certain loans to clients in 
which we also hold equity interests, may be subject to claims of equitable subordination. If we were deemed to have the ability to control or otherwise exercise influence over 
the business and affairs of one or more of our portfolio companies resulting in economic hardship to other creditors of that company, this control or influence may constitute 
grounds for equitable subordination and a court may treat one or more of our loans as if it were unsecured or common equity in the portfolio company. In that case, if the 
portfolio company were to liquidate, we would be entitled to repayment of our loan on a pro-rata basis with other unsecured debt or, if the effect of subordination was to place 
us at the level of common equity, then on an equal basis with other holders of the portfolio company’s common equity only after all of its obligations relating to its debt and 
preferred securities had been satisfied. 

In addition to these risks, in the event we elect to convert our debt position to equity, or otherwise take control of a portfolio company (such as through placing a 

member of our management team on its Board), as part of a restructuring, we face additional risks acting in that capacity.  It is not uncommon for unsecured, or otherwise 
unsatisfied creditors, to sue parties that elect to use their debt positions to later control a company following a restructuring or bankruptcy.  Apart from lawsuits, key customers 
and suppliers might act in a fashion contrary to the interests of a portfolio company if they were left unsatisfied in a restructuring or bankruptcy.  Any combination of these 
factors might lead to the loss in value of a company subject to such activity and may divert the time and attention of our management team and investment team to help to 
address such issues in a portfolio company. 

52

  
 
The potential inability of our portfolio companies in the healthcare industry to charge desired prices with respect to prescription drugs could impact their revenues and 
in turn their ability to repay us.

Some of our portfolio companies in the healthcare industry are subject to risks associated with the pricing for prescription drugs. It is uncertain whether customers of 

our healthcare industry portfolio companies will continue to utilize established prescription drug pricing methods, or whether other pricing benchmarks will be adopted for 
establishing prices within the industry. Legislation may lead to changes in the pricing for Medicare and Medicaid programs. Regulators have conducted investigations into the 
use of prescription drug pricing methods for federal program payment, and whether such methods have inflated drug expenditures by the Medicare and Medicaid programs. 
Federal and state proposals have sought to change the basis for calculating payment of certain drugs by the Medicare and Medicaid programs. Any changes to the method for 
calculating prescription drug costs may reduce the revenues of our portfolio companies in the healthcare industry which could in turn impair their ability to timely make any 
principal and interest payments owed to us.

Risks Related to Our Securities 

Investing in shares of our common stock involves an above average degree of risk. 

The investments we make in accordance with our investment objective may result in a higher amount of risk, volatility or loss of principal than alternative investment 

options. Our investments in portfolio companies may be highly speculative and aggressive, and therefore, an investment in our common stock may not be suitable for investors 
with lower risk tolerance. 

Our common stock may trade below its NAV per share, which could limit our ability to raise additional equity capital. 

If our common stock is trading below its NAV per share, we will generally not be able to issue additional shares of our common stock at its market price without first 
obtaining the approval for such issuance from our independent directors and stockholders. If our common stock trades below NAV, the higher cost of equity capital may result 
in it being unattractive to raise new equity, which may limit our ability to grow. The risk of trading below NAV is separate and distinct from the risk that our NAV per share 
may decline. We cannot predict whether shares of our common stock will trade above, at or below our NAV. 

Provisions of the Maryland General Corporation Law and of our charter and bylaws could deter takeover attempts and have an adverse impact on the price of our 
common stock. 

The Maryland General Corporation Law and our charter and bylaws contain provisions that may have the effect of discouraging, delaying, or making difficult a change 

in control of our company or the removal of our incumbent directors. Under our charter, our Board is divided into three classes serving staggered terms, which will make it 
more difficult for a hostile bidder to acquire control of us. In addition, our Board may, without stockholder action, authorize the issuance of shares of stock in one or more 
classes or series, including preferred stock. Subject to compliance with the 1940 Act, our Board may, without stockholder action, amend our charter to increase the number of 
shares of stock of any class or series that we have authority to issue. The existence of these provisions, among others, may have a negative impact on the price of our common 
stock and may discourage third party bids for ownership of our company. These provisions may prevent any premiums being offered to you for shares of our common stock in 
connection with a takeover.

Sales of substantial amounts of our common stock in the public market may have an adverse effect on the market price of our common stock. 

Sales of substantial amounts of our common stock, or the availability of such common stock for sale (including as a result of the conversion of any convertible notes 

issued and outstanding or that we may issue in the future), could adversely affect the prevailing market prices for our common stock, which may also lead to further dilution of 
our earnings per share. If this occurs and continues, it could impair our ability to raise additional capital through the sale of securities should we desire to do so.

53

 
  
 
Regulations governing our operation as a BDC affect our ability to, and the way in which we, raise additional equity capital. Any issuance of our common stock at a 
price below the current NAV could materially dilute your interest in our common stock and reduce our NAV per share. 

Subject to limited exceptions, we are not generally able to issue and sell our common stock at a price per share below NAV. We may, however, sell our common stock, 

warrants, options, or other rights to acquire such common stock, at a price below the current NAV if our Board determines that such sale is in the best interest of our 
stockholders and if stockholders, including a majority of those stockholders that are not affiliated with us, approved of such sale. In any such case, the price at which our 
securities are to be issued and sold may not be less than a price that, in the determination of the Board, closely approximates the market value of such securities (less any 
distributing commission or discount). We do not currently have authorization from our stockholders to issue common stock at a price below its then current NAV per share. We 
did not sell any of our securities at a price below NAV during the year ended December 31, 2021.

We may in the future seek to obtain approval from our stockholders to issue shares of our common stock at prices below the then current NAV per share of our common 
stock, subject to certain limitations and with the approval from our independent directors. If we receive such approval, we may periodically issue shares of our common 
stock at a price below the then current NAV per share of common stock. Any such issuance could materially dilute your interest in our common stock and reduce our 
NAV per share. 

We may in the future seek to obtain approval from our stockholders to issue shares of our common stock at prices below the then current NAV per share of our common 

stock. Such approval would allow us to access the capital markets in a way that we typically are unable to do as a result of restrictions described above. Any decision to sell 
shares of our common stock below the then current NAV per share of our common stock is subject to the determination by our Board that such issuance and sale is in our and 
our stockholders’ best interests. 

Any sale or other issuance of shares of our common stock at a price below NAV per share would result in an immediate dilution to your interest in our common stock 

and a reduction of our NAV per share. This dilution would occur as a result of a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting 
interest in us than the increase in our assets resulting from such issuance. Because the number of future shares of common stock that may be issued below our NAV per share 
and the price and timing of such issuances, if any, are not currently known, we cannot predict the actual dilutive effect of any such issuance. We also cannot determine the 
resulting reduction in our NAV per share of any such issuance at this time. We caution you that such effects may be material, and we undertake to describe all the material risks 
and dilutive effects of any offering that we may make at a price below our then current NAV in the future in a prospectus supplement issued in connection with any such 
offering. We cannot predict whether shares of our common stock will trade above, at or below our NAV. 

We may allocate the net proceeds from an offering in ways with which you may not agree. 

We have significant flexibility in investing the net proceeds of an offering and may use the net proceeds from an offering in ways with which you may not agree or for 

purposes other than those contemplated at the time of the offering. 

If we issue preferred stock, debt securities or convertible debt securities, the NAV and market value of our common stock may become more volatile. 

We cannot assure you that the issuance of preferred stock and/or debt securities would result in a higher yield or return to the holders of our common stock. The 

issuance of preferred stock, debt securities or convertible debt would likely cause the NAV and market value of our common stock to become more volatile. If the distribution 
rate on the preferred stock, or the interest rate on the debt securities, were to approach the net rate of return on our investment portfolio, the benefit of leverage to the holders of 
our common stock would be reduced. If the distribution rate on the preferred stock, or the interest rate on the debt securities, were to exceed the net rate of return on our 
portfolio, the use of leverage would result in a lower rate of return to the holders of common stock than if we had not issued the preferred stock or debt securities. Any decline 
in the NAV of our investment would be borne entirely by the holders of our common stock. Therefore, if the market value of our portfolio were to decline, the leverage would 
result in a greater decrease in NAV to the holders of our common stock than if we were not leveraged through the issuance of preferred stock. This decline in NAV would also 
tend to cause a greater decline in the market price for our common stock. 

There is also a risk that, in the event of a sharp decline in the value of our net assets, we would be in danger of failing to maintain required asset coverage ratios which 
may be required by the preferred stock, debt securities, convertible debt or units or of a downgrade in the ratings of the preferred stock, debt securities, convertible debt or our 
current investment income might not be sufficient to meet the distribution requirements on the preferred stock or the interest payments on the debt securities. If we do not 
maintain our required asset coverage ratios, we may not be permitted to declare dividend distributions. In order to counteract such an 

54

  
 
event, we might need to liquidate investments in order to fund redemption of some or all of the preferred stock, debt securities or convertible debt. In addition, we would pay 
(and the holders of our common stock would bear) all costs and expenses relating to the issuance and ongoing maintenance of the preferred stock, debt securities, convertible 
debt or any combination of these securities. Holders of preferred stock, debt securities, convertible debt or any combination of these securities may have different interests than 
holders of common stock and may at times have disproportionate influence over our affairs.

Holders of any preferred stock that we may issue will have the right to elect members of the Board and have class voting rights on certain matters.

The 1940 Act requires that holders of shares of preferred stock must be entitled as a class to elect two directors at all times and to elect a majority of the directors if 

distributions on such preferred stock are in arrears by two years or more, until such arrearage is eliminated. In addition, certain matters under the 1940 Act require the separate 
vote of the holders of any issued and outstanding preferred stock, including changes in fundamental investment restrictions and conversion to open-end status and, accordingly, 
preferred stockholders could veto any such changes. Restrictions imposed on the declarations and payment of dividends or other distributions to the holders of our common 
stock and preferred stock, both by the 1940 Act and by requirements imposed by rating agencies, might impair our ability to maintain our ability to be subject to tax as a RIC.

Terms relating to redemption may materially adversely affect your return on any debt securities that we may issue. 

If you are holding debt securities issued by us and such securities are redeemable at our option, we may choose to redeem your debt securities at times when prevailing 
interest rates are lower than the interest rate paid on your debt securities. In addition, if you are holding debt securities issued by us and such securities are subject to mandatory 
redemption, we may be required to redeem your debt securities at times when prevailing interest rates are lower than the interest rate paid on your debt securities. In this 
circumstance, you may not be able to reinvest the redemption proceeds in a comparable security at an effective interest rate as high as your debt securities being redeemed.

We may redeem our Notes at a redemption price set forth under the terms of the individual indentures (Refer to "Note 5 - Debt" included in the notes to our 

consolidated financial statements appearing elsewhere in this report). If we choose to redeem our Notes when the fair market value is above par value, you would experience a 
loss of any potential premium.

A downgrade, suspension, or withdrawal of the credit rating assigned by a rating agency to us or our debt securities, if any, or change in the debt markets could 
cause the liquidity or market value of our debt securities to decline significantly.  

Our credit ratings are an assessment by rating agencies of our ability to pay our debts when due. Consequently, real or anticipated changes in our credit ratings will 

generally affect the market value of our outstanding debt and equity securities and our ability to raise capital. These credit ratings may not reflect the potential impact of risks 
relating to the structure or marketing of such debt and equity securities. Credit ratings are not a recommendation to buy, sell or hold any security, and may be revised or 
withdrawn at any time by the issuing organization in its sole discretion.

Neither we nor any underwriter undertakes any obligation to maintain our credit ratings or to advise holders of our debt and equity securities of any changes in our 
credit ratings. There can be no assurance that a credit rating will remain for any given period of time or that such credit ratings will not be lowered or withdrawn entirely if 
future circumstances relating to the basis of the credit rating, such as adverse changes in our company, so warrant. An increase in the competitive environment, inability to 
cover distributions, or increase in leverage could lead to a downgrade in our credit ratings and limit our access to the debt and equity markets capability impairing our ability to 
grow the business. The conditions of the financial markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future.

Our shares may trade at discounts from NAV or at premiums that are unsustainable over the long term. 

Shares of BDCs may trade at a market price that is less than the NAV that is attributable to those shares. Our shares have historically traded above and below our NAV. 
The possibility that our shares of common stock will trade at a discount from NAV or at a premium that is unsustainable over the long term is separate and distinct from the risk 
that our NAV may decrease. It is not possible to predict whether our shares will trade at, above or below NAV in the future.

55

  
 
Our stockholders will experience dilution in their ownership percentage if they opt out of our dividend reinvestment plan. 

All distributions in cash payable to stockholders that are participants in our dividend reinvestment plan are automatically reinvested in shares of our common stock. As 

a result, our stockholders that opt out of our dividend reinvestment plan will experience dilution in their ownership percentage of our common stock over time.

If our investments do not meet our performance expectations, you may not receive distributions. 

We intend to make distributions on a quarterly basis to our stockholders. We may not be able to achieve operating results that will allow us to make distributions at a 

specific level or to increase the amount of these distributions from time to time. In addition, due to the asset coverage test applicable to us as a BDC, we may be limited in our 
ability to make distributions. Also, restrictions and provisions in any future credit facilities may limit our ability to make distributions. As a RIC, if we do not distribute at least 
a certain percentage of our income each taxable year as dividends for U.S. federal income tax purposes to our stockholders, we will suffer adverse tax consequences, including 
the inability to be subject to tax as a RIC. We cannot assure you that you will receive distributions at a particular level or at all. 

We may be subject to restrictions on our ability to make distributions to our stockholders.

Restrictions imposed on the declaration of dividends or other distributions to holders of our common stock, by both the 1940 Act and by requirements imposed by 

rating agencies, might impair our ability to make the required distributions to our stockholders in order to be subject to tax as a RIC. While we intend to prepay our Notes and 
other debt to the extent necessary to enable us to distribute our income as required to maintain our ability to be subject to tax as a RIC, there can be no assurance that such 
actions can be effected in time or in a manner to satisfy the requirements set forth in the Code.

Our distribution proceeds may exceed our earnings. Therefore, portions of the distributions that we make may represent a return of capital to stockholders, which will 
lower their tax basis in their shares.

The tax treatment and characterization of our distributions may vary significantly from time to time due to the nature of our investments. The ultimate tax 
characterization of our distributions made during a taxable year generally will not finally be determined until after the end of that taxable year. We may make distributions 
during a taxable year that exceed our investment company taxable income, determined without regard to any deduction for dividends paid, and net capital gains for that taxable 
year. In such a situation, the amount by which our total distributions exceed investment company taxable income, determined without regard to any deduction for dividends 
paid, and net capital gains generally would be treated as a return of capital up to the amount of a stockholder’s tax basis in the shares, with any amounts exceeding such tax 
basis generally treated as a gain from the sale or exchange of such shares. A return of capital generally is a return of a stockholder’s investment rather than a return of earnings 
or gains derived from our investment activities. Moreover, we may pay all or a substantial portion of our distributions from the proceeds of the sale of shares of our common 
stock or from borrowings in anticipation of future cash flow, which could constitute a return of stockholders’ capital and will lower such stockholders’ tax basis in our shares, 
which may result in increased tax liability to stockholders when they sell such shares. The tax liability to stockholders upon the sale of shares may increase even if such shares 
are sold at a loss. 

Our common stock price has been and continues to be volatile and may decrease substantially. 

As with any company, the price of our common stock will fluctuate with market conditions and other factors, which include, but are not limited to, the following: 

•

•

•

•

•

•

•

•

price and volume fluctuations in the overall stock market from time to time; 

significant volatility in the market price and trading volume of securities of RICs, BDCs or other financial services companies; 

any inability to deploy or invest our capital; 

fluctuations in interest rates; 

any shortfall in revenue or net income or any increase in losses from levels expected by investors or securities analysts; 

the financial performance of specific industries in which we invest in on a recurring basis; 

announcement of strategic developments, acquisitions, and other material events by us or our competitors, or operating performance of companies comparable to 
us; 

changes in regulatory policies or tax guidelines with respect to RICs, SBICs or BDCs; 

56

  
 
•

•

•

•

•

•

•

•

losing our ability to either qualify or be subject to U.S. federal income tax as a RIC; 

actual or anticipated changes in our earnings or fluctuations in our operating results, or changes in the expectations of securities analysts; 

changes in the value of our portfolio of investments; 

realized losses in investments in our portfolio companies; 

general economic conditions and trends; 

inability to access the capital markets; 

loss of a major funded source; or 

departure of key personnel. 

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. 
Due to the potential volatility of our stock price, we may be the target of securities litigation in the future. Securities litigation could result in substantial costs and could divert 
management’s attention and resources from our business.

We may be unable to invest a significant portion of the net proceeds from an offering or from exiting an investment or other capital on acceptable terms, which could 
harm our financial condition and operating results. 

Delays in investing the net proceeds raised in an offering or from exiting an investment or other capital may cause our performance to be worse than that of other fully 

invested BDCs or other lenders or investors pursuing comparable investment strategies. We cannot assure you that we will be able to identify any investments that meet our 
investment objective or that any investment that we make will produce a positive return. We may be unable to invest the net proceeds of any offering or from exiting an 
investment or other capital on acceptable terms within the time period that we anticipate or at all, which could harm our financial condition and operating results. 

We anticipate that, depending on market conditions and the amount of the capital, it may take us a substantial period of time to invest substantially all the capital in 

securities meeting our investment objective. During this period, we will invest the capital primarily in cash equivalents, U.S. government securities and other high-quality debt 
investments that mature in one year or less or use the net proceeds from such offerings to reduce then-outstanding debt obligations, which may produce returns that are 
significantly lower than the returns which we expect to achieve when our portfolio is fully invested in securities meeting our investment objective. As a result, any distributions 
that we pay during such period may be substantially lower than the distributions that we may be able to pay when our portfolio is fully invested in securities meeting our 
investment objective. In addition, until such time as the net proceeds of any offering or from exiting an investment or other capital are invested in new securities meeting our 
investment objective, the market price for our securities may decline. Thus, the initial return on your investment may be lower than when, if ever, our portfolio is fully invested 
in securities meeting our investment objective.

Your interest in us may be diluted if you do not fully exercise your subscription rights in any rights offering. In addition, if the subscription price is less than our NAV 
per share, then you will experience an immediate dilution of the aggregate NAV of your shares. 

In the event we issue subscription rights, stockholders who do not fully exercise their subscription rights should expect that they will, at the completion of a rights 
offering, own a smaller proportional interest in us than would otherwise be the case if they fully exercised their rights. We cannot precisely state the amount of any such dilution 
in share ownership because we do not know at this time what proportion of the shares will be purchased as a result of such rights offering. 

In addition, if the subscription price is less than the NAV per share of our common stock, then our stockholders would experience an immediate dilution of the 
aggregate NAV of their shares as a result of the offering. The amount of any decrease in NAV is not predictable because it is not known at this time what the subscription price 
and NAV per share will be on the expiration date of a rights offering or what proportion of the shares will be purchased as a result of such rights offering. Such dilution could be 
substantial. 

The trading market or market value of our publicly issued debt securities may fluctuate. 

Our publicly issued debt securities may or may not have, and may never develop, an established trading market. In addition to our creditworthiness, many factors may 

materially adversely affect the trading market for, and market value of, our publicly issued debt securities. These factors include, but are not limited to, the following: 

57

  
 
•

•

•

•

•

•

•

•

the time remaining to the maturity of these debt securities;

the outstanding principal amount of debt securities with terms identical to these debt securities;

the ratings assigned by national statistical ratings agencies;

the general economic environment; 

the supply of debt securities trading in the secondary market, if any; 

the redemption or repayment features, if any, of these debt securities; 

the level, direction and volatility of market interest rates generally; and 

market rates of interest higher or lower than rates borne by the debt securities. You should also be aware that there may be a limited number of buyers when you 
decide to sell your debt securities. This too may materially adversely affect the market value of the debt securities or the trading market for the debt securities.

The Notes are unsecured and therefore are effectively subordinated to any secured indebtedness we have currently incurred or may incur in the future.

The Notes are not secured by any of our assets or any of the assets of our subsidiaries. As a result, while the Notes remain senior in priority to our equity securities, they 

are effectively subordinated to any secured indebtedness we or our subsidiaries have currently incurred and may incur in the future (or any indebtedness that is initially 
unsecured to which we subsequently grant security) to the extent of the value of the assets securing such indebtedness. In any liquidation, dissolution, bankruptcy or other 
similar proceeding, the holders of any of our existing or future secured indebtedness and the secured indebtedness of our subsidiaries may assert rights against the assets 
pledged to secure that indebtedness in order to receive full payment of their indebtedness before the assets may be used to pay other creditors, including the holders of the 
Notes.

The Notes are structurally subordinated to the indebtedness and other liabilities of our subsidiaries.

The Notes are obligations exclusively of Hercules Capital, Inc. and not of any of our subsidiaries. None of our subsidiaries are or act as guarantors of the Notes. 

Furthermore, the Notes are not required to be guaranteed by any subsidiaries we may acquire or create in the future. Our secured indebtedness with respect to the SBA 
debentures is held through our SBIC subsidiary. The assets of any such subsidiary are not directly available to satisfy the claims of our creditors, including holders of the Notes.

Except to the extent we are a creditor with recognized claims against our subsidiaries, all claims of creditors (including holders of preferred stock, if any, of our 
subsidiaries) will have priority over our equity interests in such subsidiaries (and therefore the claims of our creditors, including holders of the Notes) with respect to the assets 
of such subsidiaries. Even if we are recognized as a creditor of one or more of our subsidiaries, our claims would still be subordinated to any security interests in the assets of 
any such subsidiary and to any indebtedness or other liabilities of any such subsidiary senior to our claims. As a result of not having a direct claim against any of our 
subsidiaries, the Notes are structurally subordinated to all indebtedness and other liabilities (including trade payables) of our subsidiaries and any subsidiaries that we may in 
the future acquire or establish as financing vehicles or otherwise. In addition, our subsidiaries may incur substantial additional indebtedness in the future, all of which would be 
structurally senior to the Notes.

The respective indentures under which the Notes were issued contain limited protections for the holders of the Notes.

The indentures under which the Notes were issued offers limited protections to the holders of the Notes. The terms of the respective Notes indentures do not restrict our 

or any of our subsidiaries’ ability to engage in, or otherwise be a party to, a variety of corporate transactions, circumstances or events that could have an adverse impact on an 
investment in the Notes. In particular, the terms of the respective Notes indentures do not place any restrictions on our or our subsidiaries’ ability to:

•

issue securities or otherwise incur additional indebtedness or other obligations, including (1) any indebtedness or other obligations that would be equal in right of 
payment to the Notes, (2) any indebtedness or other obligations that would be secured and therefore rank effectively senior in right of payment to the Notes to the 
extent of the values of the assets securing such debt, (3) indebtedness of ours that is guaranteed by one or more of our subsidiaries and which therefore would 
rank structurally senior to the Notes and (4) securities, indebtedness or other obligations issued or incurred by our subsidiaries that would be senior in right of 
payment to our equity interests in our subsidiaries and therefore would rank structurally senior in right of payment to the Notes with respect to the assets of our 
subsidiaries, in each case other than an incurrence of indebtedness or other obligation that would cause a violation of Section 18(a)(1)(A) as modified by Section 
61(a)(1) of the 1940 Act or any successor provisions, whether or not we continue to be subject to such provisions of the 1940 Act, but giving effect to any 
exemptive relief granted to us by the SEC (currently, these provisions generally prohibit us from making additional borrowings, including through the issuance of 
additional debt or the sale of additional debt securities, unless our asset coverage, as defined in the 1940 Act, equals at least 150% thereafter after such 
borrowings);

58

 
  
 
•

•

•

•

•

•

pay distributions on, or purchase or redeem or make any payments in respect of, capital stock or other securities ranking junior in right of payment to the Notes, in 
each case other than distributions, purchases, redemptions or payments that would cause a violation of Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 
1940 Act or any successor provisions, giving effect to (i) any exemptive relief granted to us by the SEC and (ii) no-action relief granted by the SEC to another 
BDC (or to us if we determine to seek such similar no-action or other relief) permitting the BDC to declare any cash distribution notwithstanding the prohibition 
contained in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act in order to maintain the BDC’s status as a RIC under Subchapter M of the Code 
(currently, these provisions generally prohibit us from declaring any cash dividend or distribution upon any class of our capital stock, or purchasing any such 
capital stock if our asset coverage, as defined in the 1940 Act, is below 150% at the time of the declaration of the dividend or distribution or the purchase and 
after deducting the amount of such dividend, distribution or purchase);

sell assets (other than certain limited restrictions on our ability to consolidate, merge or sell all or substantially all of our assets);

enter into transactions with affiliates;

create liens (including liens on the shares of our subsidiaries) or enter into sale and leaseback transactions;

make investments; or

create restrictions on the payment of distributions or other amounts to us from our subsidiaries.

Furthermore, the terms of the respective Notes indentures do not protect their respective holders in the event that we experience changes (including significant adverse 

changes) in our financial condition, results of operations or credit ratings, as they do not require that we or our subsidiaries adhere to any financial tests or ratios or specified 
levels of net worth, revenues, income, cash flow or liquidity, except as required under the 1940 Act.

Our ability to recapitalize, incur additional debt and take a number of other actions that are not limited by the terms of the Notes may have important consequences for 

their holders, including making it more difficult for us to satisfy our obligations with respect to the Notes or negatively affecting their trading value.

Certain of our current debt instruments include more protections for their respective holders than the Notes indentures. In addition to regulatory requirements that 
restrict our ability to raise capital, our Notes and Credit Facilities contain various covenants which, if not complied with, could require accelerated repayment under the facility 
or require us to repurchase the Notes thereby materially and adversely affecting our liquidity, financial condition, results of operations and ability to pay distributions.” In 
addition, other debt we issue or incur in the future could contain more protections for its holders than the respective Notes indentures , including additional covenants and 
events of default. The issuance or incurrence of any such debt with incremental protections could affect the market for and trading levels and prices of the Notes.

An active trading market for the 2033 Notes may not develop or be sustained, which could limit the market price of the 2033 Notes or your ability to sell them.

Although the 2033 Notes are listed on the NYSE under the symbol “HCXY”, we cannot provide any assurances that an active trading market will develop or be 
sustained for the 2033 Notes or that the 2033 Notes will be able to be sold. At various times, the 2033 Notes may trade at a discount from their initial offering price depending 
on prevailing interest rates, the market for similar securities, our credit ratings, general economic conditions, our financial condition, performance and prospects and other 
factors. To the extent an active trading market is not sustained, the liquidity and trading price for the 2033 Notes may be harmed.

59

  
 
If we default on our obligations to pay our other indebtedness, we may not be able to make payments on our outstanding Notes and Credit Facilities.

Any default under the agreements governing our indebtedness, including our Notes and Credit Facilities, or other indebtedness to which we may be a party, that is not 

waived by the required lenders or holders, and the remedies sought by the holders of such indebtedness, could make us unable to pay principal, premium, if any, and interest on 
any of our indebtedness, including our Notes and Credit Facilities, or other indebtedness and substantially decrease the market value of our outstanding Notes and Credit 
Facilities debt. If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and 
interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our 
indebtedness, we could be in default under the terms of the agreements governing such indebtedness. In the event of such default, the holders of such indebtedness could elect 
to declare all the funds borrowed thereunder to be due and payable, together with accrued and unpaid interest, the lenders under the SMBC Facility and the Union Bank Facility 
or other debt we may incur in the future could elect to terminate their commitments, cease making further loans and institute foreclosure proceedings against our assets, and we 
could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to seek to obtain waivers from the required lenders under the 
SMBC Facility or Union Bank Facility or the required holders of our outstanding Notes or other debt that we may incur in the future to avoid being in default. If we breach our 
debt covenants and seek a waiver, we may not be able to obtain a waiver from the required lenders or holders. If this occurs, we would be in default under the related Credit 
Facility or Notes and the lenders or holders could exercise their rights as described above, and we could be forced into bankruptcy or liquidation. If we are unable to repay debt, 
lenders having secured obligations, including the lenders under the SMBC Facility and the Union Bank Facility, could proceed against the collateral securing the debt. Because 
the SMBC Facility and the Union Bank Facility have, and any future credit facilities will likely have, customary cross-default provisions, if our outstanding Notes are 
accelerated, we may be unable to repay or finance the amounts due.

We may not be able to prepay the Notes or Credit Facilities upon a change in control.

The indentures governing the July 2024 Notes, February 2025 Notes, June 2025 Notes, March 2026 A Notes, and March 2026 B Notes require us to offer to prepay all 

of the issued and outstanding notes upon a change in control and election by the holders, which could have a material adverse effect on our business, financial condition and 
results of operations. A change in control under the indentures occurs upon the consummation of a transaction which results in a “person” or “group” (as those terms are used in 
the Exchange Act and the rules promulgated thereunder) becoming the beneficial owner of more than 50% of our outstanding voting stock.

Upon a change in control event, holders of the notes may require us to prepay for cash some or all of the notes at a prepayment price equal to 100% of the aggregate 
principal amount of the notes being prepaid, plus accrued and unpaid interest to, but not including, the date of prepayment. If a change in control were to occur, we may not 
have sufficient funds to prepay any such accelerated indebtedness. The 2033 Notes do not require us to purchase the 2033 Notes in connection with a change of control or any 
other event.

General Risk Factors 

The effects of the outbreak of COVID-19 have negatively affected the global economy and the United States economy, and may disrupt our operations, which could 
have an adverse effect on our business, financial condition and results of operations.

The COVID-19 pandemic, which began in late 2019 has and threatens to continue to create market volatility and disruption in the U.S. and across the global capital 

markets. With the rollout of vaccination programs in the U.S. and globally, several countries, as well as certain states in the U.S., have lifted or reduced certain travel 
restrictions, business restrictions, and other quarantine measures. This has contributed to a positive economic recovery since 2020, especially in the U.S. Although the 
economic recovery and rollout of vaccination programs are promising, the potential exists for new COVID-19 variants to impede the global economic recovery. For example, 
the Delta and Omicron variants have caused a surge in the reported number of cases, hospitalizations and deaths related to the COVID-19 pandemic. These surges led to the re-
introduction of restrictions and business shutdowns in certain states within the United States and globally. Although some states and municipalities have begun to eliminate 
restrictions related to COVID-19, there remains the potential for new COVID-19 variants to cause the reintroduction of such restrictions in the future. 

 As a result, COVID-19 may continue to disrupt our portfolio companies and their businesses, and certain industries in which our portfolio companies operate.  
Disruptions to our portfolio companies may impair their ability to fulfill their obligations to us and could result in increased risk of delinquencies, defaults, declining collateral 
values associated with our existing loans, and impairments or losses on our loans. Disruption and the pressures on their liquidity caused by COVID-19 on certain of our 
portfolio companies have been, or may continue to be, incentivized to draw on most, if not all, of the unfunded portion of any revolving or delayed draw term 

60

  
 
loans made by us, subject to availability under the terms of such loans. The extent to which the COVID-19 pandemic will continue to affect the financial condition and liquidity 
of our portfolio companies’ results of operations will depend on future developments, such as the speed and extent of further vaccine distribution and the impact of COVID-19 
variants that might arise, which are highly uncertain and cannot be predicted.

 Equally the extent of the impact of the COVID-19 pandemic on our own operational and financial performance, including our ability to execute our business strategies 

and initiatives in the expected time frame, will depend to a large extent on future developments regarding the duration and severity of the COVID-19, effectiveness of 
vaccination deployment and the actions taken by governments (including stimulus measures or the lack thereof) and their citizens to contain the COVID-19 or treat its impact, 
all of which are beyond our control. An extended period of global supply chain and economic disruption, including any resulting inflation, could materially affect our business, 
results of operations, access to sources of liquidity and financial condition. Given the fluidity of the situation, neither our management nor our Board is able to predict the full 
impact of COVID-19 on our business, future results of operations, financial position, or cash flows at this time. 

Depending on funding requirements, we may need to raise additional capital to meet our unfunded commitments through additional borrowings. 

As of December 31, 2021, we had approximately $286.8 million of available unfunded commitments, including undrawn revolving facilities, which were available at 

the request of the portfolio company and unencumbered by milestones. 

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio 

company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us 
relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial 
condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet 
financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash 
requirements. Closed commitments generally fund 70-80% of the committed amount in aggregate over the life of the commitment. We believe that our assets provide adequate 
cover to satisfy all of our unfunded commitments and we intend to use cash flow from normal and early principal repayments and proceeds from borrowings and notes to fund 
these commitments. However, there can be no assurance that we will have sufficient capital available to fund these commitments as they come due, which could have a material 
adverse effect on our reputation in the market and our ability to generate incremental lending activity and subject us to lender liability claims.

Our ability to secure additional financing and satisfy our financial obligations under indebtedness outstanding from time to time will depend upon our future operating 

performance, which is subject to the prevailing general economic and credit market conditions, including interest rate levels and the availability of credit generally, and 
financial, business and other factors, many of which are beyond our control. The prolonged continuation or worsening of current economic and capital market conditions could 
have a material adverse effect on our ability to secure financing on favorable terms, if at all. 

Global macro-economic and political events, terrorist attacks, acts of war, natural disasters or other public health emergencies may affect the market for our securities, 
impact the businesses in which we invest and harm our business, operating results and financial condition. 

Global macro-economic and political events, terrorist acts, acts of war, natural disasters or other public health emergencies may affect the market for our securities, 

disrupt our operations, as well as the operations of the businesses in which we invest. Such events and acts have created, and continue to create economic and political 
uncertainties and have contributed to global economic instability. Future events, acts, or other emergencies could further weaken the domestic economy, global economy, or 
both and create additional uncertainties, which may negatively impact the businesses in which we invest directly or indirectly and, in turn, could have a material adverse impact 
on our business, operating results and financial condition. Losses from such events and acts are generally unknown and uninsurable.

We may be the target of litigation. 

We may be the target of securities litigation in the future, particularly if the trading price of our common stock and our debt securities fluctuates significantly. We could 

also generally be subject to litigation, including derivative actions by our stockholders. Additionally, we could also be generally subject to litigation, indirectly through our 
relationships with the Adviser Subsidiary, the Adviser Funds that it manages, and External Parties that it services. Any litigation could result in substantial costs and divert 
management’s attention and resources from our business and cause a material adverse effect on our business, financial condition and results of operations. 

61

 
  
 
Acquisitions or investments that we may pursue could be unsuccessful, consume significant resources and require the incurrence of additional indebtedness.

We regularly consider acquisitions and investments that complement our existing business. These possible acquisitions and investments involve or may involve 

significant cash expenditures, debt incurrence, operating losses and expenses that could have a material effect on our financial condition and operating results.

In particular, if we incur additional debt, our liquidity and financial stability could be impaired as a result of using a significant portion of available cash or borrowing 

capacity to finance an acquisition. Moreover, we may face an increase in interest expense or financial leverage if additional debt is incurred to finance an acquisition, which 
may, among other things, adversely affect our various financial ratios and our compliance with the conditions of our existing indebtedness. In addition, such additional 
indebtedness may be secured by liens on our assets.

Acquisitions involve numerous other risks, including:

•

•

•

•

•

•

•

•

•

•

•

•

diversion of management time and attention;

failures to identify material problems and liabilities of acquisition targets or to obtain sufficient indemnification rights to fully offset possible liabilities related to 
the acquired businesses;

difficulties integrating the operations, technologies and personnel of the acquired businesses;

inefficiencies and complexities that may arise due to unfamiliarity with new assets, businesses or markets;

disruptions to our ongoing business;

inaccurate estimates of fair value made in the accounting for acquisitions and amortization of acquired intangible assets which would reduce future reported 
earnings;

the inability to obtain required financing for the new acquisition or investment opportunities and our existing business;

the need or obligation to divest portions of an acquired business;

challenges associated with operating in new geographic regions;

difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects;

potential loss of our or the acquired business’ key employees, contractual relationships, suppliers or customers; and

inability to obtain required regulatory approvals.

To the extent we pursue an acquisition that causes us to incur unexpected costs or that fails to generate expected returns, our financial position, results of operations and 

cash flows may be adversely affected, and our ability to service indebtedness, including our outstanding notes, may be negatively impacted.

In addition, we may fail in our pursuit of an acquisition and, instead, one of our competitors may successfully obtain the target and deprive us of an important 

opportunity and allow them to grow larger giving them the ability to have a lower cost of capital and competitive advantage in the market (including by being able to offer 
better pricing and larger loans) and, as a larger company, potentially giving them more valuable equity currency to do other transactions.

FATCA withholding may apply to payments made to certain foreign entities.

The Foreign Account Tax Compliance Act provisions of the Code and the related Treasury Regulations and other administrative guidance promulgated thereunder, or 

collectively, FATCA, generally requires us to withhold U.S. tax (at a 30% rate) on payments of interest and taxable dividends made to a foreign financial institution or non-
financial foreign entity (including such an institution or entity acting as an intermediary) unless the foreign financial institution or non-financial foreign entity complies with 
certain information reporting, withholding, identification, certification and related requirements imposed by FATCA. Persons located in jurisdictions that have entered into an 
intergovernmental agreement with the United States to implement FATCA may be subject to different rules. Stockholders may be requested to provide additional information to 
enable us to determine whether such withholding is required.  

62

  
 
Legislative or regulatory tax changes could adversely affect you.

At any time, the U.S. federal income tax laws governing RICs or the administrative interpretations of those laws or regulations may be amended.  Any of those new 

laws, regulations or interpretations may take effect retroactively and could adversely affect the taxation of us or of you as a stockholder.  Therefore, changes in tax laws, 
regulations or administrative interpretations or any amendments thereto could diminish the value of an investment in our shares or the value or the resale potential of our 
investments.

If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As 
a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. 

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and 
procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to 
fail to meet our reporting obligations. 

In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“the Sarbanes-Oxley Act”), or the subsequent 

testing by our independent registered public accounting firm (when undertaken, as noted below), may reveal deficiencies in our internal controls over financial reporting that 
are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention 
or improvement. Inferior internal controls could also cause investors and lenders to lose confidence in our reported financial information, which could have a negative effect on 
the trading price of our common stock. 

Changes in laws or regulations governing our business could negatively affect the profitability of our operations. 

Changes in the laws or regulations, or the interpretations of the laws and regulations, which govern BDCs, SBICs, RICs or non-depository commercial lenders could 

significantly affect our operations and our cost of doing business. We are subject to federal, state and local laws and regulations, in addition to applicable foreign and 
international laws and regulations, and are subject to judicial and administrative decisions that affect our operations, including our loan originations maximum interest rates, 
fees and other charges, disclosures to portfolio companies, the terms of secured transactions, collection and foreclosure procedures, and other trade practices. If these laws, 
regulations or decisions change, or if we expand our business into jurisdictions that have adopted more stringent requirements than those in which we currently conduct 
business, then we may have to incur significant expenses in order to comply or we may have to restrict our operations. In addition, if we do not comply with applicable laws, 
regulations and decisions, then we may lose licenses needed for the conduct of our business and be subject to civil fines and criminal penalties, any of which could have a 
material adverse effect upon our business results of operations or financial condition.

Economic sanction laws in the United States and other jurisdictions may prohibit us and our affiliates from transacting with certain countries, individuals and 
companies.

Economic sanction laws in the United States and other jurisdictions may prohibit us or our affiliates from transacting with certain countries, individuals and companies. 
In the United States, the U.S. Department of the Treasury’s Office of Foreign Assets Control administers and enforces laws, executive orders and regulations establishing U.S. 
economic and trade sanctions, which prohibit, among other things, transactions with, and the provision of services to, certain non-U.S. countries, territories, entities and 
individuals. These types of sanctions may significantly restrict or completely prohibit investment activities in certain jurisdictions, and if we, our portfolio companies or other 
issuers in which we invest were to violate any such laws or regulations, we may face significant legal and monetary penalties.

The U.S. Foreign Corrupt Practices Act (“FCPA”), and other anti-corruption laws and regulations, as well as anti-boycott regulations, may also apply to and restrict our 

activities, our portfolio companies and other issuers of our investments. If an issuer or we were to violate any such laws or regulations, such issuer or we may face significant 
legal and monetary penalties. The U.S. government has indicated that it is particularly focused on FCPA enforcement, which may increase the risk that an issuer or us becomes 
the subject of such actual or threatened enforcement. In addition, certain commentators have suggested that private investment firms and the funds that they manage may face 
increased scrutiny and/or liability with respect to the activities of their underlying portfolio companies. As such, a violation of the FCPA or other applicable regulations by us or 
an issuer of our portfolio investments could have a material adverse effect on us. We are committed to complying with the FCPA and other anti-corruption laws and regulations, 
as well as anti-boycott regulations, to which we are subject. As a result, we may be adversely affected because of our unwillingness to enter into transactions that violate any 
such laws or regulations.

63

  
 
Our business is subject to increasingly complex corporate governance, public disclosure and accounting requirements that could adversely affect our business and 
financial results. 

We are subject to changing rules and regulations of federal and state government as well as the stock exchange on which our common stock is listed. These entities, 

including the Public Company Accounting Oversight Board, the SEC and the New York Stock Exchange ("NYSE") have issued a significant number of new and increasingly 
complex requirements and regulations over the course of the last several years and continue to develop additional regulations and requirements in response to laws enacted by 
Congress. The Dodd-Frank Wall Street Reform and Protection Act, as amended ("the Dodd-Frank Act"), contains significant corporate governance and executive 
compensation-related provisions, and the SEC has adopted, and will continue to adopt, additional rules and regulations that may impact us. Our efforts to comply with these 
requirements have resulted in, and are likely to continue to result in, an increase in expenses and a diversion of management’s time from other business activities. While we 
cannot predict what effect any changes in the laws or regulations or their interpretations would have on our business as a result of recent financial reform legislation, these 
changes could be materially adverse to us and our stockholders.

In addition, our failure to maintain compliance with such rules, or for our management to appropriately address issues relating to our compliance with such rules fully 

and in a timely manner, exposes us to an increasing risk of inadvertent non-compliance.  While our management team takes reasonable efforts to ensure that we are in full 
compliance with all laws applicable to its operations, the increasing rate and extent of regulatory change increases the risk of a failure to comply, which may result in our ability 
to operate our business in the ordinary course or may subject us to potential fines, regulatory findings or other matters that may materially impact our business.

We incur significant costs as a result of being a publicly traded company.

As a publicly traded company, we incur legal, accounting and other expenses, including costs associated with the periodic reporting requirements applicable to a 

company whose securities are registered under the Exchange Act as well as additional corporate governance requirements, including requirements under the Sarbanes-Oxley 
Act and other rules implemented by the SEC.

Results may fluctuate and may not be indicative of future performance. 

Our operating results may fluctuate and, therefore, you should not rely on current or historical period results to be indicative of our performance in future reporting 

periods. Factors that could cause operating results to fluctuate include, but are not limited to, variations in the investment origination volume and fee income earned, changes in 
the accrual status of our debt investments, variations in timing of prepayments, variations in and the timing of the recognition of net realized gains or losses and changes in 
unrealized appreciation or depreciation, the level of our expenses, the degree to which we encounter competition in our markets, and general economic conditions. 

We face cyber-security risks and the failure in cyber security systems, as well as the occurrence of events unanticipated in our disaster recovery systems and 
management continuity planning could impair our ability to conduct business effectively. 

Our business operations rely upon secure information technology systems for data processing, storage and reporting. Despite careful security and controls design, 
implementation and updating, our information technology systems could become subject to cyber-attacks. Network, system, application and data breaches could result in 
operational disruptions or information misappropriation, which could have a material adverse effect on our business, results of operations and financial condition. 

The occurrence of a disaster such as a cyber-attack, a natural catastrophe, an industrial accident, a terrorist attack or war, pandemic or quarantine, events unanticipated 

in our disaster recovery systems, or a support failure from external providers, could have an adverse effect on our ability to conduct business and on our results of operations 
and financial condition, particularly if those events affect our computer-based data processing, transmission, storage, and retrieval systems or destroy data. If a significant 
number of our managers were unavailable in the event of a disaster, our ability to effectively conduct our business could be severely compromised.

We depend heavily upon computer systems to perform necessary business functions. Despite our implementation of a variety of security measures, our computer 

systems could be subject to cyber-attacks and unauthorized access, such as physical and electronic break-ins or unauthorized tampering. Like other companies, we may 
experience threats to our data and systems, including malware and computer virus attacks, unauthorized access, system failures and disruptions. If one or more of these events 
occurs, it could potentially jeopardize the confidential, proprietary and other information processed and stored in, and transmitted through, our computer systems and networks, 
or otherwise cause interruptions or malfunctions in our operations, which could result in damage to our reputation, financial losses, litigation, increased costs, regulatory 
penalties and/or customer dissatisfaction or loss.

64

  
 
In addition, the costs related to cyber or other security threats or disruptions may not be fully insured or indemnified by other means. Furthermore, cybersecurity has 
become a top priority for regulators around the world, and some jurisdictions have enacted laws requiring companies to notify individuals of data security breaches involving 
certain types of personal data. If we fail to comply with the relevant laws and regulations, we could suffer financial losses, a disruption of our businesses, liability to investors, 
regulatory intervention or reputational damage.

We are dependent on information systems and systems failures could significantly disrupt our business, which may, in turn, negatively affect the market price of our 
common stock and our ability to pay distributions. 

Our business is dependent on our and third parties’ communications and information systems. Any failure or interruption of those systems, including as a result of the 

termination of an agreement with any third-party service providers, could cause delays or other problems in our activities. Our financial, accounting, data processing, backup or 
other operating systems and facilities may fail to operate properly or become disabled or damaged as a result of a number of factors including events that are wholly or partially 
beyond our control and adversely affect our business. There could be, for example: 

•

•

•

•

•

sudden electrical or telecommunication outages;

natural disasters such as earthquakes, tornadoes and hurricanes;

disease pandemics;

events arising from local or larger scale political or social matters, including terrorist acts; and 

cyber-attacks.

These events, in turn, could have a material adverse effect on our operating results and negatively affect the market price of our common stock and our ability to pay 

distributions to our stockholders.

Downgrades of the U.S. credit rating, automatic spending cuts or another government shutdown could negatively impact our liquidity, financial condition and 
earnings. 

U.S. debt ceiling and budget deficit concerns have increased the possibility of additional credit-rating downgrades and economic slowdowns, or a recession in the U.S. 

Although U.S. lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term 
sovereign credit rating on the United States. The impact of this or any further downgrades to the U.S. government’s sovereign credit rating or its perceived creditworthiness 
could adversely affect the U.S. and global financial markets and economic conditions. These developments could cause interest rates and borrowing costs to rise, which may 
negatively impact our ability to access the debt markets on favorable terms. 

In addition, disagreement over the federal budget has caused the U.S. federal government to shut down for periods of time resulting in, among other things, inadequate 
funding for and/or the shutdown of certain government agencies, including the SEC, SBA, and U.S. Food and Drug Administration ("the FDA"), on which the operation of our 
business may rely. Inadequate funding for and/or the shutdown of these government agencies prevents them from performing their normal business functions, which could 
impact, among other things, (i) our and our portfolio companies’ ability to access the public markets and obtain necessary capital in order to, among other things, properly 
capitalize, continue or expand operations, or, in the case of portfolio investments held by us, liquidate such investments; (ii) our ability to originate SBA loans; and (iii) the 
ability of the FDA and other governmental agencies to timely review and process regulatory submissions of our portfolio companies. Continued adverse political and economic 
conditions, including a prolonged U.S. federal government shutdown, could have a material adverse effect on our business, financial condition and results of operations.

Our business and operations could be negatively affected if we become subject to stockholder activism, which could cause us to incur significant expense, hinder the 
execution of our investment strategy or impact our stock price.

Stockholder activism, which could take many forms, including making public demands that we consider certain strategic alternatives, engaging in public campaigns to 
attempt to influence our corporate governance and/or our management, and commencing proxy contests to attempt to elect the activists’ representatives or others to our Board, 
or arise in a variety of situations, has been increasing in the BDC industry recently. While we are currently not aware of  any stockholder activism in our company, due to the 
potential volatility of our stock price and for a variety of other reasons, we may in the future become the target of stockholder activism. Stockholder activism could result in 
substantial costs and divert management and our Board’s attention and resources from our business. Additionally, such stockholder activism could give rise to perceived 
uncertainties as to our future and adversely affect our relationships with service providers and our portfolio companies. Also, we may be required to incur significant legal and 
other 

65

  
 
expenses related to any activist stockholder matters. Further, our stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks 
and uncertainties of any stockholder activism.

Capital markets may experience periods of disruption and instability and we cannot predict when these conditions will occur. Such market conditions could materially 
and adversely affect debt and equity capital markets in the United States and abroad, which could have a negative impact on our business, financial condition and 
results of operations. 

The global capital markets have experienced a period of disruption as evidenced by a lack of liquidity in the debt capital markets, write-offs in the financial services 

sector, the re-pricing of credit risk and the failure of certain major financial institutions. While the capital markets have improved, these conditions could deteriorate again in the 
future. During such market disruptions, we may have difficulty raising debt or equity capital, especially as a result of regulatory constraints. 

Market conditions may in the future make it difficult to extend the maturity of or refinance our existing indebtedness and any failure to do so could have a material 

adverse effect on our business. The illiquidity of our investments may make it difficult for us to sell such investments if required. 

As a result, we may realize significantly less than the value at which we have recorded our investments. In addition, significant changes in the capital markets, 

including the disruption and volatility, have had, and may in the future have, a negative effect on the valuations of our investments and on the potential for liquidity events 
involving our investments. An inability to raise capital, and any required sale of our investments for liquidity purposes, could have a material adverse impact on our business, 
financial condition and results of operations. 

Various social and political tensions in the United States and around the world, including in the Middle East, Eastern Europe, Asia, and Russia, may continue to 

contribute to increased market volatility, may have long-term effects on the United States and worldwide financial markets, and may cause further economic uncertainties or 
deterioration in the United States and worldwide. In addition, continuing uncertainty arising from the United Kingdom’s decision to leave the European Union, or Brexit, could 
lead to further market disruptions and currency volatility, potentially weakening consumer, corporate and financial confidence and resulting in lower economic growth for 
companies that rely significantly on Europe for their business activities and revenues. Under the terms of the withdrawal agreement negotiated and agreed to between the 
United Kingdom and the European Union, the United Kingdom’s departure from the European Union was followed by a transition period which ran until December 31, 2020, 
and during which the United Kingdom continued to apply European Union law and was treated for all material purposes as if it were still a member of the European Union. On 
December 24, 2020, the European Union and United Kingdom governments signed a Trade and Cooperation Agreement that became provisionally effective on January 1, 
2021, and that now governs the relationship between the United Kingdom and the European Union (the “Trade Agreement”). The Trade Agreement implements significant 
regulation around trade, transport of goods and travel restrictions between the United Kingdom and the European Union. Notwithstanding the Trade Agreement, the longer term 
economic, legal, political and social implications of Brexit are unclear at this stage. Brexit has led to ongoing political and economic uncertainty and periods of increased 
volatility in both the United Kingdom and in wider European markets for some time. We may in the future have difficulty accessing debt and equity capital markets, and a 
severe disruption in the global financial markets, deterioration in credit and financing conditions or uncertainty regarding U.S. government spending and deficit levels, Brexit, 
military conflict between Russia and Ukraine, or other global economic conditions could have a material adverse effect on our business, financial condition and results of 
operations. 

The broader fundamentals of the United States economy remain mixed. In the event that the United States economy contracts, it is likely that the financial results of 

small to mid-sized companies, like many of our portfolio companies, could experience deterioration or limited growth from current levels, which could ultimately lead to 
difficulty in meeting their debt service requirements and an increase in defaults. In addition, declines in oil and natural gas prices could adversely affect the credit quality of our 
debt investments and the underlying operating performance of our equity investments in energy-related businesses. 

In addition, volatility in the equity markets could impact our portfolio companies’ access to the debt and equity capital markets, which could ultimately limit their 

ability to grow, satisfy existing financing and other arrangements and impact their ability to perform.  Volatility in the equity markets could also impact our ability to liquidate 
or achieve value from warrants and other equity investments we have in our portfolio companies. Consequently, we can provide no assurance that the performance of certain 
portfolio companies will not be negatively impacted by economic cycles, industry cycles or other conditions, which could also have a negative impact on our future results.

66

  
 
These market and economic disruptions affect, and these and other similar market and economic disruptions may in the future affect, the U.S. capital markets, which 

could adversely affect our business and that of our portfolio companies. We cannot predict the duration of the effects related to these or similar events in the future on the 
United States economy and securities markets or on our investments. We monitor developments and seek to manage our investments in a manner consistent with achieving our 
investment objective, but there can be no assurance that we will be successful in doing so. 

Item 1B. Unresolved Staff Comments 

None. 

Item 2.  Properties 

Neither we nor any of our subsidiaries own any real estate or other physical properties materially important to our operation or any of our subsidiaries. Currently, we 
lease approximately 14,500 square feet of office space in Palo Alto, CA for our corporate headquarters. We also lease office space in Boston, MA, New York, NY, Bethesda, 
MD, Westport, CT, Chicago, IL, San Diego, CA, and London, United Kingdom.

Item 3.  Legal Proceedings 

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to 

seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted 
with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any 
pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period. 

Item 4.  Mine Safety Disclosures 

Not applicable. 

67

 
  
 
Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 

PART II

PRICE RANGE OF COMMON STOCK

Our common stock is traded on the NYSE under the symbol “HTGC.” As of February 10, 2022, we had approximately 104,553 stockholders of record. Most of the 
shares of our common stock are held by brokers and other institutions on behalf of stockholders. There are currently approximately 147 additional beneficial holders of our 
common stock. 

Shares of BDCs may trade at a market price that is less than the NAV per share. The possibilities that our shares of common stock will trade at a discount from NAV or 
at premiums that are unsustainable over the long term are separate and distinct from the risk that our NAV will decrease. At times, our shares of common stock have traded at a 
premium to NAV or at a significant discount to the NAV per share. 

Price Range of Common Stock and Distributions

The following table sets forth the range of high and low closing sales prices of our common stock, the sales price as a percentage of NAV and the distributions declared 

by us for each fiscal quarter. The stock quotations are interdealer quotations and do not include markups, markdowns or commissions. 

2019

First quarter
Second quarter
Third quarter
Fourth quarter

2020

First quarter
Second quarter
Third quarter
Fourth quarter

2021

First quarter
Second quarter
Third quarter
Fourth quarter

(1)

NAV

Price Range

High

Low

$
$
$
$

$
$
$
$

$
$
$
$

10.26  
10.59  
10.38  
10.55  

9.92  
10.19  
10.26  
11.26  

11.36  
11.71  
11.54  
11.22  

  $
  $
  $
  $

  $
  $
  $
  $

  $
  $
  $
  $

14.04  
13.75  
13.44  
14.44  

15.99  
11.83  
11.97  
14.42  

16.60  
17.66  
17.56  
18.07  

  $
  $
  $
  $

  $
  $
  $
  $

  $
  $
  $
  $

11.23  
12.57  
12.66  
12.98  

6.81  
6.64  
10.02  
11.13  

14.21  
15.98  
16.50  
16.14  

Premium/
Discount of
High Sales
Price to NAV

Premium/
Discount of
Low Sales
Price to NAV

Cash
  Distribution  
per Share

(2)

36.8 %    
29.8 %    
29.5 %    
36.9 %    

61.2 %    
16.1 %    
16.7 %    
28.1 %    

46.1 %    
50.8 %    
52.2 %    
61.1 %    

9.5 %
18.7 %
22.0 %
23.0 %

  $
  $
  $
  $

(31.4 )%   $
(34.8 )%   $
(2.3 )%   $
(1.2 )%   $

25.1 %
36.5 %
43.0 %
43.9 %

  $
  $
  $
  $

0.31  
0.33  
0.34  
0.35  

0.40  
0.32  
0.32  
0.34  

0.37  
0.39  
0.39  
0.40  

(1)

(2)

NAV per share is generally determined as of the last day in the relevant quarter and therefore may not reflect the NAV per share on the date of the high and low sales prices. The NAVs shown are based on 
outstanding shares at the end of each period.
Represents the dividend or distribution declared in the relevant quarter.

During 2021, 2020, and 2019, we issued 248,041, 280,690, and 180,135 shares, respectively, of common stock to stockholders in connection with the dividend 
reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act of 1933, as amended ("the Securities Act"). The aggregate value of the 
shares of our common stock issued under our dividend reinvestment plan during the years ended December 31, 2021, 2020, and 2019 were approximately $4.1 million, $3.3 
million, and $2.4 million, respectively.

SALES OF UNREGISTERED SECURITIES

See “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.” 

EQUITY COMPENSATION PLAN INFORMATION

68

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
 
 
  
 
ISSUER PURCHASES OF EQUITY SECURITIES

On December 17, 2018, our Board authorized a stock repurchase plan permitting us to repurchase up to $25.0 million of our common stock until June 18, 2019, after 

which the plan expired. The Company did not repurchase common stock on the open market during the years ended 2021, 2020, and 2019. Upon vesting of restricted stock 
awarded pursuant to our equity compensation plans, shares may be withheld to meet applicable tax withholding requirements. Any shares withheld are treated as common stock 
purchases by the Company in our consolidated financial statements as they reduce the number of shares received by employees upon vesting. Please refer to "Retired shares for 
restricted stock vesting" and "Retired shares from net issuance" in the consolidated statements of changes in net assets for share amounts withheld.

DISTRIBUTION POLICY

In order to be subject to tax as a RIC, we must distribute to our stockholders, in respect of each taxable year, dividends for U.S. federal income tax purposes of an 
amount generally at least equal to the Annual Distribution Requirement. Upon satisfying this requirement in respect of a taxable year, we generally will not be subject to 
corporate taxes on any income we distribute to our stockholders as dividends for U.S. federal income tax purposes.

However, as a RIC we will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as 
dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance 
Requirement. We will not be subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net 
capital gains). Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions 
treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. 
The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as 
dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over 
taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from our taxable income for that taxable year as such distributions 
may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable 
year, or returns of capital.  

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited 

from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our 
borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act. See “Item 1. Business— Regulation.” 

 On February 16, 2022, the Board declared (i) a fourth quarter cash distribution of $0.33 per share and (ii) a supplemental cash distribution of $0.60 per share, to be paid 

in four quarterly distributions of $0.15 per share beginning with the fourth quarter of 2021 (the "$0.60 Supplemental Cash Distribution"). The fourth quarter cash distribution 
and the first quarterly distribution of the $0.60 Supplemental Cash Distribution (a total of $0.48 per share) will be paid on March 16, 2022 to stockholders of record as of March 
9, 2022. 

Previously on April 21, 2021, the Board declared a supplemental cash distribution of $0.28 per share, to be paid in four quarterly distributions of $0.07 per share 
beginning with the first quarter 2021 (the "$0.28 Supplemental Cash Distribution"). The $0.15 payable as the first quarterly distribution of the $0.60 Supplemental Cash 
Distribution includes $0.07 per share as the fourth and final distribution of the $0.28 Supplemental Cash Distribution. With the declaration of the first quarterly distribution of 
the $0.60 Supplemental Cash Distribution, the Board has declared all of the $0.28 Supplemental Cash Distribution. 

Our Board maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90-100% of our taxable 

quarterly income or potential annual income for a particular taxable year. 

We maintain an “opt-out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to 
receive cash. As a result, if our Board authorizes, and we declare a cash distribution, then our stockholders who have not “opted out” of our dividend reinvestment plan will 
have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions. During 2021, 2020, and 2019, we 
issued 248,041, 280,690 and 180,135 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.

69

 
  
 
The following stock performance graph compares the cumulative stockholder return assuming that, on December 31, 2016, a person invested $100 in each of our 
common stock, the NYSE Composite Index, the S&P 500, the NASDAQ Financial 100 Index, and the KBW Regional Bank Index. The graph measures total stockholder 
return, which takes into account both changes in stock price and distributions, prior to any tax effect. It assumes that distributions paid are reinvested in like securities.

PERFORMANCE GRAPH 

This graph and other information furnished under Part II. Item 5 of the Form 10-K shall not be deemed to be “soliciting material” or to be “filed” with the SEC or 

subject to Regulation 14A or 14C, or to the liabilities of Section 18 of the Exchange Act. The stock price performance included in the above graph is not necessarily indicative 
of, or intended to forecast, future stock price performance.

70

 
 
 
  
 
Item 6. 

[Reserved] 

Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations 

FORWARD-LOOKING STATEMENTS

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc. that are forward-looking statements are 

based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or 
implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking 
statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” 
“predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve 
certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, 
the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The 
forward-looking statements contained in this report include statements as to:

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

our current and future management structure;

our future operating results; 

our business prospects and the prospects of our prospective portfolio companies; 

the impact of investments that we expect to make; 

our informal relationships with third parties including in the venture capital industry; 

the expected market for venture capital investments and our addressable market; 

the dependence of our future success on the general economy and its impact on the industries in which we invest; 

our ability to access debt markets and equity markets;

the current and future effects of the COVID-19 pandemic on us and our portfolio companies; 

the ability of our portfolio companies to achieve their objectives; 

our expected financings and investments; 

our regulatory structure and tax status; 

our ability to operate as a BDC, a SBIC and a RIC; 

the adequacy of our cash resources and working capital; 

the timing of cash flows, if any, from the operations of our portfolio companies; 

the timing, form and amount of any distributions; 

the impact of fluctuations in interest rates on our business; 

the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and 

our ability to recover unrealized depreciation on investments. 

For a discussion of factors that could cause our actual results to differ from forward-looking statements contained in this report, please see the discussion under “Item 

1A. Risk Factors.” You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the 
date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this 
report. 

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing 
elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and 
uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under “Item 1A—Risk Factors” 
and “Forward-Looking Statements” of this Item 7. 

71

 
  
 
Use of Non-GAAP Measures

In Item 1. Business and throughout this MD&A, we present our financial condition and results of operations in the way we believe will be most meaningful and 

representative of our business results. Some of the measurements we use are “non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for 
“generally accepted accounting principles” in the United States. The non-GAAP financial measures we present may not be comparable to similarly-named measures reported 
by other companies.

COVID-19 Developments

The COVID-19 pandemic, which began in late 2019, has and threatens to continue to create market volatility and disruption in the U.S. and across the global capital 

markets.  We are continuing to closely monitor the impact of COVID-19 on all aspects of our business, including impacts to our portfolio companies, employees, due diligence 
and underwriting processes, and financial markets. With the rollout of vaccination programs in the U.S. and globally, several countries, as well as certain states in the U.S., have 
lifted or reduced certain travel restrictions, business restrictions, and other quarantine measures. This has contributed to a positive economic recovery since 2020, especially in 
the U.S. Although the economic recovery and rollout of vaccination programs are promising, the potential exists for new COVID-19 variants to impede the global economic 
recovery. For example, the Delta and Omicron variants have caused a surge in the reported number of cases, hospitalizations and deaths related to the COVID-19 pandemic. 
These surges have led to the re-introduction of such restrictions and business shutdowns in certain states within the United States and globally. Although some states and 
municipalities have begun to eliminate restrictions related to COVID-19, there remains the potential for new COVID-19 variants to cause the reintroduction of such restrictions 
in the future. 

As a result of the pressures on liquidity and financial results to certain of our portfolio companies caused by the COVID-19 pandemic, portfolio companies may draw 
on most, if not all, of the unfunded portion of any revolving or delayed draw term loans made by us, subject to availability under the terms of such loans. The extent to which 
the COVID-19 pandemic will continue to affect the financial condition and liquidity of our portfolio companies’ results of operations will depend on future developments, such 
as the speed and extent of further vaccine distribution and the impact of the COVID-19 variants that might arise, which are highly uncertain and cannot be predicted.

Equally the extent of the impact of the COVID-19 pandemic on our own operational and financial performance, including our ability to execute our business strategies 

and initiatives in the expected time frame, will depend to a large extent on future developments regarding the duration and severity of the COVID-19, effectiveness of 
vaccination deployment and the actions taken by governments (including stimulus measures or the lack thereof) and their citizens to contain the COVID-19 or treat its impact, 
all of which are beyond our control. An extended period of global supply chain and economic disruption, including any resulting inflation, could materially affect our business, 
results of operations, access to sources of liquidity and financial condition. Given the fluidity of the situation, neither our management nor our Board is able to predict the full 
impact of COVID-19 on our business, future results of operations, financial position, or cash flows at this time.

Overview 

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in 

a variety of technology, life sciences, and sustainable and renewable technology industries. Our goal is to be the leading structured debt financing provider for venture capital-
backed and institutional-backed companies in a variety of technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate 
and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and 
renewable technology and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity 
investments. Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at 
various stages of their development. 

We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, 
we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes 
securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less.  Consistent with requirements under the 1940 
Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in Palo 
Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United Kingdom. 

72

 
  
 
We have elected to be treated for tax purposes as RIC under Subchapter M of the Code. As a RIC, we generally will not be subject to U.S. federal income tax on the 

portion of our investment company taxable income and net capital gain (i.e., net realized long-term capital gains in excess of net realized short-term capital losses) that we 
distribute (or are deemed to distribute) as dividends for U.S. federal income tax purposes to stockholders with respect to that taxable year. We will be subject to a 4% non-
deductible U.S. federal excise tax on certain undistributed taxable income and capital gains unless we make distributions treated as dividends for U.S. federal income tax 
purposes in a timely manner to our stockholders in respect of each calendar year subject to certain requirements as defined for RICs. In order to qualify as a RIC requires that 
we must comply with provisions contained in Subchapter M of the Code. For example, as a RIC we must earn 90% or more of our gross income during each taxable year from 
qualified sources, typically referred to as “good income,” as well as satisfy certain quarterly asset diversification and annual income distribution requirements. 

We have established Hercules Adviser LLC, a wholly owned registered investment adviser subsidiary. The Adviser Subsidiary provides investment advisory and related 
services to the Advisor Funds and External Parties. The Adviser Subsidiary is not consolidated for reporting purposes as noted in “Note 1- Description of Business”. In addition 
to the Adviser Subsidiary, we have established other wholly owned subsidiaries which are consolidated for reporting. However, certain of these subsidiaries are not 
consolidated for income tax purposes and may generate income tax expense or benefit, as well as tax assets and liabilities as a result of their ownership of certain portfolio 
investments.

Our primary business objectives are to increase our net income, net investment income, and NAV by investing in debt, typically with warrants or equity, of venture 

capital-backed and institutional-backed companies in a variety of technology-related industries at attractive current yields and the potential for equity appreciation and realized 
gains. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital 
appreciation from our warrant and equity investments.  Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which 
represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with 
future equity financing rounds. Capital that we provide is generally used for growth and general working capital purposes as well as in select cases for acquisitions or 
recapitalizations. We invest primarily in private companies but also have investments in public companies. 

We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We use the term “structured debt with warrants” to 

refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase or 
convert into common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We also 
invest in  “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position. In addition to our debt investments, we regularly 
engage in discussions with third parties with respect to various potential transactions to explore all alternatives. Through such alternatives we may acquire an investment, a 
portfolio of investments, an entire company, or sell portions of our portfolio on an opportunistic basis. 

We, our subsidiaries or our affiliates, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a 

variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from 
which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction 
will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a 
number of other factors and conditions which may include, depending on the transaction and without limitation, the approval of our Board of Directors (the "Board"), required 
regulatory or third-party consents, and/or the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of 
these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction. 

73

 
  
 
Portfolio and Investment Activity 

The total fair value of our investment portfolio was approximately $2.4 billion as of December 31, 2021, as compared to approximately $2.4 billion as of December 31, 

2020. The fair value of our debt investment portfolio as of December 31, 2021 was approximately $2.2 billion, compared to a fair value of approximately $2.1 billion as of 
December 31, 2020. The fair value of the equity portfolio as of December 31, 2021, was approximately $184.7 million, compared to a fair value of approximately $224.7 
million as of December 31, 2020. The fair value of the warrant portfolio as of December 31, 2021, was approximately $38.4 million, compared to a fair value of approximately 
$34.6 million as of December 31, 2020. 

Portfolio Activity 

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments 
represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available 
to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-
balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. From time to time, unfunded contractual 
commitments may expire without being drawn and thus do not represent future cash requirements. 

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to 

completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio 
companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated 
to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash 
requirements. 

During the year ended December 31, 2021, Hercules and the Adviser Funds directly committed or originated an aggregate total $2,639.2 million of investment 
commitments. Of the aggregated total directly committed or originated by Hercules and the Adviser Funds, $374.5 million of investment commitments were directly committed 
or originated by the Adviser Funds. Of the aggregate total direct fundings or originations, $226.4 million of debt, equity, and warrant fundings during the period, were assigned 
to, directly funded or originated by the Adviser Funds. There was no Adviser Funds activity during the year ended December 31, 2020. Our portfolio activity for the years 
ended December 31, 2021, and 2020 was comprised of the following:  

(in millions)
Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds  

(1)

New portfolio company
Existing portfolio company
Sub-total
Less: Debt commitments assigned to or directly committed by the Adviser Funds 
Net Total Debt Commitments

(3)

Gross Debt Fundings by Hercules Capital and the Adviser Funds 

(2)

New portfolio company
Existing portfolio company
Sub-total
Less: Debt fundings assigned to or directly funded by the Adviser Funds 
Net Total Debt Fundings

(3)

Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds

New portfolio company
Existing portfolio company
Sub-total
Less: Equity fundings assigned to or directly funded by the Adviser Funds 
Net Total Equity and Investment Funds and Vehicle Fundings

(3)

Unfunded Contractual Commitments 

(4)

Total

Non-Binding Term Sheets
New portfolio company
Existing portfolio company
Total

December 31, 2021

December 31, 2020

$

$

$

$

$

$

$

$

$

$

1,810.4    
801.3    
2,611.7    
(371.7 )  
2,240.0    

1,056.7    
482.6    
1,539.3    
(223.6 )  
1,315.7    

18.6    
10.5    
29.1    
(2.8 )  
26.3    

286.8    

275.0    
—    
275.0    

$

$

$

$

$

$

$

$

$

$

834.0  
339.1  
1,173.1  
—  
1,173.1  

420.5  
331.3  
751.8  
—  
751.8  

8.2  
1.3  
9.5  
—  
9.5  

179.8  

247.5  
—  
247.5  

(1)
(2)
(3)
(4)

Includes restructured loans and renewals in addition to new commitments.
Funded amounts include borrowings on revolving facilities.
Commitments and fundings include amounts assigned to, directly committed or originated, or funded by the Adviser Funds, as applicable.
Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable 
due to the borrower having not met certain milestones. This excludes $34.9 million of unfunded commitments as of December 31, 2021 to portfolio companies related to loans assigned to or directly committed 
by the Adviser Funds. 

74

 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
  
 
We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal 
repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to 
period. During the year ended December 31, 2021, we received approximately $1,185.0 million in aggregate principal repayments. Of the aggregate principal repayments, 
approximately $80.9 million were scheduled principal payments, and approximately $1,104.1 million were early principal repayments related to 49 portfolio companies. Of the 
approximately $1,104.1 million early principal repayments, approximately $247.9 million were early repayments due to merger and acquisition transactions related to eight 
portfolio companies.  

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable, and escrow receivables) as of and for each of the years 

ended December 31, 2021, and 2020 was as follows: 

(1)

(in millions)
Beginning portfolio
New fundings and restructures
Fundings assigned to or directly funded by the Adviser Funds
Warrants not related to current period fundings
Principal payments received on investments
Early payoffs
Accretion of loan discounts and paid-in-kind principal
Net acceleration of loan discounts and loan fees due to early payoff or restructure
New loan fees
Sale of investments
Gain (loss) on investments due to sales or write offs
Net change in unrealized appreciation (depreciation)
Ending portfolio

   $

   $

December 31, 2021

December 31, 2020

2,354.1      $
1,568.4     
(226.4 )  
1.1    
(80.9 )  
(1,104.1 )  
44.5    
(23.4 )  
(17.2 )  
(111.2 )  
24.7    
4.9    
2,434.5      $

2,314.5  
761.3  
—  
(0.1 )
(72.2 )
(709.0 )
44.7  
(12.5 )
(9.9 )
(32.5 )
(56.4 )
126.2  
2,354.1  

(1)

Funded amounts include $101.2 million of direct fundings of debt investments made by the Adviser Funds.

As of December 31, 2021, we held debt, warrants, or equity positions in seven companies that have filed definitive agreements for reverse merger initial public 

offerings with special purpose acquisition companies. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely 
manner or at all. 

The following table presents certain selected information regarding our debt investment portfolio:

Number of portfolio companies with debt outstanding
Percentage of debt bearing a floating rate
Percentage of debt bearing a fixed rate
Weighted average core yield 
Weighted average effective yield 
Prime rate at the end of the period

(2)

(1)

  December 31, 2021

December 31, 2020

92  

94.0 %  
6.0 %  
11.4 %  
12.9 %  
3.3 %  

97  
96.9 %
3.1 %
11.6 %
12.9 %
3.3 %

(1)

(2)

The core yield is a Non-GAAP financial measure. The core yield on our debt investments excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, other 
one-time events, and includes income from expired commitments. Please refer to the "Portfolio Yield" section below for further discussion of this measure.
The effective yield on our debt investments includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events. The effective yield is 
derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the year, excluding non-interest earning assets such as warrants and equity 
investments.

Income from Portfolio 

We generate revenue in the form of interest income, primarily from our investments in debt securities, and fee income, which is primarily comprised of commitment 

and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees 
generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form 
of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies. Our investments generally range from $15.0 million to $40.0 
million, although we may make investments in amounts above or below that range. As of December 31, 2021, our debt investments generally have a term of between two and 
five years and typically bear interest at a rate ranging from approximately 7.0% to approximately 14.5%. In addition to the cash yields received on our debt investments, in 
some instances our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees 
which may be required to be included in income prior to receipt.

75

 
  
  
   
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may 
include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time 
from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date. 

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s 
yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan 
modifications. We had approximately $42.9 million of unamortized fees as of December 31, 2021, of which approximately $36.5 million was included as an offset to the cost 
basis of our current debt investments and approximately $6.4 million was deferred contingent upon the occurrence of a funding or milestone. As of December 31, 2020, we had 
approximately $39.2 million of unamortized fees, of which approximately $32.2 million was included as an offset to the cost basis of our current debt investments and 
approximately $7.0 million was deferred contingent upon the occurrence of a funding or milestone. 

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of December 31, 2021, we had 
approximately $35.0 million in exit fees receivable, of which approximately $29.6 million was included as a component of the cost basis of our current debt investments and 
approximately $5.4 million was a deferred receivable related to expired commitments. As of December 31, 2020, we had approximately $40.9 million in exit fees receivable, of 
which approximately $37.6 million was included as a component of the cost basis of our current debt investments and approximately $3.3 million was a deferred receivable 
related to expired commitments.

We have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as 

interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to 
stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay 
these distributions may come from available cash or the liquidation of certain investments. We recorded approximately $11.2 million and $9.0 million in PIK income in the 
years ended December 31, 2021 and December 31, 2020, respectively.

Portfolio Yield

We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-

GAAP financial measures. In particular, we evaluate performance through monitoring the portfolio yields as we consider them to be effective indicators, for both management 
and stockholders, of the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described 
below:

•

•

•

“Total Yield” - The total yield is derived by dividing GAAP basis 'Total investment income' by the weighted average GAAP basis value of investment portfolio 
assets outstanding during the year, including non-interest earning assets such as warrants and equity investments at amortized cost. 

“Effective Yield” on total debt investments - The effective yield is derived by dividing GAAP basis 'Total investment income' by the weighted average GAAP 
basis value of debt investment portfolio assets at amortized cost outstanding during the year.

“Core Yield” on total debt investments – The core yield is a Non-GAAP financial measure. The core yield is derived by dividing “Core investment income” by 
the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year. “Core investment income” adjusts 
GAAP basis 'Total investment income' to exclude fee and other income accelerations attributed to early payoffs, deal restructuring, loan modifications, and 
other one-time income events, but includes income from expired commitments. 

Total Yield
Effective Yield
Core Yield (Non-GAAP)

December 31, 2021

December 31, 2020

11.9 %    
12.9 %    
11.4 %    

11.7 %
12.9 %
11.6 %

We believe that these measures are useful for our stockholders as it provides the yield of our portfolio to allow a more meaningful comparison with our competitors. As 
noted above, Core Yield, a Non-GAAP financial measure, is derived by dividing Core investment income, as defined above, by the weighted average GAAP basis value of debt 
investment portfolio assets at amortized cost outstanding. The reconciliation to  calculate “Core investment income” from GAAP basis 'Total investment income' are as follows:

76

 
 
 
 
 
 
 
   
   
   
  
 
GAAP Basis:
Total investment income
Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time 
events, but including income from expired commitments
Non-GAAP Basis:
Core investment income

2021

2020

280,976  

(32,420 )    

248,556  

287,258  

(29,934 )

257,324  

We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate 

significantly from period to period, thereby allowing for a more meaningful comparison over time. 

Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be 

considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar 
Non-GAAP financial measures used by other companies.

Another financial measure that we monitor is the total return for our investors, which was approximately 25.6% and 14.3% during the years ended December 31, 2021 

and 2020, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the 
period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by 
investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Portfolio Composition 

Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, 

consolidation, and product and market extension opportunities. 

The following table presents the fair value of the Company’s portfolio by industry sector as of December 31, 2021 and December 31, 2020:

(in thousands)
Drug Discovery & Development
Software
Internet Consumer & Business Services
(1)
All other industries 

Total

December 31, 2021

December 31, 2020

Investments at
 Fair Value

Percentage of
 Total Portfolio

Investments at
 Fair Value

Percentage of
 Total Portfolio

$

$

967,383    
585,622    
395,506    
486,011    
2,434,522    

39.7 %   $
24.1 %  
16.3 %  
19.9 %  
100.0 %   $

757,163    
780,045    
514,538    
302,332    
2,354,078    

32.2 %
33.1 %
21.9 %
12.8 %
100.0 %

(1) See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of December 31, 2021 the fair value as a percentage of 

total portfolio does not exceed 5% for any individual industry sector other than “Drug Discovery & Development”, “Software”, or “Internet Consumer & Business Services”. 

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity 

and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be 
highly concentrated in several portfolio companies. 

For the years ended December 31, 2021 and 2020, our ten largest portfolio companies represented approximately 30.5% and 27.9% of the total fair value of our 
investments in portfolio companies, respectively. As of December 31, 2021 and December 31, 2020, we had six and three investments that represented 5% or more of our net 
assets, respectively. As of December 31, 2021 and December 31, 2020, we had six and four equity investments representing approximately 49.6% and 63.7%, respectively, of 
the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. No single portfolio investment represents more 
than 10% of the fair value of our total investments as of December 31, 2021 and 2020.

As of December 31, 2021 and 2020, approximately 94.0% and 96.9% of the debt investment portfolio was priced at floating interest rates or floating interest rates with 

a Prime or LIBOR-based interest rate floor, respectively. Changes in interest rates, including Prime and LIBOR rates, may affect the interest income and the value of our 
investment portfolio for portfolio investments with floating rates. 

77

 
 
 
   
 
 
     
   
   
   
   
 
     
   
   
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Our investments in structured debt have detachable equity enhancement features, typically in the form of warrants or other equity securities designed to provide us with 

an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant 
coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing 
round. As of December 31, 2021, we held warrants in 97 portfolio companies, with a fair value of approximately $38.4 million. The fair value of our warrant portfolio 
increased by approximately $3.8 million, as compared to a fair value of $34.6 million as of December 31, 2020, primarily related to the increase in fair value of the portfolio 
companies.

Our existing warrant holdings would require us to invest approximately $67.4 million to exercise such warrants as of December 31, 2021. Warrants may appreciate or 

depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may 
exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized 
multiples in the range of approximately 1.02x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in 
the event that warrants are terminated or expire unexercised.

Portfolio Grading 

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt 
investments in our portfolio with 1 being the highest quality. See “Item 1. Business—Investment Process—Loan and Compliance Administration.” The following table shows 
the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of December 31, 2021 and 2020, respectively: 

(in thousands)

Investment Grading

1
2
3
4
5

Number of 
Companies
15
47
28
1
1
92

$

$

December 31, 2021

Debt Investments
at Fair Value

Percentage of
Total Portfolio

408,975    
1,208,323    
581,424    
8,269    
2,608    
2,209,599    

18.5 %  
54.7 %  
26.3 %  
0.4 %  
0.1 %  
100.0 %  

Number of 
Companies
16
46
28
3
4
97

$

$

December 31, 2020

Debt Investments
at Fair Value

Percentage of
Total Portfolio

410,955   
1,027,931   
621,323   
25,313   
8,913   
2,094,435   

19.6 %
49.1 %
29.7 %
1.2 %
0.4 %
100.0 %

As of December 31, 2021, our debt investments had a weighted average investment grading of 2.10 on a cost basis, as compared to 2.16 as of December 31, 2020. Our 

policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade 
our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will 
require additional funding in the near term or have not met their business plans and therefore have been downgraded until their funding is complete or their operations improve. 

As the COVID-19 pandemic and related disruption to markets and businesses continues to evolve, we are continuing to monitor and work with the management teams 

and stakeholders of our portfolio companies to navigate the significant market, operational, and economic challenges created by the continuing COVID-19 pandemic. This 
includes continuing to proactively assess and manage potential risks across our debt investment portfolio.

Non-accrual Investments

The following table shows the amortized cost of our performing and non-accrual investments as of December 31, 2021 and December 31, 2020:
As of December 31,
As of December 31,
2020
2021

(in millions)
Performing
Non-accrual

Total Investments

Amortized Cost

2,367  
24  
2,391  

  $

  $

Percentage of Total 
Portfolio at Amortized 
Cost

Amortized Cost

Percentage of Total 
Portfolio at Amortized 
Cost

99.0 %   $
1.0 %  
100.0 %   $

2,284  
31  
2,315  

98.7 %
1.3 %
100.0 %

Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt 

investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the 
ability to repay our current and future 

78

 
  
 
 
 
 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
contractual obligations. We may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is 
in the process of collection. Interest collected on non-accrual investments are generally applied to principal.

Results of Operations 

Comparison of periods ended December 31, 2021 and 2020. A comparison of the fiscal years ended December 31, 2020 and December 31, 2019 can be found in our Form 10-
K for the fiscal year ended December 31, 2020 within “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Investment Income 

Total investment income for the year ended December 31, 2021 was approximately $281.0 million as compared to approximately $287.3 million for the year ended 

December 31, 2020. Investment income is primarily composed of interest income earned on our debt investments and fee income from commitments, facilities, and other loan 
related fees.

Interest Income 

The following table summarizes the components of interest income for the years ended December 31, 2021 and 2020:

(in thousands)
Contractual interest income
Exit fee interest income
PIK interest income
Other interest income 
Total interest income

(1)

(1)  Other interest income includes OID interest income and interest recorded on other assets.

$

$

Year Ended December 31,

2021

2020

200,682    
37,494    
11,210    
3,974    
253,360    

$

$

208,017  
41,191  
9,009  
5,162  
263,379  

Interest income for the year ended December 31, 2021 totaled approximately $253.4 million as compared to approximately $263.4 million for the year ended December 
31, 2020. The decrease in interest income for the year ended December 31, 2021 as compared to the year ended December 31, 2020 is primarily attributable to a decrease in the 
weighted average principal of our debt investment portfolio outstanding between the periods.

Of the $253.4 million in interest income for the year ended December 31, 2021, approximately $238.1 million represents recurring income from the contractual 
servicing of our debt investment portfolio and approximately $15.3 million represents income related to the acceleration of income due to early loan repayments, and other one-
time events during the period. Income from the contractual servicing of our debt investment portfolio and the acceleration of interest income due to early loan repayments, 
dividends received, and other one-time events represented $245.9 million and $17.5 million, respectively, of the $263.4 million interest income for the year ended December 
31, 2020.

The following table shows the PIK related activity for the years ended December 31, 2021 and 2020, at cost: 

(in thousands)
Beginning PIK interest receivable balance
PIK interest income during the period
PIK accrued (capitalized) to principal but not
recorded as income during the period
Payments received from PIK loans
Realized gain (loss)
Ending PIK interest receivable balance

Year Ended December 31,

2021

2020

$

$

14,817    
11,210    

—    
(14,047 )  
(179 )  
11,801    

$

$

14,498  
9,009  

(5,704 )
(2,973 )
(13 )
14,817  

The increase in PIK interest income during the year ended December 31, 2021 as compared to the year ended December 31, 2020 is due to an increase in the weighted 
average principal outstanding for debt investments on accrual which bear PIK interest. PIK accrued (capitalized) to principal but not recorded as income during the year ended 
December 31, 2021 and 2020 includes the portion of PIK receivable that is capitalized as principal on the restructuring of loans, as applicable. Payments on PIK loans are 
normally received only in the event of payoffs. The PIK receivable for both December 31, 2021 and December 31, 2020 represented approximately 1% of total debt 
investments.

79

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fee Income 

Fee income from commitment, facility, and loan related fees for the year ended December 31, 2021 totaled approximately $27.6 million as compared to approximately 

$23.9 million for the year ended December 31, 2020. The increase in fee income is primarily due to an increase in the acceleration of unamortized fees, one-time fees due to 
early repayments.

Of the $27.6 million in fee income from commitment, facility, and loan related fees for the year ended December 31, 2021, approximately $7.5 million represented 
income from recurring fee amortization, approximately $3.0 million represented the acceleration of unamortized fees from expired commitments, and approximately $17.1 
million represented income related to the acceleration of unamortized fees during the period. 

Of the $23.9 million in fee income from commitment, facility, and loan related fees for the year ended  December 31, 2020, approximately $7.8 million represented 
income from recurring fee amortization, approximately $3.1 million represented the acceleration of unamortized fees from expired commitments, and approximately $13.0 
million represented income related to the acceleration of unamortized fees during the period.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the years ended December 31, 

2021 and 2020, respectively. 

Operating Expenses 

Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, and employee compensation and benefits. Our 

operating expenses totaled approximately $131.0 million and $130.1 million during the years ended December 31, 2021 and 2020, respectively. 

Interest and Fees on our Debt 

Interest and fees on our debt totaled approximately $63.1 million and $66.9 million for the years ended December 31, 2021 and 2020, respectively. A lower weighted 

average debt outstanding and lower weighted average borrowing cost during the year ended December 31, 2021, resulted in a decline of interest and fee expenses as compared 
to the year ended December 31, 2020.

We had a weighted average cost of debt of approximately 4.9% and 5.1% for the years ended December 31, 2021 and 2020, respectively. The weighted average cost of 

debt includes interest and fees on our debt, but excludes the impact of fee acceleration due to extinguishment of debt. The decrease in the weighted average cost of debt was 
primarily driven by a lower average amount outstanding of higher cost debt, which is attributable to our refinancing activities during the year. 

General and Administrative Expenses 

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, taxes, rent, expenses associated with the 

workout of underperforming investments and various other expenses. Our general and administrative expenses increased to $24.0 million from $23.2 million for the years 
ended December 31, 2021 and 2020, respectively. The increase in general and administrative expenses for the year ended December 31, 2021 is primarily attributable to an 
increase in excise taxes.

Employee Compensation 

Employee compensation and benefits totaled approximately $37.0 million for the year ended December 31, 2021 as compared to approximately $29.0 million for the 
year ended December 31, 2020. The increase between comparative periods was primarily due to increased variable compensation and payroll related expenses, and a higher 
headcount.

Employee stock-based compensation totaled approximately $11.9 million for the year ended December 31, 2021 as compared to approximately $11.1 million for the 

year ended December 31, 2020. The increase between comparative periods was primarily attributable to the issuance of additional stock-based compensation awards and higher 
weighted average grant date fair value.

Expenses allocated to the Adviser Subsidiary 

In March 2021, we entered into a shared services agreement with the Adviser Subsidiary (the “Sharing Agreement”), pursuant to which the Adviser Subsidiary utilizes 

our human capital resources, including deal professional, finance, and administrative functions, 

80

 
 
  
 
as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of 
shared services to the Adviser Subsidiary. Our total net operating expenses for the year ended  December 31, 2021 are net of expenses allocated to the Adviser Subsidiary of 
$5.0 million. As of  December 31, 2021, $0.1 million remained receivable from the Adviser Subsidiary related to the expenses allocated during the period. No amounts were 
allocated or receivable for the year ended December 31, 2020.

Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation 

Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without 

regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt 
extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event debt is extinguished before its 
stated maturity.  The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting 
period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. 

A summary of net realized gains and losses for the years ended December 31, 2021 and 2020 is as follows: 

(in thousands)
Realized gains
Realized losses
Realized loss on debt extinguishment

Net realized gains (losses)

$

$

Year Ended December 31,

2021

2020

91,617    
(66,322 )  
(4,419 )  
20,876    

$

$

23,856  
(79,961 )
—  
(56,105 )

During the year ended December 31, 2021, we recognized net realized gains of approximately $20.9 million. Net realized gains included gross realized gains of 
approximately $91.6 million, primarily from the sale of DoorDash, Inc. Palantir Technologies, Ology Bioservices, and TransMedics Group, Inc. Our gains were offset by gross 
realized losses of $66.3 million, primarily from the write-off of our investments in Intent (p.k.a. Intent Media, Inc.) and Solar Spectrum Holdings, LLC. 

During the year ended December 31, 2020, we recognized net realized losses of approximately $56.1 million on the portfolio. Net realized losses included gross 
realized losses of approximately $80.0 million, primarily from the full or partial write-off of our debt investments in Patron Technology, Motif BioSciences, Inc., and Sebacia, 
Inc., as well as the write-off of our debt, equity, and warrant investments in Optiscan Biomedical, Inc. during the period. These losses were partially offset by gross realized 
gains of approximately $23.9 million, primarily from the sale of public equity positions and the sale of our holdings due to merger and acquisition transactions. 

On July 1, 2021 and October 20, 2021, we fully redeemed and repaid the aggregate outstanding $364.2 million of principal and $1.7 million of accrued interest and fees 

pursuant to the redemption terms of the April 2025 Notes, 2027 Asset-Backed Notes, and 2028 Asset-Backed Notes agreements. Combined with other debt redemptions, we 
accelerated recognition of $4.4 million of debt issuance costs associated with the extinguishment of the debt, which is included as a realized loss within the “Loss on debt 
extinguishment” on the Consolidated Statement of Operations for the year ended December 31, 2021. There were no debt extinguishment losses recognized during the year 
ended December 31, 2020.

The net change in unrealized appreciation and depreciation of our investments is based on the fair value of each investment as determined in good faith by our Board. 

The following table summarizes the change in net unrealized appreciation or depreciation of investments for the years ended December 31, 2021, and 2020: 

(in thousands)
Gross unrealized appreciation on portfolio investments
Gross unrealized depreciation on portfolio investments
Reversal of prior period net unrealized appreciation (depreciation) upon a realization event
Net unrealized appreciation (depreciation) on debt, equity, warrant and fund investments
Other net unrealized appreciation (depreciation)
Total net unrealized appreciation (depreciation) on investments

  $

  $

Year Ended December 31,

2021

2020

  $

178,947  
(154,635 )  
(19,461 )  
4,851  
(1,540 )  
3,311  

  $

221,301  
(148,238 )
53,163  
126,226  
—  
126,226  

During the years ended December 31, 2021 and 2020, we recorded approximately $3.3 million and  $126.2 million of net unrealized appreciation on our debt, equity, 

warrant, and investment funds, respectively. The following table summarizes the key drivers of change in net unrealized appreciation (depreciation) of investments for the years 
ended  December 31, 2021, and 2020: 

81

 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
(in thousands)
Valuation appreciation (depreciation)
Reversal of prior period net unrealized appreciation (depreciation) upon a realization 
event
Other net unrealized appreciation (depreciation)

Net realized appreciation (depreciation)

Income and Excise Taxes 

For the year ended December 31,

2021
Equity, Warrants 
and 
Investment Funds

Total

Debt

2020
Equity, Warrants 
and 
Investment Funds

Total

28,159   $

24,312     $

(23,443 ) $

96,506   $

73,063  

(18,311 )  
(1,540 )  
8,308   $

(19,461 )  
(1,540 )  
3,311     $

40,002    
—    
16,559   $

13,161    
—    
109,667   $

53,163  
—  
126,226  

Debt

(3,847 )  

(1,150 )  
—    
(4,997 ) $

$

$

We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable 

and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions 
of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders 
substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable 
income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized 

gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial 
statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as 
ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

Net Change in Net Assets Resulting from Operations and Earnings Per Share 

For the years ended December 31, 2021 and 2020, we had net increases in net assets resulting from operations totaling approximately $174.2 million and approximately 

$227.3 million, respectively. The basic and fully diluted net change in net assets per common share for the year ended December 31, 2021 were $1.50 and $1.49, respectively, 
whereas the basic and fully diluted net change in net assets per common share for the year ended December 31, 2020 were $2.02 and $2.01, respectively. 

For the purpose of calculating diluted earnings per share for years ended December 31, 2021 and 2020, the dilutive effect of the 2022 Convertible Notes, Service 

Vesting Awards, and Performance Awards was considered. As disclosed in “Note 9 – Earnings Per Share”, the dilutive impact of the 2022 Convertible Notes includes only the 
portion expected to be settled in stock in the calculations of diluted shares outstanding for the year ended December 31, 2021. The effect of the 2022 Convertible Notes was 
excluded from these calculations for the year ended December, 31 2020 as our share price was less than the conversion price in effect which results in anti-dilution.

Hercules Adviser LLC

Hercules Adviser LLC, the Adviser Subsidiary, receives fee income for the services provided to the Adviser Funds. The Adviser Subsidiary’s contribution to our net 
investment income is derived from dividend income declared by the Adviser Subsidiary and interest income earned on loans to the Adviser Subsidiary.  For the years ended 
December 31, 2021 and 2020, no dividends were declared by the Adviser Subsidiary.  

 In March and July 2021, the Adviser Subsidiary entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the 
Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee and certain incentive fees. The Adviser 
Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed 
technology related and life sciences companies. 

82

 
 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
  
 
Financial Condition, Liquidity, Capital Resources and Obligations 

Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income 

earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and 
expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. 
We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”), and private offerings of securities, by 
securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries. This “Financial Condition, Liquidity and Capital Resources” section 
should be read in conjunction with the “COVID-19 Developments” section above.  

During the year ended December 31, 2021, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment 
portfolio, (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt 
offerings along with borrowings on our credit facilities, and (iv) equity offerings.

During the year ended December 31, 2021, our operating activities provided $128.6 million of cash and cash equivalents, compared to $207.8 million provided during 

the year ended December 31, 2020. The $79.2 million decrease in cash provided by operating activities was primarily attributable to increased purchases of investments of 
$580.6 million (net of assignments to the Adviser Funds), which was offset by a $401.8 million increase in principal and fee payments received on investments and $79.1 
million of proceeds from the sale of equity investments. 

During the year ended December 31, 2021, our investing activities used $106 thousand of cash, compared to $137 thousand used during the year ended December 31, 

2020. The $31 thousand decrease in cash used by investing activities was due to a decrease in purchases of capital equipment. 

During the year ended December 31, 2021, our financing activities used $229.9 million of cash, compared to $85.0 million used during the year ended December 31, 

2020. The $144.9 million increase in cash used by financing activities was primarily due to repayments of $99.0 million of SBA Debentures related to Hercules Technology III, 
L.P. ("HT III"), and an aggregate total $506.0 million paid during the year to retire the April 2025 Notes, the 2027 Asset-Backed Notes, and the 2028 Asset-Based Notes. The 
debt repayments were offset by $525.5 million of new debt issuances related to the March 2026 B Notes, September 2026 Notes, and HC IV SBA Debentures (See "Note 5 - 
Debt").   Additionally, we distributed $175.5 million in dividends during the year ended December 31, 2021, which was an increase from $152.4 million distributed during the 
year ended December 31, 2020. Lastly, we issued $10.6 million of common stock during the year ended December 31, 2021, which was lower than the $77.2 million issued 
during the year ended December 31, 2020.

As of December 31, 2021, net assets totaled $1.3 billion, with a NAV per share of $11.22. We intend to continue to operate in order to generate cash flows from 
operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to 
holders of our common stock.

Available liquidity and capital resources as of December 31, 2021

As of December 31, 2021, we had $627.7 million in available liquidity, including $133.1 million in cash and cash equivalents. We had available borrowing capacity of 

$70.1 million under the SMBC Facility, $400.0 million under the Union Bank Facility, and an additional $24.5 million available via our SBIC, subject to existing terms, 
borrowing base, advance rates, regulatory requirements and regulatory approval, as applicable. Furthermore, the Credit Facilities each have accordion provisions through which 
the available borrowing capacity can be increased by an aggregate $250.0 million.

The 1940 Act, permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total 

assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 
2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved 
the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of December 31, 2021, our asset coverage ratio under our 
regulatory requirements as a BDC was 218.9% excluding our SBA debentures.  Our exemptive order from the SEC allows us to exclude all SBA leverage from our asset 
coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while 
providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 
204.6% as of December 31, 2021.

83

 
  
 
As of December 31, 2021, we had $29.9 million outstanding under our Credit Facilities, which are floating interest rate obligations. During the year ended December 

31, 2021, we terminated our $75.0 million Wells Facility, and entered into a new $100.0 million multi-currency facility, the SMBC Facility. The remaining $1,220.5 million of 
debt outstanding are all fixed interest rate debt obligations. During the year ended December 31, 2021, we issued $375.0 million of new debt through the capital markets. On 
March 4, 2021, we issued $50.0 million in aggregate principal amount of March 2026 B Notes. The sale of the March 2026 B Notes generated net proceeds of approximately 
$49.5 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $0.5 
million. On September 16, 2021, we issued $325.0 million in aggregate principal amount of unsecured notes, the September 2026 Notes. The issuance of the notes generated 
net proceeds of approximately $320.1 million, which was primarily used to repay the remaining outstanding principal and accrued interest related to the 2027 Asset-Backed 
Notes and 2028 Asset-Backed Notes in October 2021. Aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, 
were approximately $4.1 million of costs and $0.8 million related to the discount.

In addition to the above capital market transactions, we have access of up to $175.0 million of capital through our SBIC. During the year ended December 31, 2021, we 
borrowed $150.5 million of the available capital, and have $24.5 million remaining available for draw.  As of December 31, 2021, we had one active SBIC, HC IV, to which we 
have contributed $87.5 million of regulatory capital.  During 2021, we completed the wind-down of HT III, by paying down the remaining $99.0 million of SBA Debentures, 
and on June 15, 2021, we surrendered our SBIC license for HT III.  

Lastly, as of December 31, 2021, $3.2 million of cash was classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain 

of the Company’s financing transactions. Refer to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for 
additional discussion of our debt obligations.

As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe 

we have ample liquidity to support our near-term capital requirements. As the impact of the COVID-19 pandemic and related disruption to markets and business continues to 
impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current 
circumstances. 

Equity Distribution Agreement

On May 6, 2019, we entered into the 2019 Equity Distribution Agreement, which was subsequently terminated on July 2, 2020, when we entered into a new ATM 

equity distribution agreement with JMP (the “2020 Equity Distribution Agreement”). As a result, the remaining shares that were available under the 2019 Equity Distribution 
Agreement are no longer available for issuance. The 2020 Equity Distribution Agreement provides that we may offer and sell up to 16.5 million shares of our common stock 
from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the 
market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker 
other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the year ended December 31, 2021, the Company sold 0.6 million shares of common stock. As of December 31, 2021, approximately 15.6 million shares remain 

available for issuance and sale under the 2020 Equity Distribution Agreement. During the year ended December 31, 2020, the Company sold 6.3 million shares of common 
stock, of which 6.0 million shares and 306,000 shares were issued under the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement, respectively.

Equity Offerings

There were no equity offerings during the years ending December 31, 2021 or 2020. On June 17, 2019, we closed our underwritten public offering of 5.8 million shares 

of common stock, including an over-allotment option to purchase an additional 750,000 shares of common stock (the “June 2019 Equity Offering”), that generated net 
proceeds, before expenses, of $70.5 million including the underwriting discount and commissions of $2.2 million during the year ending December 31, 2019.

Stock Repurchase

We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through 
cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing 
market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material. Our Board authorized a stock 

84

 
 
 
 
 
 
 
  
 
repurchase plan permitting us to repurchase up to $25.0 million of our common stock until June 18, 2019, after which the plan expired and was not renewed. We had no 
common stock repurchases during 2019, 2020, or 2021.

Commitments and Obligations 

Our significant cash requirements generally relate to our debt obligations. As of December 31, 2021, we had $1,250.4 million of debt outstanding, which includes 

$380.0 million due within the next year, $105.0 million within 1 to 3 years, and $765.4 million beyond 3 years. As disclosed in “Note 14 - Subsequent Events”, we have 
refinanced both the 2022 Convertible Notes and 2022 Notes which were due within the next year through our issuance of the $350.0 million January 2027 Notes.

In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of 

unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio 
companies are not reflected on our balance sheet. 

Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio 

company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us 
relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the 
financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance 
sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future 
cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and 
unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this 
report for additional discussion of our unfunded commitments.

 As of December 31, 2021, we had approximately $286.8 million of unfunded commitments, including undrawn revolving facilities, which were available at the request 

of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in a private equity fund. This 
excludes $34.9 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.  We 
intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments. 

We also had approximately $275.0 million of non-binding term sheets outstanding to five new companies, which generally convert to contractual commitments within 

approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well 
as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent 
future cash requirements.  

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent 
with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in 
the borrowing agreements.

Indemnification Agreements

We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and 

executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the 
director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the 
Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and 
the 1940 Act. We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum 
extent permitted by Maryland law subject to the restrictions in the 1940 Act.

Distributions 

Our Board maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% - 100% of our 
taxable quarterly income or potential annual income for a particular taxable year. In addition, at the end of our taxable year, our Board may choose to pay additional special 
distributions, so that we may distribute approximately all 

85

 
 
  
 
of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable 
year as part of any future distribution payments.

Distributions from our taxable income (including gains) to a stockholder generally will be treated as a dividend for U.S. federal income tax purposes to the extent of 

such stockholder’s allocable share of our current or accumulated earnings and profits. Distributions in excess of our current and accumulated earnings and profits would 
generally be treated first as a return of capital to the extent of a stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The 
determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and 
distributions paid for the full taxable year. Of the distributions declared during the years ended December 31, 2021, 2020, and 2019, 100% were distributions derived from our 
current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2022 
distributions to stockholders will actually be.

We maintain an “opt out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to 
receive cash. As a result, if our Board authorizes, and we declare a cash distribution, then our stockholders who have not “opted out” of our dividend reinvestment plan will 
have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions.

Shortly after the close of each calendar year information identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the 
sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution, if any) will be provided to our stockholders subject to information reporting. To 
the extent our taxable earnings fall below the total amount of our distributions for any taxable year, a portion of those distributions may be deemed a tax return of capital to our 
stockholders.

We expect to qualify to be subject to tax as a RIC under Subchapter M of the Code. In order to be subject to tax as a RIC, we are required to satisfy certain annual gross 

income and quarterly asset composition tests, as well as make distributions to our stockholders each taxable year treated as dividends for federal income tax purposes of an 
amount at least equal to 90% of the sum of our investment company taxable income, determined without regard to any deduction for dividends paid, plus our net tax-exempt 
income, if any. Upon being eligible to be subject to tax as a RIC, we would be entitled to deduct such distributions we pay to our stockholders in determining the overall 
components of our “taxable income.” Components of our taxable income include our taxable interest, dividend and fee income, reduced by certain deductions, as well as 
taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the 
recognition of income and expenses and generally excludes net unrealized appreciation or depreciation as such gains or losses are not included in taxable income until they are 
realized. In connection with maintaining our ability to be subject to tax as a RIC, among other things, we have made and intend to continue to make the requisite distributions to 
our stockholders each taxable year, which generally should relieve us from corporate-level U.S. federal income taxes.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends 

for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance 
Requirement. We will not be subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net 
capital gains). 

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated as 

dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The 
maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as 
dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over 
taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from our taxable income for that taxable year as such distributions 
may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable 
year, or returns of capital.  

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited 

from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our 
debt. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act. 

We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for 

reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay 
any applicable U.S. federal excise tax. 

86

 
  
 
Critical Accounting Policies and Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported 

amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the 
period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that 
we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our 
results of operations and financial condition. 

For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial 

statements appearing elsewhere in this report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation 
Measurements, Income Recognition, and Income Taxes. The valuation of investments is our most significant critical estimate. The most significant input to this estimate is the 
yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following 
table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming 
no other changes:

(in thousands)
Basis Point Change
(100)
(50)
50
100

Change in unrealized
appreciation (depreciation)

20,986  
10,557  
(10,955 )
(21,943 )

  $
  $
  $
  $

For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to "Note 3 - Fair Value of Financial Instruments" included in the 

notes to our consolidated financial statements appearing elsewhere in this report. 

87

 
 
 
 
 
 
  
 
Item 7A. Quantitative and Qualitative Disclosure About Market Risk 

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest 
rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash 
flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. 
Our investment income will be affected by changes in various interest rates, including LIBOR and Prime rates, to the extent our debt investments include variable interest rates. 
As of December 31, 2021, approximately 94.0% of the loans in our portfolio had variable rates based on floating Prime or LIBOR rates with a floor. As of December 31, 2021, 
approximately 21.3% of our debt investments have variable rates based on LIBOR. Additionally, all of our LIBOR rate based debt securities have interest rate floors. We are 
actively considering and discussing the preferred alternative benchmark with our portfolio companies and prioritize the inclusion of LIBOR fallback language in our 
documentation. The Alternative Reference Rates Committee ("ARRC") has recommended for US based debt securities to use the SOFR rate as the alternative benchmark. Our 
debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also 
affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio. 

Based on our Consolidated Statement of Assets and Liabilities as of December 31, 2021, the following table shows the approximate annualized increase (decrease) in 

components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt. 

(in thousands)
Basis Point Change
(75)
(50)
(25)
25
50
75
100
200

Interest Income

Interest Expense

Net Income

EPS

$
$
$
$
$
$
$
$

(73 )   $
(63 )   $
(34 )   $
  $
  $
  $
  $
  $

4,492  
8,988  
13,485  
17,981  
36,719  

(26 )
(19 )
(11 )
11  
23  
34  
45  
90  

  $
  $
  $
  $
  $
  $
  $
  $

(47 )   $
(44 )   $
(23 )   $
4,481     $
8,965     $
13,451     $
17,936     $
36,629     $

—  
—  
—  
0.04  
0.08  
0.12  
0.16  
0.32  

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations and foreign currency by using standard 
hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may 
also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. 
During the year ended December 31, 2021, we did not engage in interest rate or foreign currency hedging activities. 

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, 

credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit 
Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. 
Accordingly, no assurances can be given that actual results would not differ materially from the statement above. 

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the 

rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will 
not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment 
income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio. For additional information regarding the interest 
rate associated with each of our debt borrowings, refer to “Note 5 – Debt” included in the notes to our consolidated financial statements in this report on Form 10-K.

88

 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Item 8.  Financial Statements and Supplementary Data 

INDEX TO FINANCIAL STATEMENTS 

Report of Independent Registered Public Accounting Firm
Consolidated Statements of Assets and Liabilities as of December 31, 2021 and December 2020
Consolidated Statements of Operations for the three years ended December 31,2021
Consolidated Statements of Changes in Net Assets for the three years ended December 31,2021
Consolidated Statements of Cash Flows for the three years ended December 31, 2021
Consolidated Schedule of Investments as of December 31, 2021
Consolidated Schedule of Investments as of December 31, 2020
Notes to Consolidated Financial Statements
Consolidated Schedule of Investments in and Advances to Affiliates as of December 31, 2021
Consolidated Schedule of Investments in and Advances to Affiliates as of December 31, 2020

89

90
92
94
95
96
97
108
119
164
165

 
 
 
  
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Hercules Capital, Inc. 

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated statements of assets and liabilities, including the consolidated schedules of investments, of Hercules Capital, Inc. and its 
subsidiaries (the “Company”) as of December 31, 2021 and 2020, and the related consolidated statements of operations, changes in net assets and cash flows for each of the 
three years in the period ended December 31, 2021, including the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the 
“consolidated financial statements”).  We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in 
Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 
and 2020, and the results of its operations, changes in its net assets and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with 
accounting principles generally accepted in the United States of America.  Also in our opinion, the Company maintained, in all material respects, effective internal control over 
financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

We have also previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated statements of assets 
and liabilities, including the consolidated schedules of investments, of Hercules Capital, Inc. and its subsidiaries as of December 31, 2019, 2018, 2017, 2016, 2015, 2014, 2013 
and 2012, and the related consolidated statements of operations, changes in net assets and cash flows for each of the years ended December 31, 2012 through 2018 (none of 
which are presented herein), and we expressed unqualified opinions on those consolidated financial statements. In our opinion, the information set forth in the Senior Securities 
table of Hercules Capital, Inc. and its subsidiaries for each of the ten years in the period ended December 31, 2021 is fairly stated, in all material respects, in relation to the 
consolidated financial statements from which it has been derived.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment 
of the effectiveness of internal control over financial reporting, included in Management's Annual Report on Internal Control over Financial Reporting appearing under Item 
9A.  Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our 
audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with 
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the 
PCAOB.

We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audits to obtain reasonable assurance about 
whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting 
was maintained in all material respects.  

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, 
whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and 
disclosures in the consolidated financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well 
as evaluating the overall presentation of the consolidated financial statements.  Our procedures included confirmation of securities owned as of December 31, 2021 and 2020 by 
correspondence with the custodians, agent banks and portfolio company investees; when replies were not received, we performed other auditing procedures.  Our audit of 
internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and 
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.  Our audits also included performing such other procedures as we 
considered necessary in the circumstances.  We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of 
financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those 
policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the 
company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted 
accounting principles, and that receipts and expenditures of the company are being made only in 

90

 
 
 
 
 
 
 
 
 
 
 
  
 
accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized 
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to 
future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures 
may deteriorate.

Critical Audit Matters 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be 
communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially 
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, 
taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to 
which it relates.

Valuation of Investments - Level 3 Investments in Senior Secured Debt, Unsecured Debt, Preferred Stock, Common Stock

As described in Notes 2 and 3 to the consolidated financial statements, approximately 94.5% of the Company’s $2,435 million total investments in securities as of December 
31, 2021 represents investments in level 3 senior secured debt, unsecured debt, preferred stock and common stock whose fair value, as disclosed by management, is determined 
in good faith by the Board of Directors. Management applied significant judgment in determining the fair value of these level 3 investments, which involved the use of 
significant unobservable inputs related to i) hypothetical market yields, premiums/(discounts) and the probability weighting of alternative outcomes for debt securities; and ii) 
the revenue and/or EBITDA multiples, market equity adjustments, discounts for lack of marketability, tangible book value multiple, and cash flow discount rate for equity 
securities. 

The principal considerations for our determination that performing procedures relating to the valuation of level 3 investments in senior secured debt, unsecured debt, preferred 
stock and common stock is a critical audit matter are the significant judgment by management to determine the fair value of these level 3 investments, including the use of the 
hypothetical market yields, premiums/(discounts), the probability weighting of alternative outcomes, discounts for lack of marketability, tangible book value multiple and cash 
flow discount rate, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing audit procedures and evaluating the audit evidence obtained 
relating to the significant unobservable inputs. The audit effort involved the use of professionals with specialized skill and knowledge to assist in performing procedures and 
evaluating the audit evidence obtained.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. 
These procedures included testing the effectiveness of controls relating to the valuation of level 3 investments in senior secured debt, unsecured debt, preferred stock and 
common stock, including controls over the Company’s methods and significant unobservable inputs. These procedures also included, among others, (i) testing the completeness 
and accuracy of data provided by management, evaluating the appropriateness of management’s methods, and evaluating the reasonableness of significant unobservable inputs 
used in those methods related to the hypothetical market yields, premiums/(discounts), and the probability weighting of alternative outcomes for debt securities; and discounts 
for lack of marketability, tangible book value multiple, and cash flow discount rate for equity securities, and (ii) the involvement of professionals with specialized skill and 
knowledge to assist in developing an independent fair value range for a sample of securities and comparison of management’s estimate to the independently developed fair 
value range. Developing the independent fair value range involved testing the completeness and accuracy of data provided by management and developing independent 
significant unobservable inputs in order to evaluate the reasonableness of management’s fair value estimate of these certain level 3 investments. 

/s/ PricewaterhouseCoopers LLP
San Francisco, California
February 22, 2022

We have served as the Company’s auditor since 2010.

91

 
 
 
 
 
 
 
 
 
  
 
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES 
(in thousands, except per share data)

Assets
Investments, at fair value:

Non-control/Non-affiliate investments (cost of $2,293,398 and $2,175,651, respectively)
Control investments (cost of $84,039 and $65,257, respectively)
Affiliate investments (cost of $13,547 and $74,450, respectively)

Total investments, at fair value (cost of $2,390,984 and $2,315,358, respectively)
Cash and cash equivalents
Restricted cash
Interest receivable
Right of use asset
Other assets
Total assets

Liabilities
Debt (net of debt issuance costs - Note 5)
Accounts payable and accrued liabilities
Operating lease liability
Total liabilities

Commitments and contingencies (Note 11)

Net assets consist of:

Common stock, par value
Capital in excess of par value
Total distributable earnings

Total net assets
Total liabilities and net assets

Shares of common stock outstanding ($0.001 par value and 200,000,000 authorized)
Net asset value per share

See notes to consolidated financial statements.  
92

December 31, 2021

December 31, 2020

  $

  $

  $

  $

  $
  $

  $

2,351,560     $
73,504    
9,458    
2,434,522    
133,115    
3,150    
17,365    
6,761    
5,100    
2,600,013     $

1,236,303     $
47,781    
7,382    
1,291,466     $

117    
1,091,907    
216,523    
1,308,547     $
2,600,013     $

116,619    

11.22     $

2,288,338  
57,400  
8,340  
2,354,078  
198,282  
39,340  
19,077  
9,278  
3,942  
2,623,997  

1,286,638  
36,343  
9,312  
1,332,293  

115  
1,158,198  
133,391  
1,291,704  
2,623,997  

114,726  
11.26  

 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
   
 
 
  
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
The following table presents the assets and liabilities of our consolidated securitization trusts for the 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes (see 

“Note 5  Debt”), which were variable interest entities ("VIEs"). The assets of our securitization VIEs were restricted to only be used to settle obligations of our consolidated 
securitization VIEs, the liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our 
general credit. The assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above. As of October 20,  2021, the Company fully repaid the 
aggregate outstanding obligations of the VIEs and began the legal wind-down of the entities. As of December 31, 2021, no assets or liabilities were held in the VIEs.

(in thousands)

Assets
Restricted Cash
2027 Asset-Backed Notes, investments in securities, at value (cost of $0 and $267,657, respectively)
2028 Asset-Backed Notes, investments in securities, at value (cost of $0 and $355,236, respectively)
Total assets

Liabilities
2027 Asset-Backed Notes, net (principal of $0 and $180,988, respectively) 
2028 Asset-Backed Notes, net (principal of $0 and $250,000, respectively) 
Total liabilities

(1)

(1)

December 31, 2021

December 31, 2020

$

$

$

—     $
—    
—    
—     $

—     $
—    
—     $

39,340  
269,551  
356,097  
664,988  

178,812  
247,647  
426,459  

(1)

The Company’s 2027 Asset-Backed Notes and 2028 Asset-Backed Notes are presented net of the associated debt issuance costs. See “Note 5 – Debt”.

See notes to consolidated financial statements.  
93

 
  
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
     
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
HERCULES CAPITAL, INC. 
CONSOLIDATED STATEMENTS OF OPERATIONS 
(in thousands, except per share data)

Investment income:

Interest and dividend income

Non-control/Non-affiliate investments
Control investments
Affiliate investments

Total interest and dividend income

Fee income

Non-control/Non-affiliate investments
Control investments
Affiliate investments
Total fee income
Total investment income
Operating expenses:

Interest
Loan fees
General and administrative
Tax expenses
Employee compensation:

Compensation and benefits
Stock-based compensation

Total employee compensation

Total gross operating expenses

Expenses allocated to the Adviser Subsidiary

Total net operating expenses
Net investment income
Net realized gain (loss) and change in unrealized appreciation (depreciation)
Net realized gain (loss)

Non-control/Non-affiliate investments
Affiliate investments
Loss on extinguishment of debt
Total net realized gain (loss)

Net change in unrealized appreciation (depreciation)

Non-control/Non-affiliate investments
Control investments
Affiliate investments

Total net change in unrealized appreciation (depreciation)

Total net realized gain (loss) and change in unrealized appreciation (depreciation)
Net increase (decrease) in net assets resulting from operations

Net investment income before gains and losses per common share:

Basic

Change in net assets resulting from operations per common share:

Basic

Diluted

Weighted average shares outstanding

Basic

Diluted

Distributions paid per common share:

Basic

2021

For the Year Ended December 31,
2020

2019

249,341     $
4,009    
10    
253,360    

259,989     $
2,857    
533    
263,379    

27,557    
59    
—    
27,616    
280,976    

54,447    
8,657    
16,111    
7,928    

36,970    
11,930    
48,900    
136,043    
(5,035 )  
131,008    
149,968    

87,438    
(62,143 )  
(4,419 )  
20,876    

(57,818 )  
(2,677 )  
63,806    
3,311    
24,187    
174,155     $

1.29     $

1.50     $
1.49     $

114,742    
115,955    

23,858    
21    
—    
23,879    
287,258    

59,605    
7,269    
18,910    
4,285    

28,996    
11,053    
40,049    
130,118    
—    
130,118    
157,140    

(41,956 )  
(14,149 )  
—    
(56,105 )  

128,238    
(2,271 )  
259    
126,226    
70,121    
227,261     $

1.39     $

2.02     $
2.01     $

111,985    
112,267    

1.55     $

1.38     $

241,491  
4,014  
2,008  
247,513  

20,157  
18  
186  
20,361  
267,874  

54,596  
7,078  
19,183  
2,226  

30,993  
10,526  
41,519  
124,602  
—  
124,602  
143,272  

16,523  
—  
—  
16,523  

15,074  
1,595  
(2,866 )
13,803  
30,326  
173,598  

1.41  

1.71  

1.71  

101,132  

101,569  

1.33  

$

$

$

$

$

$

See notes to consolidated financial statements.  
94

 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
   
 
   
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
   
 
 
 
 
   
 
   
 
 
 
 
 
   
 
   
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS 
(dollars and shares in thousands)

Common Stock

Shares

Par Value

Capital in
excess
of par value

Distributable
Earnings
(loss)

Treasury
Stock

Net
Assets

Balance at December 31, 2018

Net increase in net assets resulting from operations
Public offering, net of offering expenses
Issuance of common stock due to stock option exercises
Retired shares from net issuance of stock options exercises
Issuance of common stock under restricted stock plan
Retirement of common stock under repurchase plan
Retired shares for restricted stock vesting
Distributions reinvested in common stock
Distributions
Stock-based compensation 
Tax reclassification of stockholders' equity in accordance with generally 
accepted accounting principles

(1)

Balance at December 31, 2019

Net increase in net assets resulting from operations
Public offering, net of offering expenses
Issuance of common stock due to stock option exercises
Retired shares from net issuance of stock options exercises
Issuance of common stock under restricted stock plan
Retired shares for restricted stock vesting
Distributions reinvested in common stock
Distributions
Stock-based compensation 
Tax reclassification of stockholders' equity in accordance with generally 
accepted accounting principles

(1)

Balance at December 31, 2020

Net increase in net assets resulting from operations
Public offering, net of offering expenses
Issuance of common stock due to stock option exercises
Retired shares from net issuance of stock options exercises
Issuance of common stock under restricted stock plan
Retired shares for restricted stock vesting
Distributions reinvested in common stock
Distributions
Stock-based compensation 
Tax reclassification of stockholders' equity in accordance with generally 
accepted accounting principles

(1)

Balance at December 31, 2021

96,501   $
—  
10,377  
72  
(44 )  
832  
—  
(554 )  
180  
—  
—  

—  

107,364   $

—  
6,272  
54  
(47 )  
862  
(59 )  
280  
—  
—  

—  

114,726   $

—  
639  
284  
(69 )  

1,027  
(236 )  
248  
—  
—  

—  

116,619   $

96   $
—    
11    
—    
—    
1    
—    
—    
—    
—    
—    

—    
108   $

—    
6    
—    
—    
1    
—    
—    
—    
—    

—    
115   $

—    
1    
—    
—    
1    
—    
—    
—    
—    

—    
117   $

1,052,269   $
—    
132,525    
910    
(616 )  
(1 )  
(4,062 )  
(5,412 )  
2,402    
—    
8,642    

(41,551 )  
1,145,106   $

—    
77,174    
662    
(682 )  
(1 )  
(1,817 )  
3,339    
—    
8,473    

(74,056 )  
1,158,198   $

—    
10,619    
3,903    
(1,205 )  
(1 )  
(5,514 )  
4,074    
—    
10,385    

(88,552 )  
1,091,907   $

(92,859 ) $
173,598    
—    
—    
—    
—    
—    
—    
—    
(134,455 )  
—    

41,551    
(12,165 ) $

227,261    
—    
—    
—    
—    
—    
—    
(155,761 )  
—    

74,056    
133,391   $

174,155    
—    
—    
—    
—    
—    
—    
(179,575 )  
—    

88,552    
216,523   $

(4,062 ) $
—    
—    
—    
—    
—    
4,062    
—    
—    
—    
—    

—    
—   $

—    
—    
—    
—    
—    
—    
—    
—    
—    

—    
—   $

—    
—    
—    
—    
—    
—    
—    
—    
—    

—    
—   $

955,444  
173,598  
132,536  
910  
(616 )
—  
—  
(5,412 )
2,402  
(134,455 )
8,642  

—  
1,133,049  

227,261  
77,180  
662  
(682 )
—  
(1,817 )
3,339  
(155,761 )
8,473  

—  
1,291,704  

174,155  
10,620  
3,903  
(1,205 )
—  
(5,514 )
4,074  
(179,575 )
10,385  

—  
1,308,547  

(1)

Stock-based compensation includes $125, $106, and $78 of restricted stock and option expense related to director compensation for the years ended December 31, 2021, 2020 and 2019, respectively. 

See notes to consolidated financial statements.  
95

 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HERCULES CAPITAL, INC. 
CONSOLIDATED STATEMENTS OF CASH FLOWS 
(in thousands) 

Cash flows from operating activities:

Net increase in net assets resulting from operations
Adjustments to reconcile net increase in net assets resulting from
operations to net cash provided by (used in) operating activities:

Purchases of investments
Fundings assigned to Adviser Funds
Principal and fee payments received on investments
Proceeds from the sale of investments
Net unrealized (appreciation) depreciation
Net realized (gain) loss
Accretion of paid-in-kind principal
Accretion of loan discounts
Accretion of loan discount on convertible notes
Loss on extinguishment of debt
Accretion of loan exit fees
Change in loan income, net of collections
Unearned fees related to unfunded commitments
Amortization of debt fees and issuance costs
Depreciation and amortization
Stock-based compensation and amortization of restricted stock grants 
Change in operating assets and liabilities:

(1)

Interest receivable
Other assets
Accounts payable
Accrued liabilities

Net cash provided by (used in) operating activities

Cash flows from investing activities:
Purchases of capital equipment
Net cash (used in) investing activities
Cash flows from financing activities:

Issuance of common stock
Offering expenses
Retirement of employee shares, net
Distributions paid
Issuance of debt
Repayment of debt
Debt issuance costs
Fees paid for credit facilities and debentures

Net cash used in financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period

Cash, cash equivalents and restricted cash at end of period

Supplemental disclosures of cash flow information and non-cash investing and financing activities:

Interest paid
Income tax, including excise tax, paid
Distributions reinvested

2021

For the Year Ended December 31,
2020

2019

  $

174,155  

  $

227,261     $

173,598  

(1,467,129 )
125,295  
1,183,014  
111,890  
(3,311 )
(25,295 )
(11,210 )
(3,842 )
671  
4,419  
(23,512 )
35,045  
(2,034 )
6,368  
317  
10,385  

1,712  
2,175  
—  
9,508  
128,621  

(106 )
(106 )

10,829  
(209 )
(2,816 )
(175,501 )
1,736,975  
(1,787,043 )
(5,632 )
(6,475 )
(229,872 )
(101,357 )
237,622  
136,265  

  $

51,469     $
3,759     $
4,074     $

(761,258 )  
—    
781,240    
32,777    
(126,226 )  
56,105    
(9,039 )  
(4,356 )  
671    
—    
(25,648 )  
16,780    
(291 )  
5,154    
415    
8,473    

1,130    
802    
(16 )  
3,828    
207,802    

(137 )  
(137 )  

77,478    
(298 )  
(1,837 )  
(152,422 )  
824,474    
(827,405 )  
(1,419 )  
(3,610 )  
(85,039 )  
122,626    
114,996    
237,622     $

58,274     $
2,458     $
3,339     $

(1,025,711 )
—  
600,161  
39,573  
(13,803 )
(16,523 )
(8,605 )
(3,532 )
671  
—  
(24,295 )
18,177  
1,403  
5,899  
262  
8,642  

(3,248 )
(10,373 )
(205 )
17,245  
(240,664 )

(595 )
(595 )

133,992  
(1,456 )
(5,118 )
(132,053 )
1,042,226  
(719,773 )
(4,554 )
(2,866 )
310,398  
69,139  
45,857  
114,996  

51,818  
1,430  
2,402  

  $

  $
  $
  $

(1)

Stock-based compensation includes $125, $106, and $78 of restricted stock and option expense related to director compensation for the years ended December 31, 2021, 2020, and 2019, respectively.

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum 

to the total of the same such amounts in the Consolidated Statements of Cash Flows:

(Dollars in thousands)
Cash and cash equivalents
Restricted cash

Total cash, cash equivalents and restricted cash presented in the Consolidated Statements of Cash Flows

2021

For the Year Ended December 31,
2020

2019

  $

  $

  $

133,115  
3,150  
136,265     $

198,282     $
39,340      
237,622     $

64,393  
50,603  
114,996  

See “Note 2 – Summary of Significant Accounting Policies” for a description of restricted cash and cash equivalents.

See notes to consolidated financial statements.  
96

 
 
 
 
 
 
 
 
 
 
 
 
   
 
     
   
 
 
     
   
 
   
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
   
   
     
   
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
   
 
 
 
 
   
 
 
 
   
 
 
 
   
 
   
 
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
 
 
   
 
  
 
 
   
 
   
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
  
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of 
Investment

Maturity Date

Interest Rate and Floor 

(1)

Principal
Amount

(2)

Cost 

Value

Footnotes

Portfolio Company
Debt Investments
Communications & Networking
1-5 Years Maturity
Cytracom Holdings LLC
Rocket Lab Global Services, LLC

Subtotal: 1-5 Years Maturity
Subtotal: Communications & Networking (7.58%)*
Consumer & Business Products
1-5 Years Maturity
Grove Collaborative, Inc.

Senior Secured

Subtotal: 1-5 Years Maturity
Subtotal: Consumer & Business Products (1.78%)*
Diversified Financial Services
Under 1 Year Maturity
Newfront Insurance Holdings, Inc.
Subtotal: Under 1 Year Maturity
1-5 Years Maturity
Gibraltar Business Capital, LLC

Total Gibraltar Business Capital, LLC

Hercules Adviser LLC
Subtotal: 1-5 Years Maturity
Subtotal: Diversified Financial Services (2.48%)*
Drug Discovery & Development
Under 1 Year Maturity
Chemocentryx, Inc.

Convertible Note

  Unsecured
  Unsecured

  Unsecured

Senior Secured
Senior Secured

February 2025
June 2024

3-month LIBOR + 9.31% or Floor rate of 10.31%  
PRIME + 4.90% or Floor rate of 8.15%, PIK 
Interest 1.25%, 3.25% Exit Fee

April 2025

PRIME + 5.50% or Floor rate of 8.75%, 6.75% 
Exit Fee

August 2022

PIK Interest 0.19% or Floor rate of 0.19%

September 2026
September 2026

FIXED 14.50%
FIXED 11.50%

May 2023

FIXED 5.00%

Senior Secured

December 2022

PRIME + 3.30% or Floor rate of 8.05%, 6.25% 
Exit Fee

Subtotal: Under 1 Year Maturity
1-5 Years Maturity
Albireo Pharma, Inc.

Senior Secured

July 2024

Aldeyra Therapeutics, Inc.

Senior Secured

October 2023

Applied Genetic Technologies Corporation

Senior Secured

April 2024

Aveo Pharmaceuticals, Inc.

Senior Secured

September 2024

Axsome Therapeutics, Inc.

Senior Secured

October 2026

Bicycle Therapeutics PLC

Senior Secured

October 2024

BiomX, INC

BridgeBio Pharma, Inc.
Cellarity, Inc.

Senior Secured

September 2025

Senior Secured
Senior Secured

November 2026
June 2026

Center for Breakthrough Medicines Holdings, 
LLC
Century Therapeutics

Senior Secured

May 2023

Senior Secured

April 2024

PRIME + 5.90% or Floor rate of 9.15%, 6.95% 
Exit Fee
PRIME + 3.10% or Floor rate of 8.60%, 6.95% 
Exit Fee
PRIME + 6.50% or Floor rate of 9.75%, 6.95% 
Exit Fee
PRIME + 6.40% or Floor rate of 9.65%, 6.95% 
Exit Fee
PRIME + 5.70% or Floor rate of 8.95%, 5.82% 
Exit Fee
PRIME + 5.60% or Floor rate of 8.85%, 5.00% 
Exit Fee
PRIME + 5.70% or Floor rate of 8.95%, 6.55% 
Exit Fee
FIXED 9.00%, 2.00% Exit Fee
PRIME + 5.70% or Floor rate of 8.95%, 3.75% 
Exit Fee
PRIME + 5.50% or Floor rate of 8.75%, 7.50% 
Exit Fee
PRIME + 6.30% or Floor rate of 9.55%, 3.95% 
Exit Fee

See notes to consolidated financial statements.   
97

$
$

$

$

$
$
  $
$

$

$

$

$

$

$

$

$

$
$

$

$

9,000  
88,542  

  $

23,520  

403  

15,000  
10,000  
25,000  
8,850  

18,951  

10,000  

15,000  

20,000  

40,000  

50,000  

24,000  

9,000  

38,000  
30,000  

5,000  

10,000  

8,802  
88,286  

97,088  
97,088  

23,162  

23,162  
23,162  

403  
403  

14,662  
9,823  
24,485  
8,850  
33,335  
33,738  

20,036  

20,036  

10,229  

15,639  

20,416  

40,842  

49,542  

24,271  

8,980  

37,462  
29,422  

5,005  

10,075  

  $

8,725  
90,505  

  (11)(16)(17)
  (13)(15)

99,230  
99,230  

23,298  

  (18)

23,298  
23,298  

403  
403  

13,818  
9,394  
23,212  
8,850  
32,062  
32,465  

  (9)

  (7)
  (7)

  (7)

20,036  

  (10)

20,036  

10,268  

  (10)(11)

15,653  

20,339  

40,776  

  (11)(14)

48,859  

  (10)(12)

24,454  

  (5)(10)(11)(12)(16)

8,980  

  (5)(10)(11)

37,462  
29,422  

5,005  

  (14)

10,361  

  (11)

 
 
   
     
    
    
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
   
 
 
 
 
 
   
   
  
 
  
 
 
   
   
  
 
   
   
   
 
 
   
   
   
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
   
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
 
 
   
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
 
 
   
   
 
 
   
   
   
 
 
   
   
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Portfolio Company
Chemocentryx, Inc.

Type of 
Investment

Maturity Date

Senior Secured

February 2025

Codiak Biosciences, Inc.

Senior Secured

October 2025

Corium, Inc.

Senior Secured

September 2026

Eloxx Pharmaceuticals, Inc.

Senior Secured

April 2025

enGene, Inc.

G1 Therapeutics, Inc.

Geron Corporation

Hibercell, Inc.

Humanigen, Inc.

Senior Secured

July 2025

Senior Secured

November 2026

Senior Secured

October 2024

Senior Secured

May 2025

Senior Secured

March 2025

Kaleido Biosciences, Inc.

Senior Secured

January 2024

Locus Biosciences

Nabriva Therapeutics

Senior Secured

July 2025

Senior Secured

June 2023

Phathom Pharmaceuticals, Inc.

Senior Secured

October 2026

Scynexis, Inc.

Senior Secured

March 2025

Seres Therapeutics, Inc.

Senior Secured

November 2023

Syndax Pharmaceutics Inc.

Senior Secured

April 2024

TG Therapeutics, Inc.

Senior Secured

January 2026

uniQure B.V.

Senior Secured

December 2025

Unity Biotechnology, Inc.

Senior Secured

August 2024

Valo Health, LLC (p.k.a. Integral Health 
Holdings, LLC)
X4 Pharmaceuticals, Inc.

Senior Secured

May 2024

Senior Secured

July 2024

Yumanity Therapeutics, Inc.

Senior Secured

January 2024

Subtotal: 1-5 Years Maturity
Subtotal: Drug Discovery & Development (71.53%)*
Healthcare Services, Other
1-5 Years Maturity
Better Therapeutics, Inc.

Senior Secured

August 2025

Blue Sprig Pediatrics, Inc.

Senior Secured

November 2026

Carbon Health Technologies, Inc.

Senior Secured

March 2025

Equality Health, LLC

Senior Secured

February 2026

Subtotal: 1-5 Years Maturity
Subtotal: Healthcare Services, Other (8.68%)*
Information Services
1-5 Years Maturity
Capella Space

Senior Secured

November 2024

Yipit, LLC

Senior Secured

September 2026

Subtotal: 1-5 Years Maturity
Subtotal: Information Services (4.93%)*

(1)

Interest Rate and Floor 
PRIME + 3.25% or Floor rate of 8.50%, 7.15% 
Exit Fee
PRIME + 5.00% or Floor rate of 8.25%, 5.50% 
Exit Fee
PRIME + 5.70% or Floor rate of 8.95%, 7.75% 
Exit Fee
PRIME + 6.25% or Floor rate of 9.50%, 6.55% 
Exit Fee
PRIME + 5.00% or Floor rate of 8.25%, 6.35% 
Exit Fee
PRIME + 5.90% or Floor rate of 9.15%, 9.86% 
Exit Fee
PRIME + 5.75% or Floor rate of 9.00%, 6.55% 
Exit Fee
PRIME + 5.40% or Floor rate of 8.65%, 4.95% 
Exit Fee
PRIME + 5.50% or Floor rate of 8.75%, 6.75% 
Exit Fee
PRIME + 6.10% or Floor rate of 9.35%, 7.55% 
Exit Fee
PRIME + 6.10% or Floor rate of 9.35%, 4.95% 
Exit Fee
PRIME + 4.30% or Floor rate of 9.80%, 6.95% 
Exit Fee
PRIME + 2.25% or Floor rate of 5.50%, PIK 
Interest 3.35%, 7.50% Exit Fee
PRIME + 5.80% or Floor rate of 9.05%, 3.95% 
Exit Fee
PRIME + 4.40% or Floor rate of 9.65%, 4.85% 
Exit Fee
PRIME + 6.00% or Floor rate of 9.25%, 4.99% 
Exit Fee
PRIME + 2.15% or Floor rate of 5.40%, PIK 
Interest 3.45%, 5.95% Exit Fee
PRIME + 4.70% or Floor rate of 7.95%, 7.28% 
Exit Fee
PRIME + 6.10% or Floor rate of 9.35%, 6.25% 
Exit Fee
PRIME + 6.45% or Floor rate of 9.70%, 3.85% 
Exit Fee
PRIME + 3.75% or Floor rate of 8.75%, 8.80% 
Exit Fee
PRIME + 4.00% or Floor rate of 8.75%, 5.92% 
Exit Fee

PRIME + 5.70% or Floor rate of 8.95%, 5.95% 
Exit Fee
3-month LIBOR + 5.00% or Floor rate of 6.00%, 
PIK Interest 4.45%
PRIME + 5.60% or Floor rate of 8.85%, 4.61% 
Exit Fee
PRIME + 6.25% or Floor rate of 9.50%, PIK 
Interest 1.55%

PRIME + 5.00% or Floor rate of 8.25%, PIK 
Interest 1.10%, 4.00% Exit Fee
1-month LIBOR + 9.08% or Floor rate of 
10.08%

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

See notes to consolidated financial statements.   
98

Principal
Amount

(2)

Cost 

Value

Footnotes

5,000  

  $

5,161  

  $

5,070  

  (10)

25,000  

91,500  

12,500  

7,000  

58,125  

32,500  

17,000  

20,000  

22,500  

8,000  

5,000  

87,116  

16,000  

24,051  

20,000  

51,450  

77,500  

22,701  

11,500  

32,500  

12,732  

8,000  

25,022  

46,125  

35,444  

20,025  

45,900  

25,459  

90,997  

12,443  

6,858  

57,873  

32,704  

17,041  

20,235  

23,505  

7,977  

5,500  

86,075  

15,826  

24,777  

20,646  

50,470  

78,755  

23,293  

11,547  

34,140  

13,256  

916,421  
936,457  

7,966  

24,653  

45,964  

35,141  

113,724  
113,724  

19,751  

45,022  

64,773  
64,773  

25,316  

  (11)

90,997  

  (15)

12,443  

  (14)

6,858  

  (5)(10)

57,874  

  (10)(11)(12)(14)(16)

32,744  

  (10)(12)

17,014  

  (14)

19,985  

  (9)(10)

23,384  

  (12)

7,900  

  (14)

5,459  

  (5)(10)

86,075  

  (10)(12)(13)(14)(15)(16)

15,778  

25,183  

20,653  

  (12)(16)

50,470  

  (10)

78,755  

  (5)(10)(11)(12)(15)

23,627  

  (9)

11,492  

  (11)

34,085  

  (11)(12)

13,187  

915,928  
935,964  

7,966  

  (14)(16)

24,653  

  (13)(16)

45,964  

  (16)(18)

35,056  

  (12)(13)(16)

113,639  
113,639  

19,424  

  (13)(14)(18)

45,022  

  (16)(17)

64,446  
64,446  

 
 
   
     
    
    
 
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
 
 
   
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of 
Investment

Maturity Date

Interest Rate and Floor 

(1)

Principal
Amount

(2)

Cost 

Value

Footnotes

Portfolio Company
Internet Consumer & Business Services
Under 1 Year Maturity
Nextroll, Inc.

Subtotal: Under 1 Year Maturity
1-5 Years Maturity
AppDirect, Inc.

Senior Secured

June 2022

PRIME + 3.75% or Floor rate of 7.00%, PIK 
Interest 2.95%, 3.50% Exit Fee

Senior Secured

August 2024

Carwow LTD

Senior Secured

December 2024

ePayPolicy Holdings, LLC
Houzz, Inc.
Rhino Labs, Inc.

RVShare, LLC

SeatGeek, Inc.

Skyword, Inc.

Tectura Corporation

Total Tectura Corporation

Thumbtack, Inc.

Senior Secured
Convertible Debt
Senior Secured

December 2024
May 2028
March 2024

Senior Secured

December 2026

Senior Secured

June 2023

Senior Secured

September 2024

Senior Secured
Senior Secured
Senior Secured

July 2024
July 2024
July 2024

Senior Secured

September 2023

Zepz (p.k.a. Worldremit Group Limited)

Senior Secured

February 2025

PRIME + 5.90% or Floor rate of 9.15%, 7.95% 
Exit Fee
PRIME + 4.70% or Floor rate of 7.95%, PIK 
Interest 1.45%, 4.95% Exit Fee
3-month LIBOR + 8.50% or Floor rate of 9.50%  
PIK Interest 5.50%
PRIME + 5.50% or Floor rate of 8.75%, PIK 
Interest 2.25%
1-month LIBOR + 5.50% or Floor rate of 6.50%, 
PIK Interest 4.00%
PRIME + 5.00% or Floor rate of 10.50%, PIK 
Interest 0.50%
PRIME + 3.88% or Floor rate of 9.38%, PIK 
Interest 1.90%, 4.00% Exit Fee
PIK Interest 5.00%
FIXED 8.25%
PIK Interest 5.00%

PRIME + 3.45% or Floor rate of 8.95%, PIK 
Interest 1.50%, 3.95% Exit Fee
3-month LIBOR + 9.25% or Floor rate of 
10.25%, 3.00% Exit Fee

Subtotal: 1-5 Years Maturity
Subtotal: Internet Consumer & Business Services (26.74%)*
Manufacturing Technology
Under 1 Year Maturity
Bright Machines, Inc.

Senior Secured

November 2022

PRIME + 5.70% or Floor rate of 8.95%, 6.95% 
Exit Fee

Senior Secured

December 2024

PRIME + 5.00% or Floor rate of 8.25%, 4.95% 
Exit Fee

Subtotal: Under 1 Year Maturity
Subtotal: Manufacturing Technology (1.15%)*
Semiconductors
1-5 Years Maturity
Fungible Inc.

Subtotal: 1-5 Years Maturity
Subtotal: Semiconductors (1.46%)*
Software
Under 1 Year Maturity
Khoros (p.k.a Lithium Technologies)
Pymetrics, Inc.

Senior Secured
Senior Secured

October 2022
October 2022

Regent Education

Senior Secured

January 2022

Subtotal: Under 1 Year Maturity
1-5 Years Maturity
3GTMS, LLC.

Senior Secured

February 2025

Agilence, Inc.

Senior Secured

October 2026

6-month LIBOR + 8.00% or Floor rate of 9.00%  
PRIME + 5.50% or Floor rate of 8.75%, PIK 
Interest 1.75%, 4.00% Exit Fee
FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit 
Fee

6-Month LIBOR + 9.28% or Floor rate of 
10.28%
1-month LIBOR + 9.00% or Floor rate of 10.00%  

See notes to consolidated financial statements.   
99

$

$

£

$
$
$

$

$

$

$
$
$
  $
$

$

$

$

$
$

$

$

$

21,555  

  $

22,164  

  $

22,164  

  (12)(13)(18)

30,790  

21,250  

8,169  
20,676  
16,136  

15,000  

60,607  

12,426  

10,680  
8,250  
13,023  
31,953  
25,618  

103,000  

15,000  

20,000  

56,208  
9,667  

2,951  

10,000  

9,400  

22,164  

31,416  

28,632  

8,011  
20,676  
15,765  

14,701  

59,983  

12,665  

240  
8,250  
13,023  
21,513  
25,965  

101,674  

341,001  
363,165  

14,995  

14,995  
14,995  

19,072  

19,072  
19,072  

55,834  
9,845  

3,064  

68,743  

9,812  

9,138  

22,164  

32,248  

28,632  

  (5)(10)(13)

7,967  
20,425  
15,876  

  (11)(16)
  (9)(13)
  (13)(14)

14,701  

  (14)(16)

60,316  

  (13)

12,521  

  (13)

—  
8,250  
19  
8,269  
26,372  

  (7)(8)(13)
  (7)(8)
  (7)(8)(13)

  (12)(13)

100,472  

  (5)(10)(12)(15)(18)

327,799  
349,963  

14,995  

  (18)

14,995  
14,995  

19,072  

  (14)(18)

19,072  
19,072  

55,834  
9,845  

  (16)
  (13)

2,608  

  (8)(13)

68,287  

9,656  

  (16)(17)

9,138  

  (16)

 
 
   
     
    
    
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
 
 
   
   
   
   
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
   
 
 
   
   
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
  
 
 
   
   
  
 
 
   
   
   
 
 
   
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
 
   
 
   
   
 
 
 
 
 
   
 
   
 
   
   
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
   
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
   
   
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Portfolio Company
Brain Corporation

Campaign Monitor Limited
Ceros, LLC
Cloud 9 Software
CloudBolt Software, Inc.

Type of 
Investment

Maturity Date

Senior Secured

April 2025

Senior Secured
Senior Secured
Senior Secured
Senior Secured

November 2025
September 2026
April 2024
October 2024

Cybermaxx Intermediate Holdings, Inc.

Senior Secured

August 2026

Dashlane, Inc.

Delphix Corp.

Demandbase, Inc.

Enmark Systems

Esentire, Inc.

Senior Secured

July 2025

Senior Secured

February 2023

Senior Secured

August 2025

Senior Secured

September 2026

Senior Secured

May 2024

Gryphon Networks Corp.

Senior Secured

January 2026

Ikon Science Limited

Senior Secured

October 2024

Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.)

Senior Secured

July 2023

Logicworks
Mixpanel, Inc.

Senior Secured
Senior Secured

January 2024
August 2024

Mobile Solutions Services

Senior Secured

December 2025

Nuvolo Technologies Corporation

Senior Secured

July 2025

Pollen, Inc.

Senior Secured

November 2023

Total Pollen, Inc.

Reltio, Inc.

ShadowDragon, LLC

Senior Secured

November 2023

Senior Secured

July 2023

Senior Secured

December 2026

Tact.ai Technologies, Inc.

Senior Secured

February 2024

ThreatConnect, Inc.

Udacity, Inc.

Zimperium, Inc.
Subtotal: 1-5 Years Maturity
Greater than 5 Years Maturity
Imperva, Inc.
Subtotal: Greater than 5 Years Maturity
Subtotal: Software (40.46%)*

Senior Secured

May 2026

Senior Secured

September 2024

Senior Secured

July 2024

(1)

Interest Rate and Floor 
PRIME + 3.70% or Floor rate of 6.95%, PIK 
Interest 1.00%, 3.95% Exit Fee
6-month LIBOR + 7.90% or Floor rate of 11.15%  
3-month LIBOR + 8.89% or Floor rate of 9.89%  
3-month LIBOR + 8.20% or Floor rate of 9.20%  
PRIME + 6.70% or Floor rate of 9.95%, 2.95% 
Exit Fee
6-month LIBOR + 9.28% or Floor rate of 
10.28%
PRIME + 3.05% or Floor rate of 7.55%, PIK 
Interest 1.10%, 7.10% Exit Fee
PRIME + 5.50% or Floor rate of 10.25%, 5.00% 
Exit Fee
PRIME + 5.25% or Floor rate of 8.50%, 2.00% 
Exit Fee
6-Month LIBOR + 6.83% or Floor rate of 7.83%, 
PIK Interest 2.19%
3-month LIBOR + 9.96% or Floor rate of 
10.96%
3-month LIBOR + 9.69% or Floor rate of 
10.69%
3-month LIBOR + 9.00% or Floor rate of 
10.00%
3-month LIBOR + 10.14% or Floor rate of 
11.14%
PRIME + 7.50% or Floor rate of 10.75%
PRIME + 4.70% or Floor rate of 7.95%, PIK 
Interest 1.80%, 3.00% Exit Fee
6-month LIBOR + 9.87% or Floor rate of 
10.87%
PRIME + 7.70% or Floor rate of 10.95%, 1.75% 
Exit Fee
PRIME + 4.75% or Floor rate of 8.00%, PIK 
Interest 0.50%, 4.50% Exit Fee
PRIME + 5.25% or Floor rate of 8.50%, PIK 
Interest 1.35%, 4.50% Exit Fee

PRIME + 5.70% or Floor rate of 8.95%, PIK 
Interest 1.70%, 4.95% Exit Fee
3-month LIBOR + 9.00% or Floor rate of 
10.00%
PRIME + 4.00% or Floor rate of 8.75%, PIK 
Interest 2.00%, 5.50% Exit Fee
3-month LIBOR + 9.00% or Floor rate of 
10.00%
PRIME + 4.50% or Floor rate of 7.75%, PIK 
Interest 2.00%, 3.00% Exit Fee
1-month LIBOR + 8.95% or Floor rate of 9.95%  

$

$
$
$
$

$

$

$

$

$

$

$

$

$

$
$

$

$

$

$

  $
$

$

$

$

$

$

$

Principal
Amount

(2)

Cost 

Value

Footnotes

10,016  

  $

9,943  

  $

9,943  

  (13)(14)(16)

33,000  
17,978  
9,953  
10,000  

8,000  

20,719  

60,000  

16,875  

8,000  

21,000  

5,232  

6,913  

8,571  

10,000  
20,431  

19,074  

15,000  

7,457  

13,041  

20,498  
10,248  

6,000  

5,185  

11,144  

50,895  

15,633  

20,000  

32,459  
17,474  
9,856  
9,923  

7,801  

21,807  

61,736  

16,463  

7,798  

20,699  

5,106  

6,719  

8,403  

9,862  
20,292  

18,575  

14,967  

7,528  

13,005  

20,533  
10,336  

5,828  

5,305  

10,831  

50,646  

15,347  
437,659  

19,851  
19,851  
526,253  

33,000  
17,474  
9,953  
10,035  

  (18)
  (16)(17)
  (12)
  (11)(12)(18)

7,801  

  (16)

21,734  

  (11)(13)(16)(18)

62,345  

  (12)(15)(18)

16,463  

  (16)(18)

7,798  

  (11)(16)(17)

20,750  

  (5)(10)(11)(17)

5,088  

  (11)(16)

6,767  

  (5)(10)(16)(17)

8,375  

  (17)

9,965  
21,030  

  (12)(16)
  (12)(13)(18)

18,834  

  (16)(17)

15,017  

  (12)(18)

7,314  

  (13)

13,092  

  (13)(14)

20,406  
10,542  

  (13)(18)

5,828  

  (16)(17)

5,245  

  (13)

10,859  

  (12)(16)(17)

51,722  

  (12)(13)

  (12)(17)

  (18)

15,347  
441,115  

20,000  
20,000  
529,402  

Senior Secured

January 2027

3-month LIBOR + 7.75% or Floor rate of 8.75%  

See notes to consolidated financial statements.   
100

 
 
   
     
    
    
 
 
 
   
   
 
   
   
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
 
   
   
   
 
 
   
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
   
   
 
 
   
   
   
   
 
 
 
 
 
   
 
   
 
   
   
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of 
Investment

Maturity Date

Interest Rate and Floor 

(1)

Principal
Amount

(2)

Cost 

Value

Footnotes

Portfolio Company
Sustainable and Renewable Technology
Under 1 Year Maturity
Impossible Foods, Inc.

Pineapple Energy LLC
Subtotal: Under 1 Year Maturity
1-5 Years Maturity
Pineapple Energy LLC
Subtotal: 1-5 Years Maturity
Subtotal: Sustainable and Renewable Technology (2.07%)*
Total: Debt Investments (168.86%)*

Senior Secured

July 2022

Senior Secured

January 2022

PRIME + 3.95% or Floor rate of 8.95%, 9.00% 
Exit Fee
FIXED 10.00%

Senior Secured

December 2023

PIK Interest 10.00%

$

$

$

15,022  

  $

19,379  

  $

19,378  

  (12)

280  

7,500  

  $

280  
19,659  

7,500  
7,500  
27,159  
2,219,586  

  $

247  
19,625  

  (6)(9)(16)

  (6)(8)(13)(16)

7,500  
7,500  
27,125  
2,209,599  

See notes to consolidated financial statements.   
101

 
 
   
     
    
    
 
 
   
   
  
 
  
 
 
 
 
 
 
   
   
  
 
  
 
 
 
 
 
   
   
 
 
   
   
   
   
 
 
 
 
 
   
   
  
 
  
 
 
 
   
   
 
 
   
   
   
   
 
 
   
   
   
   
 
 
   
   
 
 
Portfolio Company
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc.

Total Peerless Network Holdings, Inc.

Subtotal: Communications & Networking (0.48%)*
Consumer & Business Products
TechStyle, Inc. (p.k.a. Just Fabulous, Inc.)
Subtotal: Consumer & Business Products (0.03%)*
Diversified Financial Services
Gibraltar Business Capital, LLC

Total Gibraltar Business Capital, LLC

Hercules Adviser LLC
Subtotal: Diversified Financial Services (2.49%)*
Drug Delivery
AcelRx Pharmaceuticals, Inc.
Aytu BioScience, Inc. (p.k.a. Neos Therapeutics, Inc.)
BioQ Pharma Incorporated
PDS Biotechnology Corporation (p.k.a. Edge 
Therapeutics, Inc.)
Subtotal: Drug Delivery (0.02%)*
Drug Discovery & Development
Albireo Pharma, Inc.
Applied Molecular Transport
Avalo Therapeutics, Inc. (p.k.a. Cerecor, Inc.)
Aveo Pharmaceuticals, Inc.
Bicycle Therapeutics PLC
BridgeBio Pharma, Inc.
Chemocentryx, Inc.
Concert Pharmaceuticals, Inc.
Dare Biosciences, Inc.
Dynavax Technologies
Genocea Biosciences, Inc.
Hibercell, Inc.
Humanigen, Inc.
Kaleido Biosciences, Inc.
NorthSea Therapeutics
Paratek Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Ltd.
Savara, Inc.
Sio Gene Therapies, Inc. (p.k.a. Axovant Gene Therapies 
Ltd.)
Tricida, Inc.
uniQure B.V.
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)  
X4 Pharmaceuticals, Inc.
Subtotal: Drug Discovery & Development (1.90%)*
Healthcare Services, Other
23andMe, Inc.
Carbon Health Technologies, Inc.
Subtotal: Healthcare Services, Other (0.56%)*
Information Services
Planet Labs, Inc.
Yipit, LLC
Zeta Global Corp.
Subtotal: Information Services (0.72%)*

Equity
Equity

Equity

Equity
Equity

Equity

Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity

Equity
Equity

Equity
Equity
Equity

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of
Investment

Acquisition Date

 (4)

Series 

(3)

Shares

(2)

Cost 

Value

Footnotes

10/21/2020
4/11/2008

Common Stock
Preferred Series A

  $

3,328  
1,135,000  
1,138,328  

4/30/2010

Common Stock

42,989  

3/1/2018
3/1/2018

Common Stock
Preferred Series A

3/26/2021

Member Units

12/10/2018
3/28/2014
12/8/2015
4/6/2015

9/14/2020
4/6/2021
8/19/2014
7/31/2011
10/5/2020
6/21/2018
6/15/2020
2/13/2019
1/8/2015
7/22/2015
11/20/2014
5/7/2021
3/31/2021
2/10/2021
12/15/2021
2/26/2007
8/22/2007
8/11/2015
2/2/2017

2/28/2018
1/31/2019
12/11/2020
11/26/2019

Common Stock
Common Stock
Preferred Series D
Common Stock

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series B
Common Stock
Common Stock
Preferred Series C
Common Stock
Common Stock
Common Stock
Common Stock

Common Stock
Common Stock
Preferred Series B
Common Stock

3/11/2019
3/30/2021

Common Stock
Preferred Series C

6/21/2019
12/30/2021
11/20/2007

Common Stock
Preferred Series E
Common Stock

830,000  
10,602,752  
11,432,752  
1  

176,730  
13,600  
165,000  
2,498  

25,000  
1,000  
119,087  
190,179  
98,100  
231,329  
17,241  
70,796  
13,550  
20,000  
27,933  
3,466,840  
43,243  
86,585  
983  
76,362  
944  
11,119  
16,228  

68,816  
17,175  
510,308  
198,277  

825,732  
217,880  

547,880  
41,021  
295,861  

See notes to consolidated financial statements.   
102

  $

—  
1,230  
1,230  
1,230  

128  
128  

1,884  
26,122  
28,006  
35  
28,041  

1,329  
1,500  
500  
309  

3,638  

1,000  
42  
1,000  
1,715  
1,871  
2,255  
1,000  
1,367  
1,000  
550  
2,000  
4,250  
800  
1,000  
2,000  
2,744  
1,500  
202  
1,269  

863  
332  
3,000  
1,641  
33,401  

5,094  
1,687  
6,781  

615  
3,825  
—  
4,440  

18   
6,242   
6,260   
6,260   

447   
447   

1,225   
19,393   
20,618   
11,990   
32,608   

99   
18   
168   
20  

305   

582   
14   
202   
892   
5,971   
3,859   
628   
223   
27   
281   
32   
3,264   
161   
207   
2,000   
343   
21   
14   
21  

658   
356   
4,650   
454   
24,860   

5,500   
1,864   
7,364   

3,369   
3,825   
2,220   
9,414   

(7)

(7)

(7)

(4)

(4)

(4)

(4)(10)

(4)(10)

(4)

(4)

(4)(5)(10)

(4)

(4)(10)

(4)(10)

(4)

(4)(10)

(4)

(14)

(4)(10)

(4)

(5)(10)

(4)

(4)

(4)

(4)(10)

(4)

(4)(5)(10)(15)

(4)

(4)

(4)

(4)(19)

 
 
 
  
    
    
   
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
  
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
  
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
Portfolio Company
Internet Consumer & Business Services
Black Crow AI, Inc.
Black Crow AI, Inc. affiliates
Brigade Group, Inc.
Carwow LTD
Contentful Global, Inc. (p.k.a. Contentful, Inc.)

Total Contentful Global, Inc. (p.k.a. Contentful, Inc.)

DoorDash, Inc.
Lyft, Inc.
Nerdy Inc.
Nextdoor.com, Inc.
OfferUp, Inc.

Total OfferUp, Inc.

Oportun
Reischling Press, Inc. (p.k.a. Blurb, Inc.)
Savage X Holding, LLC
Tectura Corporation

Total Tectura Corporation

Equity
Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity

TFG Holding, Inc.
Uber Technologies, Inc. (p.k.a. Postmates, Inc.)
Subtotal: Internet Consumer & Business Services (2.70%)*
Medical Devices & Equipment
Coronado Aesthetics, LLC

Equity
Equity

Equity
Equity

Total Coronado Aesthetics, LLC

Flowonix Medical Incorporated
Gelesis, Inc.

Total Gelesis, Inc.

Medrobotics Corporation

Total Medrobotics Corporation

ViewRay, Inc.
Subtotal: Medical Devices & Equipment (0.81%)*
Semiconductors
Achronix Semiconductor Corporation
Subtotal: Semiconductors (0.06%)*
Software
3GTMS, LLC.
CapLinked, Inc.

Equity
Equity
Equity
Equity

Equity
Equity
Equity

Equity

Equity

Equity
Equity

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of
Investment

Acquisition Date

 (4)

Series 

(3)

Shares

(2)

Cost 

Value

Footnotes

3/24/2021
3/24/2021
3/1/2013
12/15/2021
12/22/2020
11/20/2018

12/20/2018
12/26/2018
9/17/2021
8/1/2018
10/25/2016
10/25/2016

6/28/2013
7/31/2020
4/30/2010
5/23/2018
6/6/2016

4/30/2010
12/1/2020

10/15/2021
10/15/2021

11/3/2014
11/30/2009
12/30/2011
12/31/2011

9/12/2013
10/22/2014
10/16/2015

Preferred Series Seed
Preferred Note
Common Stock
Preferred Series D-4
Preferred Series C
Preferred Series D

Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series A
Preferred Series A-1

Common Stock
Common Stock
Class A Units
Common Stock
Preferred Series BB

Common Stock
Common Stock

Common Units
Preferred Series A-2

Preferred Series AA
Common Stock
Preferred Series A-1
Preferred Series A-2

Preferred Series E
Preferred Series F
Preferred Series G

12/16/2013

Common Stock

7/1/2011

Preferred Series C

8/9/2021
10/26/2012

Common Stock
Preferred Series A-3

See notes to consolidated financial statements.   
103

  $

872,797  
3  
9,023  
199,742  
41,000  
108,500  
149,500  
81,996  
100,738  
100,000  
1,019,255  
286,080  
108,710  
394,790  
48,365  
1,163  
42,137  
414,994,863  
1,000,000  
415,994,863  
42,989  
32,991  

180,000  
5,000,000  
5,180,000  
221,893  
227,013  
243,432  
191,626  
662,071  
136,798  
73,971  
163,934  
374,703  
36,457  

277,995  

1,000,000  
53,614  

  $

1,000  
3,000  
93  
1,151  
138  
500  
638  
945  
5,263  
1,000  
4,854  
1,663  
632  
2,295  
577  
15  
13  
900  
—  
900  
89  
318  
22,151  

—  
250  
250  
1,500  
—  
503  
500  
1,003  
250  
155  
500  
905  
333  
3,991  

160  
160  

1,000  
51  

(6)

(20)

(5)(10)

(5)(10)

(5)(10)

(4)

(4)

(4)

(4)(19)

(4)

(7)

(7)

(4)

(7)

(7)

(4)

1,120   
3,000   
—   
608   
506   
1,388   
1,894   
12,209   
4,305   
450   
6,624   
1,791   
680   
2,471   
980   
—   
71   
—   
—   
—   
216   
1,383   
35,331   

65   
500   
565   
—   
3,351   
3,593   
2,828   
9,772   
—   
—   
—   
—   
201   
10,538   

725   
725   

985   
65   

 
 
  
    
    
   
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
  
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
  
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
  
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
  
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Shares

(2)

Cost 

Value

Footnotes

Portfolio Company
Docker, Inc.
Druva Holdings, Inc. (p.k.a. Druva, Inc.)

Total Druva Holdings, Inc. (p.k.a. Druva, Inc.)

HighRoads, Inc.
Lightbend, Inc.
Palantir Technologies
SingleStore, Inc. (p.k.a. memsql, Inc.)

Total SingleStore, Inc. (p.k.a. memsql, Inc.)

Sprinklr, Inc.
Verana Health, Inc.
Subtotal: Software (3.45%)*
Surgical Devices
Gynesonics, Inc.

Total Gynesonics, Inc.

Subtotal: Surgical Devices (0.04%)*
Sustainable and Renewable Technology
Impossible Foods, Inc.
Modumetal, Inc.
NantEnergy, LLC (p.k.a. Fluidic, Inc.)
Pineapple Energy LLC
Pivot Bio, Inc.
Proterra, Inc.
Subtotal: Sustainable and Renewable Technology (0.86%)*
Total: Equity Investments (14.12%)*

Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity

Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity

Type of
Investment

 (4)

Acquisition Date
11/29/2018
10/22/2015
8/24/2017

(3)

Series 
Common Stock
Preferred Series 2
Preferred Series 3

1/18/2013
12/4/2020
9/23/2020
11/25/2020
8/12/2021

3/22/2017
7/8/2021

1/18/2007
6/16/2010
2/8/2013
7/14/2015
12/18/2018
12/18/2018

5/10/2019
6/1/2015
8/31/2013
12/10/2020
6/28/2021
5/28/2015

Common Stock
Common Stock
Common Stock
Preferred Series E
Preferred Series F

Common Stock
Preferred Series E

Preferred Series B
Preferred Series C
Preferred Series D
Preferred Series E
Preferred Series F
Preferred Series F-1

Preferred Series E-1
Common Stock
Common Units
Class A Units
Preferred Series D
Common Stock

Warrant Investments
Communications & Networking
Spring Mobile Solutions, Inc.
Subtotal: Communications & Networking (0.00%)*
Consumer & Business Products
Grove Collaborative, Inc.
Penumbra Brands, LLC (p.k.a. Gadget Guard)
TechStyle, Inc. (p.k.a. Just Fabulous, Inc.)
The Neat Company
Whoop, Inc.
Subtotal: Consumer & Business Products (0.33%)*
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.)
BioQ Pharma Incorporated
PDS Biotechnology Corporation (p.k.a. Edge 
Therapeutics, Inc.)
Subtotal: Drug Delivery (0.00%)*
Drug Discovery & Development
Acacia Pharma Inc.
ADMA Biologics, Inc.

  Warrant

4/19/2013

Common Stock

2,834,375  

  $

  Warrant
  Warrant
  Warrant
  Warrant
  Warrant

  Warrant
  Warrant
  Warrant

4/30/2021
6/3/2014
7/16/2013
8/13/2014
6/27/2018

Common Stock
Common Stock
Preferred Series B
Common Stock
Preferred Series C

9/30/2015
10/27/2014
8/28/2014

Common Stock
Common Stock
Common Stock

  Warrant
  Warrant

6/29/2018
12/21/2012

Common Stock
Common Stock

83,625  
1,662,441  
206,185  
54,054  
686,270  

110,882  
459,183  
3,929  

201,330  
89,750  

See notes to consolidated financial statements.   
104

20,000  
458,841  
93,620  
552,461  
190  
38,461  
1,418,337  
580,983  
52,956  
633,939  
700,000  
952,562  

219,298  
656,538  
1,991,157  
2,786,367  
1,523,693  
2,418,125  
9,595,178  

188,611  
1,035  
59,665  
3,000,000  
593,080  
457,841  

  $

  $

  $

  $

  $

4,284  
1,000  
300  
1,300  
307  
265  
8,670  
2,000  
279  
2,279  
3,749  
2,000  
23,905  

250  
282  
712  
429  
118  
150  
1,941  
1,941  

2,000  
500  
102  
4,767  
4,500  
543  
12,412  
142,219  

418  
418  

433  
228  
1,101  
365  
18  
2,145  

74  
1  
390  

465  

305  
295  

3   
2,387   
529   
2,916   
—   
5   
25,828   
2,239   
240   
2,479   
11,109   
1,697   
45,087   

9   
26   
81   
131   
123   
173   
543   
543   

3,430   
—   
—   
591   
3,164   
4,043   
11,228   
184,710   

—   
—   

326   
—   
2,181   
—   
1,847   
4,354   

—   
62   
1  

63   

6   
1   

(4)

(4)

(6)

(4)

(4)

(4)(5)(10)

(4)

 
 
  
    
    
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
  
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
  
 
 
 
   
   
 
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
   
   
 
 
Type of
Investment

Portfolio Company
  Warrant
Albireo Pharma, Inc.
  Warrant
Axsome Therapeutics, Inc.
  Warrant
Brickell Biotech, Inc.
  Warrant
Cellarity, Inc.
  Warrant
Century Therapeutics
  Warrant
Concert Pharmaceuticals, Inc.
  Warrant
Dermavant Sciences Ltd.
  Warrant
enGene, Inc.
  Warrant
Evofem Biosciences, Inc.
  Warrant
Genocea Biosciences, Inc.
  Warrant
Motif Bio PLC
  Warrant
Myovant Sciences, Ltd.
  Warrant
Paratek Pharmaceuticals, Inc.
  Warrant
Phathom Pharmaceuticals, Inc.
  Warrant
Scynexis, Inc.
  Warrant
Stealth Bio Therapeutics Corp.
  Warrant
TG Therapeutics, Inc.
Tricida, Inc.
  Warrant
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)   Warrant
  Warrant
X4 Pharmaceuticals, Inc.
Yumanity Therapeutics, Inc.
  Warrant
Subtotal: Drug Discovery & Development (0.36%)*
Electronics & Computer Hardware
908 Devices, Inc.
Skydio, Inc.
Subtotal: Electronics & Computer Hardware (0.08%)*
Information Services
Capella Space
InMobi Inc.
Netbase Solutions, Inc.
Subtotal: Information Services (0.04%)*
Internet Consumer & Business Services
Aria Systems, Inc.
Carwow LTD
Cloudpay, Inc.
First Insight, Inc.
Houzz, Inc.
Interactions Corporation
Landing Holdings Inc.
Lendio, Inc.
LogicSource
Rhino Labs, Inc.
RumbleON, Inc.
SeatGeek, Inc.
ShareThis, Inc.
Skyword, Inc.
Snagajob.com, Inc.

  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant

  Warrant
  Warrant
  Warrant

  Warrant
  Warrant

Total Snagajob.com, Inc.

Tapjoy, Inc.
The Faction Group LLC

  Warrant
  Warrant

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

 (4)

Acquisition Date
6/8/2020
9/25/2020
2/18/2016
12/8/2021
9/14/2020
6/8/2017
5/31/2019
12/30/2021
6/11/2014
4/24/2018
1/27/2020
10/16/2017
6/27/2017
9/17/2021
5/14/2021
6/30/2017
2/28/2019
3/27/2019
6/15/2020
3/18/2019
12/20/2019

(3)

Series 
Common Stock
Common Stock
Common Stock
Preferred Series B
Common Stock
Common Stock
Common Stock
Preferred Series 3 Class C
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Units
Common Stock
Common Stock

3/15/2017
11/8/2021

Common Stock
Common Stock

10/21/2021
11/19/2014
8/22/2017

5/22/2015
12/14/2021
4/10/2018
5/10/2018
10/29/2019
6/16/2015
3/12/2021
3/29/2019
3/21/2016
3/12/2021
4/30/2018
6/12/2019
12/14/2012
8/23/2019
4/20/2020
6/30/2016
8/1/2018

7/1/2014
11/3/2014

Common Stock
Common Stock
Preferred Series 1

Preferred Series G
Common Stock
Preferred Series B
Preferred Series B
Common Stock
Preferred Series G-3
Common Stock
Preferred Series D
Preferred Series C
Common Stock
Common Stock
Common Stock
Preferred Series C
Preferred Series B
Common Stock
Preferred Series A
Preferred Series B

Preferred Series D
Preferred Series AA

Shares

5,311  
15,541  
9,005  
100,000  
16,112  
61,273  
223,642  
84,714  
7,806  
41,176  
121,337,041  
73,710  
432,240  
64,687  
90,887  
500,000  
231,613  
31,352  
102,216  
108,334  
15,414  

49,078  
124,451  

176,200  
65,587  
60,000  

231,535  
174,163  
6,763  
75,917  
529,661  
68,187  
11,806  
127,032  
79,625  
13,106  
5,139  
1,379,761  
493,502  
444,444  
600,000  
1,800,000  
1,211,537  
3,611,537  
748,670  
8,076  

(2)

Cost 

  $

  $

61  
681  
119  
287  
37  
178  
101  
64  
266  
165  
282  
460  
546  
848  
188  
158  
1,033  
280  
256  
673  
110  
7,393  

101  
557  
658  

207  
82  
356  
645  

74  
164  
54  
96  
20  
204  
116  
39  
30  
470  
88  
842  
547  
83  
16  
782  
62  
860  
317  
234  

Value

Footnotes

(4)(10)

(4)(10)

(4)

(14)

(4)

(4)(10)

(10)(12)

(5)(10)

(4)

(4)

(10)

(4)(10)

(4)

(4)(10)(14)(15)

(4)

(4)(10)

(4)(10)(12)

(4)

(4)

(4)

(4)

(14)

(10)

(5)(10)

(5)(10)

(14)

(14)

(4)

(12)

(12)

(12)

42   
142   
—   
287   
64   
3   
354   
64   
—   
1   
—   
267   
427   
307   
142   
—   
2,172   
20   
441   
2   
3   
4,745   

618   
422   
1,040   

139   
—   
418   
557   

—   
160   
348   
105   
116   
505   
141   
84   
210   
77   
33   
1,140   
—   
7   
121   
171   
90   
382   
443   
650   

See notes to consolidated financial statements.   
105

 
 
  
    
    
   
 
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
  
 
 
   
   
  
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Portfolio Company
Thumbtack, Inc.
Xometry, Inc.
Zepz (p.k.a. Worldremit Group Limited)

Total Zepz (p.k.a. Worldremit Group Limited)

Type of
Investment

  Warrant
  Warrant
  Warrant
  Warrant

 (4)

Acquisition Date
5/1/2018
5/9/2018
2/11/2021
8/27/2021

(3)

Series 
Common Stock
Common Stock
Preferred Series D
Preferred Series E

Subtotal: Internet Consumer & Business Services (0.78%)*
Media/Content/Info
Zoom Media Group, Inc.
Subtotal: Media/Content/Info (0.00%)*
Medical Devices & Equipment
Aspire Bariatrics, Inc.
Flowonix Medical Incorporated

  Warrant

  Warrant
  Warrant
  Warrant

Total Flowonix Medical Incorporated

Intuity Medical, Inc.
Medrobotics Corporation
Outset Medical, Inc.
SonaCare Medical, LLC
Tela Bio, Inc.
Subtotal: Medical Devices & Equipment (0.16%)*
Semiconductors
Achronix Semiconductor Corporation
Fungible Inc.
Subtotal: Semiconductors (0.21%)*
Software
Bitsight Technologies, Inc.
Brain Corporation
CloudBolt Software, Inc.
Cloudian, Inc.
Couchbase, Inc.
Dashlane, Inc.
Delphix Corp.
Demandbase, Inc.
DNAnexus, Inc.
Evernote Corporation
Fuze, Inc.
Lightbend, Inc.
Mixpanel, Inc.
Nuvolo Technologies Corporation
Poplicus, Inc.
Pymetrics, Inc.
RapidMiner, Inc.
Reltio, Inc.
Signpost, Inc.
SingleStore, Inc. (p.k.a. memsql, Inc.)
Tact.ai Technologies, Inc.
Udacity, Inc.
ZeroFox, Inc.
Zimperium, Inc.
Subtotal: Software (0.85%)*

  Warrant
  Warrant
  Warrant
  Warrant
  Warrant

  Warrant
  Warrant

  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant
  Warrant

12/21/2012

Preferred Series A

1/28/2015
11/3/2014
9/21/2018

12/29/2017
3/13/2013
9/27/2013
9/28/2012
3/31/2017

Common Stock
Preferred Series AA
Preferred Series BB

Preferred Series B-1
Preferred Series E
Common Stock
Preferred Series A
Common Stock

6/26/2015
12/16/2021

Preferred Series D-2
Common Stock

11/18/2020
10/4/2021
9/30/2020
11/6/2018
4/25/2019
3/11/2019
10/8/2019
8/2/2021
3/21/2014
9/30/2016
6/30/2017
2/14/2018
9/30/2020
3/29/2019
5/28/2014
9/15/2020
11/28/2017
6/30/2020
1/13/2016
4/28/2020
2/13/2020
9/25/2020
5/7/2020
7/2/2021

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series C
Common Stock
Preferred Series F
Preferred Series D
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series C-1
Common Stock
Series Junior 1 Preferred
Preferred Series D
Common Stock
Common Stock
Preferred Series C-1
Common Stock

See notes to consolidated financial statements.   
106

Shares

190,953  
87,784  
77,215  
1,868  
79,083  

1,204  

22,572  
155,325  
725,806  
881,131  
3,076,323  
455,539  
62,794  
6,464  
15,712  

750,000  
800,000  

29,691  
194,629  
211,342  
477,454  
105,350  
560,536  
718,898  
483,248  
909,091  
62,500  
256,158  
89,685  
82,362  
50,000  
132,168  
150,943  
4,982  
69,120  
474,019  
312,596  
1,041,667  
486,359  
648,350  
20,563  

(2)

Cost 

  $

Value

Footnotes

  $

552  
47  
129  
26  
155  
4,992  

348  
348  

455  
363  
351  
714  
294  
370  
401  
188  
61  
2,483  

99  
751  
850  

284  
165  
117  
71  
462  
404  
1,594  
404  
97  
106  
89  
131  
252  
88  
—  
77  
24  
215  
314  
103  
206  
218  
101  
72  
5,594  

(4)

(5)(10)(15)

(5)(10)(15)

(12)

(4)

(4)

(14)

(14)

(4)(19)

(15)

786   
3,038   
1,962   
25   
1,987   
10,212   

—   
—   

—   
—   
—   
—   
264   
—   
1,797   
—   
13   
2,074   

1,950   
751   
2,701   

1,272   
132   
85   
33   
1,343   
415   
3,275   
443   
102   
65   
—   
—   
906   
283   
—   
218   
54   
637   
—   
704   
162   
345   
603   
56   
11,133   

 
 
  
    
    
   
 
 
 
 
 
   
   
 
 
   
   
  
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
  
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2021
(dollars in thousands)

Type of
Investment

Acquisition Date

 (4)

Series 

(3)

Shares

(2)

Cost 

Value

Footnotes

2/8/2012
11/7/2012

Preferred Series C
Common Stock

151,123  
64,440  

  $

  $

67  
139  
206  

6   
480   
486   

(4)

6/20/2013
9/13/2012
4/22/2014
4/7/2015

Preferred Series D
Preferred Series C-1
Preferred Series A
Preferred Series B

12/11/2012

Preferred Series C

471,327  
280,897  
325,000  
131,883  
456,883  
311,609  

  $
  $

120  
274  
155  
63  
218  
338  
950  
27,147  

2,388,952  

  $

  $

—   
699   
249   
86   
335   
—   
1,034   
38,399   

2,432,708   

Portfolio Company
Surgical Devices
Gynesonics, Inc.
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)
Subtotal: Surgical Devices (0.04%)*
Sustainable and Renewable Technology
Agrivida, Inc.
Fulcrum Bioenergy, Inc.
Halio, Inc. (p.k.a. Kinestral Technologies, Inc.)

  Warrant
  Warrant

  Warrant
  Warrant
  Warrant
  Warrant

Total Halio, Inc. (p.k.a. Kinestral Technologies, Inc.)

Polyera Corporation
Subtotal: Sustainable and Renewable Technology (0.08%)*
Total: Warrant Investments (2.93%)*

  Warrant

Total: Investments in Securities (185.91%)*

Investment Funds & Vehicles

2,032  

1,814  

(5)(10)(16)

Investment Funds & 
Vehicles

11/16/2020

  $
  $

  $
  $

2,032  
2,390,984  

1,814   
2,434,522   

Forbion Growth Opportunities Fund I C.V.
Total: Investments in Investment Funds & Vehicles (0.14%)*
Total: Investments (186.05%)*
*  Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(1)
(2)

Interest rate PRIME represents 3.25% as of December 31, 2021. 1-month LIBOR, 3-month LIBOR, and 6-month LIBOR represent, 0.14%, 0.24%, and 0.26%, respectively, as of December 31, 2021.
Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $121.0 million, $75.7 million, and $45.3 million, respectively. The tax cost 
of investments is $2.4 billion. 
Preferred and common stock, warrants, and equity interests are generally non-income producing. 
Except for warrants in 26 publicly traded companies and common stock in 36 publicly traded companies, all investments are restricted as of December 31, 2021 and were valued at fair value using Level 3 
significant unobservable inputs as determined in good faith by the Company’s Board. 
Non-U.S. company or the company’s principal place of business is outside the United States. 
Affiliate investment as defined under the 1940 Act in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.
Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. 
Debt is on non-accrual status as of December 31, 2021, and is therefore considered non-income producing. Note that only the PIK portion is on non-accrual for the Company’s debt investment in Tectura 
Corporation and Pineapple Energy LLC.
Denotes that all or a portion of the debt investment is convertible debt. 
Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any 
additional non-qualifying assets. 
Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).
Denotes that all or a portion of the investment is pledged as collateral under the Union Bank Facility (as defined in “Note 5 — Debt”).
Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
Denotes that all or a portion of the investment in this portfolio company is held by HC IV, the Company’s wholly owned SBIC subsidiary.
Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2021.
Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2021. Refer to “Note 11 — Commitments and Contingencies”.
Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in 
a liquidation, sale or other disposition.
Denotes second lien senior secured debt.
Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933 (“Securities Act”) and may be deemed to be “restricted 
securities” under the Securities Act. 
Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock in portfolio company Black Crow 
AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of September 30, 2021, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $3.0 million.

(3)
(4)

(5)
(6)
(7)
(8)

(9)
(10)

(11)
(12)
(13)
(14)
(15)
(16)
(17)

(18)
(19)

(20)

See notes to consolidated financial statements.   
107

 
 
  
    
    
   
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
    
 
 
 
   
   
 
 
 
   
   
 
 
 
   
   
 
  
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
   
   
   
 
 
   
 
 
   
 
  
 
 
 
 
 
   
 
   
 
    
 
 
 
 
 
 
   
 
   
 
    
 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of 
Investment 

(1)

Maturity
Date

Interest Rate and Floor 

(2)

Principal
Amount

(3)

Cost 

Value 

(4)

Senior Secured

February 2025

3-month LIBOR + 9.25% or Floor rate of 10.25%  

$

7,000  

  $

 (11)(17)(18)

Portfolio Company
Debt Investments
Communications & Networking
1-5 Years Maturity
Cytracom Holdings LLC
Subtotal: 1-5 Years Maturity
Subtotal: Communications & Networking (0.59%)*
Diversified Financial Services
1-5 Years Maturity
Gibraltar Business Capital, LLC
Subtotal: 1-5 Years Maturity
Subtotal: Diversified Financial Services (1.28%)*
Drug Delivery
1-5 Years Maturity
Antares Pharma Inc.

 (10)(11)(15)

 (7)

Subtotal: 1-5 Years Maturity
Subtotal: Drug Delivery (3.52%)*
Drug Discovery & Development
Under 1 Year Maturity
Genocea Biosciences, Inc.

 (11)

Petros Pharmaceuticals, Inc. (p.k.a. Metuchen 
Pharmaceuticals LLC)
Stealth Bio Therapeutics Corp.

 (10)(11)

Subtotal: Under 1 Year Maturity
1-5 Years Maturity
Acacia Pharma Inc.

 (5)(10)(11)

Albireo Pharma, Inc.

 (10)(11)

Aldeyra Therapeutics, Inc.

 (11)

  Unsecured

  March 2023

FIXED 14.50%

Senior Secured

July 2022

PRIME + 4.50% or Floor rate of 4.50%, 4.14% 
Exit Fee

Senior Secured

  May 2021

Senior Secured

  December 2021

Senior Secured

July 2021

PRIME + 3.00% or Floor rate of 8.00%, 5.90% 
Exit Fee
PRIME + 7.25% or Floor rate of 11.50%, 3.05% 
Exit Fee
PRIME + 5.50% or Floor rate of 9.50%, 7.69% 
Exit Fee

Senior Secured

January 2022

Senior Secured

July 2024

Senior Secured

  October 2023

Applied Genetic Technologies Corporation

 (11)

Senior Secured

  December 2023

Aveo Pharmaceuticals, Inc.

 (11)

Axsome Therapeutics, Inc.

 (10)(17)

Senior Secured

September 2023

Senior Secured

  October 2025

Bicycle Therapeutics PLC

 (5)(10)(11)(17)

Senior Secured

  October 2024

BridgeBio Pharma LLC

 (12)(13)(16)

Senior Secured

  November 2023

Total BridgeBio Pharma LLC
Century Therapeutics

 (11)

Chemocentryx, Inc.

 (10)(11)(15)

Total Chemocentryx, Inc.
Codiak Biosciences, Inc.

 (11)(17)

Dermavant Sciences Ltd.

 (10)(13)

Eidos Therapeutics, Inc.

 (10)(13)

G1 Therapeutics, Inc.

 (10)(11)(17)

Geron Corporation

 (10)(17)

Kaleido Biosciences, Inc.

 (13)

Mesoblast

 (5)(10)(11)(13)

Nabriva Therapeutics

 (5)(10)

Seres Therapeutics, Inc.

 (11)

Senior Secured

  November 2023

Senior Secured

  November 2023

Senior Secured

  April 2024

Senior Secured

  December 2022

Senior Secured

February 2024

Senior Secured

  October 2024

Senior Secured

June 2023

Senior Secured

  October 2023

Senior Secured

June 2024

Senior Secured

  October 2024

Senior Secured

January 2024

Senior Secured

  March 2022

Senior Secured

June 2023

Senior Secured

  November 2023

PRIME + 4.50% or Floor rate of 9.25%, 3.95% 
Exit Fee
PRIME + 5.90% or Floor rate of 9.15%, 6.95% 
Exit Fee
PRIME + 3.10% or Floor rate of 9.10%, 6.95% 
Exit Fee
PRIME + 6.50% or Floor rate of 9.75%, 6.95% 
Exit Fee
PRIME + 6.40% or Floor rate of 9.65%, 6.95% 
Exit Fee
PRIME + 5.90% or Floor rate of 9.15%, 4.85% 
Exit Fee
PRIME + 5.60% or Floor rate of 8.85%, 5.00% 
Exit Fee
PRIME + 3.85% or Floor rate of 8.75%, 6.35% 
Exit Fee
PRIME + 2.85% or Floor rate of 8.60%, 5.75% 
Exit Fee
PRIME + 3.10% or Floor rate of 8.85%, 5.75% 
Exit Fee

PRIME + 6.30% or Floor rate of 9.55%, 3.95% 
Exit Fee
PRIME + 3.30% or Floor rate of 8.05%, 6.25% 
Exit Fee
PRIME + 3.25% or Floor rate of 8.50%, 7.15% 
Exit Fee

PRIME + 3.75% or Floor rate of 9.00%, 5.50% 
Exit Fee
PRIME + 4.45% or Floor rate of 9.95%, 6.95% 
Exit Fee
PRIME + 3.25% or Floor rate of 8.50%, 5.95% 
Exit Fee
PRIME + 6.40% or Floor rate of 9.65%, 6.95% 
Exit Fee
PRIME + 5.75% or Floor rate of 9.00%, 6.55% 
Exit Fee
PRIME + 6.10% or Floor rate of 9.35%, 7.55% 
Exit Fee
PRIME + 4.95% or Floor rate of 9.70%, 8.70% 
Exit Fee
PRIME + 4.30% or Floor rate of 9.80%, 7.01% 
Exit Fee
PRIME + 4.40% or Floor rate of 9.65%, 4.85% 
Exit Fee

See notes to consolidated financial statements.   
108

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$

$
$

$

$

$
$

$

$

$

$

$

$

$

$

15,000  

40,000  

12,922  

6,653  

9,027  

5,452  

10,000  

15,000  

10,000  

15,000  

50,000  

15,000  

35,000  

20,000  

20,000  

75,000    
10,000  

20,000  

5,000  

25,000    
25,000  

20,000  

8,750  

20,000  

16,250  

22,500  

50,000  

5,000  

25,000  

  $

6,819  
6,819   
6,819   

14,838  
14,838   
14,838   

41,104  

41,104   
41,104   

13,892  

7,167  

10,463  

31,522   

5,775  

9,995  

15,349  

10,025  

15,069  

49,023  

14,984  

36,163  

20,541  

20,400  

77,104   
9,897  

20,704  

5,039  

25,743   
25,099  

20,615  

8,905  

20,053  

16,158  

22,916  

53,043  

5,259  

25,238  

6,955  
6,955  
6,955  

14,970  
14,970  
14,970  

41,242  

41,242  
41,242  

13,892  

7,156  

10,463  

31,511  

5,754  

10,106  

15,623  

10,163  

15,069  

49,023  

14,984  

36,930  

20,977  

20,822  

78,729  
9,897  

21,031  

5,332  

26,363  
25,223  

20,553  

9,182  

20,404  

16,158  

23,135  

53,086  

5,251  

25,990  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
  
 
 
 
 
   
   
  
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Portfolio Company
Syndax Pharmaceutics Inc.

 (13)

TG Therapeutics, Inc.

 (10)(13)

Tricida, Inc.

 (11)(13)(15)(16)

uniQure B.V.

 (5)(10)(11)

Type of 
Investment 

(1)

Maturity
Date

Senior Secured

September 2023

Senior Secured

  March 2022

Senior Secured

  April 2023

Senior Secured

June 2023

Unity Biotechnology, Inc.

 (10)

Senior Secured

  August 2024

 (11)

Valo Health, LLC (p.k.a. Integral Health Holdings, 
LLC)
X4 Pharmaceuticals, Inc.

 (11)

Senior Secured

  May 2024

Senior Secured

July 2024

Yumanity Therapeutics, Inc.

 (11)

Senior Secured

January 2024

(2)

Interest Rate and Floor 
PRIME + 5.10% or Floor rate of 9.85%, 4.99% 
Exit Fee
PRIME + 4.75% or Floor rate of 10.25%, 3.25% 
Exit Fee
PRIME + 2.35% or Floor rate of 8.35%, 11.04% 
Exit Fee
PRIME + 3.35% or Floor rate of 8.85%, 4.95% 
Exit Fee
PRIME + 6.10% or Floor rate of 9.35%, 6.25% 
Exit Fee
PRIME + 6.45% or Floor rate of 9.70%, 3.85% 
Exit Fee
PRIME + 3.75% or Floor rate of 8.75%, 8.80% 
Exit Fee
PRIME + 4.00% or Floor rate of 8.75%, 7.25% 
Exit Fee

Subtotal: 1-5 Years Maturity
Subtotal: Drug Discovery & Development (61.26%)*
Electronics & Computer Hardware
Under 1 Year Maturity
 (8)(10)(14)
Glo AB

 (17)

 (13)(17)(18)

Subtotal: Under 1 Year Maturity
Subtotal: Electronics & Computer Hardware (0.18%)*
Healthcare Services, Other
1-5 Years Maturity
The CM Group LLC
Velocity Clinical Research, Inc.
Subtotal: 1-5 Years Maturity
Subtotal: Healthcare Services, Other (1.70%)*
Information Services
Under 1 Year Maturity
Sapphire Digital, Inc. (p.k.a. MDX Medical, 
Inc.)
Subtotal: Under 1 Year Maturity
1-5 Years Maturity
 (11)
Planet Labs, Inc.

 (14)(15)(19)

 (11)(17)(18)

Yipit, LLC
Subtotal: 1-5 Years Maturity
Subtotal: Information Services (4.53%)*
Internet Consumer & Business Services
Under 1 Year Maturity
 (8)(9)
Black Crow AI, Inc.

Total Black Crow AI, Inc.
Intent (p.k.a. Intent Media, Inc.)
Snagajob.com, Inc.

 (13)

 (8)(14)

Total Snagajob.com, Inc.
Tectura Corporation

 (7)(8)(14)

Total Tectura Corporation
Subtotal: Under 1 Year Maturity
1-5 Years Maturity
AppDirect, Inc.

 (11)

ePayPolicy Holdings, LLC
EverFi, Inc.

 (13)(14)(16)

 (11)(17)

Houzz, Inc.

 (13)(14)

Senior Secured

February 2021

PRIME + 6.20% or Floor rate of 10.45%, PIK 
Interest 1.75%, 5.03% Exit Fee

Senior Secured
Senior Secured

June 2024
  November 2024

1-month LIBOR + 9.35% or Floor rate of 10.35%  
1-month LIBOR + 9.08% or Floor rate of 10.08%  

Senior Secured

  December 2021

PRIME + 6.25% or Floor rate of 9.50%, PIK 
Interest 1.70%, 5.30% Exit Fee

Senior Secured

June 2022

Senior Secured

  May 2024

PRIME + 5.50% or Floor rate of 11.00%, 3.00% 
Exit Fee
1-month LIBOR + 8.88% or Floor rate of 9.88%  

Convertible Debt
Convertible Debt

  October 2021
  October 2021

PIK Interest 1.00%
PIK Interest 1.00%

Senior Secured
Senior Secured

September 2021
June 2021

Senior Secured

June 2021

PIK Interest 10.13%, 1.20% Exit Fee
PRIME + 6.90% or Floor rate of 10.15%, 3.05% 
Exit Fee
PRIME + 7.80% or Floor rate of 11.05%, 3.05% 
Exit Fee

Senior Secured
Senior Secured
Senior Secured

  March 2021
  March 2021
  March 2021

PIK Interest 5.00%
FIXED 8.25%
PIK Interest 5.00%

Senior Secured

  August 2024

Senior Secured
Senior Secured

  December 2024
  May 2022

Senior Secured

  November 2022

PRIME + 5.90% or Floor rate of 9.15%, 7.95% 
Exit Fee
3-month LIBOR + 9.00% or Floor rate of 10.00%  
PRIME + 3.90% or Floor rate of 9.15%, PIK 
Interest 2.30%
PRIME + 3.20% or Floor rate of 8.45%, PIK 
Interest 2.50%, 4.50% Exit Fee

See notes to consolidated financial statements.   
109

Principal
Amount

(3)

Cost 

Value 

(4)

$

$

$

$

$

$

$

$

$

$
$

$

$

$

$
$
$
$
$

$

$
$
$
$
$

$

$
$

$

20,000  

  $

20,221  

  $

30,000  

75,000  

35,000  

25,000  

11,500  

32,500  

15,000  

1,631  

10,358  
9,823  

15,825  

25,000  

12,000  

3,000  
1,000  
4,000    
4,125  
43,005  

5,173  

48,178    
10,680  
8,250  
13,023  
31,953    

30,790  

8,000  
84,081  

51,403  

30,423  

78,266  

35,660  

24,938  

11,279  

33,082  

15,129  

679,248   
710,770   

2,145  

2,145   
2,145   

10,229  
9,511  
19,740   
19,740   

16,216  

16,216   

24,902  

11,782  
36,684   
52,900   

2,993  
1,000  
3,993   
4,150  
43,917  

5,281  

49,198   
240  
8,250  
13,023  
21,513   
78,854   

30,712  

7,799  
83,900  

51,854  

20,582  

30,820  

79,452  

36,849  

24,938  

11,394  

33,097  

15,350  

687,175  
718,686  

2,145  

2,145  
2,145  

10,086  
9,887  
19,973  
19,973  

16,216  

16,216  

24,957  

12,000  
36,957  
53,173  

1,565  
643  
2,208  
1,413  
43,754  

5,255  

49,009  
—  
8,250  
350  
8,600  
61,230  

30,712  

8,080  
84,987  

52,151  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
  
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
   
   
  
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
Portfolio Company
Nextroll, Inc.

 (14)(19)

SeatGeek, Inc.

 (14)

Skyword, Inc.

 (14)

Thumbtack, Inc.

 (13)(14)

Varsity Tutors LLC

 (13)(14)(17)

Wheels Up Partners LLC
Xometry, Inc.

 (13)

 (11)

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of 
Investment 

(1)

Senior Secured

Senior Secured

Maturity
Date

June 2022

June 2023

Senior Secured

September 2024

Senior Secured

September 2023

Senior Secured

  August 2023

Senior Secured
Senior Secured

July 2022
  May 2022

Senior Subordinate

  May 2022

Interest Rate and Floor 

(2)

PRIME + 3.85% or Floor rate of 9.35%, PIK 
Interest 2.95%, 3.50% Exit Fee
PRIME + 5.00% or Floor rate of 10.50%, PIK 
Interest 0.50%
PRIME + 3.88% or Floor rate of 9.38%, PIK 
Interest 1.90%, 4.00% Exit Fee
PRIME + 3.45% or Floor rate of 8.95%, PIK 
Interest 1.50%, 3.95% Exit Fee
PRIME + 5.25% or Floor rate of 10.75%, PIK 
Interest 0.55%, 3.00% Exit Fee
3-month LIBOR + 8.55% or Floor rate of 9.55%  
PRIME + 3.95% or Floor rate of 8.70%, 6.18% 
Exit Fee
PRIME + 3.95% or Floor rate of 8.70%, 6.25% 
Exit Fee

Total Xometry, Inc.
Subtotal: 1-5 Years Maturity
Subtotal: Internet Consumer & Business Services (36.06%)*
Media/Content/Info
1-5 Years Maturity
 (14)(15)
Bustle

Senior Secured

June 2023

PRIME + 4.35% or Floor rate of 9.35%, PIK 
Interest 1.95%, 4.45% Exit Fee

Subtotal: 1-5 Years Maturity
Subtotal: Media/Content/Info (1.84%)*
Medical Devices & Equipment
Under 1 Year Maturity
Intuity Medical, Inc.

 (11)(15)

Senior Secured

June 2021

Quanterix Corporation

 (11)

Senior Secured

  October 2021

Senior Secured

January 2021

PRIME + 5.00% or Floor rate of 9.25%, 6.95% 
Exit Fee
PRIME + 2.75% or Floor rate of 8.00%, 0.96% 
Exit Fee
PRIME + 4.35% or Floor rate of 8.85%

 (8)

Sebacia, Inc.
Subtotal: Under 1 Year Maturity
Subtotal: Medical Devices & Equipment (1.71%)*
Software
Under 1 Year Maturity
ZocDoc

 (11)(19)

Subtotal: Under 1 Year Maturity
1-5 Years Maturity
3GTMS, LLC.
Abrigo

 (11)(17)(18)

 (18)

Total Abrigo
Bitsight Technologies, Inc.

 (19)

Businessolver.com, Inc.

 (11)(17)

Total Businessolver.com, Inc.
Campaign Monitor Limited
 (12)(13)(14)(17)
Clarabridge, Inc.

 (11)(19)

Cloud 9 Software
CloudBolt Software Inc.

 (13)

 (17)(19)

Cloudian, Inc.

 (11)

Senior Secured

  August 2021

PRIME + 6.20% or Floor rate of 10.95%, 2.00% 
Exit Fee

Senior Secured
Senior Secured
Senior Secured

February 2025

  March 2023
  March 2023

3-Month LIBOR + 9.28% or Floor rate of 10.28%  
3-month LIBOR + 7.88% or Floor rate of 8.88%  
3-month LIBOR + 5.96% or Floor rate of 6.96%  

Senior Secured

  November 2025

Senior Secured
Senior Secured

  May 2023
  May 2023

PRIME + 6.75% or Floor rate of 10.00%, 3.50% 
Exit Fee
6-month LIBOR + 7.50% or Floor rate of 8.50%  
6-month LIBOR + 7.50% or Floor rate of 8.50%  

Senior Secured
Senior Secured

Senior Secured
Senior Secured

  November 2025
  May 2024

  April 2024
  October 2024

Senior Secured

  November 2022

6-month LIBOR + 8.90% or Floor rate of 9.90%  
PRIME + 5.30% or Floor rate of 8.55%, PIK 
Interest 2.25%
3-month LIBOR + 8.20% or Floor rate of 9.20%  
PRIME + 6.70% or Floor rate of 9.95%, 2.95% 
Exit Fee
PRIME + 3.25% or Floor rate of 8.25%, 9.75% 
Exit Fee

See notes to consolidated financial statements.   
110

Principal
Amount

(3)

Cost 

Value 

(4)

$

$

$

$

$

$
$

$

$

$

$

$

$

$

$
$
$
$
$

$
$
$
$
$

$
$

$

20,921  

  $

21,240  

  $

60,301  

12,196  

25,231  

39,264  

13,436  
11,000  

4,000  

15,000    

21,045  

11,217  

7,688  

1,000  

30,000  

10,000  
38,457  
2,312  
40,769    
12,500  

33,650  
7,650  
41,300    
33,000  
55,823  

10,000  
5,000  

15,000  

59,292  

12,291  

25,096  

39,438  

13,387  
11,431  

4,157  

15,588   
360,597   
439,451   

21,279  

21,279   
21,279   

12,365  

7,752  

1,000  
21,117   
21,117   

30,509  

30,509   

9,762  
37,993  
2,273  
40,266   
12,289  

33,248  
7,532  
40,780   
32,348  
55,359  

9,867  
4,867  

15,883  

21,526  

57,561  

12,021  

25,348  

40,272  

13,337  
11,556  

4,219  

15,775  
361,770  
423,000  

21,555  

21,555  
21,555  

12,365  

7,752  

—  
20,117  
20,117  

30,509  

30,509  

9,754  
38,264  
2,296  
40,560  
12,289  

33,640  
7,579  
41,219  
33,304  
56,940  

10,030  
4,867  

15,883  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
  
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
   
   
 
 
 
   
   
  
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
   
  
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Portfolio Company
Couchbase, Inc.

 (11)(15)(19)

Dashlane, Inc.

 (11)(14)(17)(19)

Total Dashlane, Inc.
 (13)(19)
Delphix Corp.

Envisage Technologies, LLC
 (19)
ExtraHop Networks, Inc.

 (13)(18)

FreedomPay, Inc.

 (13)(19)

Ikon Science Limited
 (14)
Jolt Software, Inc.

 (5)(10)(11)(17)(18)

Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.)
Khoros (p.k.a Lithium Technologies)
Logicworks
Mixpanel, Inc.

 (14)(19)

 (17)

 (11)(18)

 (11)

Mobile Solutions Services

 (17)(18)

Total Mobile Solutions Services
Nuvolo Technologies Corporation
Optimizely Mergerco, Inc.
Pollen, Inc.

 (14)(15)(17)

 (17)(18)

 (13)(17)(19)

Pymetrics, Inc.

 (14)

Regent Education

 (14)

Reltio, Inc.

 (13)(14)(17)(19)

Type of 
Investment 

(1)

Maturity
Date

Senior Secured

June 2024

Senior Secured

  April 2022

Senior Secured

  March 2023

Senior Secured

February 2023

Senior Secured
Senior Secured

  March 2025

September 2023

Senior Secured

June 2023

Senior Secured
Senior Secured

Senior Secured
Senior Secured
Senior Secured
Senior Secured

Senior Secured
Senior Secured

Senior Secured
Senior Secured
Senior Secured

  October 2024
  October 2022

July 2023
  October 2022
January 2024
  August 2024

  December 2025
  December 2025

  April 2023
  October 2025
  November 2023

Senior Secured

  October 2022

Senior Secured

January 2022

Senior Secured

July 2023

SingleStore, Inc. (p.k.a. memsql, Inc.)

 (11)(14)(17)

Senior Secured

  May 2023

Tact.ai Technologies, Inc.

 (11)(14)

ThreatConnect, Inc.
 (14)(17)
Udacity, Inc.

 (13)(17)(18)

Senior Secured

February 2023

Senior Secured
Senior Secured

  May 2024

September 2024

Vela Trading Technologies

 (11)(14)(18)

Senior Secured

July 2022

ZeroFox, Inc.

 (13)

Subtotal: 1-5 Years Maturity

Senior Secured

January 2023

(2)

Interest Rate and Floor 
PRIME + 5.25% or Floor rate of 10.75%, 3.75% 
Exit Fee
PRIME + 4.05% or Floor rate of 8.55%, PIK 
Interest 1.10%, 8.50% Exit Fee
PRIME + 4.05% or Floor rate of 8.55%, PIK 
Interest 1.10%, 4.95% Exit Fee

PRIME + 5.50% or Floor rate of 10.25%, 5.00% 
Exit Fee
3-month LIBOR + 9.00% or Floor rate of 10.00%  
PRIME + 7.00% or Floor rate of 10.25%, 2.50% 
Exit Fee
PRIME + 7.70% or Floor rate of 10.95%, 3.55% 
Exit Fee
3-month LIBOR + 9.00% or Floor rate of 10.00%  
PRIME + 3.00% or Floor rate of 8.50%, PIK 
Interest 1.75%, 4.50% Exit Fee
3-month LIBOR + 10.15% or Floor rate of 11.15%  
6-month LIBOR + 8.00% or Floor rate of 9.00%  
PRIME + 7.50% or Floor rate of 10.75%
PRIME + 4.70% or Floor rate of 7.95%, PIK 
Interest 1.80%, 3.00% Exit Fee
6-month LIBOR + 9.87% or Floor rate of 10.87%  
6-month LIBOR + 9.87% or Floor rate of 10.87%  

PRIME + 7.25% or Floor rate of 11.50%
6-month LIBOR + 10.00% or Floor rate of 11.00%  
PRIME + 4.75% or Floor rate of 8.00%, PIK 
Interest 0.50%, 4.50% Exit Fee
PRIME + 5.50% or Floor rate of 8.75%, PIK 
Interest 1.75%, 4.00% Exit Fee
FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit 
Fee
PRIME + 5.70% or Floor rate of 8.95%, PIK 
Interest 1.70%, 4.95% Exit Fee
PRIME + 4.70% or Floor rate of 7.95%, PIK 
Interest 0.75%, 3.95% Exit Fee
PRIME + 4.00% or Floor rate of 8.75%, PIK 
Interest 2.00%, 5.50% Exit Fee
3-month LIBOR + 8.26% or Floor rate of 9.26%  
PRIME + 4.50% or Floor rate of 7.75%, PIK 
Interest 2.00%, 3.00% Exit Fee
3-month LIBOR + 12.00% or Floor rate of 
11.50%, PIK Interest 2.50%
PRIME + 4.75% or Floor rate of 10.25%, 3.00% 
Exit Fee

$

$

$

$
$

$
$

$

$
$

$
$
$
$

$
$
$
$
$
$

$

$

$

$

$

$
$

$

$

Principal
Amount

(3)

Cost 

Value 

(4)

25,000  

  $

25,167  

  $

10,294  

10,195  

20,489    
60,000  

9,750  
15,000  

10,000  

7,000  
7,639  

8,695  
56,208  
10,000  
20,062  

5,500  
13,150  
18,650    
15,000  
50,000  
7,420  

9,497  

3,220  

10,073  

5,021  

5,081  

4,500  
35,130  

18,131  

20,000  

10,808  

10,312  

21,120   
59,932  

9,525  
14,745  

9,972  

6,744  
7,725  

8,477  
55,585  
9,801  
19,703  

5,323  
12,731  
18,054   
14,867  
48,561  
7,366  

9,409  

3,315  

9,928  

5,012  

4,995  

4,391  
34,700  

17,826  

20,118  

25,761  

10,838  

10,343  

21,181  
61,159  

9,750  
14,745  

10,126  

6,724  
7,828  

8,509  
56,207  
9,801  
19,703  

5,400  
12,672  
18,072  
14,993  
48,559  
7,366  

9,409  

3,316  

10,136  

5,137  

4,970  

4,441  
34,700  

14,505  

20,118  

668,459   

672,062  

See notes to consolidated financial statements.   
111

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
  
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
   
   
  
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of 
Investment 

(1)

Maturity
Date

Interest Rate and Floor 

(2)

Principal
Amount

(3)

Cost 

Value 

(4)

Senior Secured

January 2027

3-month LIBOR + 7.75% or Floor rate of 8.75%  

$

20,000  

  $

 (19)

Portfolio Company
Greater than 5 Years Maturity
Imperva, Inc.
Subtotal: Greater than 5 Years Maturity
Subtotal: Software (61.60%)*
Sustainable and Renewable Technology
Under 1 Year Maturity
Solar Spectrum Holdings LLC (p.k.a. Sungevity, 
Inc.)
Subtotal: Under 1 Year Maturity
1-5 Years Maturity
Impossible Foods, Inc.

 (6)(8)(14)

 (12)(13)

Senior Secured

January 2021

PIK Interest 10.00%

 (6)(8)(9)

Pineapple Energy LLC
Subtotal: 1-5 Years Maturity
Subtotal: Sustainable and Renewable Technology (4.27%)*

Senior Secured

  December 2023

Senior Secured

July 2022

PRIME + 3.95% or Floor rate of 8.95%, 9.00% 
Exit Fee
PIK Interest 10.00%

Total: Debt Investments (178.54%)*

See notes to consolidated financial statements.   
112

  $

19,828  
19,828    
718,796    

681  

681    

42,285  

7,500  
49,785    
50,466    
2,099,425  

  $

20,000  
20,000  
722,571  

—  

—  

42,548  

7,500  
50,048  
50,048  
2,094,435  

$

$

$

681  

38,868  

7,500  

$

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
     
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
Portfolio Company
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc.

Total Peerless Network Holdings, Inc.

Subtotal: Communications & Networking (0.29%)*
Consumer & Business Products
Intelligent Beauty, Inc.
Subtotal: Consumer & Business Products (0.06%)*
Diversified Financial Services
Gibraltar Business Capital, LLC

 (7)

Total Gibraltar Business Capital, LLC

 (4)

 (4)

 (4)

 (4)(15)

 (4)(15)

 (4)(16)

 (4)(10)

 (4)(10)

 (4)(5)(10)

 (4)(10)(15)

Subtotal: Diversified Financial Services (2.62%)*
Drug Delivery
AcelRx Pharmaceuticals, Inc.
 (15)
BioQ Pharma Incorporated
Kaleo, Inc.
Neos Therapeutics, Inc.
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)
Subtotal: Drug Delivery (0.38%)*
Drug Discovery & Development
Albireo Pharma, Inc.
Aveo Pharmaceuticals, Inc.
Bicycle Therapeutics PLC
BridgeBio Pharma LLC
Cerecor, Inc.
Chemocentryx, Inc.
Concert Pharmaceuticals, Inc.
Dare Biosciences, Inc.
Dynavax Technologies
Eidos Therapeutics, Inc.
Genocea Biosciences, Inc.
Paratek Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Ltd.
 (4)(15)
Savara, Inc.
Sio Gene Therapies, Inc. (p.k.a. Axovant Gene Therapies Ltd.)
Tricida, Inc.
uniQure B.V.
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)
X4 Pharmaceuticals, Inc.
Subtotal: Drug Discovery & Development (2.16%)*
Healthcare Services, Other
23andMe, Inc.
Subtotal: Healthcare Services, Other (0.58%)*
Internet Consumer & Business Services
Contentful, Inc.

 (4)(15)(16)

 (4)(5)(10)

 (5)(10)

 (4)(10)

 (4)(10)

 (4)

 (4)

 (4)

 (4)

 (4)

 (4)(10)

Total Contentful, Inc.

 (4)

 (4)

Countable Corporation (p.k.a. Brigade Group, Inc.)
DoorDash, Inc.
Fastly, Inc.
 (4)
Lyft, Inc.
Nextdoor.com, Inc.
OfferUp, Inc.

Equity
Equity

Equity

Equity
Equity

Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity
Equity

Equity

Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity
Equity

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of
Investment 

(1)

Series

Shares

(3)

Cost 

Value 

(4)

Common Stock
Preferred Series A

$

3,328    
1,135,000  
1,138,328  

Preferred Series B

111,156  

Common Stock
Preferred Series A

Common Stock
Preferred Series D
Preferred Series B
Common Stock
Common Stock

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series B
Common Stock

Common Stock

Preferred Series C
Preferred Series D

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series A
Preferred Series A-1

830,000  
10,602,752  
11,432,752  

176,730  
165,000  
82,500  
125,000  
2,498  

25,000  
190,175  
98,100  
203,579  
119,087  
17,241  
70,796  
13,550  
20,000  
15,000  
27,932  
76,362  
944  
11,119  
16,228  
68,816  
17,175  
510,308  
83,334  

360,000  

82  
217  
299  
9,023  
525,000  
6,238  
200,738  
328,190  
286,080  
108,710  
394,790  

  $

—  
1,230  
1,230  
1,230  

230  
230  

1,884  
26,122  
28,006  
28,006  

1,329  
500  
1,007  
1,500  
309  
4,645  

1,000  
1,715  
1,871  
2,000  
1,000  
1,000  
1,367  
1,000  
550  
255  
2,000  
2,744  
1,500  
203  
1,269  
863  
332  
3,000  
641  
24,310  

5,094  
5,094  

138  
500  
638  
93  
6,051  
8  
10,487  
4,854  
1,663  
632  
2,295  

8  
3,800  
3,808  
3,808  

743  
743  

2,276  
31,554  
33,830  
33,830  

219  
504  
4,117  
78  
5  
4,923  

938  
1,097  
1,761  
14,476  
314  
1,068  
895  
18  
89  
1,974  
67  
478  
52  
13  
45  
485  
621  
3,000  
536  
27,927  

7,546  
7,546  

270  
785  
1,055  
—  
58,706  
545  
9,862  
8,994  
1,867  
709  
2,576  

Total OfferUp, Inc.

See notes to consolidated financial statements.   
113

 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 (4)

Portfolio Company
Oportun
Reischling Press, Inc. (p.k.a. Blurb, Inc.)
 (7)
Tectura Corporation

Total Tectura Corporation

Uber Technologies, Inc. (p.k.a. Postmates, Inc.)
Subtotal: Internet Consumer & Business Services (6.53%)*
Medical Devices & Equipment
Flowonix Medical Incorporated
Gelesis, Inc.

 (4)

Total Gelesis, Inc.

Medrobotics Corporation

 (15)

Total Medrobotics Corporation

 (4)

Outset Medical, Inc.
 (4)(15)
ViewRay, Inc.
Subtotal: Medical Devices & Equipment (0.29%)*
Software
CapLinked, Inc.
Docker, Inc.
Druva Holdings, Inc. (p.k.a. Druva, Inc.)

Total Druva Holdings, Inc. (p.k.a. Druva, Inc.)

 (4)

HighRoads, Inc.
Lightbend, Inc.
Palantir Technologies
SingleStore, Inc. (p.k.a. memsql, Inc.)
Sprinklr, Inc.
Subtotal: Software (3.87%)*
Surgical Devices
Gynesonics, Inc.

 (15)

Total Gynesonics, Inc.

 (4)

TransMedics Group, Inc. (p.k.a Transmedics, Inc.)
Subtotal: Surgical Devices (0.32%)*
Sustainable and Renewable Technology
Impossible Foods, Inc.
Modumetal, Inc.
Pineapple Energy LLC

 (6)

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of
Investment 

(1)

Equity
Equity
Equity
Equity

Equity

Equity
Equity
Equity
Equity

Equity
Equity
Equity

Equity
Equity

Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity

Equity
Equity
Equity
Equity
Equity
Equity

Equity

Equity
Equity
Equity

Series
Common Stock
Common Stock
Common Stock
Preferred Series BB

Common Stock

Preferred Series AA
Common Stock
Preferred Series A-1
Preferred Series A-2

Preferred Series E
Preferred Series F
Preferred Series G

Common Stock
Common Stock

Preferred Series A-3
Common Stock
Preferred Series 2
Preferred Series 3

Common Stock
Preferred Series D
Common Stock
Preferred Series E
Common Stock

Preferred Series B
Preferred Series C
Preferred Series D
Preferred Series E
Preferred Series F
Preferred Series F-1

Common Stock

Preferred Series E-1
Preferred Series A-1
Class A Units

See notes to consolidated financial statements.   
114

Shares

(3)

Cost 

Value 

(4)

  $

48,365  
1,163  
414,994,863  
1,000,000  
415,994,863  
32,991  

221,893  
227,013  
191,210  
191,626  
609,849  
136,798  
73,971  
163,934  
374,703  
38,243  
36,457  

53,614  
20,000  
458,841  
93,620  
552,461  
190  
384,616  
1,668,337  
580,983  
700,000  

219,298  
656,538  
1,991,157  
2,786,367  
1,523,693  
2,418,125  
9,595,178  
162,617  

188,611  
103,584  
17,647  

  $

577  
15  
900  
—  
900  
317  
26,235  

1,500  
—  
425  
500  
925  
250  
155  
500  
905  
527  
333  
4,190  

51  
4,284  
1,000  
300  
1,300  
307  
265  
10,198  
2,000  
3,749  
22,154  

250  
282  
712  
429  
118  
150  
1,941  
2,550  
4,491  

2,000  
500  
4,767  

937  
—  
—  
—  
—  
1,683  
84,358  

—  
626  
554  
540  
1,720  
—  
—  
—  
—  
1,947  
139  
3,806  

78  
24  
3,644  
777  
4,421  
—  
165  
36,015  
2,153  
7,088  
49,944  

14  
44  
137  
213  
181  
259  
848  
3,236  
4,084  

2,540  
1  
840  

 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
Portfolio Company
Proterra, Inc.
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Subtotal: Sustainable and Renewable Technology (0.29%)*
Total: Equity Investments (17.39%)*

 (6)

 (4)

 (4)

 (4)

 (4)

 (15)

 (15)

 (10)

 (4)(15)

 (4)(10)

 (4)(15)

 (4)(10)

 (4)(5)(10)

 (4)(10)(15)

Warrant Investments
Communications & Networking
Spring Mobile Solutions, Inc.
Subtotal: Communications & Networking (0.00%)*
Consumer & Business Products
 (15)
Gadget Guard
The Neat Company
Whoop, Inc.
Subtotal: Consumer & Business Products (0.09%)*
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.)
BioQ Pharma Incorporated
Neos Therapeutics, Inc.
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)
Subtotal: Drug Delivery (0.04%)*
Drug Discovery & Development
Acacia Pharma Inc.
ADMA Biologics, Inc.
Albireo Pharma, Inc.
Axsome Therapeutics, Inc.
Brickell Biotech, Inc.
Century Therapeutics
Concert Pharmaceuticals, Inc.
CytRx Corporation
Dermavant Sciences Ltd.
Evofem Biosciences, Inc.
Genocea Biosciences, Inc.
 (10)
Motif BioSciences Inc.
Myovant Sciences, Ltd.
Ology Bioservices, Inc.
Paratek Pharmaceuticals, Inc.
Stealth Bio Therapeutics Corp.
TG Therapeutics, Inc.
Tricida, Inc.
Urovant Sciences, Ltd.
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)
X4 Pharmaceuticals, Inc.
Yumanity Therapeutics, Inc.
Subtotal: Drug Discovery & Development (0.79%)*
Electronics & Computer Hardware
 (4)(15)
908 Devices, Inc.
Subtotal: Electronics & Computer Hardware (0.09%)*
Information Services
InMobi Inc.
NetBase Solutions, Inc.
Planet Labs, Inc.
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.)
Subtotal: Information Services (0.10%)*
Internet Consumer & Business Services
Aria Systems, Inc.
Cloudpay, Inc.
First Insight, Inc.
Houzz, Inc.
Intent (p.k.a. Intent Media, Inc.)
Interactions Corporation
Just Fabulous, Inc.

 (4)(15)(16)

 (4)(15)

 (4)(10)

 (4)(10)

 (5)(10)

 (4)(10)

 (4)(10)

 (15)

 (10)

 (15)

 (15)

 (4)

 (4)

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of
Investment 

(1)

Equity
Equity

Warrant

Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Warrant

Warrant
Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Series
Preferred Series 5
Common Stock

Common Stock

Common Stock
Common Stock
Preferred Series C

Common Stock
Common Stock
Common Stock
Common Stock

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Units
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Units
Common Stock
Common Stock

Common Stock

Common Stock
Preferred Series 1
Common Stock
Common Stock

Preferred Series G
Preferred Series B
Preferred Series B
Common Stock
Common Stock
Preferred Series G-3
Preferred Series B

See notes to consolidated financial statements.   
115

Shares

(3)

Cost 

Value 

(4)

99,280  
488  

  $

  $

500  
61,502  
69,269  
189,854  

  $

  $

329  
—  
3,710  
224,679  

2,834,375  

1,662,441  
54,054  
68,627  

110,882  
459,183  
70,833  
3,929  

201,330  
89,750  
5,310  
15,541  
9,005  
40,540  
61,273  
105,694  
223,642  
7,806  
41,176  
121,337,041  
73,710  
171,389  
469,388  
500,000  
147,058  
31,353  
99,777  
102,216  
108,334  
15,414  

49,078  

65,587  
60,000  
357,752  
2,812,500  

231,535  
6,763  
75,917  
529,661  
140,077  
68,187  
206,184  

418  
418  

228  
365  
18  
611  

74  
1  
285  
390  
750  

304  
295  
61  
681  
119  
37  
178  
160  
101  
266  
165  
282  
460  
838  
644  
158  
563  
280  
383  
257  
673  
110  
7,015  

101  
101  

82  
356  
615  
283  
1,336  

73  
54  
96  
20  
168  
204  
1,102  

—  
—  

—  
—  
1,152  
1,152  

—  
579  
—  
—  
579  

184  
5  
97  
682  
—  
43  
183  
—  
460  
3  
20  
—  
1,031  
—  
960  
—  
5,307  
8  
744  
296  
87  
98  
10,208  

1,215  
1,215  

—  
498  
273  
566  
1,337  

—  
126  
91  
150  
—  
549  
2,791  

 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
   
   
 
   
   
   
 
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
Portfolio Company
Lendio, Inc.
LogicSource
RumbleON, Inc.
SeatGeek, Inc.
ShareThis, Inc.
Skyword, Inc.
Snagajob.com, Inc.

 (4)

Total Snagajob.com, Inc.

Tapjoy, Inc.
The Faction Group LLC
Thumbtack, Inc.
Xometry, Inc.
Subtotal: Internet Consumer & Business Services (0.56%)*
Media/Content/Info
WP Technology, Inc. (Wattpad, Inc.)
Zoom Media Group, Inc.
Subtotal: Media/Content/Info (0.00%)*
Medical Devices & Equipment
Aspire Bariatrics, Inc.
Flowonix Medical Incorporated

 (5)(10)

 (15)

Total Flowonix Medical Incorporated

 (15)

 (15)

 (4)(5)(10)

Gelesis, Inc.
InspireMD, Inc.
Intuity Medical, Inc.
Medrobotics Corporation
NinePoint Medical, Inc.
 (4)
Outset Medical, Inc.
Sebacia, Inc.
SonaCare Medical, LLC
Tela Bio, Inc.
Subtotal: Medical Devices & Equipment (0.20%)*
Semiconductors
Achronix Semiconductor Corporation

 (4)

Total Achronix Semiconductor Corporation

Subtotal: Semiconductors (0.07%)*
Software
Bitsight Technologies, Inc.
CloudBolt Software Inc.
Cloudian, Inc.
Couchbase, Inc.
Dashlane, Inc.
Delphix Corp.
DNAnexus, Inc.
Evernote Corporation

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Type of
Investment 

(1)

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant

Warrant
Warrant

Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Warrant
Warrant

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Series
Preferred Series D
Preferred Series C
Common Stock
Common Stock
Preferred Series C
Preferred Series B
Common Stock
Preferred Series A
Preferred Series B

Preferred Series D
Preferred Series AA
Common Stock
Preferred Series B

Common Stock
Preferred Series A

Preferred Series B-1
Preferred Series AA
Preferred Series BB

Preferred Series A-1
Common Stock
Preferred Series B-1
Preferred Series E
Preferred Series A-1
Common Stock
Preferred Series D
Preferred Series A
Common Stock

Preferred Series C
Preferred Series D-2

Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series C
Common Stock

See notes to consolidated financial statements.   
116

Shares

(3)

Cost 

Value 

(4)

  $

127,032  
79,625  
5,139  
1,379,761  
493,502  
444,444  
600,000  
1,800,000  
1,211,537  
3,611,537  
748,670  
8,076  
190,953  
87,784  

255,818  
1,204  

112,858  
155,325  
725,806  
881,131  
74,784  
23  
3,076,323  
455,539  
587,840  
62,794  
778,301  
6,464  
15,712  

360,000  
750,000  
1,110,000  

29,691  
158,506  
477,454  
263,377  
346,747  
718,898  
909,091  
62,500  

  $

39  
30  
87  
842  
547  
83  
16  
782  
62  
860  
316  
234  
553  
47  
5,355  

3  
348  
351  

455  
362  
351  
713  
78   
0   
294   
370   
170   
402   
133   
188  
61  
2,864  

160  
99  
259  
259  

208  
91  
72  
462  
303  
1,594  
97  
106  

32  
104  
32  
1,548  
—  
78  
53  
58  
27  
138  
16  
736  
262  
527  
7,180  

—  
—  
—  

—  
—  
—  
—  
156  
—  
394  
—  
—  
1,982  
—  
—  
9  
2,541  

175  
717  
892  
892  

208  
132  
29  
1,023  
297  
1,857  
153  
70  

 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 (15)

Portfolio Company
ExtraHop Networks, Inc.
 (15)
Fuze, Inc.
Lightbend, Inc.
Mixpanel, Inc.
Nuvolo Technologies Corporation
 (15)
OneLogin, Inc.
Poplicus, Inc.
Pymetrics, Inc.
RapidMiner, Inc.
Reltio, Inc.
SignPost, Inc.
SingleStore, Inc. (p.k.a. memsql, Inc.)
Tact.ai Technologies, Inc.
Udacity, Inc.
ZeroFox, Inc.
Subtotal: Software (0.58%)*
Specialty Pharmaceuticals
Alimera Sciences, Inc.
Subtotal: Specialty Pharmaceuticals (0.00%)*
Surgical Devices
Gynesonics, Inc.
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)
Subtotal: Surgical Devices (0.04%)*
Sustainable and Renewable Technology
Agrivida, Inc.
Fulcrum Bioenergy, Inc.
Kinestral Technologies, Inc.

 (15)

 (4)

 (4)

Total Kinestral Technologies, Inc.
NantEnergy, Inc. (p.k.a. Fluidic, Inc.)
Polyera Corporation
Proterra, Inc.

 (15)

Total Proterra, Inc.

Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Subtotal: Sustainable and Renewable Technology (0.12%)*
Total: Warrant Investments (2.68%)*

 (6)

Total: Investments in Securities (182.22%)*

Investment Funds & Vehicles
Forbion Growth Opportunities Fund I C.V.

 (5)(10)(17)

Total: Investments in Investment Funds & Vehicles (0.03%)*
Total: Investments before Cash and Cash Equivalents (182.25%)*

Cash & Cash Equivalents
GS Financial Square Government Fund
Total: Investments in Cash & Cash Equivalents (7.43%)*
Total: Investments after Cash and Cash Equivalents (189.68%)*

HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

Series
Common Stock
Preferred Series F
Preferred Series C-1
Common Stock
Common Stock
Common Stock
Common Stock
Common Stock
Preferred Series C-1
Common Stock
Series Junior 1 Preferred
Preferred Series D
Common Stock
Common Stock
Preferred Series C-1

Common Stock

Preferred Series C
Common Stock

Preferred Series D
Preferred Series C-1
Preferred Series A
Preferred Series B

Preferred Series D
Preferred Series C
Common Stock
Preferred Series 4

Class A Units

Type of
Investment 

(1)

Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant
Warrant

Warrant

Warrant
Warrant

Warrant
Warrant
Warrant
Warrant

Warrant
Warrant
Warrant
Warrant

Warrant

Investment Funds & 
Vehicles

Cash & Cash Equivalents

See notes to consolidated financial statements.   
117

Shares

(3)

Cost 

Value 

(4)

154,784  
256,158  
854,787  
82,362  
50,000  
381,620  
132,168  
150,943  
4,982  
69,120  
474,019  
312,596  
1,041,667  
486,359  
648,350  

30,581  

151,123  
64,441  

471,327  
280,897  
325,000  
131,883  
456,883  
61,804  
311,609  
36,630  
477,517  
514,147  
1  

  $

  $

  $

$
$

$
$

191  
89  
130  
252  
88  
305  
—  
77  
24  
215  
314  
103  
206  
218  
100  
5,245  

132  
132  

67  
139  
206  

120  
274  
155  
63  
218  
102  
338  
1  
41  
42  
—  
1,094  
25,737  

2,315,016  

  $

  $

  $

342  

342  
2,315,358  

  $
  $

96,000  
96,000  
2,411,358  

  $
  $

265  
—  
169  
516  
192  
610  
—  
182  
46  
216  
—  
714  
204  
284  
363  
7,530  

5  
5  

10  
487  
497  

—  
744  
261  
91  
352  
—  
—  
14  
376  
390  
—  
1,486  
34,622  

2,353,736  

342  

342  
2,354,078  

96,000  
96,000  
2,450,078  

 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
   
   
  
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
   
   
   
 
   
 
   
  
 
 
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
   
 
   
 
 
   
 
 
   
  
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
   
 
   
 
 
   
 
 
   
 
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2020
(dollars in thousands)

*           Value as a percent of net assets. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(1)
(2)
(3)

Preferred and common stock, warrants, and equity interests are generally non-income producing. 
Interest rate PRIME represents 3.25% as of December 31, 2020. 1-month LIBOR, 3-month LIBOR, and 6-month LIBOR represent, 0.14%, 0.24%, and 0.36%, respectively, as of December 31, 2020.
Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $166.2 million, $126.1 million, and $40.1 million, respectively. The tax cost 
of investments is $2.3 billion. 
Except for warrants in 27 publicly traded companies and common stock in 30 publicly traded companies, all investments are restricted as of December 31, 2020, and were valued at fair value using Level 3 
significant unobservable inputs as determined in good faith by the Company’s Board. No unrestricted securities of the same issuer are outstanding. 
Non-U.S. company or the company’s principal place of business is outside the United States. 
Affiliate investment as defined under the 1940 Act in which Hercules owns at least 5% but generally less than 25% of the company’s voting securities.
Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. 
Debt is on non-accrual status as of December 31, 2020, and is therefore considered non-income producing. Note that only the PIK portion is on non-accrual for the Company’s debt investments in Glo AB and 
Tectura Corporation.
Denotes that all or a portion of the debt investment is convertible debt. 
Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any 
additional non-qualifying assets. 
Denotes that all or a portion of the debt investment secures the notes offered in the 2027 Asset-Backed Notes or 2028 Asset-Backed Notes (as defined in “Note 5 — Debt”). 
Denotes that all or a portion of the debt investment is pledged as collateral under the Wells Facility (as defined in “Note 5 — Debt”).
Denotes that all or a portion of the debt investment is pledged as collateral under the Union Bank Facility (as defined in “Note 5 — Debt”).
Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
Denotes that all or a portion of the investment in this portfolio company is held by HT III, the Company’s wholly owned small business investment company, or SBIC, subsidiary.
Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2020.
Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2020. Refer to “Note 11 — Commitments and Contingencies”.
Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in 
a liquidation, sale or other disposition.
Denotes second lien senior secured debt.

(4)

(5)
(6)
(7)
(8)

(9)
(10)

(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)

(19)

See notes to consolidated financial statements.   
118

 
1. Description of Business 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed 

and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through 
its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, and London, United 
Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003. 

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) 

under the 1940 Act. From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Code of 1986. Effective 
January 1, 2006, the Company elected to be treated for tax purposes as a RIC under Subchapter M of the Code (see “Note 6 – Income Taxes”). 

The Company does not currently use Commodity Futures Trading Commission (“CFTC”) derivatives however to the extent that it uses CFTC derivatives in the future, 

it intends to do so below prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. The Company has claimed an exclusion 
from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, 
subject to registration or regulation as a “commodity pool operator” under the CEA. 

Hercules Technology III, L.P. (“HT III”) and Hercules Capital IV, L.P. (“HC IV”) are our wholly owned Delaware limited partnerships that were formed in September 
2009 and December 2010, respectively. HT III, and HC IV were licensed to operate as Small Business Investment Companies (“SBICs” or "SBIC") under the authority of the 
Small Business Administration (“SBA”) on May 26, 2010, and October 27, 2020, respectively.  SBICs are subject to a variety of regulations concerning, among other things, 
the size and nature of the companies in which they may invest and the structure of those investments. During the year, the Company wound down HT III, and surrendered its 
SBA license for HT III on June 15, 2021. As such, HT III is no longer operating as an SBIC. HC IV continues to maintain its SBA license and operate as an SBIC.  The 
Company formed Hercules Technology SBIC Management, LLC (“HTM”), a limited liability company, in November 2003. HTM is a wholly owned subsidiary of the 
Company and serves as the general partner of HC IV (see “Note 5 - Debt”).

The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), 

to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance 
with generally accepted accounting principles in the United States of America (“U.S. GAAP”). These taxable subsidiaries are not consolidated with Hercules for income tax 
purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

In May 2020, Hercules Adviser LLC (the “Adviser Subsidiary”) was formed as a wholly owned Delaware limited liability subsidiary of the Company to provide 

investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser 
Subsidiary receives fee income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange 
Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”).

2. Summary of Significant Accounting Policies 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S GAAP and pursuant to Regulation S-X. The Company’s functional 

currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency.

As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC 

Topic 946”) of the FASB Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate 
its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the 

119

 
  
Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 
946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively 
to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the 
Company held at fair value and is not consolidated.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at 

the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and 
regulatory environment, financial markets, the credit worthiness of our portfolio companies, the continued development and impact of the global outbreak of the COVID-19, 
and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.

Principles of Consolidation 

The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the 

Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. 

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity 

investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that 
most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. 

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the 

facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most 
significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant 
decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right 
to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and 
fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the 
VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. 

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the 

Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders 
whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.  As of 
December 31, 2021, the Company held no interests in a VIE. 

Fair Value Measurements 

The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell 
an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the 
fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to 
establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including 
assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the 
valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based 
on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants 
would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the 
risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the 
information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. 

120

 
  
The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to 

measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these 
assets and liabilities, are as follows: 

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally 
are equities listed in active markets. 

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the 
measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments 
and warrants held in a public company. 

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations 
that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the 
debt investments and warrants and equities held in a private company. 

Valuation of Investments 

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of 

unrealized appreciation and depreciation of investments recorded. 

As of December 31, 2021, approximately 93.6% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good 
faith by the Board. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for 
all other securities and assets, fair value is as determined in good faith by the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and 
ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed 
companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable 
technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies 
are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or 
exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy by the Board in 
accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily 
available market value, the fair value of the Company’s investments determined in good faith by its Board may differ significantly from the value that would have been used 
had a readily available market existed for such investments, and the differences could be material.

In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Investments 

purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at 
cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. 
In this case such investments shall be valued at fair value as determined in good faith by or under the direction of the Board. Investments that are not publicly traded or whose 
market quotations are not readily available are valued at fair value as determined in good faith by or under the direction of the Board. 

As part of the overall process, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of 

selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, 
including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment 
by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Board, and the Company may engage an 
independent valuation firm to value all or some of our portfolio investments. The Board is ultimately, and solely, responsible for determining the fair value of the Company’s 
investments in good faith. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available 
information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the 
duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The 
Company determines the fair value of each individual investment and records changes in fair value as unrealized appreciation or depreciation.

121

 
 
  
The Company's quarterly multi-step valuation process each quarter, which the Board has approved, is as described below: 

(1)

(2)

(3)

(4)

The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the 
portfolio investment; 

Preliminary valuation conclusions are then documented and business-based assumptions are discussed with the Company’s investment committee; 

The Audit Committee of the Board reviews the preliminary valuation of the investments in the portfolio as provided by the investment committee which 
incorporates the results of the independent valuation firm(s) as applicable; and 

The Board, upon the recommendation of the Audit Committee, discusses valuations and determines the fair value of each investment in the Company’s 
portfolio in good faith based on the input of, where applicable, the respective independent valuation firm and the investment committee. 

Debt Investments 

The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including 
technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature 
of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because 
there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from 
time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker 
quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820.

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the 
value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then 
applies the valuation methods as set forth below. 

The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The 

hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the 
yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market 
yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-
based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company 
considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical 
yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each 
investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current 
portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar 
securities as of the measurement date. 

The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date.  For syndicated debt investments, for 
which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant 
deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a 
liquidation analysis. 

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt 
investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, 
the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also 
appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. 

When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of 

the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other 
equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the 
life of the debt investment. 

122

 
  
Equity Securities and Warrants 

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited 

amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are 
valued at the closing market quote on the measurement date.

At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio 
company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation 
comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent 
equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically 
reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may 
have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black 
Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to 
a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of 
factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable 
value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors.

Investment Funds & Vehicles

The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share 

(or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment 
company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that 
NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value 
hierarchy as per ASC Topic 820.

Cash, Cash Equivalents, and Restricted Cash 

Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and 
cash equivalents are carried at cost, which approximates fair value. As of December 31, 2021, the Company held $95 thousand (Cost basis $93 thousand) of foreign cash. No 
foreign cash was held as of  December 31, 2020. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions.

Other Assets

Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated 

depreciation, deferred revenues and deposits and other assets, including escrow receivables.

Escrow Receivables

Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater 
than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based 
on the amount of the estimated recoverable balances and the contractual maturity date. As of both December 31, 2021 and December 31, 2020, there were no material past due 
escrow receivables. The approximate fair value in accordance with ASC Topic 820 of the escrow receivable balance as of December 31, 2021 and December 31, 2020 was 
approximately $0.6 million and $65 thousand, respectively.

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability 
obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of 
short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations 
represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of 
lease payments over the lease term. The Company has lease agreements with lease and non-lease components 

123

 
  
and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the 
Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The 
Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The 
Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a 
straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.

Income Recognition 

The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that 
such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is 
accreted into interest income over the term of the loan as a yield enhancement. Debt investments are placed on non-accrual status when it is probable that principal, interest or 
fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until 
the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company 
may not apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. 
Interest collected on non-accrual investments are generally applied to principal.

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and 

management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the 
contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into 
interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination 
fees. The Company had approximately $42.9 million of unamortized fees as of December 31, 2021, of which approximately $36.5 million was included as an offset to the cost 
basis of its current debt investments and approximately $6.4 million was deferred contingent upon the occurrence of a funding or milestone. As of  December 31, 2020, the 
Company had approximately $39.2 million of unamortized fees, of which approximately $32.2 million was included as an offset to the cost basis of the Company’s current debt 
investments and approximately $7.0 million was deferred contingent upon the occurrence of a funding or milestone. 

The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain 

fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default waiver fees and acceleration of previously deferred 
loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $8.5 million and $8.3 million in 
one-time fee income during the years ended December 31, 2021 and December 31, 2020, respectively.

In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the 

loan are accreted into interest income over the contractual life of the loan. As of December 31, 2021, the Company had approximately $35.0 million in exit fees receivable, of 
which approximately $29.6 million was included as a component of the cost basis of its current debt investments and approximately $5.4 million was a deferred receivable 
related to expired commitments. As of December 31, 2020, the Company had approximately $40.9 million in exit fees receivable, of which approximately $37.6 million was 
included as a component of the cost basis of its current debt investments and approximately $3.3 million was a deferred receivable related to expired commitments.

The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the 

loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company 
will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all 
principal and interest due. The Company recorded approximately $11.2 million and $9.0 million in PIK income in the years ended December 31, 2021 and 2020, respectively. 

To maintain the Company’s RIC status for taxation purposes, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of 
dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or 
the liquidation of certain investments.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate 
fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the years ended 
December 31, 2021 and December 31, 2020. 

124

 
  
Equity Offering Expenses 

The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of 

registered securities. 

Debt

The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. 

Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, 
over the remaining life of the underlying debt obligations (see “Note 5 - Debt”).  Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the 
Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss 
in the Consolidated Statement of Operations within net realized gains (losses) as a “Loss on debt extinguishment”. 

Debt Issuance Costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and 

amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In 
accordance with ASC Subtopic 835-30, Interest – Imputation of Interest, debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated 
Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.

Stock-Based Compensation 

The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock based compensation awards to employees and directors. 
Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense 
associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the 
appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price 
volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are 
classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is 
recorded as deferred compensation and included in Accounts payable and accrued liabilities.

Income Taxes 

The Company intends to operate so as to qualify to be subject to tax as a RIC under Subchapter M of the Code and, as such, will not be subject to federal income tax on 

the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable 
interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial 
reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, 
as such gains or losses are not included in taxable income until they are realized. 

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated 

as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the Excise Tax 
Avoidance Requirement. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax 
imposed on a RIC’s retained net capital gains). 

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions 

treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. 
The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as 
dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to 
carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that 
taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and 
distributed in the current taxable year, or returns of capital. 

125

 
  
We account for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable 

and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions 
of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders 
substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable 
income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax. 

The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital 

gains for reinvestment and, depending upon the level of taxable income earned in a year, the Company may choose to carry forward taxable income for distribution in the 
following year and pay any applicable U.S. federal excise tax. 

Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and net realized 

securities gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the 
financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment 
of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the 
future. Also, tax legislation requires that income be recognized for tax purposes no later than when recognized for financial reporting purposes, with certain exceptions.

Earnings Per Share (“EPS”) 

Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares 

outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS 
includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which 
future service is required as a condition to the delivery of the underlying common stock.  In accordance with ASC 260-10-45-60A, the Company uses the two-class method in 
the computation of basic EPS and diluted EPS, if applicable.

Comprehensive Income 

The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did not have other comprehensive income in 

2021, 2020, or 2019. The Company’s comprehensive income is equal to its net increase in net assets resulting from operations. 

Distributions

Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company 

maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder 
elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the 
stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions. During 2021, 2020, and 2019, the Company issued 248,041, 
280,690, and 180,135 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan. 

Segments 

The Company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, 

biotechnology, life sciences, healthcare, and sustainable and renewable technology. The Company separately evaluates the performance of each of its lending and investment 
relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single 
reportable segment. 

126

 
  
3. Fair Value of Financial Instruments 

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and 
matters of significant judgment and, therefore, cannot be determined with precision.  Investments measured at fair value on a recurring basis are categorized in the tables below 
based upon the lowest level of significant input to the valuations as of December 31, 2021 and December 31, 2020.

(in thousands)
Description
Other assets

Escrow Receivables

Investments
Senior Secured Debt
Unsecured Debt
Preferred Stock
Common Stock
Warrants

Investment Funds & Vehicles measured at Net Asset Value 

(2)

Total Investments before cash and cash equivalents

Total Investments after cash and cash equivalents

(in thousands)
Description
Cash and cash equivalents

Money Market Fund 

(1)

Other assets

Escrow Receivables

Investments
Senior Secured Debt
Unsecured Debt
Preferred Stock
Common Stock
Warrants

Investment Funds & Vehicles measured at Net Asset Value

 (2)

Total Investments before cash and cash equivalents

Total Investments after cash and cash equivalents

Balance as of 
December 31,
2021

Quoted Prices in
Active Markets for
Identical Assets
(Level 1)

Significant
Other Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

561     $

—     $

—     $

561  

—     $
—    
—    
84,460    
—    
84,460     $

—     $
—    
—    
8,843    
10,922    
19,765     $

2,156,709  
52,890  
69,439  
21,968  
27,477  
2,328,483  

2,156,709     $
52,890    
69,439    
115,271    
38,399    
2,432,708     $
1,814    
2,434,522    

2,434,522    

Balance as of 
December 31,
2020

Quoted Prices in
Active Markets for
Identical Assets
(Level 1)

Significant
Other Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

96,000     $

96,000     $

65     $

—     $

—     $
—    
—    
138,300    
—    
138,300     $

2,079,465     $
14,970    
58,981    
165,698    
34,622    
2,353,736     $
342    
2,354,078    

2,450,078    

—     $

—     $

—     $
—    
—    
—    
13,139    
13,139     $

—  

65  

2,079,465  
14,970  
58,981  
27,398  
21,483  
2,202,297  

  $

  $

  $

  $

  $

  $

  $

  $

  $

  $

  $

(1)
(2)

This investment is included in Cash and cash equivalents in the accompanying Consolidated Statement of Assets and Liabilities.
In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as 
per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and 
Liabilities.

127

 
 
 
   
   
   
 
 
   
   
   
 
 
 
   
 
   
 
   
 
 
  
 
 
   
 
   
 
   
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   
 
   
 
 
 
   
 
   
 
 
  
 
 
   
 
   
 
   
 
 
 
   
 
   
 
 
 
 
 
   
 
   
 
   
 
 
 
   
   
   
 
 
   
   
   
 
 
 
   
 
   
 
   
 
 
  
 
 
   
 
   
 
   
 
 
 
 
   
 
   
 
   
 
 
  
 
 
   
 
   
 
   
 
 
 
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
    
   
 
   
 
 
 
   
 
   
 
 
  
 
 
   
 
   
 
   
 
 
 
   
 
   
 
 
 
 
 
  
The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest 

components, using significant unobservable inputs (Level 3) for the years ended December 31, 2021 and December 31, 2020.

(in thousands)
Investments
Senior Secured Debt $
Unsecured Debt
Preferred Stock
Common Stock
Warrants
Other Assets
Escrow Receivable

Total

$

(in thousands)
Investments
Senior Secured Debt $
Unsecured Debt
Preferred Stock
Common Stock
Warrants
Other Assets
Escrow Receivable

Total

$

Balance as of
January 1, 2021

Net Realized
Gains (Losses) 

(1)

Net Change in
Unrealized
Appreciation
(Depreciation) 

(2)

Purchases 

(5)

Sales

  Repayments 

(6)

Gross
Transfers
into
Level 3 

(3)

Gross
Transfers
out of
Level 3 

(3)

Balance as of 
December 31, 2021

2,079,465   $
14,970    
58,981    
27,398    
21,483    

65    
2,202,362   $

(3,744 ) $
—    
158    
(60,904 )  
7,091    

585    
(56,814 ) $

(2,834 ) $
(1,655 )  
53,284    
15,663    
6,961    

(1,540 )  
69,879   $

1,294,669   $
39,575    
21,180    
4,371    
4,050    

—   $
—    
(62,897 )  
60,900    
(10,339 )  

(1,208,548 ) $
—    
—    
—    
—    

2,494    
1,366,339   $

(1,043 )  
(13,379 ) $

—    
(1,208,548 ) $

—   $
—    
—    
—    
—    

—    
—   $

(2,299 ) $
—    
(1,267 )  
(25,460 )  
(1,769 )  

—    
(30,795 ) $

2,156,709  
52,890  
69,439  
21,968  
27,477  

561  
2,329,044  

Balance as of
January 1, 2020

Net Realized
Gains (Losses) 

(1)

Net Change in
Unrealized
Appreciation
(Depreciation) 

(2)

Purchases 

(5)

Sales

  Repayments 

(6)

Gross
Transfers
into
Level 3 

(4)

Gross
Transfers
out of
Level 3 

(4)

Balance as of 
December 31, 2020

2,133,812   $
14,780    
69,717    
33,547    
13,722    

955    
2,266,533   $

(53,642 ) $
(408 )  
(13,286 )  
1,240    
(5,917 )  

194    
(71,819 ) $

16,426   $
132    
11,124    
9,587    
13,603    

—    
50,872   $

781,341   $
466    
5,648    
—    
3,659    

1,440    
792,554   $

—   $
—    
(40 )  
(1,240 )  
(2,603 )  

(2,524 )  
(6,407 ) $

(793,705 ) $
—    
—    
—    
—    

—    
(793,705 ) $

—   $
—    
—    
4,767    
—    

—    
4,767   $

(4,767 ) $
—    
(14,182 )  
(20,503 )  
(981 )  

—    
(40,433 ) $

2,079,465  
14,970  
58,981  
27,398  
21,483  

65  
2,202,362  

(1)
(2)
(3)

(4)

(5)

(6)

Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. 
Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations. 
Transfers out of Level 3 during the year ended December 31, 2021 relate to the initial public offerings of Proterra, Inc., 23andMe, Inc., Sprinklr, Inc., Century Therapeutics, Couchbase, Inc., Xometry, Inc., and 
Nextdoor.com, Inc. and the conversion of Level 3 debt investments into common stock investments. There were no transfers into Level 3 during the year ended December 31, 2021 related to the conversion of 
Level 3 debt investments into equity investments and other assets.
Transfers out of Level 3 during the year ended December 31, 2020 relate to the initial public offerings of Palantir Technologies, Outset Medical, Doordash, Inc., 908 Devices, Inc. and Yumanity Therapeutics, Inc., 
the acquisition of Postmates, Inc. by Uber, Inc., and the conversion of Level 3 debt investments into Level 3 common stock investments. Transfers into Level 3 during the year ended December 31, 2020 related to 
the conversion of Level 3 debt investments into Level 3 common stock investments.
Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during 
the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.
Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.

For the year ended December 31, 2021, approximately $8.7 million net unrealized depreciation and $15.7 million net unrealized appreciation relating to assets still held 
at the reporting date was recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $5.0 million and $6.1 million in 
net unrealized appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. 

128

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
 
 
 
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
 
 
  
For the year ended December 31, 2020, approximately $6.8 million and $9.6 million in net unrealized appreciation was recorded for preferred stock and common stock 

Level 3 investments, respectively, relating to assets still held at the reporting date. For the same period, approximately $6.7 million and $6.2 million in net unrealized 
appreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of December 31, 2021 and December 31, 2020. In 

addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and 
methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the 
significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the 
Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting 
Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity 
date of the escrow receivable.

Investment Type - Level 3
Debt Investments
Pharmaceuticals

Technology

Fair Value as of 
December 31, 2021
(in thousands)

Valuation
Techniques/Methodologies

$

206,461  
451,587  

  Originated Within 4-6 Months
  Market Comparable Companies

109,904  
654,320  

  Originated Within 4-6 Months
  Market Comparable Companies

2,608  
20,425  

(3)

  Liquidation 
  Convertible Note Analysis

Unobservable Input

 (1)

Origination Yield
Hypothetical Market Yield
Premium/(Discount)

Origination Yield
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes
Probability weighting of alternative outcomes

Range
11.23% - 12.84%
9.69% - 13.89%
(0.50%) - 0.75%

11.12% - 11.68%
8.98% - 14.54%
(0.50%) - 0.75%
20.00% - 50.00%
1.00% - 35.00%

Sustainable and Renewable Technology

247  
7,500  

  Convertible Note Analysis
  Expected Realizable Value 

(4)

Probability weighting of alternative outcomes
Probability weighting of alternative outcomes

40.00% - 60.00%
100% - 100%

Lower Middle Market

3,100  
81,566  

  Originated Within 4-6 Months
  Market Comparable Companies

90,504  

  Expected Realizable Value 

(4)

8,269  

  Liquidation 

(3)

Origination Yield
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes

5.17% - 5.17%
12.23% - 16.01%
0.00% - 1.50%
30.00% - 70.00%
10.64% - 10.64%
(1.00%) - (1.00%)
20.00% - 80.00%

Weighted
(2)
Average 
11.40% 
11.34% 
0.06% 

11.39% 
11.64% 
0.12% 
40.48% 
32.95% 

51.84% 
100.00% 

5.17% 
13.22% 
0.43% 
57.74% 
10.64% 
(1.00%)
80.00% 

441,524  
131,584  
2,209,599  

$

  Debt Investments Where Fair Value Approximates Cost
  Debt Investments originated within 3 months
  Debt Investments Maturing in Less than One Year

  Total Level 3 Debt Investments

(1)    The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit 

price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as 
underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value 
measurement, depending on the materiality of the investment. 

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: 

•
•

•

Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries.
Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” 
industries. 
Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and 
Renewable Technology”, and “Software” industries. 

(2)    The weighted averages are calculated based on the fair market value of each investment. 
(3)    The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.
(4)    Expected realizable value represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. 

129

 
 
 
 
 
 
 
 
 
 
   
   
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
 
   
   
 
 
 
 
 
 
 
   
   
 
 
 
   
   
 
   
   
 
 
 
   
   
 
 
 
 
   
 
 
 
 
 
 
 
 
 
  
Fair Value as of 
December 31, 2020
(in thousands)

Valuation Techniques/Methodologies

Unobservable Input

 (1)

Investment Type - Level 3
Debt Investments
Pharmaceuticals

Technology

Sustainable and Renewable Technology

Medical Devices

$

130,068   Originated Within 4-6 Months
574,149   Market Comparable Companies

114,136   Originated Within 4-6 Months
867,892   Market Comparable Companies

18,126   Liquidation
15,775   Market Comparable Companies

 (3)

7,500   Liquidation
41,242   Market Comparable Companies

 (3)

—   Liquidation

 (3)

Lower Middle Market

106,877   Market Comparable Companies

8,600   Liquidation

 (3)

Origination Yield
Hypothetical Market Yield
Premium/(Discount)
Origination Yield
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes
Hypothetical Market Yield
Premium/(Discount)
Probability weighting of alternative outcomes

Range
10.94% - 13.56%
8.43% - 14.66%
(0.50%) - 1.50%
11.49% - 13.78%
7.61% - 17.71%
(0.25%) - 2.50%
10.00% - 75.00%
9.61% - 10.04%
0.00%
0.00% - 100.00%
9.52% - 9.52%
(0.25%)
0.00%
10.26% - 15.86%
(1.00%) - 1.00%
20.00% - 80.00%

Weighted
(2)
Average 
11.84%
10.87%

12.05%
11.67%

9.72%

9.52%

11.81%

    Debt Investments Where Fair Value Approximates Cost

78,016   Debt Investments originated within 3 months
(4)
38,148   Imminent Payoffs 
93,906   Debt Investments Maturing in Less than One Year

$

2,094,435   Total Level 3 Debt Investments

(1)

The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the 
exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as 
underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value 
measurement, depending on the materiality of the investment. 

Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: 

•

•

•

•
•

Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. 

Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Internet Consumer & Business Services”, “Media/Content/Info” and “Software” 
industries. 

Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology”, “Internet Consumer & Business Services”, and “Electronics & 
Computer Hardware” industries. 

Medical Devices, above, is comprised of debt investments in the “Drug Delivery”, and “Medical Devices & Equipment” industries. 
Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Internet Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and 
Renewable Technology”, and “Software” industries. 

(2)

(3)

(4)

The weighted averages are calculated based on the fair market value of each investment. 

The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes.

Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.

130

 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
     
 
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Investment Type - Level 3 Equity and 
Warrant Investments
Equity Investments

Warrant Investments

Fair Value as of
December 31, 2021
(in thousands)

Valuation Techniques/
Methodologies

Unobservable Input 

(1)

$

26,587     Market Comparable Companies

24,910     Market Adjusted OPM Backsolve
11,990     Discounted Cash Flow

—     Liquidation

27,920     Other 
14,517     Market Comparable Companies

(6)

11,914     Market Adjusted OPM Backsolve
1,046     Other

(6)

(2)

(2)

  EBITDA Multiple 
  Revenue Multiple 
  Tangible Book Value Multiple 
  Discount for Lack of Marketability 
  Market Equity Adjustment 
  Discount Rate 
  Revenue Multiple 
  Discount for Lack of Marketability 

(7)

(2)

(4)

(2)

(3)

(3)

(2)

  EBITDA Multiple 
  Revenue Multiple 
  Discount for Lack of Marketability 
  Market Equity Adjustment 

(2)

(4)

(3)

Range
20.6x - 20.6x
1.0x - 18.4x
2.5x - 2.5x
18.81% - 34.69%
(88.67%) - 47.22%  
15.93% - 25.30%
2.1x - 2.1x
84.00% - 84.00%

Weighted 
(5)
Average 
20.6x
11.8x
2.5x
25.53%
0.81%
20.46%
2.1x
84.00%

20.6x - 26.0x
0.6x - 9.5x
18.81% - 37.35%
(88.67%) - 47.22%  

20.7x
4.5x
26.93%
(7.76%)

Total Level 3
Warrant and Equity Investments

$

118,884    

(1)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment 
factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the 
investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used 
in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.
Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. 
Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. 
Represents the range of changes in industry valuations since the portfolio company's last external valuation event.

(2)
(3)
(4)
(5) Weighted averages are calculated based on the fair market value of each investment.
(6)
(7)

The fair market value of these investments is derived based on recent market transactions.
The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.

131

 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Investment Type - Level 3 Equity and Warrant 
Investments
Level 3 Equity Investments

Fair Value as of
December 31, 2020
(in thousands)

Valuation Techniques/
Methodologies

  $

46,669     Market Comparable Companies

Level 3 Warrant Investments

12,666     Market Adjusted OPM Backsolve

—     Liquidation

27,044     Other 
10,284     Market Comparable Companies

(7)

Total Level 3 Warrant and Equity Investments

  $

11,199     Market Adjusted OPM Backsolve
107,862    

Unobservable Input
(2)

 (1)

(2)

  EBITDA Multiple 
  Revenue Multiple 
  Tangible Book Value Multiple 
  Discount for Lack of Marketability 
  Market Equity Adjustment 
  Revenue Multiple 
  Discount for Lack of Marketability 

(2)

(5)

(2)

(3)

(3)

(2)

  EBITDA Multiple 
  Revenue Multiple 
  Discount for Lack of Marketability 
  Market Equity Adjustment 

(2)

(5)

(3)

Range
5.0x - 9.8x
2.0x - 19.5x
4.1x

22.59% - 27.53%  
(79.34%) - 53.87%  
1.4x - 1.4x
75%

4.1x - 19.2x
0.6x - 10.7x

21.56% - 34.61%  
(45.5%) - 57.42%  

Weighted 
 (6)
Average
7.5x
4.5x
4.1x
24.56%
(12.70%)
1.4x
75%

16.4x
6.0x
28.02%
(12.27%)

(1)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment 
factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the 
investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used 
in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.
Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. 
Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. 
Represents the range of industry volatility used by market participants when pricing the investment.
Represents the range of changes in industry valuations since the portfolio company's last external valuation event. 

(2)
(3)
(4)
(5)
(6) Weighted averages are calculated based on the fair market value of each investment.
(7)

The fair market value of these investments is derived based on recent market transactions.

The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables 

including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt 
obligations of the Company is recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s 
outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument. 

Based on market quotations on or around December 31, 2021, the 2022 Notes and 2022 Convertible Notes were quoted for 1.019 and 1.026 per dollar at par value, 

respectively. As of December 31, 2021, the 2033 Notes were trading on the NYSE for $26.67 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 
per unit. The fair values of the SBA debentures, July 2024 Notes, February 2025 Notes, June 2025 Notes, March 2026 A Notes, March 2026 B Notes, and September 2026 
Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of 
the outstanding borrowings under the Union Bank Facility and SMBC Facility are equal to their outstanding principal balances as of December 31, 2021.

132

 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of 
December 31, 2021 and December 31, 2020:  

(in thousands)
Description
SBA Debentures
2022 Notes
July 2024 Notes
February 2025 Notes
June 2025 Notes
March 2026 A Notes
March 2026 B Notes
September 2026 Notes
2033 Notes
2022 Convertible Notes
Union Bank Facility
SMBC Facility
Total

(in thousands)
Description
SBA Debentures
2022 Notes
April 2025 Notes
July 2024 Notes
February 2025 Notes
June 2025 Notes
March 2026 A Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2033 Notes
2022 Convertible Notes
Wells Facility
Union Bank Facility
Total

4. Investments

Carrying
Value

Approximate
Fair Value

December 31, 2021
Identical Assets
(Level 1)

Observable Inputs
(Level 2)

Unobservable Inputs
(Level 3)

  $

  $

145,498     $
149,563    
104,238    
49,637    
69,433    
49,605    
49,570    
320,376    
38,718    
229,740    
—    
29,925    
1,236,303     $

151,471     $
152,906    
110,496    
51,983    
72,031    
52,646    
52,751    
315,495    
42,672    
236,049    
—    
29,925    
1,268,425     $

Carrying
Value

Approximate
Fair Value

December 31, 2020
Identical Assets
(Level 1)

  $

98,716     $

149,039    
73,351    
103,942    
49,522    
69,272    
49,550    
178,812    
247,647    
38,610    
228,177    
—    
—    

102,815     $
152,490    
76,500    
106,061    
49,664    
69,592    
50,092    
181,087    
250,469    
42,880    
236,164    
—    
—    

  $

1,286,638     $

1,317,814     $

—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    

$

$

—     $
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—     $

—     $

152,906    
—    
—    
—    
—    
—    
—    
42,672    
236,049    
—    
—    
431,627     $

151,471  
—  
110,496  
51,983  
72,031  
52,646  
52,751  
315,495  
—  
—  
—  
29,925  
836,798  

Observable Inputs
(Level 2)

Unobservable Inputs
(Level 3)

—     $

152,490    
76,500    
—    
—    
—    
—    
181,087    
250,469    
42,880    
236,164    
—    
—    
939,590     $

102,815  
—  
—  
106,061  
49,664  
69,592  
50,092  
—  
—  
—  
—  
—  
—  
378,224  

Control and Affiliate Investments

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those 

companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or 
more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are 
“affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it 
has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are 
neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting 
securities or board appointment rights held by the Adviser Funds.

133

 
 
 
 
 
 
 
   
   
   
   
 
 
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments 

for the years ended December 31, 2021, 2020, and 2019. 
(in thousands)

Portfolio Company
Control Investments
Coronado Aesthetics, LLC
Gibraltar Business Capital, LLC
Hercules Adviser LLC
Tectura Corporation
Total Control Investments

Affiliate Investments
Black Crow AI, Inc.
Pineapple Energy LLC
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Total Affiliate Investments

Total Control & Affiliate Investments

(in thousands)

Portfolio Company
Control Investments
Gibraltar Business Capital, LLC
Tectura Corporation
Total Control Investments

Affiliate Investments
Optiscan BioMedical, Corp.
Pineapple Energy LLC
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Total Affiliate Investments

Total Control & Affiliate Investments

(in thousands)

Portfolio Company
Control Investments
Gibraltar Business Capital, LLC
Tectura Corporation
Total Control Investments

Affiliate Investments
Optiscan BioMedical, Corp.
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)
Total Affiliate Investments

Total Control & Affiliate Investments

Portfolio Composition 

Type

Control
Control
Control
Control

Affiliate
Affiliate
Affiliate

Type

Control
Control

Affiliate
Affiliate
Affiliate

Type

Control
Control

Affiliate
Affiliate

$

$

$

$
$

$

$

$

$
$

$

$

$

$
$

Fair Value as of
December 31, 2021

Interest Income

Fee Income

Net Change in Unrealized 
Appreciation (Depreciation)    

Realized Gain 
(Loss)

For the Year Ended December 31, 2021

565  
43,830    
20,840  
8,269    
73,504  

1,120  
8,338  
—  
9,458  
82,962  

48,800    
8,600    
57,400  

—    
8,340  
—  
8,340  
65,740  

50,160    
9,586    
59,746  

9,193    
12,615  
21,808  
81,554  

  $

  $

  $

  $
  $

$

  $

$

  $
  $

$

  $

$

  $
  $

—  
3,178  
141  
690  
4,009  

—  
10  
—  
10  
4,019  

  $

  $

  $

  $
  $

—  
54   
—  
5   
59  

—  
—  
—  
—  
59  

  $

  $

  $

  $
  $

315  

  $

(14,616 )  
11,955  
(331 )  
(2,677 )

1,905  
(282 )
62,183  
63,806  
61,129  

  $

  $

  $
  $

—  
—  
—  
—  
—  

—  
—  
(62,143 )
(62,143 )
(62,143 )

Interest Income

Fee Income

Net Change in Unrealized 
Appreciation (Depreciation)    

Realized Gain 
(Loss)

For the Year Ended December 31, 2020

2,249  
608  
2,857  

13    
—  
520  
533  
3,390  

2,238  
1,776  
4,014  

—    
2,008  
2,008  
6,022  

  $

  $

$

  $
  $

  $

  $

$

  $
  $

Interest
Income

21  
—  
21  

—   
—  
—  
—   
21  

  $

  $

$

$
  $

For the Year Ended December 31, 2019
Net Change in 
Unrealized 
Appreciation/
(Depreciation)

Fee Income

18  
—  
18  

—   
186  
186   
204  

  $

  $

$

$
  $

(1,419 )  
(852 )  
(2,271 )

$

  $

4,532    
(3,927 )
(346 )
259  
(2,012 )

$

  $
  $

10,619    
(9,024 )  
1,595  

585    
(3,451 )
(2,866 )
(1,271 )

$

  $

$

  $
  $

—  
—  
—  

(14,146 )
—  
(3 )
(14,149 )
(14,149 )

Realized 
Gain/(Loss)

—  
—  
—  

—  
—  
—  
—  

Fair Value as of
December 31, 2020

Fair Value at 
December 31, 2019

The following table shows the fair value of the Company’s portfolio of investments by asset class as of December 31, 2021 and December 31, 2020:

(in thousands)
Senior Secured Debt
Unsecured Debt
Preferred Stock
Common Stock
Warrants
Investment Funds & Vehicles
Total

December 31, 2021

December 31, 2020

Investments at
Fair Value

Percentage of
Total Portfolio

Investments at
Fair Value

Percentage of
Total Portfolio

$

$

2,156,709    
52,890    
69,439    
115,271    
38,399    
1,814    
2,434,522    

134

88.6 %   $
2.2 %  
2.8 %  
4.7 %  
1.6 %  
0.1 %  
100.0 %   $

2,079,465   
14,970   
58,981   
165,698   
34,622   
342   
2,354,078   

88.4 %
0.6 %
2.5 %
7.0 %
1.5 %
0.0 %
100.0 %

 
 
 
 
 
   
 
 
 
   
 
 
  
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
   
 
 
 
 
 
   
   
   
   
 
 
 
 
   
 
 
 
  
 
 
 
 
   
 
   
 
  
 
   
 
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
   
   
   
   
 
 
 
   
   
   
   
 
 
 
 
 
 
 
   
 
 
 
 
  
 
   
   
 
 
 
 
   
 
 
 
   
 
 
  
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
   
   
 
 
  
 
 
 
 
   
 
 
   
 
   
   
 
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
   
   
   
   
 
 
 
   
   
   
   
 
 
 
 
 
 
 
   
 
   
 
  
 
   
 
 
 
 
 
 
   
 
 
 
   
 
 
  
   
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
   
   
 
 
  
 
 
 
 
   
 
 
   
 
   
   
 
 
 
 
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
   
   
   
   
 
 
 
 
 
 
 
 
   
 
 
 
 
  
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A summary of the Company’s investment portfolio, at value, by geographic location as of December 31, 2021 and December 31, 2020 is shown as follows: 

(in thousands)
United States
United Kingdom
Netherlands
Canada
Israel
Ireland
Germany
Australia
Total

December 31, 2021

December 31, 2020

Investments at
Fair Value

Percentage of
Total Portfolio

Investments at
Fair Value

Percentage of
Total Portfolio

$

$

2,138,184    
169,407    
82,925    
27,673    
8,980    
5,459    
1,894    
—    
2,434,522    

87.8 %   $
7.0 %  
3.4 %  
1.1 %  
0.4 %  
0.2 %  
0.1 %  
0.0 %  
100.0 %   $

2,227,341   
29,533   
37,812   
—    
—    
5,251   
1,055   
53,086   
2,354,078   

The following table shows the fair value of the Company’s portfolio by industry sector at December 31, 2021 and December 31, 2020: 

(in thousands)
Drug Discovery & Development
Software
Internet Consumer & Business Services
Healthcare Services, Other
Communications & Networking
Information Services
Diversified Financial Services
Sustainable and Renewable Technology
Consumer & Business Products
Semiconductors
Manufacturing Technology
Medical Devices & Equipment
Electronics & Computer Hardware
Surgical Devices
Drug Delivery
Media/Content/Info
Specialty Pharmaceuticals
Total

Investments at
Fair Value
$

$

December 31, 2021

December 31, 2020

Percentage of
Total Portfolio

Investments at
Fair Value

Percentage of
Total Portfolio

967,383    
585,622    
395,506    
121,003    
105,490    
74,417    
65,073    
39,387    
28,099    
22,498    
14,995    
12,612    
1,040    
1,029    
368    
—    
—    
2,434,522    

39.7 %   $
24.1 %  
16.3 %  
5.0 %  
4.3 %  
3.1 %  
2.7 %  
1.6 %  
1.2 %  
0.9 %  
0.6 %  
0.5 %  
0.0 %  
0.0 %  
0.0 %  
0.0 %  
0.0 %  
100.0 %   $

757,163   
780,045   
514,538   
27,519   
10,763   
54,510   
48,800   
55,244   
1,895   
892   
—   
26,464   
3,360   
4,581   
46,744   
21,555   
5   
2,354,078   

No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of December 31, 2021 or December 31, 2020.

Unconsolidated Subsidiaries

In accordance with Rules 3-09 and 4-08(g) of Regulation S-X (“Rule 3-09” and “Rule 4-08(g),” respectively), the Company must determine if its unconsolidated 
subsidiaries are considered “significant subsidiaries.” As of December 31, 2021 and December 31, 2020, there were no unconsolidated subsidiaries that were considered 
“significant subsidiaries”.

Concentrations of Credit Risk

The Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development", "Software”, 
“Internet Consumer & Business Services”, "Healthcare Services, Other", and “Communications & Networking" sectors. These sectors are characterized by high margins, high 
growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.  

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity 

and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be 
highly concentrated among several portfolio companies.

135

94.6 %
1.3 %
1.6 %
0.0 %
0.0 %
0.2 %
0.0 %
2.3 %
100.0 %

32.2 %
33.1 %
21.9 %
1.2 %
0.4 %
2.3 %
2.1 %
2.4 %
0.1 %
0.0 %
0.0 %
1.1 %
0.1 %
0.2 %
2.0 %
0.9 %
0.0 %
100.0 %

 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
For the years ended December 31, 2021 and December 31, 2020, the Company’s ten largest portfolio companies represented approximately 30.5% and 27.9% of the 

total fair value of the Company’s investments in portfolio companies, respectively. As of December 31, 2021 and December 31, 2020, the Company had six and three portfolio 
companies, respectively, that represented 5% or more of the Company’s net assets. As of December 31, 2021, the Company had six equity investments representing 
approximately 49.6% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. 
As of December 31, 2020, the Company had four equity investments which represented approximately 63.7% of the total fair value of the Company’s equity investments, and 
each represented 5% or more of the total fair value of such investments. 

Investment Collateral

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its 
intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. As of December 31, 2021, approximately 77.0% of 
the Company’s debt investments at fair value were in a senior secured first lien position, with 37.5% secured by a first priority security in all of the assets of the portfolio 
company, including its intellectual property, 31.6% secured by a first priority security in all of the assets of the portfolio company and the portfolio company was prohibited 
from pledging or encumbering its intellectual property, and 7.9% of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with 
security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, 
sale or other disposition. Another 20.6% of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, 
and 2.4% were unsecured.

As of December 31, 2020, approximately 84.2% of the Company’s debt investments at fair value were in a senior secured first lien position, with 43.5% secured by a 

first priority security in all of the assets of the portfolio company, including its intellectual property, 31.0% secured by a first priority security in all of the assets of the portfolio 
company and the portfolio company was prohibited from pledging or encumbering its intellectual property, 0.6% of the Company’s debt investments at fair value were senior 
secured by the equipment of the portfolio company, and 9.1% of the Company’s debt investments at fair value were in a first lien “last-out” senior secured position with 
security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, 
sale or other disposition. Another 15.1% of the Company’s debt investments at fair value were secured by a second priority security interest in the portfolio company’s assets, 
and 0.7%  were unsecured.

136

 
 
  
5. Debt

As of December 31, 2021 and December 31, 2020, the Company had the following available and outstanding debt:

(2)

(in thousands)
SBA Debentures 
2022 Notes
July 2024 Notes
February 2025 Notes
April 2025 Notes
June 2025 Notes
March 2026 A Notes
March 2026 B Notes
September 2026 Notes
2033 Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2022 Convertible Notes
Wells Facility
Union Bank Facility 
 (3) (4)
SMBC Facility

 (3) (4)

(3)

Total

(1)

(2)

(3)
(4)

Total Available

Principal

Carrying Value 

(1)

Total Available

Principal

Carrying Value 

(1)

December 31, 2021

December 31, 2020

$

$

175,000   $
150,000    
105,000    
50,000    
—    
70,000    
50,000    
50,000    
325,000    
40,000    
—    
—    
230,000    
—    
400,000    
100,000    
1,745,000   $

150,500   $
150,000    
105,000    
50,000    
—    
70,000    
50,000    
50,000    
325,000    
40,000    
—    
—    
230,000    
—    
—    
29,925    
1,250,425   $

145,498   $
149,563    
104,238    
49,637    
—    
69,433    
49,605    
49,570    
320,376    
38,718    
—    
—    
229,740    
—    
—    
29,925    
1,236,303   $

99,000  $
150,000   
105,000   
50,000   
75,000   
70,000   
50,000   
—   
—   
40,000   
180,988   
250,000   
230,000   
75,000   
400,000   
—   
1,774,988  $

99,000  $
150,000   
105,000   
50,000   
75,000   
70,000   
50,000   
—   
—   
40,000   
180,988   
250,000   
230,000   
—   
—   
—   
1,299,988  $

98,716  
149,039  
103,942  
49,522  
73,351  
69,272  
49,550  
—  
—  
38,610  
178,812  
247,647  
228,177  
—  
—  
—  
1,286,638  

Except for the SMBC Facility, Union Bank Facility, and Wells Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium 
or discount, if any, associated with the debt as of the balance sheet date.
As of December 31, 2021, the total available debt under the SBA Debentures was $175.0 million, all of which was available to HC IV. The availability of the full amount of debt is subject to regulatory 
requirements and regulatory acknowledgement of contributed capital of $87.5 million. As of December 31, 2021, the Company has contributed and received regulatory acknowledgement for $87.5 million of 
capital to HC IV. As of December 31, 2020, the total available debt under the SBA debentures was $99.0 million, all of which was drawn by HT III. 
Availability subject to the Company meeting the borrowing base requirements. 
From time to time, the Company may guarantee certain unfunded commitments through its credit facility.

Debt issuance costs, net of accumulated amortization, were as follows as of December 31, 2021 and December 31, 2020:

(in thousands)
SBA Debentures
2022 Notes
July 2024 Notes
February 2025 Notes
April 2025 Notes
June 2025 Notes
March 2026 A Notes
March 2026 B Notes
September 2026 Notes
2033 Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2022 Convertible Notes
Wells Facility 
Union Bank Facility
SMBC Facility 
Total

 (1)

(1)

(1)

$

$

December 31, 2021

December 31, 2020

5,002  
300  
762  
363  
—  
567  
395  
430  
4,624  
1,282  
—  
—  
149  
—  
1,239  
922  
16,035  

  $

  $

284  
660  
1,058  
478  
1,649  
728  
450  
—  
—  
1,390  
2,176  
2,353  
1,040  
198  
2,485  
—  
14,949  

(1)

The SMBC Facility, Union Bank Facility and Wells Facility are line-of-credit arrangements. The debt issuance costs associated with these instruments are included within Other assets on the Consolidated 
Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30. 

137

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  
as follows:

(in thousands)
Description
SBA Debentures
2022 Notes
July 2024 Notes
February 2025 Notes
April 2025 Notes
June 2025 Notes
March 2026 A Notes
March 2026 B Notes
September 2026 Notes
2033 Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2022 Convertible Notes
Wells Facility
Union Bank Facility
SMBC Facility
Total

(in thousands)
Description
SBA Debentures
2022 Notes
July 2024 Notes
February 2025 Notes
April 2025 Notes
June 2025 Notes
March 2026 A Notes
2033 Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2022 Convertible Notes
Wells Facility
Union Bank Facility
Total

For the year ended December 31, 2021, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were 

Interest expense

(1)

Amortization of debt issuance cost 
(loan fees)

(2)

Year ended December 31, 2021
Unused facility and other fees 
(loan fees)

  $

$

1,580   $
7,102    
5,009    
2,140    
1,969    
3,017    
2,250    
1,877    
2,513    
2,500    
4,888    
8,139    
10,734    
—    
672    
57    
54,447   $

452   $
360    
295    
115    
1,667    
162    
93    
85    
236    
108    
2,176    
2,351    
892    
198    
1,228    
33    
10,451   $

  Total interest expense and fees   Cash paid for interest expense  
2,272  
6,938  
5,008  
2,140  
2,635  
3,017  
1,875  
1,138  
—  
2,500  
4,972  
8,240  
10,062  
—  
672  
—  
51,469  

2,032   $
7,462    
5,304    
2,255    
3,636    
3,179    
2,343    
1,962    
2,749    
2,608    
7,064    
10,490    
11,626    
873    
3,806    
134    
67,523   $

—   $
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
675    
1,906    
44    
2,625   $

(1)

(2)

Interest expense includes amortization of original issue discounts for the year ended December 31, 2021, of $165 thousand, $671 thousand, and $48 thousand for the 2022 Notes, 2022 Convertible Notes, and 
September 2026 Notes, respectively. 
“Amortization of debt issuance cost (loan fees)” includes $1,477 thousand, $1,272 thousand, and $1,670 thousand related to debt extinguishment costs for the April 2025 Notes, 2027 Asset-Backed Notes, and 
2028 Asset-Backed Notes, respectively for the year ended December 31, 2021 disclosed as a “Loss on debt extinguishment” in the Consolidated Statement of Operations. 

For the year ended December 31, 2020, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows:

Interest expense

(1)

Amortization of debt issuance cost 
(loan fees)

Year ended December 31, 2020
Unused facility and other fees 
(loan fees)

  $

$

3,464   $
7,307    
5,009    
1,938    
3,938    
1,743    
356    
2,500    
9,116    
11,758    
10,733    
25    
1,718    
59,605   $

551    
360    
294    
103    
381    
92    
14    
108    
512    
257    
892    
175    
1,266    
5,005   $

  Total interest expense and fees   Cash paid for interest expense  
4,285  
6,938  
5,009  
1,070  
3,938  
1,509  
—  
2,500  
9,139  
11,756  
10,062  
26  
2,042  
58,274  

4,015   $
7,667    
5,303    
2,041    
4,319    
1,835    
370    
2,608    
9,628    
12,015    
11,625    
719    
4,729    
66,874   $

—   $
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
519    
1,745    
2,264   $

(1)

Interest expense includes amortization of original issue discounts for the year ended December 31, 2020, of $165 thousand, $671 thousand, for the 2022 Notes, and 2022 Convertible Notes, respectively.  

138

 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
For the year ended December 31, 2019, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows:

Interest expense

(1)

Amortization of debt issuance cost 
(loan fees)

Year ended December 31, 2019
Unused facility and other fees 
(loan fees)

  $

$

5,107   $
7,103    
320    
2,302    
3,938    
2,500    
9,209    
11,071    
10,734    
435    
1,877    
54,596   $

510   $
360    
1,686    
115    
381    
108    
279    
253    
892    
263    
834    
5,681   $

  Total interest expense and fees   Cash paid for interest expense  
5,080  
6,938  
1,305  
—  
3,938  
2,500  
9,210  
10,744  
10,062  
449  
1,592  
51,818  

5,617   $
7,463    
2,006    
2,417    
4,319    
2,608    
9,488    
11,324    
11,626    
1,326    
3,480    
61,674   $

—   $
—    
—    
—    
—    
—    
—    
—    
—    
628    
769    
1,397   $

(in thousands)
Description
SBA Debentures
2022 Notes
2024 Notes
July 2024 Notes
April 2025 Notes
2033 Notes
2027 Asset-Backed Notes
2028 Asset-Backed Notes
2022 Convertible Notes
Wells Facility
Union Bank Facility
Total

(1)

Interest expense includes amortization of original issue discounts for the year ended December 31, 2019, of $165 thousand, $671 thousand, and $110 thousand for the 2022 Notes, 2022 Convertible Notes, and July 
2024 Notes, respectively. 

As of December 31, 2021, December 31, 2020, and December 31, 2019, the Company was in compliance with the terms of all borrowing arrangements. There are no 

sinking fund requirements for any of the Company’s debt.

SBA Debentures 

The Company reported the following SBA debentures outstanding principal balances as of December 31, 2021 and December 31, 2020:

(in thousands) 
Issuance/Pooling Date
September 21, 2011
March 21, 2012
September 19, 2012
March 27, 2013
March 26, 2021
June 25, 2021
July 28, 2021
August 20, 2021
October 21, 2021
November 1, 2021
November 15, 2021
November 30, 2021
December 20, 2021
December 23, 2021
December 28, 2021
Total SBA Debentures

(2)

(2)

(2)

(2)

(2)

(2)

(2)

Maturity Date

  September 1, 2021
  March 1, 2022
  September 1, 2022
  March 1, 2023
  September 1, 2031
  September 1, 2031
  September 1, 2031
  September 1, 2031
  March 1, 2032
  March 1, 2032
  March 1, 2032
  March 1, 2032
  March 1, 2032
  March 1, 2032
  March 1, 2032

(1)

Interest Rate 
3.16%
3.28%
3.05%
3.16%
1.58%
1.58%
1.58%
1.58%
0.91%
0.91%
0.91%
0.91%
0.90%
0.91%
0.92%

  $

  $

December 31, 2021

December 31, 2020

—     $
—      
—  
—  
37,500  
16,200  
5,400  
5,400  
14,000  
21,000  
5,200  
20,800  
10,000  
10,000  
5,000  
150,500  

  $

25,000  
25,000  
24,250  
24,750  
—  
—  
—  
—  
—  
—  
—  
—  
—  
—  

99,000  

(1)
(2)

Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.
As of December 31, 2021, $86.00 million of drawn SBA Debentures are scheduled to be pooled on March 22, 2022. The interest rate disclosed is the current effective interim interest rate.

Our SBICs are periodically examined and audited by the SBA’s staff to determine its compliance with SBA regulations. Our SBICs were in compliance with the terms 

of the SBIC’s leverage as of December 31, 2021 and December 31, 2020, as a result of having sufficient capital as defined under the SBA regulations.

HT III

On May 26, 2010, HT III received a license to operate as an SBIC. As an SBIC, HT III could borrow funds from the SBA against eligible investments and additional 

contributions to regulatory capital. During the year ended December 31, 2021, the Company paid down $99.0 million of SBA debentures. During the year ended December 31, 
2020, the Company paid down $50.0 million of SBA debentures. As of December 31, 2021, HT III had no SBA guaranteed debentures outstanding. As of December 31, 2020, 
HT III had a total of $99.0 million of SBA guaranteed debentures outstanding. As of December 31, 2021 and December 31, 2020, HT III has paid the SBA commitment fees 
and facility fees of approximately $5.1 million and $5.1 million, respectively.

139

 
 
 
 
 
 
 
   
   
   
   
   
   
   
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
 
 
 
 
 
  
As noted in "Note 1 - Description of Business", the Company has wound down HT III, and on June 15, 2021 surrendered its SBA license and is no longer operating as 

an SBIC. All assets have been transferred to an affiliated entity as part of the wind down. As of December 31, 2020, the Company held investments through HT III in 29 
companies with a fair value of approximately $137.4 million, accounting for approximately 5.8% of the Company’s total investment portfolio. As of December 31, 2020, HT 
III held approximately $201.2 million in tangible assets which accounted for approximately 7.7% of the Company’s total assets as of December 31, 2020.

HC IV

On October 27, 2020, HC IV was licensed to operate as an SBIC under the SBA. The license has a 10-year term. With the license, HC IV has access to $175.0 million 

of capital through the SBA debenture program, in addition to the Company’s regulatory capital commitment of $87.5 million to HC IV which will be used for investment 
purposes. As of December 31, 2021, HC IV has the capacity to issue a total of $175.0 million in SBA guaranteed debentures, subject to SBA approval, of which $150.5 million 
was outstanding as of December 31, 2021. As of December 31, 2020, HC IV had no outstanding SBA debentures. 

As of December 31, 2021, HC IV has paid the SBA commitment fees and facility fees of approximately $1.8 million and $3.7 million, respectively. As of December 

31, 2021, the Company held investments in HC IV in 15 companies with a fair value of approximately $244.5 million, accounting for approximately 10.0% of the Company’s 
total investment portfolio. HC IV held approximately $245.7 million in tangible assets which accounted for approximately 9.5% of the Company’s total assets as of December 
31, 2021. As of December 31, 2020, HC IV had no material assets other than $19.1 million of cash from the regulatory capital committed. 

2022 Notes

On October 23, 2017, the Company issued $150.0 million in aggregate principal amount of 4.625% interest-bearing unsecured notes that mature on October 23, 2022 

(the “2022 Notes”), unless repurchased in accordance with their terms. Interest on the 2022 Notes is due semiannually in arrears on April 23 and October 23 of each year, 
commencing on April 23, 2018. The 2022 Notes rank pari passu, or equally, in right of payment with all of the Company’s existing and future liabilities that are not so 
subordinated, or junior. The 2022 Notes effectively rank subordinated, or junior, to any of the Company’s secured indebtedness (including unsecured indebtedness that the 
Company later secures) to the extent of the value of the assets securing such indebtedness. The 2022 Notes rank structurally subordinated, or junior, to all existing and future 
indebtedness (including trade payables) incurred by subsidiaries, financing vehicles or similar facilities of the Company. The 2022 Notes are not guaranteed by any of the 
Company’s current or future subsidiaries. 

The Company was permitted to redeem some or all of the 2022 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 
indenture. On February 22, 2022, pursuant to the redemption terms of the 2025 Notes indenture, the Company fully repaid the aggregate outstanding $150.0 million of principal 
and $2.3 million of accrued interest.  In addition, the Company paid $3.3 million of prepayment premium fees, which together with the accelerated recognition of $0.3 million 
of debt issuance costs will be recognized as a realized loss on extinguishment of the debt.

2022 Convertible Notes

On January 25, 2017, the Company issued $230.0 million in aggregate principal amount of 4.375% interest-bearing unsecured notes due on February 1, 2022 (the 

“2022 Convertible Notes”), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2022 Convertible Notes. The 
Company may not redeem the 2022 Convertible Notes at its option prior to maturity. The $230.0 million issued aggregate principal of the 2022 Convertible Notes includes an 
additional $30.0 million aggregate principal amount issued pursuant to the initial purchaser’s exercise in full of its overallotment option. Interest on the 2022 Convertible Notes 
is due semiannually in arrears on February 1 and August 1 of each year. The 2022 Convertible Notes are unsecured obligations of the Company and rank pari passu, or equally 
in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

Prior to the close of business on the business day immediately preceding August 1, 2021, holders were permitted to convert their 2022 Convertible Notes under certain 
circumstances set forth in the terms of the 2022 Convertible Notes. On or after August 1, 2021 until the close of business on the scheduled trading day immediately preceding 
the maturity date, holders may convert their 2022 Convertible Notes at any time. Upon conversion, the Company is required to pay or deliver, as the case may be, at its election, 
cash, shares of its common stock or a combination of cash and shares of its common stock. The conversion rate was initially 60.9366 shares of common stock per $1,000 
principal amount of 2022 Convertible Notes (equivalent to an initial conversion price of approximately $16.41 per share of common stock). The conversion rate is subject to 
adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the Company 
will increase the 

140

 
  
conversion rate for a holder who elects to convert its 2022 Convertible Notes in connection with such a corporate event in certain circumstances. 

In May 2021 and November 2021, the Company provided notice of adjustment in the conversion rate to give effect to the dividends distributed in 2021. As of 
December 31, 2021, the conversion rate was 62.2621  shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion 
price of approximately $16.06 per share of common stock). In addition, if certain corporate events occur, holders of the 2022 Convertible Notes may require the Company to 
repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2022 Convertible Notes to be repurchased, 
plus accrued and unpaid interest through, but excluding, the required repurchase date.

The 2022 Convertible Notes are accounted for in accordance with ASC Subtopic 470-20, Debt with Conversion and Other Options. In accounting for the 2022 
Convertible Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the 2022 Convertible Notes were 
approximately 98.5% and 1.5%, respectively. The original issue discount of 1.5% or $3.4 million, attributable to the conversion feature of the 2022 Convertible Notes was 
recorded in “capital in excess of par value” in the Consolidated Statements of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated 
interest expense as well as accretion of the original issue discount resulting in an estimated effective interest rate of approximately 4.76%. 

On July 26, 2021, the Company provided notice to the 2022 Convertible Notes holders by which the Company irrevocably elected to settle conversions using the 
combination settlement method as provided within the 2022 Convertible Note Indenture. Accordingly, the 2022 Convertible Notes holders will receive a cash payment of up to 
$1,000 for each $1,000 principal amount of 2022 Convertible Notes converted and the balance, if any, to be settled in shares of common stock of the Company. The Company 
will not issue fractional shares of common stock upon the conversion of the Notes. In lieu of issuing fractional shares, the Company will pay cash. 

On February 1, 2022, the Company fully repaid the aggregate outstanding $230.0 million principal, $5.0 million of accrued interest and fees, and issued 981,169 shares 

related to noteholders who elected to convert pursuant to the redemption terms of the 2022 Convertible Notes indenture. 

July 2024 Notes

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 

Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the July 2024 Notes is due 
semiannually. The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated 
indebtedness issued by the Company. 

February 2025 Notes

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 

2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is 
due semiannually. The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated 
indebtedness issued by the Company. 

141

 
 
  
April 2025 Notes

On April 26, 2018, the Company issued $75.0 million in aggregate principal amount of 5.25% interest-bearing unsecured notes due April 30, 2025 (the “April 2025 

Notes”), unless repurchased in accordance with the terms of the Fifth Supplemental Indenture to the Base Indenture, dated April 26, 2018. Interest on the April 2025 Notes was 
payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The April 2025 Notes traded on the NYSE under the symbol “HCXZ”. The April 
2025 Notes were general unsecured obligations and ranked pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness 
issued by the Company. 

On July 1, 2021, the Company fully redeemed the aggregate outstanding $75.0 million of principal and $0.6 million of accrued interest pursuant to the redemption 

terms of the April 2025 Notes Indenture. The Company accelerated recognition of $1.5 million of debt issuance costs associated with the extinguishment of the debt. 

June 2025 Notes

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), 

unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering pursuant to the 2025 Note Purchase Agreement. 
Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and 
future unsecured unsubordinated indebtedness issued by the Company. 

March 2026 A Notes

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.5% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 

A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes is 
due semiannually. The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated 
indebtedness issued by the Company.

March 2026 B Notes

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B 

Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. The sale of the March 2026 B 
Notes generated net proceeds of approximately $49.5 million. Aggregate offering expenses in connection with the transaction, including fees and commissions, were 
approximately $0.5 million. Interest on the March 2026 B Notes is due semiannually. The March 2026 B Notes are general unsecured obligations of the Company that rank pari 
passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

September 2026 Notes

On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the 

“September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021.  The issuance of the September 
2026 Notes generated net proceeds of approximately $320.1 million.  The aggregate offering expenses in connection with the transaction, including the underwriter’s discount 
and commissions, were approximately $4.1 million of costs and $0.8 million related to the discount. Interest on the September 2026 Notes is payable semi-annually in arrears 
on March 16 and September 16 of each year, commencing on March 16, 2022. The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in 
right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the September 2026 
Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture.

2033 Notes

On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% interest-bearing unsecured notes due October 30, 2033 (the “2033 
Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is 
payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are 
general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated 

142

 
  
indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the 
terms of the 2033 Notes indenture after October 30, 2023. 

2027 Asset-Backed Notes 

On November 1, 2018, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $200.0 million in aggregate 

principal amount of 4.605% interest-bearing asset-backed notes due on November 22, 2027 (the “2027 Asset-Backed Notes”). The 2027 Asset-Backed Notes were issued by 
Hercules Capital Funding Trust 2018-1 (the “2018 Securitization Issuer”) pursuant to a note purchase agreement, dated as of October 25, 2018, by and among the Company, 
Hercules Capital Funding 2018-1 LLC, as trust depositor, the 2018 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of 
senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. As of 
October 21, 2020, the securitization was past its reinvestment period, and it was no longer able to reinvest principal collections into additional eligible loans. Accordingly, 
available funds from principal collections were used to pay $65.6 million and $19.0 million of the outstanding principal balance on the 2027 Asset-Backed Notes during the 
year ended December 31, 2021 and the year ended December 31, 2020, respectively. Interest on the 2027 Asset-Backed Notes will be paid, to the extent of funds available. 

On October 20, 2021, the Company fully repaid the aggregate outstanding $115.4 million of principal and repaid $0.4 million of accrued interest and fees pursuant to 

the redemption terms of the 2027 Asset-Backed Notes agreement. The Company accelerated recognition of $1.2 million of debt issuance costs associated with the 
extinguishment of the debt, and all restricted cash previously held back was released to the Company.

2028 Asset-Backed Notes

On January 22, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $250.0 million in aggregate 

principal amount of 4.703% interest-bearing asset-backed notes due on February 22, 2028 (the “2028 Asset-Backed Notes”). The 2028 Asset-Backed Notes were issued by 
Hercules Capital Funding Trust 2019-1 (the “2019 Securitization Issuer”) pursuant to a note purchase agreement, dated as of January 14, 2019, by and among the Company, 
Hercules Capital Funding 2019-1 LLC, as trust depositor, the 2019 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, MUFG Securities Americas 
Inc., as a co-manager, and Wells Fargo Securities, LLC., as a co-manager, and are backed by a pool of senior loans made to certain portfolio companies of the Company and 
secured by certain assets of those portfolio companies and are to be serviced by the Company. As of January 21, 2021, the securitization was past its reinvestment period, and it 
was no longer able to reinvest principal collections into additional eligible loans. Accordingly, available funds from principal collections were used to pay $76.2 million of the 
outstanding principal balance on the 2028 Asset-Backed Notes during the year ended December 31, 2021. There were no payments on the outstanding principal balance for the 
year ended December 31, 2020. Interest on the 2028 Asset-Backed Notes will be paid, to the extent of funds available. 

On October 20, 2021, the Company fully repaid the aggregate outstanding $173.8 million of principal and repaid $0.7 million of accrued interest and fees pursuant to 

the redemption terms of the 2028 Asset-Backed Notes agreement. The Company accelerated recognition of $1.5 million of debt issuance costs associated with the 
extinguishment of the debt, and all restricted cash previously held back was released to the Company.

Credit Facilities

As of December 31, 2021, the Company had two available credit facilities, the Union Bank Facility and SMBC Facility. As of December 31, 2020, the Company had two 

available credit facilities, the Union Bank Facility and Wells Facility. For the year ended December 31, 2021 and 2020, the weighted average interest rate was 2.54% and 
3.15%, respectively, and the average debt outstanding under the Credit Facilities was $28.8 million and $55.4 million, respectively.

Wells Facility 

On June 29, 2015, the Company, through a special purpose wholly owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into an Amended and 

Restated Loan and Security Agreement (the “Wells Facility”) with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the 
lenders party thereto from time to time. 

On January 11, 2019, Hercules Funding II entered into the Seventh Amendment to the Wells Facility (the “Wells Facility Seventh Amendment”). Among other changes, 
the Wells Facility Seventh Amendment amends certain key provisions of the Wells Facility to reduce the current interest rate to LIBOR plus 3.00% with an interest rate floor of 
3.00% and extends the maturity date to January 2023, unless terminated earlier in accordance with its terms. In addition, the Wells Fargo Capital Finance, LLC has committed 

143

 
  
$75.0 million in credit capacity with an accordion feature, in which the Company can increase the credit line up to an aggregate of $125.0 million, funded by additional lenders 
and with the agreement of Wells Fargo and subject to other customary conditions. The Wells Facility has an advance rate of 55% against eligible debt investments, and it is 
secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee of up to 0.375% depending on the average monthly outstanding 
balance under the facility relative to the maximum amount of commitments at such time.

On July 2, 2019, Hercules Funding II entered into the Eighth Amendment to the Wells Facility (the “Wells Facility Eighth Amendment”). The Wells Facility Eighth 
Amendment amends certain provisions of the Wells Facility to, among other things, revise certain provisions thereof to further permit a third party special servicer to act as 
servicer after an event of default instead of the Company with respect to split-funded notes receivable owned by Hercules Funding II and an affiliate thereof (including 
Hercules Funding IV LLC).

On November 29, 2021, the Company terminated the Wells Facility and voluntarily prepaid all amounts outstanding under the Wells Facility. Pursuant to the 
termination, the Company paid approximately $0.1 million in fees and expenses. No loans were or remain outstanding. As a result of the termination, all of the Company’s 
security interests and other liens granted by the Company to secure the Company’s obligations under the Wells Facility have been terminated and released, with the exception of 
$3.2 million of cash, which has been pledged as collateral for a letter of credit issued on behalf of a portfolio company of the Company.  As of December 31, 2021, $3.2 million 
is included within Restricted Cash on the Company's Consolidated Statement of Assets and Liabilities.

Union Bank Facility 

On February 20, 2020, the Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into 

the credit facility (the “Union Bank Facility”) with MUFG Union Bank, as the arranger and administrative agent, and the lenders party to the Union Bank Facility from time to 
time. The Union Bank Facility replaced the Company’s credit facility (the “2019 Union Bank Facility”) entered into on February 20, 2019 with MUFG Union Bank, as the 
arranger and administrative agent, and the lenders party thereto. The 2019 Union Bank Facility replaced the Company’s credit facility (the “Prior Union Bank Facility”) entered 
into on May 5, 2016 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. Any references to amounts related to the Union Bank 
Facility prior to February 20, 2020 were incurred and relate to the Prior Union Bank Facility or the 2019 Union Bank Facility, as applicable. 

Under the Union Bank Facility, the lenders have made commitments of $400.0 million. The Union Bank Facility contains an accordion feature, in which the Company 

can increase the credit line up to an aggregate of $200.0 million, funded by existing or additional lenders and with the agreement of MUFG Union Bank and subject to other 
customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings. Debt under the Union Bank 
Facility generally bears interest at a rate per annum equal to LIBOR plus 2.50%. The Union Bank Facility matures on February 22, 2024, unless sooner terminated in 
accordance with its terms. The Union Bank Facility is secured by all of the assets of Hercules Funding IV.  The Union Bank Facility requires payment of a non-use fee during 
the revolving credit availability period as follows: (i) 0.50% if less than or equal to 50% utilization; (ii) 0.375% if more than 50% utilization but less than or equal to 80% 
utilization; and (iii) 0.20% if more than 80% is utilized. 

The Union Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to 

Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain 
certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of 
$723.0 million.

The Union Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer 

defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

SMBC Facility 

On November 9, 2021, the Company entered into a revolving credit agreement with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative 

agent, and the lenders and issuing banks to the SMBC Facility. The SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies in an 
initial aggregate amount of up to $100.0 million. The SMBC Facility also has an accordion feature that allows for an increase in the total commitments of up to $150.0 million, 
subject to certain conditions. Additionally, the SMBC Facility provides for the issuance of letters of credit on the account of the Company or its designee in U.S. dollars and 
certain agreed upon foreign currencies in an aggregate face amount not to exceed $15.0 million. The 

144

 
  
Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security 
interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder. Availability under the SMBC 
Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026. 

Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. Interest under the SMBC Facility for (i) 

loans for which the Company elects the base rate option, (A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, is payable at 
an “alternate base rate” (which is the greater of (x) zero and (y) the highest of (a) the prime rate as published in the print edition of The Wall Street Journal, Money Rates 
Section, (b) the federal funds effective rate plus 0.5% and (c) the one-month Eurocurrency rate plus 1% per annum) plus 0.875% per annum and (B) if the borrowing base is 
less than the product of 1.60 and the revolving credit exposure, the alternate base rate plus 1.00% per annum; (ii) loans for which the Company elects the Eurocurrency option, 
(A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to the Eurocurrency rate plus 1.875% per 
annum and (B) if the borrowing base is less than the product of 1.60 and the revolving credit exposure, is payable at a rate equal to the Eurocurrency rate plus 2.00% per 
annum; and (iii) loans for which the Company elects the RFR option, (A) if the borrowing base is equal to or greater than the product of 1.60 and the revolving credit exposure, 
is payable at a rate equal to RFR plus 1.9934% per annum and (B) if the borrowing base is less than the product of 1.60 and the revolving credit exposure, is payable at a rate 
equal to RFR plus 2.1193% per annum. The SMBC Facility will be subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average 
usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company will be required to pay letter of credit participation fees 
and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility.

The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of 

representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also 
includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset 
coverage ratios, and our status as a RIC. 

6. Income Taxes

To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an 
amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions 
paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the 
management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the 
Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders. 

As previously noted, federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and 

realized gains recognized for financial reporting purposes. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate 
tax character. During the year ended December 31, 2021, the Company reclassified $63.3 million from accumulated realized gains (losses) to additional paid-in capital for book 
purposes primarily related to realized losses from portfolio companies which are held in taxable subsidiaries and are not consolidated with the Company for income tax 
purposes. 

During the year ended December 31, 2020, the Company reclassified $67.7 million from accumulated realized gains (losses) to additional paid-in capital for book 

purposes primarily related to realized losses from portfolio companies which are held in taxable subsidiaries and are not consolidated with the Company for income tax 
purposes. In addition, the Company reclassified $6.6 million 

145

 
  
from undistributed ordinary income to additional paid-in capital for book purposes during the year ended December 31, 2020 relating to accelerated revenue recognition for the 
tax years prior to December 31, 2017, which are closed tax years. 

During the year ended December 31, 2019, the Company reclassified $25.3 million from accumulated realized gains (losses) to additional paid-in capital for book 

purposes primarily related to realized losses from exited portfolio companies which were held in taxable subsidiaries and were not consolidated with the Company for income 
tax purposes. 

During the years ended December 31, 2021, 2020 and 2019, the Company reclassified amounts from undistributed ordinary income or accumulated realized gains 

(losses) to additional paid-in capital for book purposes, as follows:

(in thousands)
Undistributed net investment income (distributions in excess of investment income)
Accumulated realized gains (losses)
Additional paid-in capital

2021

$

Year Ended December 31,
2020

$

19,486    
69,066    
(88,552 )  

$

(26,297 )  
100,353  
(74,056 )

2019

11,831  
29,720  
(41,551 )

For income tax purposes, distributions paid to stockholders are reported as ordinary income, return of capital, long-term capital gains, or a combination thereof. The tax 

character of distributions paid for the year ended December 31, 2021 was ordinary income in the amount of $122.6 million and long-term capital gains in the amount of $55.2 
million. The tax character of distributions paid for the year ended December 31, 2020 was ordinary income in the amount of $118.0 million and long-term capital gains in the 
amount of $36.7 million. The tax character of distributions paid for the year ended December 31, 2019 was ordinary income in the amount of $122.2 million and long-term 
capital gains in the amount of $12.0 million.

The aggregate gross unrealized appreciation of the Company’s investments over cost for U.S. federal income tax purposes was $121.0 million, $166.2 million, and 

$70.3 million, as of December 31, 2021, 2020, and 2019, respectively. The aggregate gross unrealized depreciation of the Company’s investments under cost for U.S. federal 
income tax purposes was $75.7 million, $126.1 million, and $144.1 million, as of December 31, 2021, 2020, 2019, respectively. The net unrealized appreciation over cost for 
U.S. federal income tax purposes was $45.3 million and  $40.1 million as of December 31, 2021 and 2020, respectively. The net unrealized depreciation over cost for U.S. 
federal income tax purposes was $73.8 million as December 31, 2019. The aggregate cost of securities for U.S. federal income tax purposes was $2.4 billion and $2.3 billion as 
of December 31, 2021 and 2020, respectively.

As of December 31, 2021, 2020 and 2019, the components of distributable earnings on a tax basis detailed below differ from the amounts reflected in the Company’s 

Consolidated Statements of Assets and Liabilities by temporary book or tax differences primarily arising from the treatment of loan related yield enhancements. 

(in thousands)
Accumulated capital gains
Other temporary differences
Undistributed ordinary income
Unrealized appreciation (depreciation)
Components of distributable earnings

2021

Year Ended December 31,
2020

2019

$

$

43,005    
(16,206 )  
149,069    
40,655    
216,523    

$

$

9,923  
(11,711 )
97,401  
37,778  
133,391  

  $

  $

4,722  
(6,728 )
63,271  
(73,430 )
(12,165 )

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated 

as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its 
ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 
1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years 
(the "Excise Tax Avoidance Requirement"). The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income 
tax (such as the tax imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions 
from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be 
carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and 
payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable 
year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the 
distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. 

146

 
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
   
 
 
 
   
 
 
 
   
 
  
The Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type 
requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable 
subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company 
for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any 
income generated by these taxable subsidiaries generally would be subject to tax at normal corporate tax rates based on its taxable income.

For the year ended December 31, 2021, the Company paid approximately $3.8 million of income tax, including excise tax, and had $7.2 million accrued, including $7.0 

million of excise tax, but unpaid tax expense as of December 31, 2021. For the year ended December 31, 2020, the Company paid approximately $2.5 million of income tax, 
including excise tax, and had $3.0 million accrued relating to unpaid excise tax expense as of the balance sheet date. For the year ended December 31, 2019, the Company paid 
approximately $1.4 million of income tax, including excise tax, and had $1.3 million accrued relating to unpaid excise tax expense as of the balance sheet date.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to 

be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a 
tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision 
for income taxes. 

Based on an analysis of the Company’s tax position, there are no uncertain tax positions that met the recognition or measurement criteria. The Company is currently not 

undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2018 - 
2020 federal tax years for the Company remain subject to examination by the Internal Revenue Service. The 2017 – 2020 state tax years for the Company remain subject to 
examination by the state taxing authorities.

7. Stockholders’ Equity

On May 6, 2019, the Company entered into an At-The-Market (“ATM”) equity distribution agreement with JMP Securities LLC (“JMP”) (the “2019 Equity 
Distribution Agreement”). The 2019 Equity Distribution Agreement provides that the Company may offer and sell up to 12.0 million shares of its common stock from time to 
time through JMP, as its sales agent. 

On July 2, 2020, the Company terminated the 2019 Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP (the “2020 

Equity Distribution Agreement”). As a result, the remaining shares that were available under the 2019 Equity Distribution Agreement are no longer available for issuance. The 
2020 Equity Distribution Agreement provides that the Company may offer and sell up to 16.5 million shares of its common stock from time to time through JMP, as its sales 
agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under 
the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market 
maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the year ended December 31, 2021, the Company sold 0.6 million shares of common stock under the 2020 Equity Distribution Agreement. For the same period, 

the Company received total accumulated net proceeds of approximately $10.6 million, including $0.2 million of offering expenses.

During the year ended December 31, 2020, the Company sold 6.3 million shares of common stock, of which 6.0 million shares and 0.3 million shares were issued under 

the 2019 Equity Distribution Agreement and the 2020 Equity Distribution Agreement, respectively. or the same period, the Company received total accumulated net proceeds 
of approximately $77.2 million, including $1.0 million of offering expenses, from these sales, of which $73.6 million, including offering expenses of $0.8 million, was received 
under the 2019 Equity Distribution Agreement, and $3.6 million, including offering expenses of $0.2 million, was received under the 2020 Equity Distribution Agreement.

The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of 

December 31, 2021 approximately 15.6 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.  

On June 17, 2019, the Company closed the June 2019 Equity Offering. The June 2019 Equity Offering generated net proceeds, before expenses, of $70.5 million, 

including the underwriting discount and commissions of $2.2 million.

147

 
  
 The Company has issued stock options for common stock subject to future issuance, of which 210,569 and 438,809 were outstanding as of December 31, 2021 and 

December 31, 2020, respectively.

8. Equity Incentive Plans 

The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key 
employees, and members of the Board.  The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-
Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018, and authorize 
us to issue up to 18.7 million shares of common stock and 300,000 shares of restricted stock under the 2018 Plan and Director Plan, respectively. Unless earlier terminated by 
the Board, the 2018 Plan and Director Plan will terminate on May 12, 2028. Outstanding awards issued under plans that precede the 2018 Plan and Director Plan remain 
outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with 
their terms. 

The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock 

and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows 
participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with 
respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the 
applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time 
of option exercise or vesting on restricted stock.

The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability 
awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the 
relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the years 
ended December 31, 2021, 2020, and 2019, the Company recognized $11.9 million, $11.1 million, and $10.5 million of stock based compensation expense in the Consolidated 
Statement of Operations, respectively.  As of  December 31, 2021 and 2020, approximately $15.8 million and $13.6 million of total unrecognized compensation costs expected 
to be recognized over the next 1.8 and 1.6 years, respectively. 

Service-Vesting Awards

The Company grants equity-based awards which have service conditions, and generally begin to vest one-third after one year after the date of grant and ratably over the 
succeeding 2 years in accordance with the individual award terms (the “Service Vesting Awards”). The grant date fair value of Service Vesting Awards granted during the years 
ended December 31, 2021, 2020, and 2019, were approximately $12.1 million, $11.2 million and $17.2 million, respectively.

The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair 

values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the three 
years ended December 31, 2021, 2020, and 2019 are summarized below:

2021

Weighted Average Grant 
Date
Fair Value per Share

Shares

Year ended, December 31,

2020

Shares

Weighted Average Grant 
Date
Fair Value per Share

2019

Weighted Average Grant 
Date
Fair Value per Share

Shares

Unvested Shares Beginning 
of Period
Granted
(1)
Vested 
Forfeited
Unvested Shares 
End of Period

989,100   $
751,074   $
(620,116 ) $
(82,210 ) $

1,037,848   $

13.69    
14.80    
13.69    
14.17    

14.51    

782,346   $
779,211   $
(543,486 ) $
(28,971 ) $

989,100   $

13.07    
12.46    
13.15    
13.82    

13.69    

1,113,403   $
1,313,759   $
(865,607 ) $
(779,209 ) $

782,346   $

13.31    
13.08    
13.26    
13.28    

13.07    

(1) With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for 
four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.   

In addition to the restricted stock equity based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the 

years ended December 31, 2021, 2020, and 2019, was approximately $144,000, $10,000 and 

148

 
 
 
 
   
 
 
 
 
   
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
$43,000, respectively. During the years ended December 31, 2021, 2020, and 2019, approximately $37,000, $28,000, and $41,000 of share-based cost due to stock option grants 
was expensed, respectively. 

Performance-Vesting Awards

The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value 

of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR 
relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that 
a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and 
generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date using a Monte-Carlo simulation 
multiplied by the target payout level and is recognized over the service period. The unvested shares as of January 1, 2019 was 1,299,757. During the year ended December 31, 
2019, 812,348 shares of Performance Awards were forfeited, which left 487,409 shares of Performance Awards unvested for each of the years ended December 31, 2021, 2020, 
and 2019, as there were no Performance Awards granted or vested during the periods ended December 31, 2021, 2020, or 2019.  For certain Performance Awards, distribution 
equivalent units (“DEUs”) will accrue in the form of additional shares, but will not be paid unless the Performance Awards to which such DEUs relate actually vest. No DEUs 
have been issued during the periods ended December 31, 2021, 2020, or 2019.

Liability Classified Awards 

The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar 

value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). The remaining maximum total potential 
value of the Liability Awards granted is $11.2 million, which assumes all performance conditions are met for each Liability award. If the performance conditions are not met, 
the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The awards are recorded as deferred compensation 
within Accounts Payable and Accrued Liabilities included on the Consolidated Statement of Assets and Liabilities.

Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after 

four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to 
attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions 
being met and recognized over the service period. As of December 31, 2021, the Company determined that the weighted average expected probability of the performance 
conditions being met within each Liability Award was 100%. The expected probability is re-evaluated each period, and may be adjusted to reflect changes in this assumption. 
These other Liability Awards vest over a three year service term. 

As of December 31, 2021, all Liability Awards are unvested and there was approximately $4.5 million of total unrecognized compensation costs expected to be 
recognized over a weighted average period of 2.2 years. For the year ended December 31, 2021, there was approximately $1.7 million of accumulated compensation expense 
related to the Liability Awards recognized in the Consolidated Statement of Operations and $5.7 million accrued within Accounts Payable and Accrued Liabilities in the 
Consolidated Statements of Assets and Liabilities. No Liability Awards vested during the periods presented.

As of December 31, 2020, all Liability Awards are unvested and there was approximately $2.0 million of total unrecognized compensation costs expected to be 
recognized over a weighted average period of 1.3 years. For the year ended December 31, 2020, there was approximately $2.7 million of accumulated compensation expense 
related to the Liability Awards recognized in the Consolidated Statement of Operations and $4.0 accrued within Accounts Payable and Accrued Liabilities in the Consolidated 
Statements of Assets and Liabilities. No Liability Awards vested during the periods presented.

149

 
  
9. Earnings Per Share 

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: 

(in thousands, except per share data)
Numerator

Net increase in net assets resulting from operations
Less: Distributions declared-common and restricted shares
Undistributed earnings
Undistributed earnings-common shares
Add: Distributions declared-common shares

Numerator for basic and diluted change in net assets per common share

Denominator
Basic weighted average common shares outstanding
Incremental shares from assumed conversion of 2022 Convertible Notes
Common shares issuable
Weighted average common shares outstanding assuming dilution

Change in net assets per common share
Basic
Diluted

2021

Year Ended December 31,
2020

2019

174,155     $
(179,575 )  
(5,420 )  
(5,420 )  
177,864    
172,444     $

114,742    
512    
701    
115,955    

227,261     $
(155,761 )  
71,500    
70,995    
154,658    
225,653     $

111,985    
—    
282    
112,267    

1.50     $
1.49     $

2.02     $
2.01     $

173,598  
(134,455 )
39,143  
39,062  
134,174  
173,236  

101,132  
—  
437  
101,569  

1.71  
1.71  

  $

  $

  $
  $

In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating 
securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per 
share. 

As disclosed in “Note 5 – Debt”, the Company has irrevocably elected combination settlement for the 2022 Convertible Notes. Therefore in calculating the dilutive 
impact of the 2022 Convertible Notes, only the portion expected to be settled in stock has been included in the calculations of diluted shares outstanding for the for the year 
ended December 31, 2021. For the years ended  December 31, 2020, and 2019, the effect of the 2022 Convertible Notes under the treasury stock method was anti-dilutive and, 
accordingly, was excluded from the calculation of diluted earnings per share. 

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the years ended 

December 31, 2021, 2020 and 2019, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the 
periods, are as follows: 

Anti-dilutive Securities

2021

Year Ended December 31,
2020

2019

2022 Convertible Notes
Unvested common stock options
Unvested restricted stock units
Unvested restricted stock awards
Unvested Retention PSUs

—    
690    
20    
861    
—    

5,543,097    
66,578    
—    
10,049    
—    

3,445,622  
24,448  
—  
—  
—  

As of December 31, 2021 and 2020, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common 

stock entitles the holder to one vote. 

150

 
 
 
 
 
   
   
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
   
 
 
 
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
   
 
 
 
 
   
 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10. Financial Highlights 

Following is a schedule of financial highlights for the five years ended December 31, 2021, 2020, 2019, 2018, and 2017:

Per share data 
Net asset value at beginning of period

(1)
:

Net investment income
Net realized gain (loss)
Net unrealized appreciation (depreciation)
Total from investment operations
Net increase (decrease) in net assets from capital share transactions 
Distributions of net investment income 
Distributions of capital gains 
Stock-based compensation expense included in investment income 

(6)

(6)

(1)

(2)

Net asset value at end of period

(3)

Ratios and supplemental data:
Per share market value at end of period
Total return 
Shares outstanding at end of period
Weighted average number of common shares outstanding
Net assets at end of period
Ratio of total expense to average net assets 
Ratio of net investment income before investment gains and losses to average net assets 
Portfolio turnover rate 
Weighted average debt outstanding
Weighted average debt per common share

(5)

(4)

(4)

2021

2020

Year Ended December 31,
2019

2018

2017

  $

  $

  $

  $

  $
  $

11.26  
1.29  
0.18  
0.03  
1.50  
(0.08 )
(1.06 )
(0.49 )
0.09  
11.22  

  $

  $

10.55  
1.39  
(0.50 )
1.13  
2.02  
0.01  
(1.03 )
(0.36 )
0.07  
11.26  

  $

  $

9.90  
1.41  
0.16  
0.14  
1.71  
0.20  
(1.15 )
(0.18 )
0.07  
10.55  

  $

  $

  $

9.96  
1.20  
(0.12 )
(0.23 )
0.85  
0.23  
(1.26 )

—    

0.12  
9.90  

  $

16.59  
25.62 %  

  $

116,619  
114,742  
1,308,547  

  $

9.86 %  
11.28 %  
51.58 %  

14.42  
14.31 %  

  $

114,726  
111,985  
1,291,704  

  $

11.30 %  
13.64 %  
32.38 %  

14.02  
39.36 %  

  $

107,364  
101,132  
1,133,049  

  $

11.95 %  
13.74 %  
31.30 %  

11.05  
(7.56 %)

  $

96,501  
90,929  
955,444  

  $

10.73 %  
11.78 %  
38.76 %  

1,248,177  
10.88  

  $
  $

1,309,903  
11.70  

  $
  $

1,177,379  
11.64  

  $
  $

826,931  
9.09  

  $
  $

9.90  
1.17  
(0.32 )
0.11  
0.96  
0.26  
(1.07 )
(0.18 )
0.09  
9.96  

13.12  
1.47 %

84,424  
82,519  
840,967  

11.37 %
11.61 %
49.03 %

784,455  
9.51  

(1)

(2)

(3)

(4)

(5)

(6)

All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the 
common shares outstanding as of the relevant balance sheet date.

Stock option expense is a non-cash expense that has no effect on net asset value. Pursuant to ASC Topic 718, net investment income includes the expense associated with the granting of stock options which is 
offset by a corresponding increase in paid-in capital. 

The total return for the years ended December 31, 2021, 2020, 2019, 2018, and 2017 equals to the change in the ending market value over the beginning of the period price per share plus distributions paid per 
share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales 
load that must be paid by investors.

The ratios are calculated based on weighted average net assets for the relevant period and are annualized.

The portfolio turnover rate for the years ended December 31, 2021, 2020, 2019, 2018, and 2017 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average 
investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

Includes distributions on unvested restricted stock awards. 

151

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
11. Commitments and Contingencies 

The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio 
companies. A portion of these unfunded contractual commitments as of December 31, 2021 are dependent upon the portfolio company reaching certain milestones before the 
debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow 
the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events 
that affect the financial condition or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual 
commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are 
available at the request of the portfolio company and unencumbered by future or unachieved milestones.

As of  December 31, 2021 and December 31, 2020, the Company had approximately $286.8 million and $179.8 million, respectively, of unfunded commitments, 

including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. These amounts 
also exclude unfunded commitments related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in "Note -13 
Related Party Transactions".

The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially 

consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations 
imbedded in the borrowing agreements.

152

 
 
  
As of December 31, 2021  and December 31, 2020, the Company’s unfunded contractual commitments available at the request of the portfolio company, including 

undrawn revolving facilities, and unencumbered by milestones were as follows:

(in thousands)
Portfolio Company
Debt Investments:
Phathom Pharmaceuticals, Inc.
Skydio, Inc.
Syndax Pharmaceutics Inc.
Blue Spring Peditrics, Inc.
Brain Corporation
G1 Therapeutics, Inc.
Dashlane, Inc.
Equality Health, LLC
RVShare, LLC
Carbon Health Technologies, Inc.
Bicycle Therapeutics PLC
Demandbase, Inc.
Better Therapeutics, Inc.
Ceros, LLC
Yipit, LLC
Logicworks
Khoros (p.k.a Lithium Technologies)
ThreatConnect, Inc.
3GTMS, LLC.
Ikon Science Limited
Agilence, Inc.
Cybermaxx Intermediate Holdings, Inc.
Enmark Systems
Mobile Solutions Services
ShadowDragon, LLC
Gryphon Networks Corp.
ePayPolicy Holdings, LLC
Cytracom Holdings LLC
Pineapple Energy LLC
SingleStore, Inc. (p.k.a. memsql, Inc.)
Udacity, Inc.
Pollen, Inc.
Clarabridge, Inc.
Axsome Therapeutics, Inc.
Geron Corporation
Varsity Tutors LLC
CloudBolt Software Inc.
Nuvolo Technologies Corporation
Reltio, Inc.
Optimizely Mergerco, Inc.
Codiak Biosciences, Inc.
Businessolver.com, Inc.
The CM Group LLC
Velocity Clinical Research, Inc.

Total Unfunded Debt Commitments:

Investment Funds & Vehicles:
Forbion Growth Opportunities Fund I C.V.

Total Unfunded Commitments in Investment Funds & Vehicles:

Unfunded Commitments 

(1)

 as of
December 31, 2020

December 31, 2021

$

$

43,250    
37,500    
30,000    
30,000    
20,000    
19,375    
19,300    
17,500    
13,500    
11,625    
10,000    
9,375    
4,000    
3,845    
2,250    
2,000    
1,812    
1,600    
1,583    
1,050    
800    
471    
457    
424    
333    
268    
250    
225    
120    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
—    
282,913    

3,839    
3,839    

Total Unfunded Commitments

  $

286,752    

$

—  
—  
—  
—  
—  
10,000  
10,000  
—  
—  
—  
15,000  
—  
—  
—  
425  
2,000  
—  
1,800  
5,036  
1,050  
—  
—  
—  
848  
—  
—  
250  
250  
—  
25,000  
15,000  
13,000  
7,500  
10,000  
6,500  
5,210  
5,000  
5,000  
5,000  
2,500  
20,000  
6,375  
750  
750  
174,244  

5,527  
5,527  

179,771  

(1)

For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments 
which are unavailable due to the borrower having not met certain milestones. This amount also excludes $34.9 million of unfunded commitments as of December 31, 2021, to portfolio companies related to loans 
assigned to or directly committed by the Adviser Funds as described in "Note -13 Related Party Transactions". There were no unfunded commitments related to the Adviser Funds as of December 31, 2020. For 
investment funds and vehicles, amount represents uncalled capital commitments in a private equity fund.

153

 
  
 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
   
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
  
The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type:

(in thousands)
Unfunded Debt Commitments:
Expiring during:

2022
2023
2024
2025
2026

Total Unfunded Debt Commitments

Unfunded Commitments in Investment Funds & Vehicles:
Expiring during:

2030

Total Unfunded Commitments in Investment Funds & Vehicles

Total Unfunded Commitments

December 31, 2021

December 31, 2020

  $

  $

$

199,681    
43,675    
25,800    
2,232    
11,525    
282,913    

3,839    
3,839    
286,752    

$

129,710  
15,000  
6,375  
14,892  
8,267  
174,244  

5,527  
5,527  
179,771  

The following tables provide the Company’s contractual obligations as of December 31, 2021 and December 31, 2020 include: 

As of December 31, 2021:
Contractual Obligations 
Debt 
Lease and License Obligations 

(2)(3)

(1)

(4)

Total

As of December 31, 2020:
Contractual Obligations 
Debt 
Lease and License Obligations 

(5)(3)

(1)

(4)

Total

(1)
(2)

(3)
(4)
(5)

Total

Less than 1 year

Payments due by period (in thousands)
1 - 3 years

3 - 5 years

After 5 years

1,250,425     $
8,283    
1,258,708     $

380,000     $
3,120    
383,120     $

105,000     $
2,958    
107,958     $

574,925     $
1,427    
576,352     $

190,500  
778  
191,278  

Total

Less than 1 year

Payments due by period (in thousands)
1 - 3 years

3 - 5 years

After 5 years

1,299,988     $
10,581    
1,310,569     $

25,000     $
3,031    
28,031     $

454,000     $
5,345    
459,345     $

300,000     $
1,427    
301,427     $

520,988  
778  
521,766  

  $

  $

  $

  $

Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in an investment fund. 
Includes $150.5 million in principal outstanding under the SBA Debentures, $150.0 million of the 2022 Notes, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $70.0 million of the 
June 2025 Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes, and $230.0 million of the 2022 
Convertible Notes as of  December 31, 2021. There was $29.9 million outstanding under the SMBC Facility and no amounts outstanding under the Union Facility as of December 31, 2021.
Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”.
Facility leases and licenses including short-term leases.
Includes $99.0 million in principal outstanding under the SBA Debentures, $150.0 million of the 2022 Notes, $105.0 million of the July 2024 Notes, $50.0 million of the February 2025 Notes, $75.0 million of the 
April 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the March 2026 A Notes, $40.0 million of the 2033 Notes, $181.0 million of the 2027 Asset-Backed Notes, $250.0 million of the 2028 
Asset-Backed Notes, and $230.0 million of the 2022 Convertible Notes as of December 31, 2020. There was no outstanding debt under the Wells Facility and Union Facility as of December 31, 2020.

Certain premises are leased or licensed under agreements which expire at various dates through December 2028. Total rent expense, including short-term leases, 
amounted to approximately $3.1 million, $3.1 million, and $2.7 million, during the years ended December 31, 2021, 2020, and 2019, respectively. The Company recognizes an 
operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a 
straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company 
considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is 
appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be 
utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.

154

 
 
   
 
 
 
   
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
  
 
 
 
 
   
   
 
     
 
 
 
 
 
   
 
 
 
 
 
 
 
   
   
   
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
   
 
 
 
 
 
   
 
   
 
   
 
   
 
 
 
 
 
 
 
   
   
   
 
 
 
 
 
 
 
 
 
  
The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to 

operating leases as of December 31, 2021 and 2020:

(in thousands)
Total operating lease cost
Cash paid for amounts included in the measurement of lease liabilities
ROU assets obtained in exchange for lease liabilities

Weighted-average remaining lease term (in years)
Weighted-average discount rate

Year Ended December 31, 2021

Year Ended December 31, 2020

$
$
$

2,900    
2,322    
—    

$
$
$

As of December 31, 2021

As of December 31, 2020

4.30  
4.81 %  

2,951  
2,795  
—  

4.10  
5.44 %

The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of December 

31, 2021:

(in thousands)
2022
2023
2024
2025
Thereafter

Total lease payments
Less: imputed interest

Total operating lease liability

$

$

As of December 31, 2021

2,966  
2,305  
653  
693  
1,512  
8,129  
(747 )
7,382  

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties 
may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at 
this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; 
however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in 
any future reporting period.

12. Indemnification 

The Company has entered into indemnification agreements with its directors and executive officers. The indemnification agreements are intended to provide its 

directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that the Company 
shall indemnify the director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her 
corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted 
by Maryland law and the 1940 Act. 

The Company and its executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by the Company to the 

maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act. 

13. Related Party Transactions

As disclosed in "Note 2 - Summary of Significant Accounting Policies", the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair 

value. Refer to "Note 4 – Investments" for information related to income, gains and losses recognized related to the Company’s investment. 

In March and July 2021, the Adviser Subsidiary entered into investment management agreements with its privately-offered Adviser Funds, and it receives management 

fees based on the assets under management of the Adviser Funds and may receive incentive fees based on the performance of the Adviser Funds. Additionally, the Company 
entered into a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, pursuant to which the Adviser Subsidiary utilizes human capital resources 
(including administrative functions) and other resources and infrastructure (including office space and technology) of the Company. Under the terms of the Sharing Agreement, 
the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under 
management depending on the nature of the expense. The Company’s total expenses for the year ended December 31, 2021 are net of expenses allocated to the Adviser 
Subsidiary of $5.0 million. As of December 31, 2021, the Adviser Subsidiary owed the Company $0.1 million related to expenses allocated to the Adviser Subsidiary. As of 
and for the year ended December 31, 2020, no amounts were due to or outstanding from the Adviser Subsidiary and the Company did not allocate any expenses to the Adviser 
Subsidiary.  

155

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance 

with the Company’s allocation policy. During the year ended December 31, 2021, $374.5 million of all investment commitments of the Company and the Adviser Subsidiary 
were assigned to or directly committed by the Adviser Funds. During the year ended December 31, 2021, fundings of $226.4 million were assigned to, directly originated, or 
funded by the Adviser Funds. The Company received $125.2 million from the Adviser Funds relating to the assigned investments during the year ended December 31, 2021.  
No investments were assigned to, directly originated, or funded by the Adviser Funds, nor were any amounts received in the year ended December 31, 2020. 

14. Subsequent Events

Distribution Declaration

 On February 16, 2022, the Board declared (i) a fourth quarter cash distribution of $0.33 per share and (ii) a supplemental cash distribution of $0.60 per share, to be paid 

in four quarterly distributions of $0.15 per share beginning with the fourth quarter of 2021 (the "$0.60 Supplemental Cash Distribution"). The fourth quarter cash distribution 
and the first quarterly distribution of the $0.60 Supplemental Cash Distribution (a total of $0.48 per share) will be paid on March 16, 2022 to stockholders of record as of March 
9, 2022. 

Previously on April 21, 2021, the Board declared a supplemental cash distribution of $0.28 per share, to be paid in four quarterly distributions of $0.07 per share 
beginning with the first quarter 2021 (the "$0.28 Supplemental Cash Distribution"). The $0.15 payable as the first quarterly distribution of the $0.60 Supplemental Cash 
Distribution includes $0.07 per share as the fourth and final distribution of the $0.28 Supplemental Cash Distribution. With the declaration of the first quarterly distribution of 
the $0.60 Supplemental Cash Distribution, the Board has declared all of the $0.28 Supplemental Cash Distribution. 

Notes Issuance 

On January 20, 2022, the Company issued $350.0 million in aggregate principal bearing interest of 3.375% due January 2027 (the "January 2027 Notes"). The 

Company used the proceeds to redeem the 2022 Convertible Notes and 2022 Notes in February 2022.

Note Redemptions

On February 1, 2022, the Company fully repaid the aggregate outstanding $230.0 million principal, $5.0 million of accrued interest and fees, and issued 981,169 shares 

related to noteholders who elected to convert pursuant to the redemption terms of the 2022 Convertible Notes indenture. 

On January 21, 2022, the Company gave notice to the trustee of the 2022 Notes informing the noteholders of the Company's election to redeem the notes in accordance 

with the terms of the 2022 Notes indenture agreement. On February 22, 2022, pursuant to the redemption terms of the 2025 Notes indenture, the Company fully repaid the 
aggregate outstanding $150.0 million of principal and $2.3 million of accrued interest.  In addition, the Company paid $3.3 million of prepayment premium fees, which 
together with the accelerated recognition of $0.3 million of debt issuance costs will be recognized as a realized loss on extinguishment of the debt.

Equity Offering  

During January 2022, through its ATM program, the Company sold approximately 1.5 million shares of common stock for $25.8 million of net proceeds. 

156

 
 
  
Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 

Not Applicable. 

Item 9A. Controls and Procedures 

1. Disclosure Controls and Procedures 

The Company’s chief executive and chief financial officers, under the supervision and with the participation of the Company’s management, conducted an evaluation of 

the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. As of the end of the period covered by this Annual 
Report, the Company’s chief executive and chief financial officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that 
information required to be disclosed by the Company in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized, and reported 
within the time periods specified in SEC rules and forms, and that information required to be disclosed by the Company in the reports that the Company files or submits under 
the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s chief executive and chief financial officers, as appropriate to 
allow timely decisions regarding required disclosure. 

2. Internal Control Over Financial Reporting 

a. Management’s Annual Report on Internal Control over Financial Reporting 

The Company is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal 

control over financial reporting. As defined by the SEC, internal control over financial reporting is a process designed under the supervision of the Company’s principal 
executive and principal financial and accounting officer, approved and monitored by the Company’s Board, and implemented by management and other personnel, to provide 
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. 

The Company’s internal control over financial reporting is supported by written policies and procedures, that (1) pertain to the maintenance of records that, in 

reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (2) provide reasonable assurance that transactions are recorded as 
necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of the Company are being made only in accordance 
with authorizations of the Company’s management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, 
use or disposition of the Company’s assets that could have a material effect on the financial statements. 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of 

effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies 
or procedures may deteriorate. 

Management of the Company conducted an assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2021 based 

on criteria established in Internal Control— Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("the COSO 
Framework"). Based on this assessment, management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2021. 

The effectiveness of the Company’s internal control over financial reporting as of December 31, 2021 has been audited by PricewaterhouseCoopers LLP, an 
independent registered public accounting firm who also audited the Company’s consolidated financial statements, as stated in their report, which is included in this Annual 
Report on Form 10K. 

Changes in Internal Control over Financial Reporting in 2021 

There have been no changes in the Company’s internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, which 

occurred during the Company’s most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control 
over financial reporting. 

157

 
  
Item 9B. Other Information 

The following tables are being provided to update, as of December 31, 2021, certain information in the Company’s registration statement on Form N-2 (File No. 333-

261732) filed with the SEC on December 17, 2021.

Fees and Expenses

The following table is intended to assist you in understanding the various costs and expenses that an investor in our common stock will bear directly or indirectly. 

However, we caution you that some of the percentages indicated in the table below are estimates and may vary. The footnotes to the fee table state which items are estimates. 
Except where the context suggests otherwise, whenever this prospectus contains a reference to fees or expenses paid by “you” or “us” or that “we” will pay fees or expenses, 
stockholders will indirectly bear such fees or expenses as investors in Hercules Capital, Inc.

Stockholder Transaction Expenses (as a percentage of the public offering price):
Sales load (as a percentage of offering price)
Offering expenses
Dividend reinvestment plan fees
Total stockholder transaction expenses (as a percentage of the public offering price)

(1)

Annual Expenses (as a percentage of net assets attributable to common stock):
Operating expenses
Interest and fees paid in connection with borrowed funds
Acquired fund fees and expenses
Total annual expenses

(5)

—  %  
—  %
—  %
—  %

(2)

(3)

(4)

5.11  %
4.75  %
0.01  %
9.87  %

(6)(7)

(8)

(10)

(9)

(1)
(2)
(3)

In the event that our securities are sold to or through underwriters, a corresponding prospectus supplement to the Prospectus will disclose the applicable sales load.
In the event that we conduct an offering of our securities, a corresponding prospectus supplement to this prospectus will disclose the estimated offering expenses.
The expenses associated with the administration of our dividend reinvestment plan are included in “Operating expenses.” We pay all brokerage commissions incurred with respect to open market purchases, if any, 
made by the administrator under the plan. For more details about the plan, see “Dividend Reinvestment Plan.”
Total stockholder transaction expenses may include sales load and will be disclosed in a future prospectus supplement, if any.
“Net assets attributable to common stock” equals the weighted average net assets for the year ended December 31, 2021, which is approximately $1,329.2 million.
“Operating expenses” represent our actual operating expenses incurred for the twelve months ended December 31, 2021.

(4)
(5)
(6)
(7) We do not have an investment adviser and are internally managed by our executive officers under the supervision of our Board. As a result, we do not pay investment advisory fees, but instead we pay the operating 

costs associated with employing investment management professionals.
“Interest and fees paid in connection with borrowed funds” represent our interest, fees, and credit facility expenses incurred for the year ended December 31, 2021.
“Total annual expenses” is the sum of “Operating expenses”, “Interest and fees paid in connection with borrowed funds”, and "Acquired fund fees and expenses". “Total annual expenses” is presented as a 
percentage of weighted average net assets attributable to common stockholders, because the holders of shares of our common stock (and not the holders of our debt securities or preferred stock, if any) bear all of 
our fees and expenses, including the fees and expenses of our wholly-owned consolidated subsidiaries, all of which are included in this fee table presentation.
“Acquired fund fees and expenses” represent the estimated indirect expense incurred due to investments in other investment companies and private funds.

(8)
(9)

(10)

158

 
 
 
 
  
 
  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
  
Senior Securities

Information about our senior securities is shown in the following table for the periods as of December 31, 2021, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 
and 2011 which is derived from our audited financial statements for these periods, which have been audited by PricewaterhouseCoopers LLP, our independent registered public 
accounting firm. The “N/A” indicates information that the SEC expressly does not require to be disclosed for certain types of senior securities.

(4)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

(7)

Class and Year
Securitized Credit Facility with Wells Fargo Capital Finance
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
Securitized Credit Facility with Union Bank, NA
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
Securitized Credit Facility with SMBC
December 31, 2021
Small Business Administration Debentures (HT II)
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
Small Business Administration Debentures (HT III)
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
Small Business Administration Debentures (HC IV)
December 31, 2021
2016 Convertible Notes
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
April 2019 Notes
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015

(5)

(6)

Total Amount
Outstanding
Exclusive of
Treasury
Securities 

(1)

Asset Coverage
per Unit

 (2)

Average
Market
Value
per Unit

(3)

10,186,830   $
—    
—    
—    
50,000,000   $
5,015,620   $
—    
13,106,582   $
—    
—    
—    

—    
—    
—    
—    
—    
—    
—    
39,849,010   $
103,918,736   $
—    
—    

29,924,726   $

125,000,000   $
76,000,000   $
76,000,000   $
41,200,000   $
41,200,000   $
41,200,000   $
41,200,000   $
—    

100,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
149,000,000   $
99,000,000   $
—    

150,500,000   $

75,000,000   $
75,000,000   $
75,000,000   $
17,674,000   $
17,604,000   $
—    

84,489,500   $
84,489,500   $
84,489,500   $
64,489,500   $

73,369    
—    
—    
—    
26,352    
290,234    
—    
147,497    
—    
—    
—    

—    
—    
—    
—    
—    
—    
—    
48,513    
23,423    
—    
—    

85,479    

5,979    
14,786    
16,075    
31,535    
31,981    
35,333    
39,814    
—    

7,474    
7,542    
8,199    
8,720    
8,843    
9,770    
11,009    
12,974    
16,336    
26,168    
—    

16,996    

10,623    
15,731    
16,847    
74,905    
74,847    
—    

13,300    
14,460    
15,377    
20,431    

N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  

N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  

N/A  

N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  

N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  

N/A  

885  
1,038  
1,403  
1,290  
1,110  
N/A  

986  
1,021  
1,023  
1,017  

$
$
$
$
$

$
$
$
$

$

$
$

$

$
$

$

$
$
$
$
$
$
$

$
$
$
$
$
$
$
$
$
$

$

$
$
$
$
$

$
$
$
$

159

 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
   
 
 
 
   
 
 
   
 
 
   
   
   
 
 
 
 
 
 
 
 
   
   
   
 
 
 
 
 
 
 
 
 
 
   
   
   
 
   
   
   
 
 
   
   
   
 
 
   
   
   
 
   
   
   
 
 
   
   
   
 
  
December 31, 2016
December 31, 2017
September 2019 Notes
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
2022 Notes
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
2024 Notes
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
December 31, 2019
2025 Notes
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
2033 Notes
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
July 2024 Notes
December 31, 2019
December 31, 2020
December 31, 2021
February 2025 Notes
December 31, 2020
December 31, 2021
June 2025 Notes
December 31, 2020
December 31, 2021
March 2026 A Notes
December 31, 2020
December 31, 2021
March 2026 B Notes
December 31, 2021
September 2026 Notes
December 31, 2021
2017 Asset-Backed Notes
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
2021 Asset-Backed Notes
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
2027 Asset-Backed Notes
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021
2028 Asset-Backed Notes
December 31, 2019
December 31, 2020
December 31, 2021
2022 Convertible Notes
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020

64,489,500   $
—    

85,875,000   $
85,875,000   $
85,875,000   $
45,875,000   $
45,875,000   $
—    

150,000,000   $
150,000,000   $
150,000,000   $
150,000,000   $
150,000,000   $

103,000,000   $
103,000,000   $
252,873,175   $
183,509,600   $
83,509,600   $
—    

75,000,000   $
75,000,000   $
75,000,000   $
—   $

40,000,000   $
40,000,000   $
40,000,000   $
40,000,000   $

105,000,000   $
105,000,000   $
105,000,000   $

50,000,000   $
50,000,000   $

70,000,000   $
70,000,000   $

50,000,000   $
50,000,000   $

50,000,000   $

325,000,000   $

129,300,000   $
89,556,972   $
16,049,144   $
—    

129,300,000   $
129,300,000   $
109,205,263   $
49,152,504   $
—    

200,000,000   $
200,000,000   $
180,988,022   $
—   $

250,000,000   $
250,000,000   $
—   $

230,000,000   $
230,000,000   $
230,000,000   $
230,000,000   $

22,573    
—    

13,086    
14,227    
15,129    
28,722    
31,732    
—    

10,935    
12,888    
16,227    
17,271    
17,053    

12,614    
12,792    
5,757    
8,939    
23,149    
—    

25,776    
32,454    
34,541    
—    

48,330    
60,851    
64,765    
63,948    

23,181    
24,672    
24,361    

51,812    
51,159    

37,009    
36,542    

51,812    
51,159    

51,159    

7,871    

8,691    
13,642    
80,953    
—    

10,048    
10,190    
13,330    
33,372    
—    

9,666    
12,170    
14,314    
—    

9,736    
10,362    
—    

7,132    
8,405    
10,583    
11,264    

$

$
$
$
$
$

$
$
$
$
$

$
$
$
$
$

$
$
$

$
$
$
$

$
$
$

$
$
$
$

$
$
$

$
$

$
$
$
$

1,022  
N/A  

1,003  
1,016  
1,026  
1,009  
1,023  
N/A  

1,014  
976  
1,008  
1,017  
1,019  

1,010  
1,014  
1,016  
1,025  
1,011  
N/A  

962  
1,032  
1,020  
N/A  

934  
1,054  
1,072  
1,067  

N/A  
N/A  
N/A  

N/A  
N/A  

N/A  
N/A  

N/A  
N/A  

N/A  

N/A  

1,000  
1,004  
1,375  
N/A  

1,000  
996  
1,002  
1,001  
N/A  

1,006  
1,004  
1,001  
N/A  

1,004  
1,002  
N/A  

1,028  
946  
1,021  
1,027  

$

$
$
$
$
$

$
$
$
$
$

$
$
$
$
$

$
$
$
$

$
$
$
$

$
$
$

$
$

$
$

$
$

$

$

$
$
$

$
$
$
$

$
$
$
$

$
$
$

$
$
$
$

160

 
 
 
   
   
   
 
 
   
   
   
 
   
   
   
 
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
   
   
   
 
 
   
   
   
 
 
   
   
   
 
   
   
   
 
   
   
   
 
  
(8)

December 31, 2021
Total Senior Securities
December 31, 2011
December 31, 2012
December 31, 2013
December 31, 2014
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
December 31, 2019
December 31, 2020
December 31, 2021

$

$
$
$
$
$
$
$
$
$
$
$

230,000,000   $

11,121    

$

1,026  

310,186,830   $
599,664,500   $
559,921,472   $
626,587,644   $
600,468,500   $
667,658,558   $
802,862,104   $
980,465,192   $
1,302,918,736   $
1,299,988,022   $
1,250,424,726   $

2,409    
1,874    
2,182    
2,073    
2,194    
2,180    
2,043    
1,972    
1,868    
1,993    
2,046    

N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  
N/A  

(1)
(2)

(3)
(4)

(5)

(6)

(7)
(8)

Total amount of each class of senior securities outstanding at the end of the period presented.
The asset coverage ratio for a class of senior securities representing indebtedness is calculated as our consolidated total assets, less all liabilities and indebtedness not represented by senior securities, including 
senior securities not subject to asset coverage requirements under the 1940 Act due to exemptive relief from the SEC, divided by senior securities representing indebtedness. This asset coverage ratio is multiplied 
by $1,000 to determine the Asset Coverage per Unit.
Not applicable because senior securities are not registered for public trading.
Issued by Hercules Technology II, L.P. ("HT II"), one of our prior SBIC subsidiaries, to the Small Business Association ("SBA"). On July 13, 2018, we completed repayment of the remaining outstanding HT II 
debentures and subsequently surrendered the SBA license with respect to HT II. These categories of senior securities were not subject to the asset coverage requirements of the 1940 Act as a result of exemptive 
relief granted to us by the SEC.
Issued by HT III, one of our prior SBIC subsidiaries, to the SBA. On May 5, 2021, we completed repayment of the remaining outstanding HT III debentures and subsequently surrendered the SBA license with 
respect to HT III. These categories of senior securities were not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC.
Issued by HC IV, one of our SBIC subsidiaries, to the SBA. These categories of senior securities are not subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by 
the SEC.
The Company’s Wells Facility and Union Bank Facility had no borrowings outstanding during the periods noted above.
The total senior securities and Asset Coverage per Unit shown for those securities do not represent the asset coverage ratio requirement under the 1940 Act, because the presentation includes senior securities not 
subject to the asset coverage requirements of the 1940 Act as a result of exemptive relief granted to us by the SEC. As of December 31, 2021, our asset coverage ratio under our regulatory requirements as a 
business development company was 218.9% excluding our SBA debentures as a result of our exemptive order from the SEC which allows us to exclude all SBA leverage from our asset coverage ratio.

161

 
 
   
   
   
 
 
 
  
Item 10.  Directors, Executive Officers and Corporate Governance 

PART III

Information in response to this Item is incorporated herein by reference to the information provided in the Company’s definitive Proxy Statement for the Company’s 

2022 Annual Meeting of Stockholders, or the 2022 Proxy Statement, to be filed with the SEC pursuant to Regulation 14A under the Exchange Act under the headings 
“Proposal I: Election Of Directors,” “Information About Executive Officers Who Are Not Directors” and “Certain Relationships And Transactions.” 

The Company has adopted a code of business conduct and ethics that applies to directors, officers and employees. The code of business conduct and ethics is available 
on the Company’s website at http//www.htgc.com. The Company will report any amendments to or waivers of a required provision of the code of business conduct and ethics 
on the Company’s website or in a Form 8-K. 

Item 11.  Executive Compensation 

The information with respect to compensation of executives and directors is contained under the caption “Executive Compensation” in the Company’s 2022 Proxy 

Statement and is incorporated in this Annual Report by reference in response to this item. 

Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 

The information with respect to security ownership of certain beneficial owners and management is contained under the captions “Security Ownership of Certain 
Beneficial Owners and Management” and “Executive Compensation” in the Company’s 2022 Proxy Statement and is incorporated in this Annual Report by reference in 
response to this item. 

Item 13.  Certain Relationships and Related Transactions and Director Independence 

The information with respect to certain relationships and related transactions is contained under the caption “Certain Relationships and Transactions” and the caption 

“Proposal I: Election of Directors” in the Company’s 2022 Proxy Statement and is incorporated in this Annual Report by reference in response to this item. 

Item 14.  Principal Accountant Fees and Services 

The information with respect to principal accountant fees and services is contained under the captions “Principal Accountant Fees and Services” and “Proposal III: 

Ratification of Selection of Independent Registered Public Accountants” in the Company’s 2022 Proxy Statement and is incorporated in this Annual Report by reference to this 
item.

162

 
  
Item 15.  Exhibits and Financial Statement Schedules 

1.

  Financial Statements

PART IV

  The following financial statements of the “Company” are filed herewith:

  AUDITED FINANCIAL STATEMENTS
  Consolidated Statements of Assets and Liabilities as of December 31, 2021 and December 31, 2020
  Consolidated Statements of Operations for the three years ended December 31, 2021 
  Consolidated Statements of Changes in Net Assets for the three years ended December 31, 2021 
  Consolidated Statements of Cash Flows for the three years ended December 31, 2021 
  Consolidated Schedule of Investments as of December 31, 2021 
  Consolidated Schedule of Investments as of December 31, 2020
  Notes to Consolidated Financial Statements 

2.

  The following financial statement schedule is filed herewith:

  Consolidated Schedule of Investments In and Advances to Affiliates as of December 31, 2021
  Consolidated Schedule of Investments In and Advances to Affiliates as of December 31, 2020

3.

  Exhibits required to be filed by Item 601 of Regulation S-K.

163

92
94
95
96
97
108
119

164
165

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
Item 16.  Form 10-K Summary

Not applicable. 

HERCULES CAPITAL, INC.

CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of and for the year ended December 31, 2021
(in thousands)

Schedule 12-14

Control Investments

Portfolio Company

Investment 

(1)

Amount of 
Interest and 
Fees Credited 
(2)
to Income 

Realized Gain 
(Loss)

Fair Value as of 
December 31, 
2020

Gross 
Additions 

(3)

Gross 
Reductions 

(4)

Net Change in 
Unrealized 
Appreciation/ 
(Depreciation)

Fair Value as of 
December 31, 
2021

Majority Owned Control Investments

Coronado Aesthetics, LLC

 (11)

Gibraltar Business Capital, LLC 

(5)

Hercules Adviser LLC 

(6)

 Total Majority Owned Control Investments

Other Control Investments

Tectura Corporation

(7)

Total Other Control Investments

Total Control Investments

Affiliate Investments

Black Crow AI, Inc. 

(8)

Pineapple Energy LLC 

(9)

Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) 

(10)

Total Affiliate Investments

Total Control and Affiliate Investments

  Preferred Stock
  Common Stock
Unsecured Debt
Preferred Stock
Common Stock
Unsecured Debt
Member Units

Senior Debt
Preferred Stock
Common Stock

Preferred Stock
Convertible Debt
Senior Debt
Common Stock
Senior Debt
Common Stock

  $

$

$

$
$

$

$
$

—  
—  
3,232    
—    
—    
141    
—    
3,373    

695    
—    
—    
695    
4,068    

—    
—    
10    
—    
—    
—    
10    
4,078    

  $

$

$

$
$

$

$
$

—  
—  
—    
—    
—    
—    
—    
—    

—    
—    
—    
—    
—    

—    
—    
—    
—    
(641 )  
(61,502 )  
(62,143 )  
(62,143 )  

  $

$

$

$
$

$

$
$

—  
—  
14,970    
31,554    
2,276    
—    
—    
48,800    

8,600    
—    
—    
8,600    
57,400    

—    
—    
7,500    
840    
—    
—    
8,340    
65,740    

  $

$

$

$
$

$

$
$

250  
—  
9,646   
—   
—   
8,850   
35   
18,781   

—   
—   
—   
—   
18,781   

1,000   
2,208   
280   
—   
—   
—   
3,488   
22,269   

$

$

$
$

$

$
$

—  
—  
—    
—    
—    
—    
—    
—    

—    
—    
—    
—    
—    

—    
(3,993 )  
—    
—    
(681 )  
(61,502 )  
(66,176 )  
(66,176 )  

 $

$

$

$
$

$

$
$

 $

250  
65  

(1,404 )  
(12,161 )  
(1,051 )  
—    
11,955    
(2,346 )  

(331 )  
—    
—    
(331 )  
(2,677 )  

120    
1,785    
(33 )  
(249 )  
681    
61,502    
63,806    
61,129    

$

$

$
$

$

$
$

500  
65  
23,212  
19,393  
1,225  
8,850  
11,990  
65,235  

8,269  
—  
—  
8,269  
73,504  

1,120  
—  
7,747  
591  
—  
—  
9,458  
82,962  

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

Stock and warrants are generally non-income producing and restricted.

Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of 
one or more existing securities for one or more new securities. 

Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross 
reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.

As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest.

Hercules Adviser LLC is a wholly owned subsidiary providing investment management and other services to the Adviser Funds and other External Parties.

As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In 
May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.

As of March 23, 2021, the Company’s investments in Black Crow AI, Inc. became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the voting securities of the 
portfolio company. 

As of December 11, 2020, the Company’s investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the voting securities of the 
portfolio company.

As of June 30, 2021, the Company's investments in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) were written off for a realized loss. 

As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio 
company.

164

 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
   
   
   
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
As of and for the year ended December 31, 2020
(in thousands)

Portfolio Company

Investment 

(1)

Amount of 
Interest 
Credited to 
 (2)
Income

Realized Gain 
(Loss)

Fair Value as of 
December 31, 
2019

Gross 
Additions 

(3)

Gross 
Reductions 

(4)

Net Change in 
Unrealized 
Appreciation/ 
(Depreciation)

Fair Value as of 
December 31, 
2020

Control Investments

Majority Owned Control Investments
(5)
Gibraltar Business Capital, LLC 

                    Total Majority Owned Control Investments

Other Control Investments

Tectura Corporation 

(6)

                     Total Other Control Investments
Total Control Investments

Affiliate Investments

Optiscan BioMedical, Corp. 

(7)

Pineapple Energy LLC 
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) 

(9)

(8)

Total Affiliate Investments

Total Control and Affiliate Investments

  Unsecured Debt
  Preferred Stock
  Common Stock

  Senior Debt
  Preferred Stock
  Common Stock

  Convertible Debt
  Preferred Warrants
  Preferred Stock
  Senior Debt
  Common Stock
  Senior Debt
  Common Stock

  $

  $

  $

  $
  $

  $

  $
  $

2,249     $
—    
—    
2,249     $

608     $
—    
—    
608     $
2,857     $

13     $
—    
—    
—    
—    
520    
—    
533     $
3,390     $

—     $
—    
—    
—     $

—     $
—    
—    
—     $
—     $

(421 )   $
(573 )  
(13,152 )  
—    
—    
(3 )  
—    
(14,149 )   $
(14,149 )   $

14,780     $
33,000    
2,380    
50,160     $

9,586     $
—    
—    
9,586     $
59,746     $

—     $
209    
8,984    
—    
—    
12,615    
—    
21,808     $
81,554     $

59    $
—   
—   
59    $

—    $
—   
—   
—    $
59    $

408    $
—   
—   
7,500   
4,767   
—   
—   
12,675    $
12,734    $

—     $
—    
—    
—     $

(134 )   $
—    
—    
(134 )   $
(134 )   $

(408 )   $
(573 )  
(13,152 )  
—    
—    
(12,269 )  
—    
(26,402 )   $
(26,536 )   $

131     $

(1,446 )  
(104 )  
(1,419 )   $

(852 )   $
—    
—    
(852 )   $
(2,271 )   $

—     $
364    
4,168    
—    
(3,927 )  
(346 )  
—    
259     $
(2,012 )   $

14,970  
31,554  
2,276  
48,800  

8,600  
—  
—  
8,600  
57,400  

—  
—  
—  
7,500  
840  
—  
—  
8,340  
65,740  

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

Stock and warrants are generally non-income producing and restricted.

Represents the total amount of interest or dividends credited to income for the period an investment was an affiliate or control investment.

Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of 
one or more existing securities for one or more new securities. 

Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross 
reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.

As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest.

As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In 
May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.

As of December 31, 2020, the Company’s investments in Optiscan BioMedical, Corp. were deemed wholly worthless and written off for a realized loss.

As of December 11, 2020, the Company’s investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the voting securities of the 
portfolio company.

As of September 30, 2017, the Company's investment in Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) became classified as an affiliate investment due to a reduction in equity ownership. 

165

 
 
 
 
 
   
 
 
   
   
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
   
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
   
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
 
 
 
 
   
 
   
 
   
 
  
 
   
 
   
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
  
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of and for the year ended December 31, 2021

HERCULES CAPITAL, INC.

(in thousands)

Portfolio Company

Industry

Type of Investment 

(1)

  Maturity Date

Interest Rate and Floor

Principal 
or Shares

Cost

Value 

(2)

Schedule 12-14

Control Investments
        Majority Owned Control Investments

Coronado Aesthetics, LLC

  Medical Devices & Equipment
  Medical Devices & Equipment

  Preferred Series A Equity
  Common Stock

Total Coronado Aesthetics, LLC

Gibraltar Business Capital, LLC

  Diversified Financial Services
  Diversified Financial Services
  Diversified Financial Services
  Diversified Financial Services

  Unsecured Debt
  Unsecured Debt
  Preferred Series A Equity
  Common Stock

  September 2026
  September 2026

  Interest rate FIXED 14.50%   $
  Interest rate FIXED 11.50%   $

Total Gibraltar Business Capital, LLC

Hercules Adviser LLC

  Diversified Financial Services
  Diversified Financial Services

  Unsecured Debt
  Member Units

Total Hercules Adviser LLC

Total Majority Owned Control Investments (4.99%)*
Other Control Investments

  May 2023

  Interest rate FIXED 5.00%   $

5,000,000   $
180,000    
  $
15,000    
10,000    
10,602,752    
830,000    
  $
8,850    
1    
  $
  $

250     $
—      
250     $
14,662      
9,823      
26,122      
1,884      
52,491     $
8,850      
35      
8,885     $
61,626     $

Tectura Corporation

  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services

Total Tectura Corporation

Total Other Control Investments (0.63%)*
Total Control Investments (5.62%)*

Affiliate Investments

Black Crow AI, Inc.

Pineapple Energy LLC

  Internet Consumer & Business 
Services
  Sustainable and Renewable 
Technology
  Sustainable and Renewable 
Technology
  Sustainable and Renewable 
Technology

Total Pineapple Energy LLC
     Total Affiliate Investments (0.72%)*
     Total Control and Affiliate Investments (6.34%)*

  Senior Secured Debt

  July 2024

  PIK Interest 5.00%

  $

10,680   $

240     $

  Senior Secured Debt

  July 2024

  Interest rate FIXED 8.25%   $

8,250    

8,250      

  Senior Secured Debt

  July 2024

  PIK Interest 5.00%

  $

13,023    

13,023      

  Preferred Series BB Equity

  Common Stock

  Preferred Series Seed

1,000,000    

414,994,863    

  $
  $
  $

—      

900      

22,413     $
22,413     $
84,039     $

872,797   $

1,000     $

  Senior Secured Debt

   December 2023

  PIK Interest 10.00%

  $

7,500   $

7,500     $

  Senior Secured Debt

  January 2022

  Interest rate FIXED 10.00%   $

280    

280      

  Common Stock

3,000,000    

4,767      

  $
  $
  $

12,547     $
13,547     $
97,586     $

500  
65  
565  
13,818  
9,394  
19,393  
1,225  
43,830  
8,850  
11,990  
20,840  
65,235  

—  

8,250  

19  

—  

—  

8,269  
8,269  
73,504  

1,120  

7,500  

247  

591  

8,338  
9,458  
82,962  

*     Value as a percent of net assets
(1) Stock and warrants are generally non-income producing and restricted.
(2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

166

 
 
 
 
 
 
   
 
   
   
     
 
   
   
     
 
   
   
   
  
   
   
   
   
  
  
   
   
   
 
   
   
   
   
  
   
   
   
   
   
   
   
     
 
   
  
   
   
   
   
  
   
   
   
   
   
   
   
   
     
 
   
   
   
  
  
   
   
   
   
 
 
  
Portfolio Company

Industry

Type of Investment 

(1)

  Maturity Date

Interest Rate and Floor

Principal 
or Shares

Cost

Value 

(2)

As of and for the year ended December 31, 2020
(in thousands)

Control Investments
        Majority Owned Control Investments

Gibraltar Business Capital, LLC

  Diversified Financial Services
  Diversified Financial Services
  Diversified Financial Services

  Unsecured Debt
  Preferred Series A Equity
  Common Stock

  March 2023

  Interest rate FIXED 14.50%   $

15,000   $
10,602,752    
830,000    
  $
  $

14,838     $
26,122      
1,884      
42,844     $
42,844     $

Total Gibraltar Business Capital, LLC

Total Majority Owned Control Investments (3.78%)*
Other Control Investments

Tectura Corporation

  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services
  Internet Consumer & Business 
Services

Total Tectura Corporation

Total Other Control Investments (0.67%)*
Total Control Investments (4.44%)*

Affiliate Investments

Pineapple Energy LLC

Total Pineapple Energy LLC
Solar Spectrum Holdings LLC, 
(p.k.a. Sungevity, Inc.)

  Sustainable and Renewable 
Technology
  Sustainable and Renewable 
Technology

  Sustainable and Renewable 
Technology
  Sustainable and Renewable 
Technology
  Sustainable and Renewable 
Technology

Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)

     Total Affiliate Investments (0.65%)*
     Total Control and Affiliate Investments (5.09%)*

  Senior Secured Debt

  March 2021

  PIK Interest 5.00%

  $

10,680   $

240     $

  Senior Secured Debt

  March 2021

  Interest rate FIXED 8.25%   $

8,250    

8,250      

  Senior Secured Debt

  March 2021

  PIK Interest 5.00%

  $

13,023    

13,023      

  Preferred Series BB Equity

  Common Stock

1,000,000    

414,994,863    

  $
  $
  $

—      

900      

22,413     $
22,413     $
65,257     $

  Senior Secured Debt

  December 2023

  PIK Interest 10.00%

  $

7,500   $

7,500     $

  Common Stock

17,647    

4,767      

  Senior Secured Debt

  January 2021

  PIK Interest 10.00%

  $

  Common Stock

  Class A Warrants

  $
681   $

488    

0.69    

  $
  $
  $

12,267     $
681      

61,502      

—      

62,183     $
74,450     $
139,707     $

14,970  
31,554  
2,276  
48,800  
48,800  

—  

8,250  

350  

—  

—  

8,600  
8,600  
57,400  

7,500  

840  

8,340  
—  

—  

—  

—  
8,340  
65,740  

*     Value as a percent of net assets
(1) Stock and warrants are generally non-income producing and restricted.
(2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

167

 
 
 
 
 
 
 
   
 
   
   
     
 
   
   
     
 
  
   
   
   
  
   
   
   
   
   
   
   
     
 
   
  
   
   
   
   
  
   
   
   
   
   
   
   
   
     
 
  
   
   
   
   
   
   
   
   
  
   
   
   
 
 
  
3. Exhibits

Please note that the agreements included as exhibits to this Form 10-K are included to provide information regarding their terms and are not intended to provide any 

other factual or disclosure information about us or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the 
applicable agreement that have been made solely for the benefit of the other parties to the applicable agreement and may not describe the actual state of affairs as of the date 
they were made or at any other time. 

Exhibit 
Number

  Description

3(a)

3(b)

3(c)

3(d)

3(e)

3(f)

4(a)

4(b)

4(c)

4(d)

4(e)

4(f)

4(g)

4(h)

4(i)

4(j)

4(k)

4(l)

  Articles of Amendment and Restatement.

(2)

  Articles of Amendment, dated March 6, 2007.

(4)

  Articles of Amendment, dated April 5, 2011.

(9)

  Articles of Amendment, dated April 3, 2015.

(14)

  Articles of Amendment, dated February 23, 2016.

(17)

  Amended and Restated Bylaws of Hercules Capital, Inc.

(17)

  Specimen certificate of the Company’s common stock, par value $.001 per share.

 (1)

  Form of Dividend Reinvestment Plan.

(28)

  Indenture, dated March 6, 2012 between the Registrant and U.S. Bank National Association.

(10)

  First Supplemental Indenture, dated April 17, 2012 between the Registrant and U.S. Bank, National Association.

(10)

  Second Supplemental Indenture, dated as of September 24, 2012, between the Registrant and U.S. Bank, National Association.

(11) 

  Third Supplemental Indenture, dated as of July 14, 2014, between the Registrant and U.S. Bank, National Association.

(12)

  Form of 6.25% Note due 2024, dated as of July 14, 2014 (July 2024 Note) (included as part of Exhibit 4(f).

(12)

  Form of 6.25% Note due 2024, dated as of August 11, 2014 (Over-Allotment July 2024 Note).

(13)

  Form of 6.25% Note due 2024, dated as of May 2, 2016 (Additional July 2024 Note).

(20)

  Form of 6.25% Note due 2024, dated as of June 27, 2016 (Additional July 2024 Note).

(21)

  Form of 6.25% Note due 2024, dated as of July 5, 2016 (Additional July 2024 Note).

(22)

  Form of 6.25% Note due 2024, dated as of October 11, 2016 (Additional July 2024 Note).

(24)

4(m)

  Indenture, dated January 25, 2017, between Hercules Capital, Inc. and U.S. Bank National Association, as Trustee.

(25)

4(n)

4(o)

4(p)

4(q)

4(r)

4(s)

4(t)

4(u)

  Form of 4.375% Convertible Senior Note Due 2022, dated as of January 25, 2017 (included as part of Exhibit 4(m)).

(25)

  Statement of Eligibility of Trustee on Form T-1.

(30)

  Fourth Supplemental Indenture, dated as of October 23, 2017, between the Registrant and U.S. Bank National Association.

(31)

  Form of 4.625% Note due 2022, dated as of October 23, 2017 (included as part of Exhibit 4(p)).

(31)

  Fifth Supplemental Indenture, dated as of April 26, 2018, between the Registrant and U.S. Bank National Association.

(34)

  Form of 5.25% Note due 2025, dated as of April 23, 2018 (included as part of Exhibit 4(r)).

(34)

  Sixth Supplemental Indenture, dated as of September 24, 2018, between the Registrant and U.S. Bank National Association.

(37)

  Form of 6.25% Note due 2033, dated September 24, 2018 (included as part of Exhibit 4(t)).

(37)

168

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
4(v)

4(w)

4(x)

4(y)

4(z)

4(aa)

  Seventh Supplemental Indenture, dated as of September 16, 2021, between the Registrant and U.S. Bank, National Association.

(55)

  Form of 2.625% Note due 2026, dated September 16, 2021 (included as part of Exhibit 4).

(55)

  Indenture, dated as of November 1, 2018, between Hercules Capital Funding Trust 2018-1, as Issuer, and U.S. Bank National Association, as Trustee.

(39)

  Amended and Restated Trust Agreement, dated as of November 1, 2018, between Hercules Capital Funding 2018-1 LLC, as Trust Depositor, and Wilmington Trust, National 

Association, as Owner Trustee.

(39)

  Indenture, dated as of January 22, 2019, between Hercules Capital Funding Trust 2019-1, as Issuer, and U.S. Bank National Association, as Trustee.

(41)

  Amended and Restated Trust Agreement, dated as of January 22, 2019, between Hercules Capital Funding 2019-1 LLC, as Trust Depositor, and Wilmington Trust, National 

Association, as Owner Trustee.

(41)

4(ab)*

  Description of the Registrant’s Securities. 

10(a)

10(b)

10(c)

10(d)

10(e)

10(f)

10(g)
10(h)

10(i)

10(j)

10(k)

10(l)

10(m)

10(n)

10(o)

10(p)

10(q)

  Hercules Capital, Inc. Amended and Restated 2004 Equity Incentive Plan.

(6)

  Hercules Technology Growth Capital, Inc. 2006 Non-Employee Director Plan (2007 Amendment and Restatement).

(7)

  Form of Custodian Agreement between the Company and Union Bank of California, N.A.

(2)

  Form of Restricted Stock Unit Award Agreement.

(6)

  Form of Incentive Stock Option Award under the 2004 Equity Incentive Plan.

(2)

  Form of Nonstatutory Stock Option Award under the 2004 Equity Incentive Plan.

(2)

  Form of Transfer Agency and Registrar Services Agreement between the Company and American Stock Transfer & Trust Company.
  Warrant Agreement dated as of June 22, 2004, between the Company and American Stock Transfer & Trust Company, as warrant agent.

(5)

(2)

  Lease Agreement, dated as of June 13, 2006, between the Company and 400 Hamilton Associates.

(3)

  Form of SBA Debenture.

(8)

  Form of Amended and Restated Indemnification Agreement.

(27)

  Amended and Restated Loan and Security Agreement by and among Hercules Funding II, LLC, the Lenders thereto and Wells Fargo Capital Finance, LLC, dated as of June 

29, 2015.

(15)

  Amended and Restated Sales and Servicing Agreement among Hercules Funding II, LLC, Hercules Technology Growth Capital, Inc. and Wells Fargo Capital Finance, LLC, 

dated as of June 29, 2015.

(15)

  First Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo 

Foothill, LLC), dated as of December 16, 2015.

(16)

  Second Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells 

Fargo Foothill, LLC), dated as of March 8, 2016.

 (26)

  Third Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells Fargo 

Foothill, LLC), dated as of April 7, 2016.

(18)

  Fourth Amendment to Amended and Restated Loan and Security Agreement by and among Hercules Funding II LLC and Wells Fargo Capital Finance, LLC (f/k/a Wells 

Fargo Foothill, LLC), dated as of April 3, 2017.

(29)

169

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10(r)

10(s)

10(t)

10(u)

10(v)

10(w)

10(x)

10(y)

10(z)

10(aa)

10(bb)

10(cc)

10(dd)

10(ee)

10(ff)

10(gg)

10(hh)

10(ii)

10(jj)

10(kk)

(38)

(40)

  Fifth Amendment to the Amended and Restated Loan and Security Agreement, dated as of July 31, 2018, by and among Hercules Funding II LLC as borrower, Wells Fargo 

Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as Administrative Agent, and the Lenders party thereto from time to time.

(38)

  Sixth Amendment to the Amended and Restated Loan and Security Agreement, dated as of October 26, 2018, by and among Hercules Funding II LLC as borrower, Wells 

Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as Administrative Agent, and the Lenders party thereto from time to time.

  Seventh Amendment to the Amended and Restated Loan and Security Agreement, dated as of January 11, 2019, by and among Hercules Funding II LLC as borrower, Wells 

Fargo Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as Administrative Agent, and the Lenders party thereto from time to time.

  Loan and Security Agreement by and among Hercules Funding III, LLC, as borrower, MUFG Union Bank, N.A., as the arranger and administrative agent, and the lenders 

party thereto from time to time, dated as of May 5, 2016.

(19)

  Sale and Servicing Agreement by and among Hercules Funding III LLC, as borrower, Hercules Capital, Inc., as originator and servicer, and MUFG Union Bank, N.A., as 

agent, dated as of May 5, 2016.

(19)

  First Amendment to Loan and Security Agreement by and among Hercules Funding III LLC, as borrower, MUFG Union Bank, N.A., as the arranger and administrative agent, 

and the lenders party thereto from time to time, dated as of July 14, 2016.

(23)

  Second Amendment to the Loan and Security Agreement, dated as of May 25, 2018, by and among Hercules Funding III, LLC, as borrower, MUFG Union Bank, N.A., as the 

arranger and administrative agent, and the lenders party thereto.

(36)

  Form of Performance Restricted Stock Unit Award Agreement.

(6)

  Retention Agreement, dated as of October 26, 2017, by and between Hercules Capital, Inc. and Manuel A. Henriquez.

(32)

  Retention Agreement, dated as of October 26, 2017, by and between Hercules Capital, Inc. and Scott Bluestein.

(32)

  Asset Purchase Agreement, dated as of November 1, 2017 by and between Ares Capital Corporation, a Maryland corporation and, together with each Seller Designee 

permitted pursuant to the Agreement, and Bearcub Acquisitions LLC, a Delaware limited liability company.

(33)

  Form of Retention Performance Stock Unit Award Agreement.

(35)

  Form of Cash Retention Bonus Award Agreement.

(35)

  Sale and Servicing Agreement, dated as of November 1, 2018, by and among Hercules Capital Funding Trust 2018-1, as Issuer, Hercules Capital, Inc., as Seller and Servicer, 

Hercules Capital Funding 2018-1 LLC, as Trust Depositor, and U.S. Bank National Association, as Trustee, Backup Servicer, Custodian and Paying Agent.

(39)

  Sale and Contribution Agreement, dated as of November 1, 2018, between Hercules Capital, Inc., as Seller, and Hercules Capital Funding 2018-1 LLC, as Trust Depositor.

(39)

  Note Purchase Agreement, dated as of October 25, 2018, by and among Hercules Capital, Inc., as Originator and Servicer, Hercules Capital Funding 2018-1 LLC, as Trust 

Depositor, Hercules Capital Funding Trust 2018-1, as Issuer, and Guggenheim Securities, LLC, as Initial Purchaser.

(39)

  Administration Agreement, dated November 1, 2018, by and among Hercules Capital, Inc., as Administrator, Hercules Capital Funding Trust 2018-1, as Issuer, Wilmington 

Trust, National Association, as Owner Trustee, and U.S. Bank National Association, as Trustee.

(39)

  Sale and Servicing Agreement, dated as of January 22, 2019, by and among Hercules Capital Funding Trust 2019-1, as Issuer, Hercules Capital, Inc., as Seller and Servicer, 

Hercules Capital Funding 2019-1 LLC, as Trust Depositor, and U.S. Bank National Association, as Trustee, Backup Servicer, Custodian and Paying Agent.

(41)

  Sale and Contribution Agreement, dated as of January 22, 2019, between Hercules Capital, Inc., as Seller, and Hercules Capital Funding 2019-1 LLC, as Trust Depositor.

(41)

  Note Purchase Agreement, dated as of January 14, 2019, by and among Hercules Capital, Inc., as Originator and Servicer, Hercules Capital Funding 2019-1 LLC, as Trust 

Depositor, Hercules Capital Funding Trust 2019-1, as Issuer, and Guggenheim Securities, LLC, as Initial Purchaser.

170

(41)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10(ll)

  Administration Agreement, dated January 22, 2019, by and among Hercules Capital, Inc., as Administrator, Hercules Capital Funding Trust 2019-1, as Issuer, Wilmington 

10(mm)

  Hercules Capital, Inc. Amended and Restated 2018 Equity Incentive Plan.

(42)

Trust, National Association, as Owner Trustee, and U.S. Bank National Association, as Trustee.

(41)

10(nn)

10(oo)

10(pp)

10(qq)

10(rr)

10(ss)

10(tt)

10(uu)

10(vv)

10(ww)

10(xx)

10(yy)

10(zz)*

10(aaa)

10(bbb)

10(ccc)

10(ddd)

10(eee)

10(fff)

10(ggg)

10(hhh)

10(iii)

14.1*

14.2*

  Hercules Capital, Inc. 2018 Non-Employee Director Plan.

(42)

  Form of Restricted Stock Unit Award Agreement.

(42)

  Form of Restricted Stock Award Agreement (2018 Equity Incentive Plan).

(42)

  Form of Restricted Stock Award Agreement (Director Plan).

(42)

  Form of Nonstatutory Stock Option Award Agreement.

(42)

  Form of Incentive Stock Option Award Agreement.

(42)

  Underwriting Agreement, dated June 12, 2019, by and among Hercules Capital, Inc. and Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC and Keefe, Bruyette & 

Woods, Inc., as representatives of the several underwriters named on Schedule I.

  First Amendment to the Loan and Security Agreement, dated as of June 28, 2019, by and among Hercules Funding IV LLC, as borrower, MUFG Union Bank, N.A., as the 

arranger and administrative agent, and the lenders party thereto from time to time.

(43)

(44)

  Eighth Amendment to Amended and Restated Loan and Security Agreement, dated as of July 2, 2019, by and among Hercules Funding II LLC, as borrower, Wells Fargo 

Capital Finance, LLC (f/k/a Wells Fargo Foothill, LLC), as the arranger and the administrative agent, and the lenders party thereto from time to time.

(44)

  Intercreditor Agreement, dated as of July 2, 2019, by and among Wells Fargo Capital Finance, LLC, as arranger and administrative agent, MUFG Union Bank, N.A., as 
arranger and administrative agent, Hercules Funding II LLC, Hercules Funding IV LLC, Hercules Capital, Inc., and U.S. Bank National Association, as special servicer.

(44)

  Note Purchase Agreement, dated July 16, 2019, by and among Hercules Capital, Inc. and the Purchasers party thereto.

(45)

  Separation Agreement, dated as of July 13, 2019, by and between Hercules Capital, Inc. and Manuel Henriquez.

(46)

  Custodial Agreement by and between Hercules Capital, Inc. and State Street Bank and Trust Company, dated as of November 9, 2021.

  Note Purchase Agreement, dated February 5, 2020, by and among Hercules Capital, Inc. and the Purchasers party thereto.

(48)

  Loan and Security Agreement, dated February 20, 2020 by and among Hercules Funding IV LLC, as borrower, MUFG Union Bank, N.A., as the administrative agent, lender 

and swingline lender and the lenders part thereto from time to time.

(49)

  Sale and Servicing Agreement, dated as of February 20, 2020, by and among Hercules Funding IV LLC, as borrower, Hercules Capital, Inc., as originator and servicer, and 

MUFG Union Bank, N.A., as agent.

(49)

  Equity Distribution Agreement, dated July 2, 2020, between Hercules Capital, Inc. and JMP Securities, LLC.

(51)

  First Supplement to the Note Purchase Agreement, dated as of November 2, 2020, by and among Hercules Capital, Inc. and the Additional Purchasers party thereto.

(52)

  Revolving Credit Agreement, dated as of November 9, 2021, among Hercules Capital, Inc., the lenders and using bank from time to time party thereto and Sumitomo Mitsui 

Banking Corporation, as administrative agent.

(54)

  Custodial Agreement by and between Hercules Growth Capital, Inc. and Wells Fargo Bank, National Association, dated as of July 29, 2015. 

(53)

  Custodial Agreement by and between Hercules Funding IV LLC and Wells Fargo Bank, National Associated, dated as of April 23, 2021.

(53)

  Safekeeping Custody Agreement between Hercules Funding IV LLC and City National Bank, a National Banking Association dated as of June 23, 2021. 

(53)

  Code of Ethics. 

  Code of Business Conduct and Ethics.

171

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
21.1*

23.1*

31.1*

31.2*

32.1*

  List of Subsidiaries. 

  Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm. 

  Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended. 

  Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended. 

  Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), as 

amended. 

32.2*

  Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), as 

amended.

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)

Previously filed as part of Pre-Effective Amendment No. 2, as filed on June 8, 2005 (File No. 333-122950), to the Registration Statement on Form N-2 of the Company. 
Previously filed as part of Pre-Effective Amendment No. 1, as filed on May 17, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on August 1, 2006. 
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 9, 2007. 
Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on February 22, 2005.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on January 5, 2017.
Previously filed as part of the Securities to be Offered to Employees in Employee Benefit Plans on Form S-8, as filed on October 2, 2007. 
Previously filed as part of the Annual Report on Form 10-K of the Company, as filed on March 16, 2009.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2011.
Previously filed as part of Post-Effective Amendment No. 1, as filed on April 17, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of Post-Effective Amendment No. 5, as filed on September 24, 2012 (File No. 333-179431), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of Post-Effective Amendment No. 5, as filed on July 14, 2014 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of Post-Effective Amendment No. 6, as filed on August 11, 2014 (File No. 333-187447), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on April 20, 2015 (File No. 333-203511)
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on June 30, 2015.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on December 18, 2015.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 25, 2016.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2016.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on May 10, 2016.
Previously filed as part of Post-Effective Amendment No. 3, as filed on May 2, 2016 (File No. 333-203511), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of Post-Effective Amendment No. 6, as filed on June 27, 2016 (File No. 333-203511), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of Post-Effective Amendment No. 7, as filed on July 5, 2016 (File No. 333-203511), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 19, 2016.
Previously filed as part of the Post-Effective Amendment No. 10, as filed on October 14, 2016 (File No. 333-203511), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on January 25, 2017.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 8, 2016.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 22, 2016.
Previously filed as part of Post-Effective Amendment No. 1, as filed on June 10, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company. 
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 7, 2017.
Previously filed as part of the of the Registration Statement on Form N-2 of the Company, as filed on April 29, 2019 (File No. 333-231089). 
Previously filed as part of the Post-Effective Amendment No. 2, as filed on October 25, 2017 (File No. 333-214767), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on October 26, 2017.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on November 2, 2017.
Previously filed as part of Post-Effective Amendment No. 4, as filed on April 26, 2018 (File No. 333-214767), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on May 3, 2018.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on June 1, 2018.
Previously filed as part of Post-Effective Amendment No. 2, as filed on September 24, 2018 (File No. 333-224281), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on November 1, 2018.

172

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)

Previously filed as part of the Current Report on Form 8-K of the Company, as filed on November 2, 2018.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on January 17, 2019.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on January 22, 2019.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on January 31, 2019.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on June 18, 2019.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 3, 2019.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 16, 2019.
Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on August 1, 2019.
Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on October 30, 2019.
Previously filed as part of the Quarterly Report on Form 8-K of the Company, as filed on February 6, 2020.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 20, 2020.
Reserved.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on July 2, 2020.
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on November 4, 2020.
Previously filed as part of the Post-Effective Amendment No. 11, as filed on December 17, 2021 (File No. 333-261732), to the Registration Statement on Form N-2 of the Company.
Previously filed as part of the Current Report on Form 8-K of the company, as filed on November 10,2021
Previously filed as part of the Current Report on Form 8-K of the Company, as filed on September 21, 2021.

* 

Filed herewith 

173

 
 
 
  
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the 

undersigned, thereunto duly authorized. 

HERCULES CAPITAL, INC.

SIGNATURES

Date: February 22, 2022

By:

/S/ Scott Bluestein

Scott Bluestein

Chief Executive Officer and Chief Investment Officer

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the following 

capacities on February 22, 2022. 

Signature

/S/ Scott Bluestein
Scott Bluestein

/S/ Seth H. Meyer 
Seth H. Meyer

/S/ Robert P. Badavas
Robert P. Badavas

/S/ Thomas Fallon
Thomas Fallon

/S/ Joseph F. Hoffman
Joseph F. Hoffman

/S/ Brad Koenig
Brad Koenig 

/S/ Doreen Woo Ho
Doreen Woo Ho

/S/ Wade Loo
Wade Loo

/S/ Gayle Crowell
Gayle Crowell

/S/ Pam Randhawa
Pam Randhawa

Title

Director, President, Chief Executive Officer, and
Chief Investment Officer (Principal Executive Officer)

Chief Financial Officer, and
Chief Accounting Officer (Principal Accounting and Financial Officer)

Chairman of the Board

Director

Director

Director

Director

Director

Director

Director

174

Date

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

February 22, 2022

 
 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
  
DESCRIPTION OF OUR SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934

Exhibit 4(ab)

As of December 31, 2021, Hercules Capital, Inc. (“we,” “our,” “Hercules,” or the “Company”) had the following three classes of securities registered under Section 12 of the 
Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) our common stock, par value $0.001 per share (“common stock”), (ii) and (iii) our 6.25% Notes due 
2033 (the “2033 Notes” and, collectively with the April 2025 Notes, the “Debt Securities”).

DESCRIPTION OF OUR CAPITAL STOCK

The following description is based on relevant portions of the Maryland General Corporation Law, as amended (the “MGCL”), and on our charter and bylaws. This summary 
may not contain all of the information that is important to you, and we refer you to the MGCL and our charter and bylaws for a more detailed description of the provisions 
summarized below. 

Common Stock

Under the terms of our charter, our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.001 per share. Under our charter, our Board of 
Directors is authorized to classify and reclassify any unissued shares of stock into other classes or series of stock, and to cause the issuance of such shares, without obtaining 
stockholder approval. In addition, as permitted by the MGCL, but subject to the Investment Company Act of 1940, as amended (the “1940 Act”), our charter provides that the 
Board of Directors, without any action by our stockholders, may amend the charter from time to time to increase or decrease the aggregate number of shares of stock or the 
number of shares of stock of any class or series that we have authority to issue. Under Maryland law, our stockholders generally are not personally liable for our debts or 
obligations.

All shares of our common stock have equal rights as to earnings, assets, distributions and voting privileges, except as described below and, when they are issued, will be duly 
authorized, validly issued, fully paid and nonassessable.

Distributions may be paid to the holders of our common stock if, as and when authorized by our Board of Directors and declared by us out of assets legally available therefor. 
Shares of our common stock have no conversion, exchange, preemptive or redemption rights. In the event of a liquidation, dissolution or winding up of Hercules each share of 
our common stock would be entitled to share ratably in all of our assets that are legally available for distribution after we pay all debts and other liabilities and subject to any 
preferential rights of holders of our preferred stock, if any preferred stock is outstanding at such time. Each share of our common stock is entitled to one vote on all matters 
submitted to a vote of stockholders, including the election of directors. Except as provided with respect to any other class or series of stock, the holders of our common stock 
will possess exclusive voting power. There is no cumulative voting in the election of directors, which means that holders of a majority of the outstanding shares of common 
stock will elect all of our directors, and holders of less than a majority of such shares will be unable to elect any director.

Preferred Stock

Our charter authorizes our Board of Directors to classify and reclassify any unissued shares of stock into other classes or series of stock, including preferred stock. Prior to 
issuance of shares of each class or series, the Board of Directors is required by Maryland law and by our charter to set the terms, preferences, conversion or other rights, voting 
powers, restrictions, limitations as to dividends or other distributions, qualifications and terms or conditions of redemption for each class or series. Thus, the Board of Directors 
could authorize the issuance of shares of preferred stock with terms and conditions which could have the effect of delaying, deferring or preventing a transaction or a change in 
control that might involve a premium price for holders of our common stock or otherwise be in their best interest.

Limitation on Liability of Directors and Officers; Indemnification and Advance of Expenses

Maryland law permits a Maryland corporation to include in its charter a provision limiting the liability of its directors and officers to the corporation and its stockholders for 
money damages except for liability resulting from (a) actual receipt of an improper benefit or profit in money, property or services or (b) active and deliberate dishonesty 
established by a final judgment as being material to the cause of action. Our charter contains such a provision which eliminates directors’ and officers’ liability to the maximum 
extent permitted by Maryland law, subject to the requirements of the 1940 Act.

 
 
  
 
 
 
 
  
  
 
 
   
  
  
 
 
Our charter authorizes us, to the maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to indemnify any present or former director or 
officer or any individual who, while a director or officer and at our request, serves or has served another corporation, real estate investment trust, partnership, joint venture, 
trust, employee benefit plan or other enterprise as a director, officer, partner or trustee, from and against any claim or liability to which such person may become subject or 
which such person may incur by reason of his or her service in any such capacity, except with respect to any matter as to which such person shall have been finally adjudicated 
in any proceeding not to have acted in good faith in the reasonable belief that their action was in our best interest or to be liable to us or our stockholders by reason of willful 
misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of such person’s office. Our charter also provides that, to the maximum 
extent permitted by Maryland law, with the approval of our Board of Directors and provided that certain conditions described in our charter are met, we may pay certain 
expenses incurred by any such indemnified person in advance of the final disposition of a proceeding upon receipt of an undertaking by or on behalf of such indemnified person 
to repay amounts we have so paid if it is ultimately determined that indemnification of such expenses is not authorized under our charter. Our bylaws obligate us, to the 
maximum extent permitted by Maryland law and subject to the requirements of the 1940 Act, to indemnify any present or former director or officer or any individual who, 
while a director or officer and at our request, serves or has served another corporation, real estate investment trust, partnership, joint venture, trust, employee benefit plan or 
other enterprise as a director, officer, partner or trustee and who is made, or threatened to be made, a party to the proceeding by reason of his or her service in any such capacity 
from and against any claim or liability to which that person may become subject or which that person may incur by reason of his or her service in any such capacity, except 
with respect to any matter as to which such person shall have been finally adjudicated in any proceeding not to have acted in good faith in the reasonable belief that their action 
was in our best interest or to be liable to us or our stockholders by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the 
conduct of such person’s office. Our bylaws also provide that, to the maximum extent permitted by Maryland law, with the approval of our Board of Directors and provided that 
certain conditions described in our bylaws are met, we may pay certain expenses incurred by any such indemnified person in advance of the final disposition of a proceeding 
upon receipt of an undertaking by or on behalf of such indemnified person to repay amounts we have so paid if it is ultimately determined that indemnification of such expenses 
is not authorized under our bylaws.  Our charter and bylaws also permit us to indemnify and advance expenses to any individual who served a predecessor of us in any of the 
capacities described above and any of our employees or agents or any employees or agents of our predecessor.

Maryland law requires a corporation (unless its charter provides otherwise, which our charter does not) to indemnify a director or officer who has been successful in the defense 
of any proceeding to which he or she is made, or threatened to be made, a party by reason of his or her service in that capacity. Maryland law permits a corporation to 
indemnify its present and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in 
connection with any proceeding to which they may be made, or threatened to be made, a party by reason of their service in those or other capacities unless it is established that 
(a) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (1) was committed in bad faith or (2) was the result of active and 
deliberate dishonesty, (b) the director or officer actually received an improper personal benefit in money, property or services or (c) in the case of any criminal proceeding, the 
director or officer had reasonable cause to believe that the act or omission was unlawful. However, under Maryland law, a Maryland corporation may not indemnify for an 
adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received, unless in either case a 
court orders indemnification, and then only for expenses. In addition, Maryland law permits a corporation to advance reasonable expenses to a director or officer upon the 
corporation’s receipt of (a) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for 
indemnification by the corporation and (b) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is 
ultimately determined that the standard of conduct was not met.

We currently have in effect a directors’ and officers’ insurance policy covering our directors and officers and us for any acts and omissions committed, attempted or allegedly 
committed by any director or officer during the policy period. The policy is subject to customary exclusions.

 Provisions of the MGCL and Our Charter and Bylaws

The MGCL and our charter and bylaws contain provisions that could make it more difficult for a potential acquiror to acquire us by means of a tender offer, proxy contest or 
otherwise. These provisions are expected to discourage certain coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of 
us to negotiate first with our Board of Directors. We believe that the benefits of these provisions outweigh the potential disadvantages of discouraging any such acquisition 
proposals because, among other things, the negotiation of such proposals may improve their terms.

 
  
  
  
  
  
 
 
 
Classified Board of Directors

Our Board of Directors is divided into three classes of directors serving staggered three-year terms. The terms of the first, second and third classes will expire at our annual 
meeting of stockholders in 2021, 2022 and 2023, respectively. Upon expiration of their current terms, directors of each class will be elected to serve until the third annual 
meeting following their election and until their respective successors are duly elected and qualify. Each year one class of directors will be elected by the stockholders. A 
classified board may render a change in control or removal of our incumbent management more difficult. We believe, however, that the longer time required to elect a majority 
of a classified Board of Directors will help to ensure the continuity and stability of our management and policies.

Election of Directors

Our charter provides that, except as otherwise provided in the bylaws, the affirmative vote of the holders of a majority of the outstanding shares of stock entitled to vote in the 
election of directors will be required to elect each director. Our bylaws currently provide that directors are elected by a plurality of the votes cast in the election of directors. 
Pursuant to our charter and bylaws, our Board of Directors may amend the bylaws to alter the vote required to elect directors.

Number of Directors; Vacancies; Removal

Our charter provides that the number of directors will be set only by the Board of Directors in accordance with our bylaws. Our bylaws provide that a majority of our entire 
Board of Directors may at any time increase or decrease the number of directors. However, the number of directors may never be less than one nor, unless the bylaws are 
amended, more than 12. We have elected to be subject to the provision of Subtitle 8 of Title 3 of the MGCL regarding the filling of vacancies on the Board of Directors. 
Accordingly, except as may be provided by the Board of Directors in setting the terms of any class or series of preferred stock, any and all vacancies on the Board of Directors 
may be filled only by the affirmative vote of a majority of the remaining directors in office, even if the remaining directors do not constitute a quorum, and any director elected 
to fill a vacancy shall serve for the remainder of the full term of the directorship in which the vacancy occurred and until a successor is elected and qualifies, subject to any 
applicable requirements of the 1940 Act.

Our charter provides that a director may be removed only for cause, as defined in the charter, and then only by the affirmative vote of at least two-thirds of the votes entitled to 
be cast in the election of directors.

Action by Stockholders

Under the MGCL, stockholder action may be taken only at an annual or special meeting of stockholders or by unanimous consent in lieu of a meeting (unless the charter 
provides for stockholder action by less than unanimous written consent, which our charter does not). These provisions, combined with the requirements of our bylaws regarding 
the calling of a stockholder-requested special meeting of stockholders discussed below, may have the effect of delaying consideration of a stockholder proposal until the next 
annual meeting.

Advance Notice Provisions for Stockholder Nominations and Stockholder Proposals

Our bylaws provide that with respect to an annual meeting of stockholders, nominations of persons for election to the Board of Directors and the proposal of business to be 
considered by stockholders may be made only (1) pursuant to our notice of the meeting, (2) by the Board of Directors or (3) by a stockholder who was a stockholder of record 
both at the time of giving of notice by the stockholder and at the time of the annual meeting, who is entitled to vote at the meeting and who has complied with the advance 
notice procedures of the bylaws. With respect to special meetings of stockholders, only the business specified in our notice of the meeting may be brought before the meeting. 
Nominations of persons for election to the Board of Directors at a special meeting may be made only (1) pursuant to our notice of the meeting, (2) by the Board of Directors or 
(3) provided that the Board of Directors has determined that directors will be elected at the meeting, by a stockholder who was a stockholder of record both at the time of giving 
of notice by the stockholder and at the time of the special meeting, who is entitled to vote at the meeting and who has complied with the advance notice provisions of the 
bylaws.

The purpose of requiring stockholders to give us advance notice of nominations and other business is to afford our Board of Directors a meaningful opportunity to consider the 
qualifications of the proposed nominees and the advisability of any other proposed business and, to the extent deemed necessary or desirable by our Board of Directors, to 
inform stockholders and make recommendations about such qualifications or business, as well as to provide a more orderly procedure for conducting meetings of stockholders. 
Although our bylaws do not give our Board of Directors any power to disapprove stockholder nominations for the election of directors or proposals recommending certain 
action, they may have the effect of precluding a contest for the election of directors or the consideration of 

 
  
  
  
  
  
  
  
  
  
  
  
 
 
stockholder proposals if proper procedures are not followed and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of 
directors or to approve its own proposal without regard to whether consideration of such nominees or proposals might be harmful or beneficial to us and our stockholders.

Calling of Special Meeting of Stockholders

Our bylaws provide that special meetings of stockholders may be called by our Board of Directors and certain of our officers. Additionally, our bylaws provide that, subject to 
the satisfaction of certain procedural and informational requirements by the stockholders requesting the meeting, a special meeting of stockholders shall be called by our 
secretary upon the written request of stockholders entitled to cast not less than a majority of all of the votes entitled to be cast at such meeting.

Approval of Extraordinary Corporate Action; Amendment of Charter and Bylaws

Under Maryland law, a Maryland corporation generally cannot dissolve, amend its charter, merge, convert, sell all or substantially all of its assets, engage in a share exchange or
engage in similar transactions outside the ordinary course of business, unless approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes 
entitled to be cast on the matter. However, a Maryland corporation may provide in its charter for approval of these matters by a lesser percentage, but not less than a majority of 
all of the votes entitled to be cast on the matter. Our charter generally provides for approval of charter amendments and extraordinary transactions by the stockholders entitled 
to cast at least a majority of the votes entitled to be cast on the matter. Our charter also provides that certain charter amendments and any proposal for our conversion, whether 
by merger or otherwise, from a closed-end company to an open-end company or any proposal for our liquidation or dissolution requires the approval of the stockholders entitled 
to cast at least 75% of the votes entitled to be cast on such matter. However, if such amendment or proposal is approved by at least 75% of our continuing directors (in addition 
to approval by our Board of Directors), such amendment or proposal may be approved by the stockholders entitled to cast a majority of the votes entitled to be cast on such a 
matter. The “continuing directors” are defined in our charter as our current directors, as well as those directors whose nomination for election by the stockholders or whose 
election by the directors to fill vacancies is approved by a majority of the continuing directors then on the Board of Directors.

Our charter and bylaws provide that the Board of Directors will have the exclusive power to make, alter, amend or repeal any provision of our bylaws.

No Appraisal Rights

Except with respect to appraisal rights arising in connection with the Control Share Act discussed below, as permitted by the MGCL, our charter provides that stockholders will 
not be entitled to exercise appraisal rights.

Control Share Acquisitions

The Maryland Control Share Acquisition Act (the “Control Share Act”) provides that holders of control shares of a Maryland corporation acquired in a control share acquisition 
have no voting rights except to the extent approved by a vote of two-thirds of the votes entitled to be cast on the matter. Shares owned by the acquiror, by officers or by 
directors who are employees of the corporation are excluded from shares entitled to vote on the matter. Control shares are voting shares of stock which, if aggregated with all 
other shares of stock owned by the acquiror or in respect of which the acquiror is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable 
proxy), would entitle the acquiror to exercise voting power in electing directors within one of the following ranges of voting power:

•

•

•

one-tenth or more but less than one-third;

one-third or more but less than a majority; or

a majority or more of all voting power.

The requisite stockholder approval must be obtained each time an acquiror crosses one of the thresholds of voting power set forth above. Control shares do not include shares 
the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval. A control share acquisition means the acquisition of issued and 
outstanding control shares, subject to certain exceptions.

A person who has made or proposes to make a control share acquisition may compel the Board of Directors of the corporation to call a special meeting of stockholders to be 
held within 50 days of demand to consider the voting rights of the shares. The right to compel 

 
  
  
  
  
  
  
  
  
  
  
 
 
 
  
  
 
 
the calling of a special meeting is subject to the satisfaction of certain conditions, including an undertaking to pay the expenses of the meeting. If no request for a meeting is 
made, the corporation may itself present the question at any stockholders meeting.

If voting rights are not approved at the meeting or if the acquiring person does not deliver an acquiring person statement as required by the statute, then the corporation may 
repurchase for fair value any or all of the control shares, except those for which voting rights have previously been approved. The right of the corporation to repurchase control 
shares is subject to certain conditions and limitations. Fair value is determined, without regard to the absence of voting rights for the control shares, as of the date of the last 
control share acquisition by the acquiror or of any meeting of stockholders at which the voting rights of the shares are considered and not approved. If voting rights for control 
shares are approved at a stockholders meeting and the acquiror becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal 
rights. The fair value of the shares as determined for purposes of appraisal rights may not be less than the highest price per share paid by the acquiror in the control share 
acquisition.

The Control Share Act does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction or (b) to acquisitions 
approved or exempted by the charter or bylaws of the corporation.

Our bylaws contain a provision exempting from the Control Share Act any and all acquisitions by any person of our shares of stock.

Business Combinations

Under the Maryland Business Combination Act (the “Business Combination Act”), “business combinations” between a Maryland corporation and an interested stockholder or 
an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These 
business combinations include a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity 
securities. An interested stockholder is defined as:

•

•

any person who beneficially owns 10% or more of the voting power of the corporation’s shares; or

an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of 10% or 
more of the voting power of the then outstanding voting stock of the corporation.

A person is not an interested stockholder under this statute if the Board of Directors approved in advance the transaction by which such stockholder otherwise would have 
become an interested stockholder. However, in approving a transaction, the Board of Directors may provide that its approval is subject to compliance, at or after the time of 
approval, with any terms and conditions determined by the board.

After the 5-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the Board of 
Directors of the corporation and approved by the affirmative vote of at least:

•

•

80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and

two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or 
with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder.

These super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under Maryland law, for their shares in the 
form of cash or other consideration in the same form as previously paid by the interested stockholder for its shares.

The statute permits various exemptions from its provisions, including business combinations that are exempted by the Board of Directors before the time that the interested 
stockholder becomes an interested stockholder. Our Board of Directors has adopted a resolution exempting any business combination between us and any other person from the 
provisions of the Business Combination Act, provided that the business combination is first approved by the Board of Directors, including a majority of the directors who are 
not interested persons as defined in the 1940 Act.

Conflict with 1940 Act

Our bylaws provide that, if and to the extent that any provision of the MGCL, or any provision of our charter or bylaws conflicts with any provision of the 1940 Act, the 
applicable provision of the 1940 Act will control.

 
  
  
  
  
  
 
 
  
  
  
 
  
  
  
  
 
 
 Regulatory Restrictions

Our wholly-owned subsidiaries, HT III and HC IV, have obtained SBIC licenses. The SBA prohibits, without prior SBA approval, a “change of control” or transfers which 
would result in any person (or group of persons acting in concert) owning 10% or more of any class of capital stock of a SBIC. A “change of control” is any event which would 
result in a transfer of the power, direct or indirect, to direct the management and policies of a SBIC, whether through ownership, contractual arrangements or otherwise.

DESCRIPTION OF OUR DEBT SECURITIES

6.25% Notes due 2033

On September 24, 2018, we issued $40.0 million in aggregate principal amount of the 2033 Notes. The 2033 Notes will mature on October 30, 2033, unless previously 
repurchased in accordance with their terms. The 2033 Notes bear interest at a rate of 6.25% per year payable quarterly in arrears on January 30, April 30, July 30, and October 
30 of each year, commencing on October 30, 2018 and trade on the NYSE under the symbol “HCXY.”
The 2033 Notes are our direct unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness 
issued by us. 

We may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the indenture after October 30, 2023. No 
sinking fund is provided for the 2033 Notes. The 2033 Notes were issued in denominations of $25 and integral multiples of $25 thereof. 

The 2033 Notes were issued pursuant to the Base Indenture, as supplemented by the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018 (the “2033 
Notes Indenture,” and together with the 2022 Notes Indenture, the “indenture”). As of December 31, 2019, the Company was in compliance with the terms of the 2033 Notes 
Indenture.

General

For purposes of this description, any reference to the payment of principal of or premium or interest, if any, on Debt Securities will include additional amounts if required by 
the terms of the Debt Securities.

The indenture does not limit the amount of Debt Securities that may be issued thereunder from time to time. Debt Securities issued under the indenture, when a single trustee is 
acting for all Debt Securities issued under the indenture, are called the “indenture securities.” The indenture also provides that there may be more than one trustee thereunder, 
each with respect to one or more different series of indenture securities. See “Resignation of Trustee” section below. At a time when two or more trustees are acting under the 
indenture, each with respect to only certain series, the term “indenture securities” means the one or more series of Debt Securities with respect to which each respective trustee 
is acting. In the event that there is more than one trustee under the indenture, the powers and trust obligations of each trustee described in this prospectus will extend only to the 
one or more series of indenture securities for which it is trustee. If two or more trustees are acting under the indenture, then the indenture securities for which each trustee is 
acting would be treated as if issued under separate indentures.

We have the ability to issue indenture securities with terms different from those of indenture securities previously issued and, without the consent of the holders thereof, to 
reopen a previous issue of a series of indenture securities and issue additional indenture securities of that series unless the reopening was restricted when that series was created.

Certain Covenants 

In addition to standard covenants relating to payment of principal and interest, maintaining an office or agency, payment of taxes and related matters, the following covenants 
apply to each of the Debt Securities.

Statement as to Compliance 

We have agreed to deliver to the Trustee, within 120 calendar days after the end of each fiscal year ending after the date hereof so long as any Debt Security is outstanding, an 
Officers’ Certificate stating to the knowledge of the signers thereof whether the Company is in 

 
  
  
 
  
 
 
 
 
 
 
   
  
  
  
 
 
 
 
 
 
default in the performance of any of the terms, provisions or conditions of the indenture. For purposes of this covenant, such default shall be determined without regard to any 
period of grace or requirement of notice under the indenture.

1940 Act Compliance

We have agreed that, for the period of time during which the Debt Securities are outstanding, we will not violate (whether or not it is subject to)  Section 18(a)(1)(A) as 
modified by Section 61(a)(1) of the 1940 Act or as may be applicable to us from time to time or any successor provisions thereto, giving effect to any exemptive relief granted 
to the Company by the Securities and Exchange Commission (“Commission”) (even if we are no longer subject to such provisions of the 1940 Act).

We have also agreed that for the period of time during which the Debt Securities are Outstanding, pursuant to Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 
Act as may be applicable to the Company from time to time or any successor provisions thereto of the 1940 Act, we will not declare any dividend (except a dividend payable in 
our stock), or declare any other distribution, upon a class of our capital stock, or purchase any such capital stock, unless, in every such case, at the time of the declaration of any 
such dividend or distribution, or at the time of any such purchase, we have an asset coverage (as defined in the 1940 Act) of at least the threshold specified in Section 18(a)(1)
(B) as modified by Section 61(a)(1) of the 1940 Act as may be applicable to us from time to time after deducting the amount of such dividend, distribution or purchase price, as 
the case may be, and in each case giving effect to (i) any exemptive relief granted to the Company by the Commission and (ii) any no-action relief granted by the Commission 
to another business development company (or to the Company if it determines to seek such similar no-action or other relief) permitting the business development company to 
declare any cash dividend or distribution notwithstanding the prohibition contained in Section 18(a)(1)(B) as modified by Section 61(a)(1) of the 1940 Act as may be applicable 
to us from time to time in order to maintain such business development company’s status as a regulated investment company under Subchapter M of the Internal Revenue Code 
of 1986, as amended.

Global Securities

The Debt Securities were issued as registered securities in book-entry form only. A global security represents one or any other number of individual Debt Securities. Generally, 
all Debt Securities represented by the same global securities will have the same terms.

Each Debt Security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that 
we select. The financial institution that we select for this purpose is called the depositary. The Depository Trust Company, New York, New York, known as DTC, is the 
depositary for the Debt Securities.

A global security may not be transferred to or registered in the name of anyone other than the depositary or its nominee, unless special termination situations arise. We describe 
those situations below under “Special Situations when a Global Security Will Be Terminated.” As a result of these arrangements, the depositary, or its nominee, will be the sole 
registered owner and holder of all Debt Securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. 
Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another 
institution that has an account with the depositary. Thus, an investor whose security is represented by a global security will not be a holder of the Debt Security, but only an 
indirect holder of a beneficial interest in the global security.

 
 
 
 
 
  
  
  
  
 
 
 
Special Considerations for Global Securities

As an indirect holder, an investor’s rights relating to a global security will be governed by the account rules of the investor’s financial institution and of the depositary, as well 
as general laws relating to securities transfers. The depositary that holds the global security will be considered the holder of the Debt Securities represented by the global 
security.

Accordingly, an investor should be aware of the following:

•

•

•

•

•

•

•

•

•

An investor cannot cause the Debt Securities to be registered in his or her name, and cannot obtain certificates for his or her interest in the Debt 
Securities, except in the special situations we describe below.

An investor will be an indirect holder and must look to his or her own bank or broker for payments on the Debt Securities and protection of his or her 
legal rights relating to the Debt Securities, as we describe under “Issuance of Securities in Registered Form” above.

An investor may not be able to sell interests in the Debt Securities to some insurance companies and other institutions that are required by law to own 
their securities in non-book-entry form.

An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the Debt Securities must be 
delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective.

The depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s 
interest in a global security. We and the trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests 
in a global security. We and the trustee also do not supervise the depositary in any way.

If we redeem less than all the Debt Securities of a particular series being redeemed, DTC’s practice is to determine by lot the amount to be redeemed 
from each of its participants holding that series.

An investor is required to give notice of exercise of any option to elect repayment of its Debt Securities, through its participant, to the Trustee and to 
deliver the related Debt Securities by causing its participant to transfer its interest in those Debt Securities, on DTC’s records, to the Trustee.

DTC requires that those who purchase and sell interests in a global security deposited in its book-entry system use immediately available funds. Your 
broker or bank may also require you to use immediately available funds when purchasing or selling interests in a global security.

Financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in a global security, may 
also have their own policies affecting payments, notices and other matters relating to the Debt Securities. There may be more than one financial 
intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. 

Special Situations when a Global Security will be Terminated

In a few special situations described below, a global security will be terminated and interests in it will be exchanged for certificates in non-book-entry form (certificated 
securities). After that exchange, the choice of whether to hold the certificated Debt Securities directly or in street name will be up to the investor. Investors must consult their 
own banks or brokers to find out how to have their interests in a global security transferred on termination to their own names, so that they will be holders. We have described 
the rights of legal holders and street name investors under “Issuance of Securities in Registered Form” above.

If a global security is terminated, only the depositary, and not we or the Trustee, is responsible for deciding the names of the institutions in whose names the Debt Securities 
represented by the global security will be registered and, therefore, who will be the holders of those Debt Securities.

Payment and Paying Agents

 
  
  
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
 
We will pay interest to the person listed in the Trustee’s records as the owner of the Debt Security at the close of business on a particular day in advance of each due date for 
interest, even if that person no longer owns the Debt Security on the interest due date. That day, often approximately two weeks in advance of the interest due date, is called the 
“record date.” Because we will pay all the interest for an interest period to the holders on the record date, holders buying and selling Debt Securities must work out between 
themselves the appropriate purchase price. The most common manner is to adjust the sales price of the Debt Securities to prorate interest fairly between buyer and seller based 
on their respective ownership periods within the particular interest period. This prorated interest amount is called “accrued interest.”

Payments on Global Securities

We will make payments on a global security in accordance with the applicable policies of the depositary as in effect from time to time. Under those policies, we will make 
payments directly to the depositary, or its nominee, and not to any indirect holders who own beneficial interests in the global security. An indirect holder’s right to those 
payments will be governed by the rules and practices of the depositary and its participants.

Payments on Certificated Securities

We will make payments on a certificated Debt Security as follows. We will pay interest that is due on an interest payment date by check mailed on the interest payment date to 
the holder at his or her address shown on the trustee’s records as of the close of business on the regular record date. We will make all payments of principal and premium, if 
any, by check at the office of the Trustee in New York, New York and/or at other offices that may be designated by the Trustee or in a notice to holders against surrender of the 
Debt Security.

Alternatively, if the holder asks us to do so, we will pay any amount that becomes due on the Debt Security by wire transfer of immediately available funds to an account at a 
bank in New York City, on the due date. To request payment by wire, the holder must give the Trustee or other paying agent appropriate transfer instructions at least 15 business 
days before the requested wire payment is due. In the case of any interest payment due on an interest payment date, the instructions must be given by the person who is the 
holder on the relevant regular record date. Any wire instructions, once properly given, will remain in effect unless and until new instructions are given in the manner described 
above.

Payment when Offices are Closed

If any payment is due on a Debt Security on a day that is not a business day, we will make the payment on the next day that is a business day. Payments made on the next 
business day in this situation will be treated under the indenture as if they were made on the original due date. Such payment will not result in a default under any Debt Security 
or the indenture, and no interest will accrue on the payment amount from the original due date to the next day that is a business day.

Book-entry and other indirect holders should consult their banks or brokers for information on how they will receive payments on their Debt Securities.

Events of Default

You will have rights if an Event of Default occurs in respect of the Debt Securities of your series and is not cured, as described later in this subsection.

The term “Event of Default” in respect of the Debt Securities of your series means any of the following:

•

•

•

•

we do not pay the principal of, or any premium on, a Debt Security of the series on its due date;

we do not pay interest on a Debt Security of the series when due, and such default is not cured within 30 days;

we do not deposit any sinking fund payment in respect of Debt Securities of the series on its due date, and do not cure this default within five days;

we remain in breach of a covenant in respect of Debt Securities of the series for 60 days after we receive a written notice of default stating we are in 
breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of Debt Securities of the series;

 
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
•

•

we file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur and remain undischarged or unstayed for a period of 60 
days; and

on the last business day of each of 24 consecutive calendar months, we have an asset coverage of less than 100%, giving effect to any exemptive relief 
granted to us by the SEC.

An Event of Default for a particular series of Debt Securities does not necessarily constitute an Event of Default for any other series of Debt Securities issued under the same or 
any other indenture. The trustee may withhold notice to the holders of Debt Securities of any default, except in the payment of principal, premium or interest, if it considers the 
withholding of notice to be in the best interests of the holders.

Remedies if an Event of Default Occurs

If an Event of Default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the Debt Securities of the affected series may 
declare the entire principal amount of all the Debt Securities of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. In certain 
circumstances, a declaration of acceleration of maturity may be canceled by the holders of a majority in principal amount of the Debt Securities of the affected series.

The trustee is not required to take any action under the indenture at the request of any holders unless the holders offer the trustee reasonable protection from expenses and 
liability (called an “indemnity”). If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding Debt Securities of the relevant series may 
direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those 
directions in certain circumstances. No delay or omission in exercising any right or remedy will be treated as a waiver of that right, remedy or Event of Default.

Before you are allowed to bypass your trustee and bring your own lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating 
to the Debt Securities, the following must occur:

•

•

•

•

•

•

•

•

the holder must give your trustee written notice that an Event of Default has occurred and remains uncured;

the holders of at least 25% in principal amount of all outstanding Debt Securities of the relevant series must make a written request that the trustee take 
action because of the default and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action;

the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and

the holders of a majority in principal amount of the Debt Securities must not have given the trustee a direction inconsistent with the above notice during 
that 60 day period.

However, you are entitled at any time to bring a lawsuit for the payment of money due on your Debt Securities on or after the due date.

Holders of a majority in principal amount of the Debt Securities of the affected series may waive any past defaults other than:

the payment of principal, any premium or interest; or

in respect of a covenant that cannot be modified or amended without the consent of each holder.

Book-entry and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and 
how to declare or cancel an acceleration of maturity.

Each year, we will furnish to each trustee a written statement of certain of our officers certifying that to their knowledge we are in compliance with the indenture and the Debt 
Securities, or else specifying any default.

Merger or Consolidation

 
 
 
  
  
  
  
  
 
 
 
 
 
 
 
  
  
  
  
 
 
Under the terms of the indenture, we are generally permitted to consolidate or merge with another entity. We may also be permitted to sell all or substantially all of our assets to 
another entity. However, we may not take any of these actions unless all the following conditions are met:

•

•

•

•

•

where we merge out of existence or sell our assets, the resulting entity must agree to be legally responsible for our obligations under the Debt Securities;

immediately after giving effect to such transaction, no Default or Event of Default shall have happened and be continuing;

under the indenture, no merger or sale of assets may be made if as a result any of our property or assets or any property or assets of one of our 
subsidiaries, if any, would become subject to any mortgage, lien or other encumbrance unless either (a) the mortgage, lien or other encumbrance could 
be created;

pursuant to the limitation on liens covenant in the indenture without equally and ratably securing the indenture securities or (b) the indenture securities 
are secured equally and ratably with or prior to the debt secured by the mortgage, lien or other encumbrance; and

we must deliver certain certificates and documents to the trustee.

Modification or Waiver

There are three types of changes we can make to the indenture and the Debt Securities issued thereunder.

Changes Requiring Approval

First, there are changes that we cannot make to Debt Securities without specific approval of all of the holders. The following is a list of those types of changes:

•

•

•

•

•

•

•

•

•

•

•

•

change the stated maturity of the principal of or interest on a Debt Security;

reduce any amounts due on a Debt Security;

reduce the amount of principal payable upon acceleration of the maturity of a security following a default;

adversely affect any right of repayment at the holder’s option;

change the place (except as otherwise designed by the Trustee) or currency of payment on a Debt Security;

impair your right to sue for payment;

adversely affect any right to convert or exchange a Debt Security in accordance with its terms;

modify the subordination provisions in the indenture in a manner that is adverse to holders of the Debt Securities;

reduce the percentage of holders of Debt Securities whose consent is needed to modify or amend the indenture;

reduce the percentage of holders of Debt Securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive 
certain defaults;

modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to 
the quorum or voting requirements or the waiver of certain covenants; and

change any obligation we have to pay additional amounts.

Changes Not Requiring Approval

 
  
 
 
 
 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
The second type of change does not require any vote by the holders of the Debt Securities. This type is limited to clarifications and certain other changes that would not 
adversely affect holders of the outstanding Debt Securities in any material respect. We also do not need any approval to make any change that affects only Debt Securities to be 
issued under the indenture after the change takes effect.

 
  
 
 
 
Changes Requiring Majority Approval

Any other change to the indenture and the Debt Securities would require the following approval:

•

•

if the change affects only one series of Debt Securities, it must be approved by the holders of a majority in principal amount of that series; and

if the change affects more than one series of Debt Securities issued under the same indenture, it must be approved by the holders of a majority in 
principal amount of all of the series affected by the change, with all affected series voting together as one class for this purpose. 

The holders of a majority in principal amount of all of the series of Debt Securities issued under an indenture, voting together as one class for this purpose, may waive our 
compliance with some of our covenants in that indenture. However, we cannot obtain a waiver of a payment default or of any of the matters covered by the bullet points 
included above under “—Changes Requiring Approval.”

Further Details Concerning Voting

Debt Securities will not be considered outstanding, and therefore not eligible to vote, if we have deposited or set aside in trust money for their payment or redemption. Debt 
Securities will also not be eligible to vote if they have been fully defeased as described later under “Defeasance—Full Defeasance.”

We will generally be entitled to set any day as a record date for the purpose of determining the holders of outstanding indenture securities that are entitled to vote or take other 
action under the indenture. If we set a record date for a vote or other action to be taken by holders of one or more series, that vote or action may be taken only by persons who 
are holders of outstanding indenture securities of those series on the record date and must be taken within eleven months following the record date.

Book-entry and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the 
indenture or the Debt Securities or request a waiver.

Defeasance

Covenant Defeasance

Under current U.S. federal tax law, we can make the deposit described below and be released from some of the restrictive covenants in the indenture under which the particular 
series was issued. This is called “covenant defeasance.” In that event, you would lose the protection of those restrictive covenants but would gain the protection of having 
money and government securities set aside in trust to repay your Debt Securities. If applicable, you also would be released from the subordination provisions as described under 
the “Indenture Provisions—Subordination” section below. In order to achieve covenant defeasance, we must do the following:

•

•

•

if the Debt Securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such Debt 
Securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, 
principal and any other payments on the Debt Securities on their various due dates;

we must deliver to the trustee a legal opinion of our counsel confirming that, under current U.S. federal income tax law, we may make the above deposit 
without causing you to be taxed on the Debt Securities any differently than if we did not make the deposit and just repaid the Debt Securities ourselves 
at maturity; and

we must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as 
amended, and a legal opinion and officers’ certificate stating that all conditions precedent to covenant defeasance have been complied with.

If we accomplish covenant defeasance, you can still look to us for repayment of the Debt Securities if there were a shortfall in the trust deposit or the trustee is prevented from 
making payment. For example, if one of the remaining Events of Default occurred (such as our bankruptcy) and the Debt Securities became immediately due and payable, there 
might be a shortfall. Depending on the event causing the default, you may not be able to obtain payment of the shortfall.

 
  
  
 
 
 
  
  
  
  
  
    
  
 
 
 
  
  
 
 
 
Full Defeasance

If there is a change in U.S. federal tax law, as described below, we can legally release ourselves from all payment and other obligations on the Debt Securities of a particular 
series (called “full defeasance”) if we put in place the following other arrangements for you to be repaid:

•

•

•

•

•

if the Debt Securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such Debt 
Securities a combination of money and United States government or United States government agency notes or bonds that will generate enough cash to 
make interest, principal and any other payments on the Debt Securities on their various due dates.

we must deliver to the trustee a legal opinion confirming that there has been a change in current U.S. federal tax law or an IRS ruling that allows us to 
make the above deposit without causing you to be taxed on the Debt Securities any differently than if we did not make the deposit and just repaid the 
Debt Securities ourselves at maturity. Under current U.S. federal tax law, the deposit and our legal release from the Debt Securities would be treated as 
though we paid you your share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for your Debt 
Securities and you would recognize gain or loss on the Debt Securities at the time of the deposit;

we must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as 
amended, and a legal opinion and officers’ certificate stating that all conditions precedent to defeasance have been complied with;

Defeasance must not result in a breach of the indenture or any other material agreements; and

Satisfy the conditions for covenant defeasance contained in any supplemental indentures.

If we ever did accomplish full defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the Debt Securities. You could not look to us 
for repayment in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever 
became bankrupt or insolvent. If applicable, you would also be released from the subordination provisions described later under “Indenture Provisions—Subordination.”

Form, Exchange and Transfer of Certificated Registered Securities

Holders may exchange their certificated securities, if any, for Debt Securities of smaller denominations or combined into fewer Debt Securities of larger denominations, as long 
as the total principal amount is not changed.

Holders may exchange or transfer their certificated securities, if any, at the office of their trustee. We have appointed the trustee to act as our agent for registering Debt 
Securities in the names of holders transferring Debt Securities. We may appoint another entity to perform these functions or perform them ourselves.

Holders will not be required to pay a service charge to transfer or exchange their certificated securities, if any, but they may be required to pay any tax or other governmental 
charge associated with the transfer or exchange. The transfer or exchange will be made only if our transfer agent is satisfied with the holder’s proof of legal ownership.

We may appoint additional transfer agents or cancel the appointment of any particular transfer agent. We may also approve a change in the office through which any transfer 
agent acts.

If any certificated securities of a particular series are redeemable and we redeem less than all the Debt Securities of that series, we may block the transfer or exchange of those 
Debt Securities during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders 
to prepare the mailing. We may also refuse to register transfers or exchanges of any certificated securities selected for redemption, except that we will continue to permit 
transfers and exchanges of the unredeemed portion of any Debt Security that will be partially redeemed.

Resignation of Trustee

Each trustee may resign or be removed with respect to one or more series of indenture securities provided that a successor trustee is appointed to act with respect to these series. 
In the event that two or more persons are acting as trustee with respect to different series 

 
  
  
 
 
 
 
 
  
  
  
  
  
  
  
  
  
 
 
of indenture securities under the indenture, each of the trustees will be a trustee of a trust separate and apart from the trust administered by any other trustee.

Indenture Provisions—Subordination

Upon any distribution of our assets upon our dissolution, winding up, liquidation or reorganization, the payment of the principal of (and premium, if any) and interest, if any, on 
any indenture securities denominated as subordinated Debt Securities is to be subordinated to the extent provided in the indenture in right of payment to the prior payment in 
full of all senior indebtedness (as defined below), but our obligation to you to make payment of the principal of (and premium, if any) and interest, if any, on such subordinated 
Debt Securities will not otherwise be affected. In addition, no payment on account of principal (or premium, if any), sinking fund or interest, if any, may be made on such 
subordinated Debt Securities at any time unless full payment of all amounts due in respect of the principal (and premium, if any), sinking fund and interest on senior 
indebtedness has been made or duly provided for in money or money’s worth.

In the event that, notwithstanding the foregoing, any payment by us is received by the trustee in respect of subordinated Debt Securities or by the holders of any of such 
subordinated Debt Securities before all senior indebtedness is paid in full, the payment or distribution must be paid over to the holders of the senior indebtedness or on their 
behalf for application to the payment of all the senior indebtedness remaining unpaid until all the senior indebtedness has been paid in full, after giving effect to any concurrent 
payment or distribution to the holders of the senior indebtedness. Subject to the payment in full of all senior indebtedness upon this distribution by us, the holders of such 
subordinated Debt Securities will be subrogated to the rights of the holders of the senior indebtedness to the extent of payments made to the holders of the senior indebtedness 
out of the distributive share of such subordinated Debt Securities.

By reason of this subordination, in the event of a distribution of our assets upon our insolvency, certain of our senior creditors may recover more, ratably, than holders of any 
subordinated Debt Securities. The indenture provides that these subordination provisions will not apply to money and securities held in trust under the defeasance provisions of 
the indenture.

Senior indebtedness is defined in the indenture as the principal of (and premium, if any) and unpaid interest on:

•

•

our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed (other than 
indenture securities issued under the indenture and denominated as subordinated Debt Securities), unless in the instrument creating or evidencing the same or under 
which the same is outstanding it is provided that this indebtedness is not senior or prior in right of payment to the subordinated Debt Securities; and

renewals, extensions, modifications and refinancings of any of this indebtedness. 

The Trustee under the Indenture

U.S. Bank National Association is the trustee under the indenture.

 
  
  
  
  
  
  
  
 
    
  
  
 
 
 
 
This Agreement (the “Agreement”) is made as of November 9, 2021 (the “Effective Date”) between:

(1)

 Each entity identified on Appendix A, whose jurisdiction of formation is identified opposite its name (the “Client”); and

CUSTODY AGREEMENT

(2) STATE STREET BANK AND TRUST COMPANY, a bank and trust company organized under the laws of The Commonwealth of Massachusetts, U.S.A. 

Exhibit 10(zz)

Execution Version

(the “Custodian”).

1

Definitions and Interpretation

            Defined terms and the general rules of interpretation agreed by the Parties are set forth in Schedule 1.   

2

3

Appointment of the Custodian

The Client hereby appoints the Custodian to provide the services set out in Sections 3 through 15 below (the “Services”) subject to and in accordance with 
the terms of this Agreement. 

Safekeeping Securities

3.1  Holding Securities.   The  Custodian  will  hold  Securities  delivered  or  credited  to  its  account  under  this  Agreement  directly  or  through  accounts  at 

Subcustodians or CSDs. In turn, Subcustodians will hold Securities directly or through accounts at CSDs.

3.2  Client Entitlements and Segregation. The Custodian will take the following steps to reflect the Client’s ownership of Securities and to separately 
identify the Securities of the Client from the proprietary assets of the Custodian, Subcustodians, and CSDs, in accordance with Local Market 
Practice: 

1.3.1

1.3.2

1.3.3

1.3.4

1.3.5

Accounts at the Custodian. Open and maintain on the records of the Custodian one or more securities accounts in the name of the 
Client or such other name as the Client may reasonably request (each, a “Securities Account”) and credit Securities to them;

Accounts  at  the  Subcustodians  or  CSDs.    Open  and  maintain  securities  accounts  at  the  Subcustodians  or  CSDs  in  which  the 
Custodian is a direct participant, cause Subcustodians to open and maintain securities accounts at CSDs in which the Subcustodian
is a participant, and cause Securities to be credited to the relevant accounts. Such accounts: (i) may be commingled (or omnibus) 
accounts  for  Securities  of  multiple  customers  of  the  Custodian  (or  Subcustodian,  in  the  case  of  accounts  opened  by  the 
Subcustodian  at  a  CSD)    or,  in  limited  markets,  segregated  (or  separate)  accounts  for  Securities  of  the  Client;  and  (ii)    must  not 
include any proprietary securities of the Custodian, the Subcustodian or the CSD;

Physical  Securities.  Physically  segregate  bearer  Securities  from  the  proprietary  assets  of  the  Custodian,  and  require  that  the 
Subcustodians physically segregate bearer Securities from the Subcustodian’s and the Custodian’s proprietary assets;

Registration Names.  Register certificated Securities (other than bearer securities) in the name of the Client or in the name of the 
Custodian, a Subcustodian, a CSD or a nominee of any of them, or otherwise in accordance with Local Market Practice and the laws 
and regulations applicable to the Custodian; and

Records of Transactions; Reconciliation. Maintain records of the Client’s transactions in the Securities Accounts and reconcile its 
records  of  clients’  securities  holdings  against  the  records  of  its  Subcustodians  and  CSDs  in  which  it  is  a  direct  participant  in 
accordance with the Custodian’s standard 

 
procedures and Local Market Practice. Subcustodians will likewise maintain records of their client’s transactions and reconcile their 
records of the securities holdings of their clients against the records of the CSDs in which they are a direct participant in accordance 
with the Subcustodians’ standard procedures and Local Market Practice.

Securities Interchangeable. Securities of the Client (whether held in separate or commingled accounts) are fungible with all other securities of 
the same issue held in such accounts by the Custodian and its Subcustodians.  This means that the Client’s redelivery rights in respect of the 
Securities are not in respect of the Securities actually deposited with the Custodian or a Subcustodian from time to time, but rather in respect of 
Securities of the same number, class, denomination and issue as those Securities. 

Acceptance of Securities. Except as otherwise agreed in writing with the Client, the Custodian will only accept custody of Securities and other 
assets that it is operationally equipped and licensed to hold in the relevant market where it provides custodial services either directly or through 
an existing Subcustodian and may decline to accept custody of certain securities or asset types that it determines present an unacceptable risk 
profile or that it or its Subcustodians are not operationally equipped or permitted to hold under any law or regulation.

1.4

1.5

4

Cash 

4.1   Cash Accounts.  The Custodian will open and maintain in the name of the Client one or more cash deposit accounts (each a “Cash Account”) in 

such currencies as may be required in connection with the investment activity of the Client.  

4.2   Location of Cash Deposits.  Cash received for the Client will be deposited with the Custodian, or with a Subcustodian, depending on the currency 
and/or  the  market.  The  Custodian  will  designate  each  currency  in  a  particular  market  as  On  Book  Cash  or  Off  Book  Cash.  “On  Book  Cash” 
means the currency is maintained in a deposit account with, and recorded as a liability on the balance sheet of, the Custodian (through any of 
its branches) and “Off Book Cash” means the currency is maintained in a deposit account with, and recorded as a liability on the balance sheet 
of, a Subcustodian (through any of its branches).  The Custodian may change the designation of a currency as On Book or Off Book from time 
to  time.    Clients  will  find  the  designation  of  currencies  as  On  Book  Cash  and  Off  Book  Cash,  and  any  changes  to  such  designations,  in  the 
Client Publications. 

4.3   Cash Records.  The Custodian will reflect Cash balances held in all On Book and Off Book Client deposit accounts on its books and records and 

report the balances to the Client. 

4.4   Banking Relationship.  In accepting deposits under this Agreement, the Custodian  (for On Book Cash) or the relevant Subcustodian (for Off Book 
Cash) acts as banker and does not hold the money deposited on trust or segregated from its proprietary assets. Accordingly, the Client is an 
unsecured creditor of the Custodian (for On Book Cash) or the relevant Subcustodian (for Off Book Cash), subject to such rights as may arise 
in an Insolvency Event as determined under the laws of the jurisdiction of the Custodian or relevant Subcustodian. With respect to Off Book 
Cash, the Custodian is only responsible for returning the actual amount that the Custodian receives from the Subcustodian.  

4.5  Interest and Charges. Cash Accounts may be interest bearing or non-interest bearing and may be subject to charges or fees on the deposit balance 

or on a per account basis. The Custodian or the relevant Subcustodian will determine on a periodic basis:

5.1.1

5.1.2

the interest rates, if any, (which may be positive, zero or negative) or equivalent charges or fees paid or charged to the Client 
from time to time with respect to a Cash Account; and 

the overdraft rates or equivalent charges or fees and the applicable overdraft thresholds (if any) that will trigger interest charges 
from time to time for overdrafts,

in each case, acting in their sole discretion, taking into account market conditions and other relevant commercial considerations. Interest and 
overdraft rates or other account charges or fees will vary by currency. Details on current rates and deposit account charges are available upon 
request. 

4.6   Overdrafts. The Client must maintain sufficient funds in the Cash Accounts to settle all transactions in the applicable currencies in a timely manner. 
The  Custodian  or  its  Subcustodians  may,  but  are  not  required  to,  extend  credit  under  this  Agreement.  The  Custodian  reserves  the  right  to 
decline to process any Proper Instruction or settle any transaction that would result in an overdraft of the Cash Account. If an overdraft arises in 
the Cash Account, the Client agrees to repay the principal amount of the overdraft upon demand by the Custodian or within five Business Days, 
whichever is earlier, plus any applicable overdraft fees and interest on the principal overdraft.

6

Transaction Settlement

6.1

6.2

6.3

6.4

6.5

Settlement. The Custodian will settle all transactions in accordance with Local Market      Practice, which may not always be on a delivery-
versus-payment  or  receipt-versus-payment  basis.  Except  as  otherwise  provided  below  regarding  Contractual  Settlement,  the  Custodian  will 
credit or debit the appropriate Cash Account on an actual settlement or payment basis. 

Contractual Settlement. In order to facilitate transaction settlement, the Custodian may provisionally credit settlement, maturity or redemption 
proceeds, or income, dividends and other distributions, on a contractual settlement or predetermined income basis (“Contractual Settlement”), 
for markets, securities and eligible clients as determined and notified by the Custodian in the Client Publications.  The Custodian can terminate 
or suspend Contractual Settlement for markets, securities or particular clients at any time.

Use  of  Funds.  Where  Contractual  Settlement  applies,  the  Custodian  will  credit  or  debit  the  appropriate  Cash  Account  on  the  contractual 
settlement date or payable date for the relevant transaction. This means that (i) the Client will have use of the funds from the date that a sale 
was contracted to settle or the payable date, which may be earlier than the date payment actually occurs and (ii) the Custodian will have use of 
the funds debited from the Cash Account from the date that a purchase was contracted to settle until the date that settlement actually occurs.

Reversal.  The Custodian may reverse any Contractual Settlement credit at any time before actual receipt of the cash payment associated with 
the credit if the Custodian determines, in its reasonable judgement, that such payment will not be received within 30 days for that transaction or 
if the Custodian suspends or terminates the provision of Contractual Settlement for those Securities in that market. The Custodian will generally 
notify the Client two Business Days before any such reversal. 

Secured Liability. To the extent that the Custodian has not received the cash payment associated with a credit, the amount credited remains a 
Secured Liability under this Agreement.

7

Corporate Actions 

7.1

7.2

Transmit Information. The Custodian will promptly transmit or make available to the Client all material written information customarily provided 
by a professional global custodian regarding an applicable Corporate Action, or a brief synopsis of that information, affecting Securities then 
being held under this Agreement, where (i) that information is received  directly from issuers of such Securities or from CSDs or Subcustodians 
or  (ii)  that  information  is  publicly  available  in  the  relevant  market  from  standard  vendors  routinely  used  by  professional  global  custodians 
provided that the Custodian can verify the accuracy of such information.  The Custodian will transmit or make available such Corporate Action 
data  it  receives  from  primary  sources  (issuers,  CSDs  and  Subcustodians)  without  further  review  although  it  will  generally  note  if  such 
information  is  single  sourced.  The  Custodian  generally  will  not  transmit  or  make  available  such  Corporate  Action  data  it  receives  from 
secondary sources (vendors) unless the accuracy of that information can be verified against at least one additional source.

Exercise. The Custodian will process the Client’s elections with respect to any voluntary Corporate Action at the direction of the Client provided 
it has actual possession of the relevant Securities and it has received Proper Instructions by the deadline specified in the Custodian’s Corporate 
Action  notification  (“Corporate  Actions  Deadline  Date”).  The  Custodian  will  use  reasonable  efforts  to  effect  Proper  Instructions  received  after 
that deadline but will have no responsibility for any failure to exercise such instructions accurately or timely. In the absence of receiving Proper 
Instructions by the Corporate Actions Deadline Date, the Custodian may take the 

default action specified in the corporate action notification. In the event of a mandatory Corporate Action, the Custodian will act without Proper 
Instructions in accordance with Section 22.10.  

7.3

Class Actions.  The Custodian will transmit written information received by the Custodian regarding any class action litigation to the extent set 
out  in  the  Client  Publications.  The  Custodian  will  not  support  class  action  participation  by  the  Client  beyond  such  forwarding  of  written 
information.  In no event will the Custodian act as a lead plaintiff in a class action. 

7.4

Fractional Positions. Fractional positions resulting from Corporate Actions will be dealt with in accordance with the Client Publications. 

8

Proxy Servicing

8.1

8.2

Transmit Information.  The Custodian will forward to the Client all proxies received by the Custodian relating to the Securities then held under 
this  Agreement,  for  the  markets  designated  in  the  Client  Publications,  unless  otherwise  instructed  by  the  Client.  The  Custodian  will  use  an 
agent to assist in the receipt and distribution of proxies and will share the Client’s position and contact information to facilitate such collection 
and distribution. 

Voting. The Custodian provides proxy voting services for the markets designated in the Client Publications. The Custodian will cause eligible 
proxies to be promptly executed by the registered holder in accordance with Proper Instructions and delivered to the issuer of the Securities or 
its designated agent.   In order for the Custodian to provide the voting services, the Custodian must have received such Proper Instructions, 
must have actual possession of the relevant Securities, and all requirements set out in the Client Publications must have been met, including 
where applicable receiving an executed power of attorney, in each case by the deadline specified in the Custodian’s proxy notification. 

9

Income Collection

9.1

9.2

Monitoring and Crediting. The Custodian will use reasonable efforts to monitor and collect on a timely basis, in accordance with Local Market 
Practice, all income and other payments to which the Client is entitled in respect of the Securities held under this Agreement and Securities on 
loan through the securities lending program sponsored by the Custodian or its Affiliates.  The Custodian will credit such amounts to the Cash 
Account of the Client as received, except where Contractual Settlement applies. 

Repatriation of Income.  The Client is responsible for directing the repatriation of income into the base currency of the Portfolio or another 
currency selected by the Client, and may enter into separate arrangements to do so, as set out in Section 13 of this Agreement.

10 Statements and Reports

10.1

10.2

Contents. The  Custodian  will  make  available  reports  to  the  Client  regarding  the  Portfolio  on  a  periodic  basis  as  selected  by  the  Client  from 
certain online tools made available from time to time by the Custodian or as otherwise agreed with the Client. The reports will include Cash 
balances,  an  itemized  statement  of  Securities  and  Cash  and  Securities  transaction  activity.    Market  values  contained  in  these  reports  are 
unaudited and based on the Custodian’s standard pricing vendors and practices. These reports will not include net asset value calculations.

Cash and Securities Not Held. The Custodian may agree to incorporate information in respect of cash or securities not held by the Custodian. 
In making available such information to the Client, the Custodian will rely upon the information provided by the Client or a third party without any 
requirement to verify the accuracy of such information.  The Custodian will not perform any other Services in relation to such cash or securities.

11 Tax Withholding and Tax Relief

11.1

Withholding. The Custodian will withhold (or cause to be withheld) the amount of any tax which is required to be withheld by the Custodian or 
Subcustodian  under  the  Law  applicable  to  the  Custodian  or  Subcustodian  based  on  the  Client’s  domicile  and  entity  type  in  respect  of  any 
dividend, interest income or other distribution in relation to any Security, and/or the proceeds or income from the sale or other transfer of any 
Security held by 

11.2

11.3

the Custodian.  If the Client has not provided the requisite information and documentation, the Custodian is obligated to arrange for maximum 
withholding. In certain markets, the Client will be required to hire a local tax agent to calculate withholding, as set out in the Client Publications.

Tax Relief. The Custodian will apply for a reduction of withholding tax and refund of any tax paid or tax credits in respect of income payments 
on  Securities  based  on  the  Client’s  entitlement  under  relevant  tax  treaties  or  laws  which  apply  in  each  market  that  supports  a  standard  tax 
reclaim process, in all cases as may be set out from time to time in the Client Publications. The Custodian does not facilitate tax reclaims for tax 
transparent or pass-through (i.e., multiple-beneficiary) entities such as partnerships, LLCs, common trusts or any other types of entities that are 
generally ineligible for tax treaty or domestic law tax entitlements, even where the partners or beneficial holders of such entities may be eligible.  

Documentation.  In order for the Custodian to perform the services in this Section 10, the Client will provide the Custodian such information 
and documentation as may be required from time to time by the Custodian for tax purposes, including documentary evidence of its tax domicile, 
and  its  entity  type  and  details  of  any  special  ruling  or  treatment  to  which  the  Client  may  be  entitled  in  relation  to  countries  where  the  Client 
engages  or    proposes  to  engage  in  investment  activity  or  where  Securities  are  or  will  be  held.  The  Client  is  responsible  for  ensuring  the 
documentation and information provided is true and accurate in all material respects and will promptly provide the Custodian with all necessary 
corrections or updates upon becoming aware of any changes or inaccuracies in the documentation or information supplied. The provision of 
documentation and information under this Section 10.3 will be taken to be a Proper Instruction upon which the Custodian will be entitled to rely 
for all purposes under this Section 10, including calculating withholding and determining available tax relief, without the need to undertake any 
further inquiries or verification. 

11.4

Client  Responsible  for  Taxes.  The  Client  will  be  liable  for  all  taxes,  levies  or  similar  obligations  which  arise  as  a  result  of  the  Client’s 
investment activity, including in relation to any Cash or Securities held by the Custodian on behalf of the Client, or any related transactions. If 
any taxes become payable in relation to any prior payment made to the Client by the Custodian, the Custodian may withhold any credit balance 
in the Client’s Cash Accounts to the extent necessary to satisfy such tax obligation. The Client will also remain liable for any tax deficiency.

11.5

No Tax Advice. The Client acknowledges that the Custodian is not, and will not be deemed to be, providing tax advice or tax counsel.

12 Physical Safekeeping of Investment Documents 

12.1

Document Safekeeping. The Custodian may agree to provide physical safekeeping for Investment Documents delivered to it  and will return 
such Investment Documents to the Client upon receipt of Proper Instructions, subject to additional documentation and other requirements as 
the Custodian may specify from time to time. 

12.2

No Other Services. The Custodian will not otherwise perform any other Services in relation to such Investment Documents.

13 Alternative Asset Servicing

13.1

Alternative Assets. The Custodian may agree to reflect the Client’s Alternative Assets on its books, records or statements. Unless otherwise 
agreed in writing, the Custodian will not perform any other services or assume any obligations in relation to Alternative Assets. The Custodian 
may,  in  limited  cases,  agree  to  register  the  Client’s  interests  in  Alternative  Assets  in  the  name  of  the  Custodian,  subject  to  additional 
documentation and other requirements as the Custodian may specify from time to time.  

14 Foreign Exchange 

14.1

Role  of  Custodian.  The  role  of  the  Custodian  with  respect  to  foreign  exchange  transactions  is  limited  to  facilitating  the  processing  and 
settlement of such transactions. The Custodian does not have any agency, trust 

or fiduciary obligation to the Client or any other person in connection with the execution of any foreign exchange transactions, other than the 
obligation as agent to process the Proper Instructions given by the Client.

14.2

Role of Counterparties. If the Client enters into any foreign exchange transaction with State Street Bank and Trust Company, a Subcustodian 
or any of their Affiliates, the Client does so on the basis that these entities are acting as a principal dealer and counterparty, and not as fiduciary 
or  agent  to  the  Client,  and  the  execution  services  are  governed  by  separate  arrangements  (including  pricing)  and  do  not  form  part  of  the 
Services provided by the Custodian under this Agreement. This applies to foreign exchange transactions entered into by the Client directly with 
the trading desk of these entities or by Proper Instruction to the Custodian using the indirect foreign exchange services described in the Client 
Publications.

15 Subcustodians

15.1

15.2

15.3

Use of Subcustodians. The Custodian is authorized to utilize Subcustodians in connection with its performance of the Services, and will notify 
the Client of the Subcustodians so employed from time to time through the Client Publications.    

Selection and Monitoring.  The Custodian will use reasonable skill, care and diligence in the selection, monitoring and continued utilization of 
Subcustodians  by  taking  the  following  actions:    (i)  annually  assess  the  financial  condition  of  each  Subcustodian  by  reviewing  their  publicly 
available financial information, (ii) on a daily basis monitoring the performance by each Subcustodian’ of its duties relative to the Services, and 
(iii) confirming on an annual basis that each Subcustodian is licensed to act as a subcustodian in its relevant market.  

Special Subcustodians.  At the request of the Client, the Custodian may agree to appoint one or more qualified banks, trust companies or 
other  entities  designated  by  the  Client  to  act  as  a  subcustodian  (each  a  “Special  Subcustodian”)    for  purposes  specified  by  the  Client.    In 
connection with the appointment of a Special Subcustodian, the Custodian shall enter into a tri-party subcustodian agreement with the Special 
Subcustodian and the Client in form and substance approved the Custodian, provided that such agreement shall comply with Law applicable to 
the Client and shall be consistent with the terms and provisions of this Agreement, to the extent practicable.

16 Central Securities Depositories 

16.1

16.2

Use  of  Central  Securities  Depositories.  The  Custodian  and  its  Subcustodians  will  use  CSDs  in  connection  with  the  performance  of  the 
Services, and will notify the Client of the CSDs so employed from time to time through the Client Publications. 

Rules of Central Securities Depositories.   Where the Custodian or its Subcustodians use CSDs, the Client acknowledges that they will do so 
in  accordance  with  the  terms  and  conditions  of  participation  or  membership  in  such  CSDs  and  the  rules  and  procedures  governing  the 
operation thereof.

17 Delegation

17.1

17.2

Use of Delegates. The  Custodian  will  have  the  right,  without  prior  notice  to  or  the  consent  of  the  Client,  to  employ  Delegates  to  provide  or 
assist it in the provision of any part of the Services other than Services required by Law applicable to either Party to be performed by a qualified 
custodian or CSD. Unless otherwise agreed in a fee schedule, the Custodian will be responsible for the compensation of its Delegates. 

Provision of Information Regarding Delegates. The Custodian will provide or make available to the Client on a quarterly or other periodic 
basis information regarding its global operating model for the delivery of the Services, which information will include the identities of Delegates 
affiliated  with  the  Custodian  that  perform  or  may  perform  any  part  of  the  Services,  and  the  locations  from  which  such  Delegates  perform 
Services, as well as such other information about its Delegates as the Client may reasonably request from time to time.  

17.3

Third Parties. Nothing in this Section limits or restricts the Custodian’s right to use Affiliates or third parties to perform or discharge, or assist it 
in the performance or discharge of, any obligations or duties under this Agreement other than the provision of the Services. 

18 Standard of Care and Liability 

18.1

18.2

Standard  of  Care.  The  Custodian  will  at  all  times  exercise  the  reasonable  skill,  care  and  diligence  expected  of  a  professional  provider  of 
custody services to institutional investors and act in good faith and in accordance with generally applicable industry standards and practices in 
the performance of its duties under this Agreement.

Liability for Losses. Subject to the limitations and exclusions of liability in this Agreement, the Custodian will be liable for Losses suffered or 
incurred by the Client to the extent such Losses are caused by the negligence, wilful default, or fraud of the Custodian in the performance of its 
obligations  under  this  Agreement.  The  parties  agree  that  “negligence”  will  mean  a  breach  by  the  Custodian  of  its  obligation  to  exercise  the 
standard of care described in Section 17.1 above. 

18.3

Responsibility  for  Subcustodians.  The  Custodian  will  be  liable  to  the  Client  for  the  acts  and  omissions  of  its  Subcustodians  as  if  it  had 
committed such acts and omissions itself; provided that:

18.3.1

18.3.2

compliance  with  the  standard  of  care  set  out  in  Section  17.1  will  be  assessed  in  accordance  with  the  standards  and 
circumstances  prevailing  at  the  time  of  the  act  or  omission  in  the  local  market  or  jurisdiction  in  which  the  Subcustodian  is 
providing the relevant Services; and

the Custodian will  have no liability for Losses resulting from the insolvency or other financial default of a Subcustodian that is 
not an Affiliate of the Custodian except to the extent that such Losses are caused by the failure of the Custodian to exercise 
reasonable skill, care and diligence in the selection, monitoring and continued utilization of the Subcustodian as required under 
Section 14.2. 

18.4

18.5

18.6

Responsibility for Special Subcustodians. Notwithstanding the provisions of Section 17.3 to the contrary, the Custodian shall not be liable to 
the Client for Losses suffered or incurred by the Client resulting from the acts or omissions of a Special Subcustodian, except to the extent such 
Losses  are  caused  by  the  negligence,  wilful  default  or  fraud  of  the  Custodian.    In  the  event  of  any  such  Loss,  the  Custodian  shall  use 
commercially reasonable efforts to enforce such rights as it may have against any Special Subcustodian.

 Responsibility for Delegates. The Custodian will be liable to the Client for the acts and omissions of its Delegates as if it had committed such 
acts and omissions itself. 

Force Majeure. Neither Party will be in breach of this Agreement or liable for Losses arising by reason of the occurrence of a Force Majeure 
Event that prevents, hinders or delays it from or in performing its obligations under this Agreement, except, in the case of the Custodian, to the 
extent that such Losses are attributable to its breach of its business continuity obligations under this Agreement.

18.7

No Liability for Certain Losses. The Custodian will not be liable to the Client for any Losses to the extent they arise from or are caused by: 

18.7.1

18.7.2

the Custodian acting upon any (i) Proper Instruction or (ii) if a Proper Instruction is not required in a particular circumstance, any 
other  instruction,  information,  notice,  request,  consent,  certificate,  instrument  or  other  writing  that  the  Custodian  reasonably 
believes to be genuine and to be signed or otherwise given by or on behalf of a person authorized to do so; 

a delay in processing or any failure to process any Proper Instruction to the extent permitted under Section 22, subject to the 
satisfaction of the conditions set out in that Section, as applicable;  

18.7.3

the failure of the Client or any person authorized by it to comply with the Client’s obligations under this Agreement; or

18.7.4

any  other  acts  and  omissions  of  the  Client,  any  person  authorized  by  it  or  any  third  party,  including  any  Third  Party  Agent, 
Market Participant, Authorized Data Source, CSD, or Financial Market Utility.  

18.8

Mutual Exclusion of Indirect and Other Loss.  Notwithstanding any other provision of this Agreement, neither Party will be liable to the other 
for:    (i)  indirect,  consequential,  speculative,  punitive  or  special  Loss  or  (ii)  loss  of  profit,  revenue,  opportunity,  business,  anticipated  savings, 
goodwill and damage to reputation, or Loss of any similar kind; in each case whether or not a Party has been advised of or otherwise could 
have anticipated the possibility of such losses, except to the extent any such losses cannot be excluded or limited as a matter of Law applicable 
to either Party. 

19 Error Correction

19.1

Error Correction.  If an error results from an act or omission of the Custodian in performing the services under this Agreement, the Custodian 
may  take  such  remedial  action  as  it  considers  appropriate  under  the  circumstances,  which  may  include  effecting  corrective  transactions 
involving the Client’s assets, where and to the extent reasonably necessary to place the Client in the position (or its equivalent) it would have 
been  had  the  error  not  occurred.    The  Custodian  will  be  responsible  for  Losses  arising  from  its  errors  in  accordance  with  the  terms  of  this 
Agreement and will be entitled to retain gains arising from its errors or related remedial actions unless otherwise prohibited by Law.  Where an
error results in a series of related Losses and gains, the Custodian will be entitled to net gains against Losses when permitted by Law.  The 
Custodian will have no duty to notify or account to the Client for any Loss or gain associated with an error it has fully remediated.

20 Limits on the Scope of the Services

20.1

20.2

20.3

20.4

20.5

20.6

No Fiduciary or Implied Duties. The Custodian is responsible only for the duties it has expressly undertaken under this Agreement and no 
other  duties  will  be  implied  or  inferred,  including  any  fiduciary  duties,  except  to  the  extent  such  fiduciary  duties  may  not  be  disclaimed  as  a 
matter of Law.

Investment and Other Risk, Client Compliance Matters. The Client bears the risk of investing in Securities or other assets or holding cash 
denominated  in  any  currency  or  holding  assets  in  a  particular  market,  including  investment  risk  and  risk  arising  from  the  political,  regulatory, 
legal or financial infrastructure of such market or otherwise arising from Local Market Practice. The Custodian is not responsible for monitoring 
or enforcing compliance by the Client or its Investment Manager(s) with any investment or other restriction, guideline or requirement imposed 
by the Client’s constituent documents or by contract or Law applicable to the Client in connection with investment activity undertaken by or on 
behalf of the Client. 

Data  Accuracy.    The  Custodian  has  no  responsibility  for,  or  duty  to  review,  verify  or  otherwise  perform  any  investigation  as  to  the 
completeness, accuracy or sufficiency of, any data or information provided by or on behalf of the Client, any persons authorized by the Client, 
any  Third  Party  Agent,  any  Market  Participant  or  any  Authorized  Data  Sources,  except  to  the  extent  the  Custodian  has  agreed  in  writing  to 
perform reconciliations, variance or tolerance checks or other specific forms of data review under this Agreement.

Title.  The Custodian is not responsible for title or entitlement to, validity or genuineness, including good deliverable form, of any asset received 
by the Custodian. 

Proceedings. The Custodian is not responsible for commencing legal or administrative proceedings on behalf of the  Client or relating to the 
assets held under this Agreement, including in respect of the late payment of income or other payments due to the Client or amounts payable 
on Securities in default if payment is refused after due demand and presentment.

Laws Applicable to the Custodian or Subcustodian. Laws applicable to the Custodian or a Subcustodian may from time to time prohibit or 
cause delays in the Custodian holding assets, acting on Proper Instructions or providing the Services to the Client in the manner contemplated 
by this Agreement. In such cases, the Custodian or Subcustodian will be entitled to comply with the Law and, where permitted by such Law, the 
Parties will seek to resolve the situation to the Parties’ mutual satisfaction.

20.7

Securities on Loan.  Asset servicing is not generally performed for securities on loan unless otherwise noted in this Agreement or agreed by 
the Parties in writing.  Provision of such services with respect to securities on loan may be covered by a separate securities lending or services 
agreement.

21 Indemnity

21.1

21.2

21.3

21.4

21.5

Indemnity by Client. Subject to this Section 20 and the exclusions and limitations of liability elsewhere in this Agreement, including Section 
17.8, the Client will indemnify the Custodian against any direct Losses incurred by the Custodian (including Losses incurred by Subcustodians 
or Delegates for which the Custodian is liable) in connection with the performance of its duties under this Agreement, including acting on Proper 
Instructions  and  Losses  incurred  by  virtue  of  being  the  holder  of  record  of  the  Client’s  Securities,    except,  in  each  case,  to  the  extent  such 
Losses  result  from  the  Custodian’s  negligence,  wilful  default  or  fraud  (or  that  of  its  Subcustodians  or  Delegates)  in  the  discharge  of  the 
Custodian’s duties under this Agreement.

Indemnity  by  Custodian.  Subject  to  this  Section  20  and  the  exclusions  and  limitations  of  liability  elsewhere  in  this  Agreement,  including 
Section 17.7 and 17.8, the Custodian will indemnify the Client against any direct Losses incurred by the Client, in each case, to the extent such 
Losses result from the negligence, wilful default or fraud of the Custodian (or that of its Subcustodians or Delegates) in the discharge of the
Custodian’s duties under this Agreement.

Duty  to  Mitigate.  Each  Party  will  use  reasonable  efforts  to  mitigate  any  Losses  in  respect  of  which  it  claims  indemnification  under  this 
Agreement. 

Notice of Claims. A Party seeking indemnification under this Section (“Indemnified Party”) against a third-party claim (“Indemnified Claim”) will 
promptly provide written notice of such claim to the Party obligated to indemnify (“Indemnifying Party”). The failure to notify the Indemnifying 
Party will not relieve such Party of any liability under this Section, except to the extent that such failure materially prejudices the investigation 
and/or defense of the Indemnified Claim.  

Right to Control Third Party Claims. The Indemnifying Party will, at its own expense, be entitled but not obligated to control and direct the 
investigation and defense of any Indemnified Claim, except where the Custodian is the Indemnified Party and is seeking indemnification from 
multiple customers for claims based on common facts or otherwise related to the Indemnified Claim, in which case the Custodian will have the 
right to control and direct the investigation and defense of such claim, at the expense of (i) the Indemnifying Party or (ii) all of the customers 
from  which  indemnification  is  sought,  including  the  Indemnifying  Party,  pro  rata,  as  appropriate.    Where  the  Indemnifying  Party  controls  and 
directs the investigation of the defence of the Indemnified Claim, the Indemnified Party may retain separate counsel at its own expense. If a 
conflict  of  interest  exists  between  the  Parties  with  respect  to  the  defense  of  such  claim,  the  reasonable  cost  of  separate  counsel  will  be  an 
indemnified expense.

21.6

Settlement  of  Claims.    Neither  Party  may  settle  an  Indemnified  Claim  without  the  consent  of  the  other  Party,  which  consent  will  not  be 
unreasonably withheld, conditioned or delayed, provided that the Indemnifying Party will have the right to settle an Indemnified Claim without 
the consent of the Indemnified Party if such settlement:

21.6.1

21.6.2

21.6.3

involves only the payment of money; 

fully and unconditionally releases the Indemnified Party from any liability in exchange for the amount paid in settlement; and 

does not include any admission of fault or liability in relation to the Indemnified Party.  

21.7

Cooperation.  In all cases, each Party will, as applicable, provide reasonable cooperation and assistance to the other Party and keep the other 
Party apprised as to the status of the Indemnified Claim, including any discussions relating to the settlement of the claim and the details of any 
settlement offer.

22 Obligations of the Client

22.1

22.2

22.3

22.4

22.5

22.6

Provide  Information.  The  Client  will  provide  or  cause  to  be  provided  to  the  Custodian  all  data,  information,  documents  and  instructions 
concerning the Client and the investment activity of the Client in relation to the Portfolio as may be reasonably necessary or as the Custodian 
may reasonably request, in each case in a complete, accurate and timely manner, in order to enable the Custodian to discharge its duties under 
this Agreement.   

AML Compliance.  The Client will comply with all applicable anti-money laundering, sanctions or other financial crime legislation applicable to it 
and will provide the Custodian with all necessary sanctions questionnaires, declarations and other documentation in order for the Custodian to 
comply with its anti-money laundering policy.

Pass Through Representations. To the extent that the Custodian is required to give (or is deemed to have given) any representation, warranty 
or undertaking to a third party relating to the Client in accordance with normal market practice in connection with the execution of transaction 
documents  or  the  issuance  or  transmission  of  trade  notifications,  confirmations  and/or  settlement  instructions,  whether  using  facsimile 
transmission, industry messaging or matching utilities and/or the proprietary software of Third Party Agents and Market Participants, CSDs or 
other Financial Market Utilities, the Client will be deemed to have made such representation, warranty or undertaking to the Custodian.

Operational Requirements.  The Client will adhere to the deadlines and other operational requirements set out in the Client Publications, to 
facilitate meeting the requirements of CSD’s, Third Party Agents and Market Participants.

Client  Review  and  Notification.    In  accordance  with  standard  market  practice,  the  Client  will  employ  commercially  reasonable  review  and 
control measures with respect to information provided by the Custodian under this Agreement and give the Custodian prompt written notice of 
any suspected error or omission or the Client’s inability to access any such Information so as to prevent, stem or mitigate any Losses that may 
arise from the use of inaccurate data or the inaccessibility of data.

Fees.  In consideration for the Services provided by the Custodian, the Client will pay the Fees as agreed in a written fee schedule or otherwise 
agreed in writing by the Parties from time to time. The Fees and any other amounts payable under this Agreement are stated exclusive of any 
sales, use, excise, value-added, services, consumption, withholding or other similar tax that is assessed on the supply of the Services under an 
agreement.  Any such tax will  be payable by the Client. 

22.7

Client Publications.  The Client will ensure that it provides the Custodian with and regularly updates, as necessary, e-mail and other contact 
details for its representatives to enable timely distribution and receipt of the Client Publications.

23 Proper Instructions

23.1

23.2

23.3

Dealings  in  Cash  and  Securities.  The  Custodian  will  effect  all  transactions  and  dealings  in  Cash  and  Securities  under  this  Agreement  in 
accordance with Proper Instructions, subject to any other rights it may have under this Agreement.  

Appointment of Authorized Persons.  The  Client  and  each  Investment  Manager  will  provide  the  Custodian  with  a  list  of  the  names  and  (if 
applicable) signatures, of Authorized Persons in a form agreed by the parties from time to time.  The Custodian may rely upon the authority of 
each Authorized Person until it receives written notice to the contrary from the Client and has had a reasonable time to act on such notice.

Authentication  Procedures.  The  Custodian  will  implement  Authentication  Procedures.    The  Client  acknowledges  that  the  Authentication 
Procedures are intended to provide a commercially reasonable degree of protection against unauthorized transactions of certain types and are 
not designed to detect errors.  Any purported Proper Instruction received by the Custodian in accordance with an Authentication Procedure will 
be 

taken to have originated from an Authorized Person and will constitute a Proper Instruction under this Agreement for all purposes. 

23.4

23.5

23.6

Security  Measures  by  Client.  The  Client  is  responsible  for  ensuring  that  appropriate  security  measures  are  implemented  to  prevent 
unauthorized  disclosure  or  use  of  any  Authentication  Procedure  made  available  to  it  or  an  Investment  Manager  in  connection  with  this 
Agreement.

No Duty to Verify.  Except  to  the  extent  the  Custodian  is  required  to  comply  with  Authentication  Procedures  under  Section  22.3  above,  the 
Custodian has no duty to verify that personnel of the Client or any Investment Manager engaged in investment activity are authorized to do so 
or that any instructions received by the Custodian are duly authorized.  

Decline/Delay  in  Processing.  The  Custodian  reserves  the  right  to  decline  to  process  or  delay  the  processing  of  any  purported  Proper 
Instruction where: 

23.6.1

23.6.2

23.6.3

the Custodian, in good faith, determines that the instruction may not have been properly authorized; 

the instruction is inaccurate, incomplete or unclear; 

the  instruction  conflicts  with  the  terms  of  this  Agreement  or  any  Law  applicable  to  either  Party,  Local  Market  Practice  or  the 
Custodian’s standard operating procedures; or

23.6.4

the Custodian has not been given a reasonable time period to effect the instruction.

In these circumstances, the Custodian will promptly seek authentication, clarification,  correction or amendment of any Proper Instruction, as 
the case may be. 

23.7

Cancellation and Amendment. The Custodian will use reasonable efforts to act on Proper Instructions to cancel or amend previously issued 
Proper Instructions if:

23.7.1

23.7.2

the Custodian has not already acted on the previously issued Proper Instructions; and

the Proper Instruction to cancel or amend is received before the applicable deadlines specified from time to time in the Client 
Publications or applicable event notification.

The Custodian is not responsible or liable if the request to cancel or amend cannot be satisfied.

23.8

23.9

Oral Instructions. If applicable, the Custodian may act on an oral instruction (given in accordance with an agreed Authentication Procedure) 
before receipt of any written confirmation and irrespective of whether any subsequent written confirmation conforms to the oral instruction.

Conflicting Claims. If there is a dispute or conflicting claim with respect to Securities or Cash held by the Custodian under this Agreement, the 
Custodian is entitled to refuse to act on a Proper Instruction of the Client or any Investment Manager in relation to the particular Securities or 
Cash until either (i) the dispute or conflicting claims have been finally determined by a court of competent jurisdiction or settled by agreement 
between the conflicting parties, and the Custodian has received written evidence satisfactory to it of such determination or agreement, or (ii) the 
Custodian has received an indemnity, security or both, satisfactory to it and sufficient to hold it harmless from and against any and all Losses 
which the Custodian may incur as a result of its actions.  

23.10

Matters Not Requiring Proper Instructions. The Client authorises the Custodian in the absence of Proper Instructions to attend to all matters 
which may be necessary or appropriate to discharge its duties and give effect to the terms of this Agreement, including the execution, in the 
Client’s name or on its behalf, of any affidavits, certificates of ownership and other certificates and documents relating to Securities.

24 Creditors Rights

24.1

Security. To secure the full and timely satisfaction of all Secured Liabilities, the Client hereby grants to the Custodian a security interest in and 
a  right  of  retention,  sale  and  set  off,  as  applicable,  against  (i)  all  of  the  Client’s  Cash,  Securities,  and  other  assets,  whether  now  existing  or 
hereafter acquired, in the possession or 

24.2

24.3

24.4

under  the  control  of  the  Custodian  or  its  Subcustodians  pursuant  to  this  Agreement  and  (ii)  any  and  all  cash  proceeds  of  any  of  the  above 
(collectively, the “Collateral”).  

Rights of the Custodian. In the event that the Client fails to satisfy in full any of the Secured Liabilities as and when due and payable, the 
Custodian will have, in addition to all other rights and remedies arising under this Agreement or under applicable Law, the rights and remedies 
of a secured party under applicable Law.   Without prejudice to the Custodian’s other rights and remedies, the Custodian will be entitled, in each 
case as and to the extent reasonably necessary to satisfy in full the Secured Liabilities and any related transaction expenses, to (a) exercise its 
right of retention and withhold delivery of any Collateral and otherwise refuse to act on any Proper Instruction relating to such Collateral, (b) sell 
or otherwise realize any Collateral, and (c) set off the net proceeds of such sale or realization of Collateral and/or the amount of any deposit 
balances standing to the credit of the Client in any Cash Account(s) against such Secured Liabilities. 

Exercise of Rights. The Custodian may exercise its rights and remedies against the Collateral in any manner (including by any method, at any 
time or place, and on any terms) as it deems, in good faith, to be commercially reasonable under the circumstances, and will use reasonable 
efforts  to  effect  any  sale  of  Collateral  at  the  prevailing  market  price  in  the  relevant  market.    Without  limiting  the  foregoing,  the  Client 
acknowledges that it will be commercially reasonable for the Custodian to, among other things: (i) accelerate or cause the acceleration of the 
maturity of any fixed term deposits comprised in the Collateral and (ii) effect any necessary currency conversions through its own trading desk 
at such exchange rates as it determines in its reasonable discretion, which rates may include a mark-up from the rates the Custodian receives 
on the interbank market.  

Notice. The Custodian will use reasonable efforts to give the Client prior notice of any exercise of the right to sell or otherwise realize Collateral 
set forth above, provided that the Custodian will not be obligated to give prior notice to the Client or delay exercising its rights pending or after 
the provision of such notice if, in its reasonable judgment, giving such notice or any such delay would prejudice its ability to obtain satisfaction in 
full of the Secured Liabilities.

25 Confidentiality and Use of Data

25.1

Confidentiality

24.1.1       No Disclosure Without Consent. Subject to Section 24.2 and Section 24.3, Confidential Information will not be disclosed by the 

Receiving Party to any third party without the prior consent of the Disclosing Party. 

1.2.2

No limitations of obligations under Agreement or at Law. Except as expressly contemplated by this Agreement, nothing in 
this Section 24 will limit the confidentiality and data-protection obligations of the Custodian and its Affiliates under this Agreement 
and Law applicable to the Custodian.

1.3

Use of Confidential Information and Data  

24.2.1  Use  of  Confidential  Information  and  Data  generally.   Subject  to  this  Section  24.2  and  Section  24.3,  all  Confidential  Information, 
including Data, will be used by the Receiving Party for the purpose of providing or receiving services, as applicable, pursuant to 
this Agreement or otherwise discharging its obligations under this Agreement.  

24.2.2  Use of Data for Indicators. The Custodian and its Affiliates may use Data to develop, publish or otherwise distribute to third parties 
certain investor behavior “indicators” or “indices” that represent broad trends in the flow of investment funds into various markets, 
sectors or investment instruments (collectively, the “Indicators”), but only so long as (i) the Data is combined or aggregated with 
(A) information relating to other customers of the Custodian and/or (B) information derived from other sources, in each case such 
that the Indicators do not allow for attribution to or identification of such Data with the Client, (ii) the Data represents less than a
statistically  meaningful  portion  of  all  of  the  data  used  to  create  the  Indicators  and  (iii)  the  Custodian  publishes  or  otherwise 
distributes to third 

 
parties  only  the  Indicators  and  under  no  circumstance  publishes,  makes  available,  distributes  or  otherwise  discloses  any  of  the 
Data to any third party, whether aggregated, anonymized or otherwise, except as expressly permitted under this Agreement. 

1.3.3

Economic benefit from Indicators. The Client acknowledges that the Custodian may seek and realize economic benefit from the 
publication or distribution of the Indicators.

1.4

Disclosure of Confidential Information and Data 

25.1.1

Disclosure  of  Confidential  Information  to  Representatives.  The  Receiving  Party  may  disclose  the  Disclosing  Party's 
Confidential  Information  without  the  Disclosing  Party’s  consent  to  its  attorneys,  accountants,  auditors,  consultants  and  other 
similar  advisors  that  have  a  reasonable  need  to  know  such  Confidential  Information  (“Representatives”),  provided  such 
Confidential  Information  is  disclosed  under  obligations  of  confidentiality  that  prohibit  the  disclosure  or  use  of  such  Confidential 
Information  by  the  Representatives  for  any  purpose  other  than  the  specific  engagement  with  the  Receiving  Party  for  which  the 
Representative has been retained and that are otherwise no less restrictive than the confidentiality obligations contained in this 
Agreement.  The  Parties  acknowledge  that  use  of  Confidential  Information  by  a  Representative  to  represent  its  other  clients  in 
dealing  with  the  Disclosing  Party  would  constitute  a  breach  of  this  Section  24.3.    Where  the  Custodian  is  the  Receiving  Party, 
“Representatives” will include its Affiliates and Service Providers (as defined below). 

25.1.2

Disclosure and Use of Confidential Information by Custodian. The Custodian may disclose and permit use (as applicable) of 
Confidential Information of the Client without the Client’s consent:

25.1.2.1 to  its  Affiliates  and  any  of  its  third-party  agents  and  service  providers  (“Service  Providers”)  in  connection  with  the 
provision  of  services,  the  discharge  of  its  obligations  under  this  Agreement  or  the  carrying  out  of  any  Proper 
Instruction, including in accordance with the standard practices or requirements of any Financial Market Utility or in 
connection with the settlement, holding or administration of Cash, Securities or other instruments; 

25.1.2.2 to its Affiliates in connection with the management of the businesses of the Custodian and its Affiliates, including, but 
not  limited  to,  financial  and  operational  management  and  reporting,  risk  management,  legal  and  regulatory 
compliance and client service management and marketing.

Where possible, such Confidential Information must be disclosed under obligations of confidentiality or in a manner 
consistent with industry practice.

Confidential Information and Cloud Computing and Storage. Each Party may store Confidential Information with third-party 
providers  of  information  technology  services,  and  permit  access  to  Confidential  Information  by  such  providers  as  reasonably 
necessary  for  the  receipt  of  cloud  computing  and  storage  services  and  related  hardware  and  software  maintenance  and 
support. Such Confidential Information must be disclosed under obligations of confidentiality.

Disclosure  of  Confidential  Information  to  comply  with  law.  The  Receiving  Party  may  disclose  the  Disclosing  Party's 
Confidential  Information  to  the  extent  such  disclosure  is  required  to  satisfy  any  legal  requirement  (including  in  response  to 
court-issued  orders,  investigative  demands,  subpoenas  or  similar  processes  or  to  satisfy  the  requirements  of  any  applicable 
regulatory authority). 

Harm  of  Unauthorized  Disclosure  of  Confidential  Information.  Each  Party  acknowledges  that  the  disclosure  to  any  non-
authorized  third  party  of  Confidential  Information  or  the  use  of  Confidential  Information  in  breach  of  this  Agreement,  may 
immediately  give  rise  to  continuing  irreparable  injury  inadequately  compensable  in  damages  at  law,  and  in  such  cases  the 
Receiving Party agrees to waive any defense that an adequate remedy at law is available if the Disclosing Party seeks to obtain 
injunctive relief against any such breach or any threatened breach.  

25.1.3

25.1.4

25.1.5

25.1.6

25.1.7

Responsibility for Representatives. Each Party will be responsible for any use or disclosure of Confidential Information of the 
Disclosing  Party  in  breach  of  this  Agreement  by  its  Representatives  as  though  such  Party  had  used  or  disclosed  such 
Confidential Information itself.  

No  Disclosure  to  Custodian  Asset  Manager  Division.  In  no  event  will  the  Custodian  allow  representatives  of  its  asset 
management  division  or  Affiliates  engaged  in  asset  management  to  have  access  to  or  to  use  Confidential  Information  of  the 
Client, including Data.

26

Term and Termination

26.1

Term. This Agreement will commence on the Effective Date and will continue until terminated in accordance with this Section.

26.2 Termination Rights.

26.2.1Prior Notice.  The Parties agree that:

26.2.1.1 the Client may terminate this Agreement by giving not less than 30 days’ prior written notice to the Custodian; and 

26.2.1.2 the Custodian may terminate this Agreement by giving not less than 270 days’ prior written notice to the Client.

26.2.2

Immediate Effect.  A Party may terminate this Agreement with immediate effect at any time by written notice to the other Party, 
if:

26.2.2.1 an Insolvency Event occurs in relation to the other Party;

26.2.2.2 such  other  Party  is  the  Client  and  fails  to  pay  any  undisputed  Fees  as  and  when  due  and  has  failed  to  cure  such 

breach within 30 days of receipt of notice from the Custodian requesting it to do so; or

26.2.2.3 such other Party commits a material breach of an obligation under this Agreement and has failed to cure such breach 

within 30 days of receipt of notice requesting it to do so.

If the Custodian terminates this Agreement pursuant to sub-sections 25.2.2.1 or 25.2.2.2, the Custodian will 
continue to provide the Services for a period of up to 270 days subject to payment in full of any overdue undisputed 
Fees  and  prepayment  of  the  Fees  reasonably  expected  to  be  incurred  during  such  270-day  period,  or  such  other 
financial assurance reasonably acceptable to the Custodian.  

26.3 Actions on Termination.

25.3.1 

Successor  Custodian.  Upon  termination  of  the  Agreement,  the  Custodian  will  deliver  the  Portfolio  to  the  successor  custodian 

designated by the Client in Proper Instructions. 

25.3.2   Remaining Portfolio.   If any part of the Portfolio remains in the possession of the Custodian or its Subcustodians after the date of 
termination because the Client fails to designate a successor custodian or otherwise, the Custodian may continue to provide the 
Services to the Client in consideration of the Fees, as if the Agreement had not terminated. However, the Custodian may, after not 
less  than  30  days’  notice  in  writing  to  the  Client,  cease  providing  the  Services  and  transfer  the  Portfolio  to  the  Client,  and  the 
Client will do all things and execute all documents necessary or desirable in order to effect that transfer. 

25.3.3    Payment  of  Fees.    Upon  termination  of  this  Agreement,  Fees  will  become  due  and  payable  for  the  period  to  the  date  of  such 
termination, or, if later, to the date at which any part of the Portfolio held by the Custodian has been fully transferred to a successor 
custodian or to the Client, other than Fees subject to a bona fide good faith dispute.

27 Representations and Warranties

27.1 Each  Party.    Each  Party  represents  and  warrants  to  the  other  that:  (i)  it  has  the  power  to  enter  into  and  perform  its  obligations  under  this 
Agreement;  and  (ii)  it  has  duly  executed  this  Agreement  by  duly  authorized  persons  so  as  to  constitute  valid  and  binding  obligations  of  that 
Party.   

27.2 Client. The Client further represents and warrants to the Custodian that: (i) it is the beneficial owner of the assets comprising the Portfolio or is 
entitled to deal with the assets comprising the Portfolio under this Agreement as if it were beneficial owner; and (ii) unless otherwise agreed, the 
Client acts as principal for the purposes of this Agreement and not as agent for another person. 

27.3 Custodian.  The Custodian further represents and warrants to the Client that: (i) it holds such authorisations and licences as are necessary to 
lawfully  perform  its  obligations  under  this  Agreement;  and  (ii)  it  will  seek  to  maintain  such  authorisations  and  licenses  for  the  term  of  this 
Agreement.

28 Record Retention and Audit Rights

28.1 Records. The Custodian will retain the records it is required to maintain under this Agreement in accordance with the Law applicable to the 

Custodian. 

28.2 Client and Regulator Access. The Custodian will allow the Client and the Client’s regulators or supervisory authorities to perform periodic on-

site audits as may be reasonably required to examine the Custodian’s performance of the Services. 

28.3 Frequency and Scope.  For inspections requested by the Client (such request will include reasonable advance notice) and agreed to by the 
Custodian, the Custodian reserves the right to impose reasonable limitations on the number, frequency, timing, and scope of such audits.  

28.4 Limitations on Disclosure.  Nothing contained in this Section will obligate the Custodian to provide access to or otherwise disclose: (i) any 
information that is unrelated to the Client and the provision of the Services to the Client; (ii) any information that is treated as confidential under 
the  Custodian’s  corporate  policies,  including,  without  limitation,  internal  audit  reports,  compliance  or  risk  management  plans  or  reports,  work 
papers  and  other  reports,  and  information  relating  to  management  functions;  or  (iii)  any  other  documents,  reports,  or  information  that  the 
Custodian is obligated or entitled to maintain in confidence as a matter of law or regulation.  In addition, any access provided to technology will
be limited to a demonstration by the Custodian of the functionality thereof and a reasonable opportunity to communicate with the Custodian’s 
personnel regarding such technology.

29 Business Continuity, Internal Controls and Information Security

29.1 Business Continuity Plans.  The Custodian will at all times maintain a business contingency plan and a disaster recovery plan and will take 
commercially  reasonable  measures  to  maintain  and  periodically  test  such  plans.    The  Custodian  will  implement  such  plans  following  the 
occurrence of an event which results in an interruption or suspension of the Services to be provided by the Custodian.

29.2 Internal Controls Review and Report. The Custodian will retain a firm of independent auditors to perform an annual review of certain internal 
controls and procedures employed by the Custodian in the provision of the Services and issue a standard System and Organization Controls 1 
or equivalent report based on such review.  The Custodian will provide a copy of the report to the Client upon request.

29.3 Information  Security  Systems  and  Controls.  The  Custodian  will  maintain  commercially  reasonable  information  security  systems  and 
controls, which include administrative, technical, and physical safeguards that are designed to: (i) maintain the security and confidentiality of the 
Client’s  data;  (ii)  protect  against  any  anticipated  threats  or  hazards  to  the  security  or  integrity  of  the  Client’s  data,  including  appropriate 
measures designed to meet legal and regulatory requirements applying to the Custodian; and (iii) protect against unauthorized access to or use 
of the Client’s data. 

29.4 Virus Detection. The Custodian will at all times employ a current version of one of the leading commercially available virus detection software 
programs to test the hardware and software applications used by it to deliver the Services for the presence of any computer code designed to 
disrupt, disable, harm, or otherwise impede operation. 

30 General

30.1

Services Not Exclusive; Acting in Various Capacities. The Custodian, its Subcustodians and their Affiliates are part of groups of companies 
and businesses that, in the ordinary course of their business:

30.1.1

provide a wide range of financial services to many clients of different kinds;

30.1.2

engage  in  transactions  for  their  own  account  (including  acting  as  banker  as  outlined  in  Section  4.4  and  acting  as  foreign  exchange 
counterparty as outlined in Section 13) or for the account of other clients; 

which may result in actual, perceived or potential conflicts between the interests of the Client and the interest of the Custodian, its Subcustodians 
and their Affiliates or between the interests of clients.  The Custodian maintains a conflicts of interest policy, and has implemented procedures and 
arrangements to identify and manage conflicts of interest.

30.2 Disclosure of Conflicts. In connection with the matters outlined in Section 29.1.1, the Custodian, its Subcustodians and their Affiliates:

30.2.1

may do business with each client on different contractual or financial terms;  

30.2.2

will seek to profit and is entitled to receive and retain profits and compensation in connection with such activities without any obligation 
to account to the Client for the same;

30.2.3

may act as principal in its own interests, or as agent for its other clients;  

30.2.4

may act or refrain from acting based upon information derived from such activities that is not available to the Client;

30.2.5

are not under a duty to notify or disclose to the Client any information which comes to their notice as a result of such activities; and

30.2.6

do not have an obligation to consider,  act in, or provide information to the Client in respect of, the interests of the Client in connection 
with  such  activities,  except  to  the  extent  (if  any)  expressly  agreed  in  writing  with  the  Client  under  the  contractual  arrangements 
governing those activities.  

The  Custodian  may  (but  is  not  required  to)  make  any  disclosure  or  notification  in  connection  with  such  activities  to  the  Client  via 
publication on MyStateStreet.com or other notification mechanism. 

30.3 Notice. Unless otherwise specified, all notices, requests, demands and other communications under this Agreement (other than routine 

operational communications), will be in writing and will be taken to have been given:

30.3.1

when delivered by hand;

30.3.2

on the next Business Day after being sent by e-mail (unless the sender receives an automated message that the e-mail has not been 
delivered); 

30.3.3

on the next Business Day after being sent by overnight courier service for next Business Day delivery; or

30.3.4

 on the third Business Day after being sent by certified or registered mail, return receipt requested;

in each case to the applicable Party at the address or e-mail address specified on Schedule 2, or such other address or e-mail address 
as a Party may specify by written notice from time to time.

30.4 Waiver. No failure on the part of any Party to exercise, and no delay on its part in exercising, any right or remedy under this Agreement 

will operate as a waiver, nor will any single or partial exercise of any right or 

remedy preclude any other or further exercise of that right or remedy, or the exercise of any other right or remedy.

30.5 Sole  Remedy.  Subject  to  the  right  to  seek  relief  under  the  specific  circumstances  expressly  permitted  in  this  Agreement,  each  of  the 
Custodian and the Client agrees that, to the maximum extent permitted by law, a claim for breach of contract under and consistent with 
the terms of this Agreement will be the sole and exclusive remedy available for any and all matters arising from or in any way relating to 
this  Agreement,  the  provision  of  the  Services  or  any  conduct  (including  omissions  and  alleged  conduct)  relating  to  the  Agreement  or 
provision of the Services, whether before, during or after the term of this Agreement.  Accordingly, to the maximum extent permitted by 
law, each of the Custodian and the Client, on behalf of itself and its Affiliates, waives any and all other rights and remedies that otherwise 
would be available to such party in law or equity.

30.6 Assignment  and  Successors.  The  terms  of  this  Agreement  are  binding  on  the  Parties’  representatives,  successors  and  permitted 
assigns  and  this  Agreement  and  any  rights  or  obligations  under  this  Agreement  may  not  be  assigned  or  transferred  without  the  prior 
written consent of the other Party. However, in the event that either Party becomes the subject of an Insolvency Event, then such Party will 
have the right to assign or transfer its rights and obligations under this Agreement to any entity to which the Party transfers its business 
and assets (including a bridge bank or similar entity) and the other Party irrevocably consents to such assignment or transfer. 

30.7 Entire Agreement. This Agreement is the complete and exclusive agreement of the Parties regarding the Services and supersedes, as of 
the Effective Date, all prior oral or written agreements, arrangements or understandings between the parties relating to the Services.

30.8 Amendments. This Agreement may be amended by written agreement between the Parties.  However, the Custodian may amend this 
Agreement  by  giving  written  notice  to  the  Client  of  such  proposed  amendment  and  the  Client  will  be  taken  to  have  consented  to  the 
amendment if the Client does not affirmatively object in writing within thirty (30) days.

30.9 Counterparts and Electronic Signatures. This Agreement may be executed in separate counterparts, each of which will be an original, 
but  which  together  will  constitute  one  and  the  same  agreement.  Counterparts  may  be  executed  in  either  original  or  electronically 
transmitted form (e.g., faxes or emailed portable document format (PDF) form), and the Parties adopt as original any signatures received 
in electronically transmitted form. This Agreement may be executed by electronic signature (whatever form the electronic signature takes) 
and the Parties agree that this method of signature is as conclusive of the intention to be bound by this Agreement as if signed by the 
Parties’ manuscript signatures.

30.10Severance. In the event that any part of this Agreement will be determined to be void or unenforceable for any reason, the rest of this 
Agreement  will  be  unaffected  (unless  the  essential  purpose  hereof  is  substantially  frustrated  by  such  determination)  and  will  be 
enforceable in accordance with the rest of its terms as if the void or unenforceable part were not a part of this Agreement.

30.11Survival.  The  provisions  of  Sections  10  (Tax  Withholding  and  Tax  Relief),  17  (Standard  of  Care  and  Liability),  20  (Indemnity),  21 
(Obligations  of  the  Client-Fees),  23  (Creditors  Rights),  24  (Confidentiality  and  Use  of  Data)  and  25.3  (Actions  on  Termination)  are 
continuing obligations and will survive termination of this Agreement for any reason.  

30.12Governing Law and Jurisdiction. This Agreement is governed by and interpreted in accordance with the laws of the Commonwealth of 

Massachusetts, and any disputes which may arise out of, under or 

in connection with this Agreement will be determined by the exclusive jurisdiction of the Massachusetts courts.

30.13Jurisdiction-Specific Terms. The additional Jurisdiction-Specific Terms set out on Schedule 3 will apply with respect to Clients domiciled 

in a designated jurisdiction.

30.14Qualified Financial Contracts. In the event that the Client is domiciled and organized outside of the United States, such Client and the 

Custodian hereby agree to be bound by the terms of the QFC addendum attached hereto as Appendix B.  

30.15The Parties; Additional Clients

30.15.1

30.15.2

 All references in this Agreement to the “Client” are to each of the  entities listed on Appendix A, individually, as if this 
Agreement were between the relevant individual Client and the Custodian.  Any reference in this Agreement to “the 
Parties” shall mean the  Custodian and the individual Client as to which the matter relates.

If any entity in addition to those listed on Appendix A would like the Custodian to render Services under the terms of 
this  Agreement,  the  entity  may  notify  the  Custodian  in  writing.    If  the  Custodian  agrees  in  writing  to  provide  the 
services, Appendix A will be taken to be amended to include such entity as a Client and that entity (together with the 
Custodian) will be bound by all Sections of this Agreement.  

 
Signed by the Parties:

EACH ENTITY SET FORTH ON APPENDIX A

By: Hercules Capital, Inc., its investment manager 

By:          _____________________

Name:   _____________________

Title:  

_____________________

Date:  

_____________________

STATE STREET BANK AND TRUST COMPANY

By:           _____________________

Name:   _____________________

Title: 

_____________________

Date:  

_____________________

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 14.1

CODE OF ETHICS

This  Code  of  Ethics  (the  “Code”)  has  been  adopted  by  the  Board  of  Directors  (the  “Board”)  of  Hercules  Capital,  Inc. 
(“Hercules Capital”) in accordance with Rule 17j-l(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) and by Hercules 
Adviser LLC (the “Adviser”) and together with the Hercules Capital, “Hercules”), in accordance with Rule 204A-1 of the Investment Advisers 
Act of 1940, as amended (the “Advisers Act”).

Rule  17j-1  under  the  1940  Act  requires  that  a  business  development  company  (“BDC”)  adopt  a  written  code  of  ethics  that 
establishes  standards  and  procedures  for  the  detection  and  prevention  of  activities  by  which  persons  having  knowledge  of  the  investments  and 
investment intentions of the BDC may abuse their position, and otherwise contain provisions reasonably necessary to prevent violations of Rule 
17j-1 and the types of conflict of interest situations to which Rule 17j-1 is addressed. Rule 204A-1 under the Advisers Act requires each registered 
investment adviser to establish, maintain and enforce a written code of ethics that, among other things, contains provisions regarding the standard 
of business conduct required by the adviser, which must reflect the Adviser’s fiduciary duty to its clients (“Adviser Clients”) and compliance with 
all applicable U.S. federal securities laws. 

This Code is intended to comply with Rule 17j-1 under the 1940 Act and Rule 204A-1 under the Advisers Act.

The purpose of this Code is to reflect the following:

(1)

the duty at all times to place the interests of (i) Adviser Clients and (ii) Hercules Capital and its shareholders, as appropriate, first;

(2)

the requirement that all personal securities transactions be conducted consistent with the Code and in such a manner as to avoid any 
actual or potential conflict of interest or any abuse of an individual’s position of trust and responsibility; and

(3)

the fundamental standard that BDC and investment advisory personnel should not take inappropriate advantage of their positions.

SECTION I: STATEMENT OF PURPOSE AND APPLICABILITY

(A)

Statement of Purpose 

It is the policy of Hercules that no affiliated person of Hercules will, in connection with the purchase or sale, directly or 
indirectly, by such person 

1

 
 
 
 
 
 
 
 
 
 
 
 
of any security held or to be acquired by Hercules Capital or an Adviser Client:

(1)

(2)

(3)

Employ any device, scheme or artifice to defraud Hercules Capital or an Adviser Client;

Make to Hercules Capital or an Adviser Client any untrue statement of a material fact or omit to state to Hercules 
Capital or an Adviser Client a material fact necessary in order to make the statement made, in light of the 
circumstances under which it is made, not misleading;

Engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon Hercules 
Capital or an Adviser Client; or

(4)

Engage in any manipulative practice with respect to Hercules Capital or an Adviser Client.

(B)

Scope of the Code

In order to prevent Access Persons, as defined in Section II, paragraph (A) below, of Hercules from engaging in any of these 
prohibited acts, practices or courses of business, the Adviser has adopted this Code and the Board has adopted this Code on 
behalf of Hercules Capital.

SECTION II: DEFINITIONS

(A)

(B)

Access Person. “Access Person” means any director, officer, or “Advisory Person” of Hercules or all employees of Hercules 
Capital who act as Supervised Persons of the Adviser and those employees that make, participate in, or obtain non-public 
information regarding the portfolio management decisions relating to investment advisory services on behalf of an Adviser 
Client or prospective client.

Advisory Person. “Advisory Person” of Hercules means: (i) any director, officer or employee of Hercules or of any company 
in a control relationship to Hercules, who, in connection with his or her regular functions or duties, makes, participates in, or 
obtains information regarding the purchase or sale of a Covered Security by Hercules, or whose functions relate to the making 
of any recommendations with respect to such purchases or sales; and (ii) any natural person in a control relationship to 
Hercules who obtains information concerning recommendations made to Hercules with regard to the purchase or sale of a 
“Covered Security.”

(C)

Beneficial Interest. “Beneficial Interest” includes any entity, person, trust, or account with respect to which an Access Person 
exercises investment 

2

 
 
 
 
 
  
 
 
 
 
 
 
discretion or provides investment advice. A beneficial interest will be presumed to include all accounts in the name of or for 
the benefit of the Access Person, his or her spouse, dependent children, or any person living with him or her or to whom he or 
she contributes economic support.

Beneficial Ownership. “Beneficial Ownership” will be determined in accordance with Rule 16a-1(a)(2) under the Securities 
Exchange Act of 1934, as amended (the “Exchange Act”), except that the determination of direct or indirect Beneficial 
Ownership will apply to all securities, and not just equity securities, that an Access Person holds or acquires. Rule 16a-1(a)(2) 
provides that the term “beneficial owner” means any person who, directly or indirectly, through any contract, arrangement, 
understanding, relationship, or otherwise, has or shares a direct or indirect pecuniary interest in any equity security. Therefore, 
an Access Person may be deemed to have Beneficial Ownership of securities held by members of his or her immediate family 
sharing the same household, or by certain partnerships, trusts, corporations, or other arrangements.

Control. “Control” will have the meaning set forth in Section 2(a)(9) of the 1940 Act.

Covered Security. “Covered Security” means a security as defined in Section 2(a)(36) of the 1940 Act and Section 202(a)(18) 
of the Advisers Act, except that it does not include (i): direct obligations of the Government of the United States; (ii) banker’s 
acceptances, bank certificates of deposit, commercial paper and high quality short-term debt instruments including repurchase 
agreements; and (iii) shares issued by registered open-end investment companies (i.e., mutual funds); however, exchange 
traded funds structured as unit investment trusts or open-end funds are considered “Covered Securities.”

Designated Officer. “Designated Officer” means the officer of Hercules designated by the Board from time to time to be 
responsible for management of compliance with this Code and/or any person or persons designated by such officer to perform 
such functions on his or her behalf.

Disinterested Director. “Disinterested Director” means a director of Hercules Capital who is not an “interested person” of 
Hercules within the meaning of Section 2(a)(19) of the 1940 Act.

Hercules. “Hercules” means Hercules Capital, Inc., a Maryland corporation, and its wholly-owned subsidiary, Hercules 
Adviser LLC, a Delaware limited liability company.

Initial Public Offering. “Initial Public Offering” means an offering of securities registered under the Securities Act of 1933, as 
amended (the “Securities Act”), the issuer of which, immediately before the registration, 

3

(D)

(E)

(F)

(G)

(H)

(I)

(J)

 
 
 
 
 
 
 
 
 
was not subject to the reporting requirements of Sections 13 or 15(d) of the Exchange Act.

(K)

(L)

(M)

Investment Personnel. “Investment Personnel” means: (i) any employee of Hercules Capital (or of any company in a control 
relationship to Hercules) or any Supervised Person of the Adviser who, in connection with his or her regular functions or 
duties, makes or participates in making recommendations regarding the purchase or sale of securities by Hercules Capital or 
one or more Adviser Clients; and (ii) any natural person who controls Hercules Capital or the Adviser and who obtains 
information concerning recommendations regarding the purchase or sale of securities by Hercules Capital or the Adviser.

Limited Offering. “Limited Offering” means an offering that is exempt from registration under the Securities Act pursuant to 
Section 4(2) or Section 4(6) or pursuant to Rule 504, Rule 505 or Rule 506 under the Securities Act.

Purchase or Sale of a Covered Security. “Purchase or Sale of a Covered Security” is broad and includes, among other things, 
the writing of an option to purchase or sell a Covered Security, or the use of a derivative product to take a position in a 
Covered Security.

SECTION III: STANDARDS OF CONDUCT

(A)

General Standards

(1)

(2)

(3)

(4)

No Access Person will engage, directly or indirectly, in any business transaction or arrangement for personal profit 
that is inconsistent with the best interests of, as applicable, Adviser Clients or Hercules Capital or its shareholders.

No Access Person will make use of any confidential information gained by reason of his or her employment by or 
affiliation with Hercules or affiliates thereof in order to derive a personal profit for himself or herself or for any 
Beneficial Interest, in violation of the fiduciary duty owed to Hercules or its shareholders.

No Access Person will recommend or authorize the purchase or sale of a Covered Security by Hercules or its 
affiliates without having disclosed, at the time of such recommendation or authorization, any Beneficial Interest in, 
or Beneficial Ownership of, such Covered Security or the issuer thereof.

No Access Person will disclose any confidential information concerning securities holdings or securities transactions 
of Hercules to persons outside Hercules, without obtaining prior written approval from the Designated Officer, or 
such person or 

4

 
 
 
 
  
 
 
 
 
 
 
persons designated to act on his or her behalf. Notwithstanding the preceding sentence, such Access Person may 
dispense such information without obtaining prior written approval:

(a)

(b)

(c)

(d)

when there is a public report containing the same information;

when such information is dispensed in accordance with compliance procedures established to prevent 
conflicts of interest between Hercules and its affiliates;

when such information is reported to directors of Hercules; or

in the ordinary course of his or her duties on behalf of Hercules.

(5)

All personal securities transactions should be conducted consistent with this Code and in such a manner as to avoid 
actual or potential conflicts of interest, the appearance of a conflict of interest, or any abuse of an individual’s 
position of trust and responsibility within Hercules.

(B)

Requirement to Obtain Preclearance

(1)

(2)

Preclearance is Required before Trading. Preclearance of trades helps to prevent personal trading from conflicting 
with Hercules transactions. No Access Person will be able to purchase or sell, directly or indirectly, any Covered 
Security in which he or she has, or by reason of such transaction acquires, any direct or indirect Beneficial 
Ownership unless that Access Person has obtained preclearance prior to engaging in such transaction.

How to Obtain Preclearance. Prior to conducting a trade, all Access Persons must enter transaction information into 
the ComplySci Preclearance System (“ComplySci”) and follow the instructions to receive approval. If preclearance 
is granted, it will be valid for 5 business days from the day that approval was granted and the trade must take place 
within those days. If Preclearance approval is not granted, Access Persons will not be permitted to engage in the 
proposed transaction and may direct further inquiries to the CCO.

(3)

Certain Transactions May be Denied Preclearance. The following transactions will generally be denied preclearance.

(a)

Company Considering Purchase or Sale. Requests for preclearance regarding any securities that Hercules is 

5

 
 
 
 
 
 
 
 
 
 
 
 
currently considering for purchase or sale will generally be denied.

(b)

(c)

(d)

Company Same Day Purchase or Sale. Requests for preclearance regarding any securities that Hercules has 
purchased or sold on the same business day as the preclearance request will generally be denied.

Restricted Security List. Requests for preclearance regarding any security listed on Hercules’s Restricted 
Security List will generally be denied.

Blackouts for Investment Personnel. Requests from Investment Personnel for preclearance that fall within a 
“blackout” period will generally be denied.

Approval of CCO’s Transaction. The CCO will conduct transactions in the manner described herein for all Access 
Persons. The Chief Executive Officer or Chief Financial Officer will approve such transactions.

Exclusions from Preclearance Requirement. The following transactions will generally be exempt from the 
preclearance requirement.

(a)

Exchange Traded Fund transactions where no constituent security held by the Exchange Traded Fund 
amounts to greater than 5% of the Exchange Traded Fund’s holdings;

(4)

(5)

(6)

Other Restrictions 

(a)

(b)

Company Acquisition of Shares in Companies that Investment Personnel Hold Through Limited Offerings. 
Investment Personnel who have been authorized to acquire securities in a Limited Offering must disclose 
that investment to the Designated Officer when they are involved in Hercules’s subsequent consideration of 
an investment in the issuer, and Hercules’s decision to purchase such securities must be independently 
reviewed by Investment Personnel with no personal interest in that issuer.

Gifts. No Access Person may accept, directly or indirectly, any gift, favor, or service or other consideration 
of more than a de minimis value (e.g., $250) from any person or entity that does business or proposes to do 
business with Hercules, and/or with whom he or she transacts business on behalf of Hercules, under 
circumstances when to do so 

6

 
 
 
 
 
 
 
 
 
 
 
would conflict with Hercules’s best interests or would impair the ability of such person to be completely 
disinterested when required, in the course of business, to make judgments and/or recommendations on 
behalf of Hercules. An Access Person must pre-clear gifts over $250 in ComplySci.

Service as Director. No Access Person will serve on the board of directors of a portfolio company of 
Hercules unless (i) such board service is consistent with the interests of Hercules and its shareholders and 
(ii) such Access Person has obtained prior written approval from the Designated Officer for such service.

Initial Public Offerings and Limited Offerings. Access Persons must obtain preclearance before, directly or 
indirectly, acquiring Beneficial Ownership in any securities in an Initial Public Offering or in a Limited 
Offering.

(c)

(d)

SECTION IV: PROCEDURES TO IMPLEMENT CODE OF ETHICS

The following reporting procedures have been established to assist Access Persons in avoiding a violation of this Code, and to assist Hercules 

in preventing, detecting, and imposing sanctions for violations of this Code. Every Access Person must follow these procedures. Questions 
regarding these procedures should be directed to the Designated Officer.

(A)

Applicability  

All Access Persons are subject to the reporting requirements set forth in Section IV(B) except:

(1)

(2)

with respect to transactions effected for, and Covered Securities held in, any account over which the Access Person 
has no direct or indirect influence or control;

a Disinterested Director, who would be required to make a report solely by reason of being a Director, need not 
make: (1) an initial holdings or an annual holdings report; and (2) a quarterly transaction report, unless the 
Disinterested Director knew or, in the ordinary course of fulfilling his or her official duties as a Director, should have 
known that during the 15-day period immediately before or after such Disinterested Director’s transaction in a 
Covered Security, Hercules purchased or sold the Covered Security, or Hercules considered purchasing or selling the 
Covered Security.

7

 
 
 
 
 
 
 
 
 
 
 
 
(3)

an Access Person need not make a quarterly transaction report if the report would duplicate information contained in 
broker trade confirmations or account statements received by Hercules with respect to the Access Person in the time 
required by subsection (B)(2) of this Section IV, if all of the information required by subsection (B)(2) of this Section 
IV is contained in the broker trade confirmations or account statements, or in the records of Hercules, as specified in 
subsection (B)(4) of this Section IV.

(B)

Report Types 

(1)

(2)

(3)

(4)

(5)

Initial Holdings Report. An Access Person must file an initial report in ComplySci not later than 10 calendar days 
after that person became an Access Person.

Quarterly Transaction Report. An Access Person must file a quarterly transaction report in ComplySci not later than 
30 calendar days after the end of a calendar quarter.

Annual Holdings Report. An Access Person must file an annual holdings report in ComplySci not later than 30 
calendar days after the end of a fiscal year.

Account Statements. In lieu of providing a quarterly transaction report, an Access Person may direct his or her broker 
to provide to the Designated Officer copies of periodic statements for all investment accounts in which they have 
Beneficial Ownership that provide the information required in quarterly transaction reports, as set forth above.

Hercules Reports. No less frequently than annually, Hercules Capital and the Adviser must furnish to the Board or 
the CCO, respectively, and the Board or CCO must consider, a written report that:

(a)

(b)

describes any issues arising under the Code or procedures since the last report to the Board, including but 
not limited to, information about material violations of the Code or procedures and sanctions imposed in 
response to the material violations; and

certifies that Hercules has adopted procedures reasonably necessary to prevent Access Persons from 
violating the Code.

(C)

Disclaimer of Beneficial Ownership. Any report required under this Section IV may contain a statement that the report will not 
be construed as an admission by the person making such report that he or she has any 

8

 
 
 
 
 
 
 
 
 
 
 
direct or indirect beneficial ownership in the Covered Security to which the report relates.

(D)

(E)

(F)

(G)

Review of Reports. The reports required to be submitted under this Section IV will be delivered to the Designated Officer. The 
Designated Officer will review such reports to determine whether any transactions recorded therein constitute a violation of the 
Code. The Designated Officer will maintain copies of the reports as required by Rule 17j-1(f).

Designated Officer Investigation. The Designated Officer may conduct such investigation as he or she considers necessary to 
determine if proposed trades comply with this Code, including post-transaction monitoring. The Designated Officer may 
impose additional measures to avoid perceived or actual conflicts of interest or to address any transactions that require 
additional review.

Acknowledgment and Certification. Upon becoming an Access Person and annually thereafter, all Access Persons will sign an 
acknowledgment and certification of their receipt of and intent to comply with this Code in ComplySci. Each Access Person 
must also certify annually that he or she has read and understands the Code and recognizes that he or she is subject to the 
Code. In addition, each access person must certify annually that he or she has complied with the requirements of the Code and 
that he or she has disclosed or reported all personal securities transactions required to be disclosed or reported pursuant to the 
requirements of the Code.

Records. Hercules will maintain records with respect to this Code in the manner and to the extent set forth below, which 
records may be maintained on microfilm or electronic storage media under the conditions described in Rule 31a-2(f) under the 
1940 Act and Rule 204-2(g) under the Advisers Act and will be available for examination by representatives of the Securities 
and Exchange Commission (the “SEC”):

(1)

(2)

(3)

A copy of this Code and any other code of ethics of Hercules that is, or at any time within the past five years has 
been, in effect will be maintained in an easily accessible place;

A record of any violation of this Code and of any action taken as a result of such violation will be maintained in an 
easily accessible place for a period of not less than five years following the end of the fiscal year in which the 
violation occurs;

A copy of each report made by an Access Person or duplicate account statement received pursuant to this Code, 
including any information provided in lieu of the reports under subsection (A)(3) of this Section IV will be 
maintained for a period of not less than five years from the end of the fiscal year in which it is made or the 

9

 
 
 
 
 
 
 
 
 
(4)

(5)

(6)

(7)

(8)

(9)

(10)

information is provided, the first two years in an easily accessible place;

A record of all persons who are, or within the past five years have been, required to make reports pursuant to this 
Code, or who are or were responsible for reviewing these reports, will be maintained in an easily accessible place;

A copy of each report required under subsection (B)(5) of this Section IV will be maintained for at least five years 
after the end of the fiscal year in which it is made, the first two years in an easily accessible place;

A record of any decision, and the reasons supporting the decision, to approve the direct or indirect acquisition by an 
Access Person of beneficial ownership in any securities in an Initial Public Offering and

Limited Offering will be maintained for at least five years after the end of the fiscal year in which the approval is 
granted.

Obligation to Report a Violation. Every Access Person who becomes aware of a possible violation of this Code by 
any person must report it to the Designated Officer, who will report it to appropriate management personnel. The 
management personnel will take such action that they consider appropriate under the circumstances. In the case of 
officers or other employees of Hercules, such action may include removal from office. The Board or CCO, as 
applicable, will be notified, in a timely manner, of remedial action taken with respect to violations of the Code.

Confidentiality. All reports of Covered Securities transactions, duplicate confirmations, account statements and other 
information filed with Hercules or furnished to any person pursuant to this Code will be treated as confidential, but 
are subject to review as provided herein and by representatives of the Securities and Exchange Commission or 
otherwise to comply with applicable law or the order of a court of competent jurisdiction.

Waivers. The Designated Officer has the authority to exempt any employee or investment transaction from any or all 
of the provisions of this Code if the Designated Officer determines that such exemption would not be against the 
interests of any shareholders and is consistent with applicable laws and regulations, including Rule 17j-1 under the 
Investment Company Act and Rule 204A-1 under the Advisers Act. The Designated Officer will prepare and file a 
written memorandum of any 

10

 
 
 
 
 
 
 
 
 
exemption granted, describing the circumstances and reasons for the exemption.

SECTION V: SANCTIONS

Upon determination that a violation of this Code has occurred, management personnel of Hercules may impose such sanctions as they deem 

appropriate, including, among other things, disgorgement of profits, a letter of censure or suspension or termination of the employment of the 
violator. All violations of this Code and any sanctions imposed with respect thereto will be reported in a timely manner to the Board.

SECTION VI: AMENDMENTS

This Code may be amended from time to time by resolution of the Board, or without a resolution of the Board to the extent the approval of such 
amendment is not required under the 1940 Act.

SECTION VII: RULE 204A-1 OF THE ADVISERS ACT

The provisions set forth in this Code shall apply in connection with the Adviser’s provision of investment advisory services to Adviser Clients and 
it shall be interpreted in a manner to fully protect the interests of Adviser Clients. In the capacity of a registered investment adviser to Adviser 
Clients, the Adviser and Supervised Persons serve as fiduciaries. Consistent with their fiduciary duties, the interests of Adviser Clients take 
priority over the personal investment objectives or other personal interests of Supervised Persons. Supervised Persons must work to mitigate or 
eliminate any conflict of interest that may exist. A conflict of interest generally exists when a person’s private interests may be contrary to the 
interests of Adviser Clients (or, when acting on behalf of Hercules Capital, when a person’s private interests may be contrary to the interests of 
Hercules Capital or its shareholders).

For purposes of compliance by the Adviser and its Supervised Persons with this Code, the administrative provisions, enforcement provisions, 
approval (including pre-approval) provisions and recordkeeping provisions (which shall be read to refer to Rule 204-2 under the Advisers Act for 
purposes of the Adviser) may continue to be governed by the systems in place for Hercules Capital.  

Adopted:  March 25, 2021
Ratified:  December 2, 2021

11

 
 
 
 
 
 
 
 
 
 
 
Exhibit 14.2

CODE OF BUSINESS CONDUCT AND ETHICS

Amended and Restated: 

December 2, 2021

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CODE OF BUSINESS CONDUCT AND ETHICS

TABLE OF CONTENTS

Introduction  1

Purpose of the Code 

Conflicts of Interest 

1

1

Corporate Opportunities 2

Confidentiality 

2

Fair Dealing  2

Protection and Proper Use of Company Assets 

2

Compliance with Applicable Laws, Rules and Regulations  3

Equal Opportunity, Harassment 

Retaining Business Records  4

Accuracy of Company Records 

3

4

Outside Employment 

Service as a Director 

4

4

Dealings with Government and Industry Regulators 

5

Media Relations 

5

Intellectual Property Information  5

Internet and E-Mail Policy 

6

Reporting Violations and Complaint Handling 

6

Sanctions for Code Violations 

7

Application/Waivers 

7

Revisions and Amendments  7

Other Policies and Procedures 

7

Internal Use  8

 
 
 
 
Introduction

This Code of Business Conduct and Ethics (the “Code”)  has  been  adopted  by  Hercules  Capital,  Inc.  (the  “Company”)  in  order  to  establish 
applicable policies, guidelines, and procedures that promote ethical practices and conduct by the Company and all its employees, officers, and directors. 
You  should  carefully  read  and  retain  a  copy  of  the  Code  for  future  reference.  The  Code  is  primarily  designed  to  assist  you  in  the  recognition  and 
resolution of potential conflicts of interest, maintain the confidentiality of our business activities, assist in the compliance with all applicable securities 
laws and reporting of any unethical or illegal conduct, and reaffirm and promote the Company’s commitment to a corporate culture that values honesty, 
integrity, and accountability.

All  officers,  directors  and  employees  (“Covered  Persons”)  of  the  Company  are  responsible  for  maintaining  this  level  of  integrity  and  for 
complying with the policies contained in this Code. If you have a question or concern about what is proper conduct for you or anyone else, please raise 
these concerns with the Chief Compliance Officer or any member of the Company’s senior management, or follow the procedures outlined in applicable 
sections of this Code.

The  Company’s  Code  of  Ethics  under  Rule  17j-1  under  the  Investment  Company  Act  of  1940,  as  amended  (the  “1940  Act”)  and  the 

Company’s Insider Trading Policy, contain separate requirements for persons covered by this Code and other persons and is not part of this Code.

This Code is intended to:

1.

help you recognize ethical issues and take the appropriate steps to resolve these issues;

Purpose of the Code

deter ethical violations and avoid any abuse of position of trust and responsibility;

2.
3. maintain confidentiality of our business activities;
4.

assist you in complying with applicable securities laws;

5.
6.

assist you in reporting any unethical or illegal conduct; and
reaffirm and promote our commitment to a corporate culture that values honesty, integrity and accountability.

As a condition of employment or continued employment, you must acknowledge annually, in writing, that you have received a copy of this 
Code, read it, and understand that the Code contains our expectations regarding your conduct. You also will receive any updates and updated versions of 
this Code and will be required to read and acknowledge such updates.

Conflicts of Interest

You  must  avoid  any  conflict,  or  the  appearance  of  a  conflict,  between  your  personal  interests  and  the  Company’s  interests.  A  “conflict  of 
interest” occurs when your private interests interfere in any way, or even appears to interfere, with the interests of, or your service to, the Company. For 
example, a conflict of interest probably exists if:

1.
2.

you, or a member of your family, receives improper personal benefits as a result of the Covered Person’s position with the Company;
you use any non-public information about us, our customers, or our other business partners for your personal gain, or the gain of a 
member of your family;

 
 
 
 
 
 
 
 
 
 
 
 
 
3.

4.
5.

6.

you use or communicate confidential information obtained in the course of your work for your or another’s personal benefit;

you take actions or have interests that may make it difficult to perform your work on behalf of the Company objectively and effectively;
you use your personal influence or personal relationship improperly to influence investment decisions, financial reporting or company 
charitable contributions to benefit yourself to the detriment of the Company; or
you accept, directly or indirectly, any gift, favor, or service or other consideration valued in excess of $250 from any person or entity that 
does or proposes to do business with the Company without obtaining pre-clearance from the Chief Compliance Officer as
required by the Company’s Code of Ethics.

Corporate Opportunities

Each of us has a duty to advance the legitimate interests of the Company when the opportunity to do so presents itself. Therefore, you may 

not:

1.

2.
3.

take  for  yourself  personally  opportunities,  including  investment  opportunities,  discovered  through  the  use  of  your  position  with  us,  or 
through the use of Company property or information;
use our property, information, or position for your personal gain or the gain of a family member; or
compete, or prepare to compete, with us.

Confidentiality

You  must  not  disclose  confidential  information  regarding  us,  our  affiliates,  our  lenders,  or  our  other  business  partners,  unless  disclosure  is 
authorized or required by law. Confidential information includes all non-public information that might be harmful to, or useful to the competitors of, the 
Company, our affiliates, our lenders or our other business partners. Even after you leave the Company, this obligation continues until the information 
becomes publicly available.

All reports and records prepared or maintained pursuant to this Code will be considered confidential and will be maintained and protected 
accordingly. Except as otherwise required by law or this Code, such matters will not be disclosed by the Company to anyone other than the Board of 
Directors and its counsel.

You must endeavor to deal fairly with our suppliers and business partners, or any other companies or individuals with whom we do business or 

come into contact with, including fellow employees and our competitors. You must not take unfair advantage of these or other parties by means of:

Fair Dealing

1. manipulation;

concealment;
2.
3.
abuse of privileged information;
4. misrepresentation of material facts; or

5.

any other unfair-dealing practice.

 
 
 
 
 
 
 
 
 
 
 
Protection and Proper Use of Company Assets

Our  assets  are  to  be  used  only  for  legitimate  business  purposes.  Theft,  carelessness  and  waste  have  a  direct  impact  on  the  Company’s 

profitability. You should protect our assets and ensure that they are used efficiently.

Incidental personal use of telephones, fax machines, copy machines, personal computers and similar equipment is generally allowed if there is 
no significant added cost to us, it does not interfere with your work duties, it is in compliance with the Company’s policy with respect to Internet usage 
and social media and is not related to an illegal activity or to any outside business.

Each of us has a duty to comply with all laws, rules and regulations that apply to our business.

Highlighted below are some of the key compliance guidelines that must be followed.

Compliance with Applicable Laws, Rules and Regulations

1.

2.

Insider trading. It is against the law to buy or sell securities using material information that is not available to the public. Individuals 
who give this “inside” information to others may be liable to the same extent as the individuals who trade while in possession of such 
information. You must not trade in our securities, or the securities of our affiliates, our lenders, or our other business partners while in the 
possession  of  “inside”  information.  All  employees  are  required  to  be  familiar  and  comply  with  our  Insider  Trading  Policy  in  the 
Company’s Compliance Manual.

“Whistleblower” protections. It is against the law to discharge, demote, suspend, threaten, harass, or discriminate in any manner against 
an  employee  who  provides  information  or  otherwise  assists  in  investigations  or  proceedings  relating  to  violations  of  federal  securities 
laws  or  other  federal  laws  prohibiting  fraud  against  shareholders.  You  must  not  discriminate  in  any  way  against  an  employee  who 
engages  in  these  “whistleblower”  activities.  You  are  encouraged  to  refer  to  our  Whistleblower  Policy  in  the  Company’s  Compliance 
Manual.

3.

1940 Act requirements. A separate code of ethics has been established to comply with Rule 17j-1 under the 1940 Act and is applicable 
to those persons designated in such code.

4. Document  retention.  You  must  adhere  to  appropriate  procedures  governing  the  retention  and  destruction  of  records  consistent  with 
applicable laws, regulations and our policies. You may not destroy, alter or falsify any document that may be relevant to a threatened or 
pending lawsuit or governmental investigation. All employees are required to be familiar and comply with our Recordkeeping Policy in 
the Company’s Compliance Manual.

Please talk to the Chief Compliance Officer or any member of senior management if you have any questions about how to comply with the 

above regulations and other laws, rules and regulations.

In  addition,  we  expect  you  to  comply  with  all  our  policies  and  procedures  that  apply  to  you.  We  may  modify  or  update  our  policies  and 
procedures in the future, and may adopt new Company policies and procedures from time to time. You are also expected to observe the terms of any 
confidentiality agreement, employment agreement or other similar agreement that applies to you.

We are committed to providing equal opportunity in all of our employment practices including selection, hiring, promotion, transfer, and 

compensation of all qualified applicants and employees

Equal Opportunity, Harassment

 
 
 
 
 
 
 
 
 
 
without regard to race, color, sex or gender, gender identity, sexual orientation, religion, age, national origin, handicap, disability, citizenship status, or 
any  other  status  protected  by  law.  With  this  in  mind,  there  are  certain  behaviors  that  will  not  be  tolerated.  These  include  harassment,  violence, 
intimidation,  and  discrimination  of  any  kind  involving  race,  color,  sex  or  gender,  gender  identity,  sexual  orientation,  religion,  age,  national  origin, 
handicap, disability, citizenship status, marital status, or any other status protected by law.

Retaining Business Records

The  law  requires  us  to  maintain  certain  types  of  corporate  records,  usually  for  specified  periods  of  time.  Failure  to  retain  those  records  for 
those  minimum  periods  could  subject  us  to  penalties  and  fines,  cause  the  loss  of  rights,  obstruct  justice,  place  us  in  contempt  of  court,  or  seriously 
disadvantage  us  in  litigation  If  we  inform  you,  or  you  believe  that  our  records  are  relevant  to  any  litigation  or  governmental  action,  or  any  potential 
litigation  or  action,  then  you  must  preserve  those  records  until  we  determine  the  records  are  no  longer  required  to  be  preserved.  This  requirement 
supersedes any previously or subsequently established destruction policies for those records. If you believe that this requirement may apply, or have any 
questions regarding the possible applicability of this requirement, please contact our Chief Compliance Officer.

Accuracy of Company Records

We require honest and accurate recording and reporting of information in order to make responsible business decisions. This includes such 

data as quality, safety, and personnel records, as well as financial records.

All financial books, records and accounts must accurately reflect transactions and events, and conform both to required accounting principles 

and to our system of internal controls. No false or  artificial entries may be made.

Without the written consent of the Chief Executive Officer, no officer or employee is permitted to:

Outside Employment

1.

2.
3.

engage in any other financial services business;

be employed or compensated by any other business for work performed; or
have  a  significant  (more  than  5%  equity)  interest  in  any  other  financial  services  business,  including,  but  not  limited  to,  banks,  brokerages, 
investment advisers, insurance companies or any other similar business.

Requests for outside employment waivers must be made in writing to the Chief Executive Officer with a copy to the Chief Compliance 

Officer of the Company.

Service as a Director

No  officer  or  employee  may  serve  as  a  director  or  officer  of  any  organization,  other  than  the  Company,  without  prior  written  authorization 
from our Chief Compliance Officer. Any request to serve on the board or as an officer of such an organization must include the name of the entity and its 
business, the names of the other board members or officers, as applicable, and a general reason for the request. The Chief Compliance Officer will consult 
with the Chief Executive Officer in connection

 
 
 
 
 
 
 
 
 
 
 
 
 
 
with any such request.

Directors  who  serve  on  the  Company’s  Board  of  Directors  are  required  to  adhere  to  the  procedures  set  forth  in  the  Company’s  Corporate  Governance  

Guidelines prior to serving on a board of another organization.

Dealings with Government and Industry Regulators

The Company’s policy forbids payments of any kind by us, our employees or any agent or other intermediary to any government official, self-
regulatory  official  or  other  similar  person  or  entity,  within  the  United  States  or  abroad,  for  the  purpose  of  obtaining  or  retaining  business,  or  for  the 
purpose of influencing favorable consideration of any application for a business activity or other matter. This policy covers all types of payments, even to 
minor government officials and industry regulators, regardless of whether the payment would be considered legal under the circumstances, provided that, 
subject to certain limitations, political contributions or donations of an amount less than the then federally-mandated maximum amount, made without the 
intent to obtain or retain business or favorably influence consideration of any application for a business activity or other matter, are permitted, as further 
explained  below.  Employees  are  required  to  avoid  even  the  appearance  of  impropriety  in  their  dealings  with  industry  and  government  regulators  and 
officials, even with respect to permissible contributions or donations.

It  is  expected  and  required  that  all  employees  fulfill  their  personal  obligations  to  governmental  and  regulatory  bodies.  Those  obligations 

include the filing of appropriate federal, state and local tax returns, as well as the filing of any applicable forms or reports required by regulatory bodies.

All employees are required to cooperate fully with management in connection with any internal or independent investigation and any claims, 
actions, arbitrations, litigations, investigations or inquiries brought by or against us. Employees are expected, if requested, to provide us with reasonable 
assistance,  including,  but  not  limited  to,  meeting  or  consulting  with  the  Company  and  our  representatives,  reviewing  documents,  analyzing  facts  and 
appearing or testifying as witnesses or interviewees or otherwise.

Employees are required to immediately notify the Chief Compliance Officer in the event they are contacted by any national, state, local or self-
regulatory authority or body regarding a potential or actual litigation, investigation, examination, or inquiry directly or indirectly involving the Company, 
unless, upon the written advice of legal counsel, such employee is prohibited by law from doing so in such case.

We must speak with a unified voice in all dealings with the press and other media. As a result, the Company’s Chief Executive Officer, or his 
or her designee, is the sole contact for media seeking information about the Company. Any requests from the media regarding the Company must be 
referred to its Chief Executive Officer, or his or her designee.

Media Relations

Intellectual Property Information

Information  generated  in  our  business  is  a  valuable  asset.  Protecting  this  information  plays  an  important  role  in  our  growth  and  ability  to 
compete. Such information includes business and research plans; objectives and strategies; trade secrets; unpublished financial information; salary and 
benefits data; and lender and other business partner lists. Employees who have access to our intellectual property information are obligated to safeguard it 
from unauthorized access and:

1.

not disclose this information to persons outside of the Company;

 
 
 
 
 
 
 
 
 
 
 
2.

3.

not use this information for personal benefit or the benefit of persons outside of the Company; and

not share this information with other employees except on a legitimate “need to know” basis.

Internet and E-Mail Policy

We provide an e-mail system and Internet access to certain of our employees to help them do their work. You may use the e-mail system and 
the Internet only for legitimate business purposes in the course of your duties. Incidental and occasional personal use is permitted, but never for personal 
gain or any improper or illegal use. Further, you are prohibited from discussing or posting information regarding the Company in any external electronic 
forum,  including  Internet  chat  rooms,  electronic  bulletin  boards  or  social  media  sites.  You  are  encouraged  to  refer  to  our  Social  Media  Policy  in  the 
Company’s Compliance Manual for more information.

Reporting Violations and Complaint Handling

You are responsible for compliance with the rules, standards and principles described in this Code. In addition, you should be alert to possible 
violations of the Code by the Company’s employees, officers and directors, and you are required to report a violation promptly. Normally, reports should 
be  made  to  one’s  immediate  supervisor.  Under  some  circumstances,  it  may  be  impractical  or  you  may  feel  uncomfortable  raising  a  matter  with  your 
supervisor. In those instances, you are encouraged to contact the Chief Compliance Officer who will investigate the matter and potentially report it to the 
Company’s Chief Executive Officer and/or Board of Directors, as the circumstance dictates. You will also be expected to cooperate in an investigation of 
a violation.

The  Company  has  also  adopted  a  Whistleblower  Policy  pursuant  to  which  you  may  report  a  concern  about  our  conduct,  the  conduct  of  a 
director, officer or employee of the Company or our accounting, internal accounting controls or auditing matters directly to the Audit Committee of the 
Board  of  Directors  of  the  Company.  All  reported  concerns  will  be  reviewed  and  by  the  Audit  Committee  and/or  by  the  Chief  Compliance  Officer  on 
behalf of the Audit Committee. The status of all outstanding concerns forwarded to the Audit Committee will be reported on a quarterly basis by the 
Company’s  Chief  Compliance  Officer.  The  Audit  Committee  may  direct  that  certain  matters  be  presented  to  the  full  Board  and  may  retain  outside 
advisors or counsel, for any concern reported to it. You are encouraged to refer to our Whistleblower Policy in the Company’s Compliance Manual and to 
report any concerns that you might have.

All reports will be investigated and, whenever possible, requests for confidentiality will be honored. And, while anonymous reports will be 
accepted, please understand that anonymity may hinder or impede the investigation of a report. All cases of questionable activity or improper actions will 
be reviewed for appropriate action, discipline or corrective actions. Whenever possible, we will keep confidential the identity of employees, officers or 
directors who are accused of violations, unless or until it has been determined that a violation has occurred.

There will be no reprisal, retaliation or adverse action taken against any employee who, in good faith, reports or assists in the investigation of, 

a violation or suspected violation, or who makes an inquiry about the appropriateness of an anticipated or actual course of action.

For reporting concerns about the Company’s conduct, the conduct of a director, officer or employee of the Company, or about the Company’s 

accounting, internal accounting controls or auditing matters, you may use the following means of communication:

 
 
 
 
 
 
 
 
 
 
 
1.

By Mail:  Chief Compliance Officer

Hercules Capital, Inc.
400 Hamilton Avenue, Suite 310 Palo Alto, CA 
94301

2.

Confidentially By Mail:  Chairperson of the Audit Committee

To be Opened by Audit Committee Only C/O Chief Compliance 
Officer
Hercules Capital, Inc. 400 Hamilton Avenue, Suite 
310 Palo Alto, CA 94301

3. Anonymously By Phone to Ethics Hotline: 650-600-5400

4.

By Email to Chief Compliance Officer: complianceofficer@htgc.com

Sanctions for Code Violations

All  violations  of  the  Code  are  subject  to  appropriate  corrective  action,  up  to  and  including  dismissal.  If  the  violation  involves  potentially 

criminal activity, the individual or individuals in question will be reported, as warranted, to the appropriate authorities.

All the directors, officers and employees of the Company are subject to this Code.

Application/Waivers

Any  material  amendment  or  waiver  of  the  Code  for  an  executive  officer  of  the  Company  or  a  member  of  the  Board  of  Directors  of  the 
Company must be made by the Board of Directors and disclosed on a Form 8-K filed with the SEC within four business days following such amendment 
or waiver.

Revisions and Amendments

This  Code  may  be  revised,  changed  or  amended  at  any  time  by  our  Board  of  Directors.  Following  any  material  revisions  or  updated,  an 
updated version of this Code will be distributed to you, and will supersede the prior version of this Code effective upon distribution. We may ask you to 
sign  an  acknowledgement  confirming  that  you  have  read  and  understood  the  revised  version  of  the  Code,  and  that  you  agree  to  comply  with  the 
provisions.

This Code will be the sole code of business conduct and ethics adopted by the Company for purposes of Section 406 of the Sarbanes-Oxley 
Act  and  the  rules  and  forms  applicable  to  registered  investment  companies  thereunder.  Insofar  as  other  policies  or  procedures  of  the  Company  may 
govern the behavior or activities of the Covered Person who are subject to this Code, they are superseded by this Code to the extent that they overlap or 
conflict with the provisions of this Code.

Other Policies and Procedures

 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Code is intended solely for the internal use by the Company and does not constitute an admission, by or on behalf of any Company, as 

to any fact, circumstance, or legal conclusion.

Internal Use

 
 
 
 
List of Subsidiaries
(as of December 31, 2021)

Name
Bearcub Acquisitions LLC
Gibraltar Acquisition LLC 
HercGBC LLC
Hercules Capital Funding Trust 2018-1
Hercules Capital Funding Trust 2019-1
Hercules Capital IV, L.P.
Hercules Capital Management LLC
Hercules Funding II, LLC
Hercules Funding IV, LLC
Hercules Technology III, L.P. 
Hercules Technology Management LLC
Hercules Technology Management Co II, Inc.
Hercules Technology Management Co III LLC
Hercules Technology Management Co IV LLC
Hercules Technology SBIC Management, LLC
HTGC UK Limited

Unconsolidated Subsidiaries 
Gibraltar Business Capital LLC
Hercules Adviser LLC
Hercules Private Credit Fund 1 L.P.
Hercules Private Fund One LLC
Hercules Private Global Venture Growth Fund GP I LLC
Hercules Private Global Venture Growth Fund I L.P.

Exhibit 21.1

Jurisdiction of Organization 
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
Delaware
United Kingdom

Delaware
Delaware
Delaware
Delaware
Delaware
Delaware

 
 
 
 
 
 
 
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-229435) and N-2 (No. 333-261732) of Hercules Capital, Inc. of our 
report dated February 22, 2022 relating to the financial statements, financial statement schedule, senior securities table and the effectiveness of internal control over financial 
reporting, which appears in this Form 10-K. We also consent to the reference to us under the heading “Senior Securities” in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
San Francisco, California
February 22, 2022

 
 
CERTIFICATION PURSUANT TO

RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED 

Exhibit 31.1 

I, Scott Bluestein, Director, President, Chief Executive Officer, and Chief Investment Officer of the Company, certify that: 

1. I have reviewed this annual report on Form 10-K of Hercules Capital, Inc. (the “registrant”) for the year ended December 31, 2021; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in 

light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, 

results of operations and cash flows of the registrant as of, and for, the periods presented in this report. 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 

13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that 

material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period 
in which this report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to 

provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with 
generally accepted accounting principles; 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the 

disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter 

(the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal 
control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s 

auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to 

adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over 

financial reporting. 

Date: February 22, 2022

  By:

/S/ SCOTT BLUESTEIN
Scott Bluestein
Director, President, Chief Executive Officer, and 
Chief Investment Officer (Principal Executive Officer)

 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO

RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED 

Exhibit 31.2 

I, Seth H. Meyer, Chief Financial Officer, and Chief Accounting Officer certify that: 

1. I have reviewed this annual report on Form 10-K of Hercules Capital, Inc. (the “registrant”) for the year ended December 31, 2021; 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in 

light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, 

results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 

13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that 

material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period 
in which this report is being prepared; 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to 

provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with 
generally accepted accounting principles; 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the 

disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter 

(the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal 
control over financial reporting; and 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s 

auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to 

adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over 

financial reporting. 

Date: February 22, 2022

  By:

/S/ SETH H. MEYER
Seth H. Meyer
Chief Financial Officer, and 
Chief Accounting Officer (Principal Accounting and Financial Officer)

 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 

Exhibit 32.1 

In connection with the accompanying Annual Report of Hercules Capital, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 (the “Report”) as 

filed with the Securities and Exchange Commission on the date hereof, I, Scott Bluestein, Director, President, Chief Executive Officer and Chief Investment Officer of the 
Company, certify, to the best of my knowledge, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes Oxley Act of 2002, that: 

(1) The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

Date: February 22, 2022

  By:

/S/ SCOTT BLUESTEIN
Scott Bluestein
Director, President, Chief Executive Officer, and
Chief Investment Officer (Principal Executive Officer)

 
 
 
 
 
 
 
 
 
 
CERTIFICATION PURSUANT TO
SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 

Exhibit 32.2 

In connection with the accompanying Annual Report of Hercules Capital, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 (the “Report”) as 
filed with the Securities and Exchange Commission on the date hereof, I, Seth H. Meyer, the Chief Financial Officer, and Chief Accounting Officer of the Company, certify, to 
the best of my knowledge, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that: 

(1) The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

Date: February 22, 2022

  By:

/S/ SETH H. MEYER
Seth H. Meyer
Chief Financial Officer, and 
Chief Accounting Officer (Principal Accounting and Financial Officer)